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Abstract 
 
Use of Statins and the Development of Incident Diabetes Mellitus: A 
Retrospective Cohort Study 
 
Busuyi Sunday Olotu, Ph.D. 
The University of Texas at Austin, 2015 
 
Supervisor:  Marvin D. Shepherd 
 
Statins are pharmaceutical agents used in lowering blood cholesterols levels. 
Several landmark statin trials have demonstrated the beneficial effects of statins in both 
primary and secondary prevention of cardiovascular disease. Although statins are 
generally safe and well tolerated, several studies have suggested that statins are 
associated with a moderate increase in risk of new-onset diabetes. These observations 
prompted the FDA to revise statin labels to now include a warning of an increased risk of 
incident diabetes mellitus as a result of increases in glycosylated hemoglobin (A1C) and 
fasting plasma glucose (FPG). However, few studies have used US-based data to 
investigate this statin-associated increased risk of diabetes. Thus, the purpose of this 
study was to evaluate whether statin use was associated with an increased risk of new-
onset diabetes. In addition, this study evaluated whether diabetes risk was increased when 
patients received intensive statin doses. 
  
vii 
 This study was a retrospective cohort analysis that utilized data from the Thomson 
Reuters MarketScan® Commercial Claims Database for the period of 2003 – 2004. The 
study population included new statin users who were aged 20 – 63 years at index and 
who do not have a history of diabetes. 
 Among the study population (N=116,224), 6.5% (or N=7,593) had incident 
diabetes. Compared to no statin use, statin use was significantly associated with increased 
risk of incident diabetes (HR=2.752; 99% C.I.=2.535 – 2.987; p<0.0001). In addition, 
each statin type (i.e., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and 
simvastatin) was associated with about a two-fold increase in risk of diabetes. Diabetes 
risk was highest among lovastatin users and lowest among rosuvastatin users. 
Furthermore, diabetes risk was higher among intensive-dose statin users compared to 
moderate-dose statin users (HR=1.540; 99% C.I.=1.393 – 1.704; p<0.0001).  
Because of the proven benefits of statins in both primary and secondary 
prevention of cardiovascular disease, and because the potential for diabetogenicity differs 
among statins, health care professionals should individualize statin therapy by identifying 
patients who would benefit  from less diabetogenic statin types. This could help optimize 
treatment by providing the highest benefit achievable while reducing the number of 
patients developing diabetes under statin therapy. 
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CHAPTER 1: INTRODUCTION 
In February 2012, the US Food and Drug Administration (FDA) approved 
important safety labeling changes for pharmaceuticals commonly called statins. Statins 
are pharmaceutical agents used to lower blood cholesterol level. The labeling change for 
statins now includes an increased risk of incident diabetes mellitus as a result of increases 
in glycosylated hemoglobin (A1C) and fasting plasma glucose (FPG) that was found to 
be associated with statin therapy.
1
 The FDA based its decision on a combination of 
results from randomized controlled trials (RCTs),
2
 meta-analyses of RCTs,
3
 systematic 
review,
4
 and a few observational studies,
5
 which indicated an increased risk of incident 
diabetes due to statin therapy. Other published results from primary and secondary statin 
                                                 
1 Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to 
cholesterol-lowering statin drugs. 2012; Available at: 
http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed 5/12, 2012. 
2 Thongtang N, Ai M, Otokozawa S, et al. Effects of maximal atorvastatin and rosuvastatin treatment on 
markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107(3):387-92; Koh KK, Quon MJ, 
Han SH, Lee Y, Kim SJ, and Shin EK. Atorvastatin causes insulin resistance and increases ambient 
glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55(12):1209-16; Sabatine MS, Wiviott 
SD, Morrow DA, McCabe CH, and Cannon CP. High-dose atorvastatin associated with worse glycemic 
control: a PROVE-IT TIMI 22 substudy. Circ J. 2004;110(Suppl I):S834; Ridker PM, Danielson E, 
Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein. N Engl J Med. 2008;359(21):2195-207. 
3 Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a 
network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-24; Sattar N, 
Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of 
randomised statin trials. Lancet. 2010;375(9716):735-42; Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai 
N, Alderman M, and Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. 
Diabetes Care. 2009;32(10):1924-9. 
4 Kostapanos MS, Liamis GL, Milionis HJ, and Elisaf MS. Do statins beneficially or adversely affect 
glucose homeostasis? Curr Vasc Pharmacol. 2010;8(5):612-31. 
5 Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in 
postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144-52; Sukhija 
R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic 
patients. J Investig Med. 2009;57(3):495-9. 
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prevention trials,
6
 meta-analyses of RCTs,
7
 and observational studies
8
 not cited by the 
FDA also furthered the discussion of the association between statin use and the risk of 
                                                 
6 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs 
usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-
LLT). JAMA. 2002;288(23):2998-3007; Downs JR, Clearfield M, Weis S, et al. Primary prevention of 
acute coronary events with lovastatin in men and women with average cholesterol levels: results of 
AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 
Ibid.1998;279(20):1615-22; Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of 
cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 
Lancet. 2006;368(9542):1155-63; Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke 
events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol 
concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): 
a multicentre randomised controlled trial. Ibid.2003;361(9364):1149-58; Shepherd J, Blauw GJ, Murphy 
MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised 
controlled trial. Ibid.2002;360(9346):1623-30; Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary 
heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention 
Study Group. N Engl J Med. 1995;333(20):1301-7; Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 
1994;344(8934):1383-9; Prevention of cardiovascular events and death with pravastatin in patients with 
coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with 
Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-57; Results of 
the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial 
infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo 
Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J. 2000;1(12):810-20; 
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: 
a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22; Kjekshus J, Apetrei E, Barrios V, et 
al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61; Tavazzi 
L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-
HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9; Freeman 
DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective 
treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-62. 
7 Baker WL, Talati R, White CM, and Coleman CI. Differing effect of statins on insulin sensitivity in non-
diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98-107; Coleman CI, 
Reinhart K, Kluger J, and White CM. The effect of statins on the development of new-onset type 2 
diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24(5):1359-62; Naci 
H, Brugts J, and Ades T. Comparative tolerability and harms of individual statins: A study-level network 
meta-analysis of 246 955 participants from 135 randomized controlled trials. Circ Cardiovasc Qual 
Outcomes. 2013; Navarese EP, Swiatkiewicz I, Sukiennik A, et al. Meta-analysis of impact of different 
types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123; Preiss D, 
Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose 
statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-64. 
8 Chen CW, Chen TC, Huang KY, Chou P, Chen PF, and Lee CC. Differential impact of statin on new-
onset diabetes in different age groups: a population-based case-control study in women from an Asian 
country. PLoS One. 2013;8(8):e71817; Jick SS, and Bradbury BD. Statins and newly diagnosed diabetes. 
Br J Clin Pharmacol. 2004;58(3):303-9; Izzo R, de Simone G, Trimarco V, et al. Primary prevention with 
statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutr Metab Cardiovasc 
3 
 
incident diabetes. Several studies have also discussed whether the cardiovascular gain by 
using high dose statins was offset by an increased risk in diabetes.
9
 
The potential increased risk in diabetes associated with statin use is significant 
because dyslipidemic patients being treated with statins already have a baseline increased 
risk of diabetes due to abnormal lipid levels, combined with comorbidities such as high 
blood pressure, increased weight and body mass index (BMI), metabolic syndrome, and 
cardiovascular diseases. 
Increased risk of diabetes as a result of statin use is not a desirable outcome 
because of the already increasing incidence and prevalence of prediabetes and diagnosed 
                                                                                                                                                 
Dis. 2013;23(11):1101-6; Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, and Mamdani MM. 
Risk of incident diabetes among patients treated with statins: population based study. BMJ. 
2013;346:f2610; Danaei G, García Rodríguez LA, Fernandez Cantero O, and Hernán MA. Statins and risk 
of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. 
Diabetes Care. 2013;36(5):1236; Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, and Tu 
JV. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed 
intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 2013;6(3):315-22; Ma T, 
Chang MH, Tien L, Liou YS, and Jong GP. The long-term effect of statins on the risk of new-onset 
diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective 
longitudinal cohort study. Drugs Aging. 2012;29(1):45-51; Ma T, Tien L, Fang C-L, Liou Y-S, and Jong 
G-P. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-
83; Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general 
population. J Am Coll Cardiol. 2012;60(14):1231-8; Zaharan NL, Williams D, and Bennett K. Statins and 
risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75(4):1118-24. 
9 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after 
acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504; LaRosa JC, Grundy SM, Waters DD, et 
al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. 
Ibid.2005;352(14):1425-35; Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL 
cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a 
double-blind randomised trial. Lancet. 2010;376(9753):1658-69; Baigent C, Blackwell L, Emberson J, et 
al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 
170,000 participants in 26 randomised trials. Ibid.:1670-81; de Lemos JA, Blazing MA, Wiviott SD, et al. 
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: 
phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16; ibid.; Pedersen TR, Faergeman O, Kastelein JJ, 
et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial 
infarction: the IDEAL study: a randomized controlled trial. Ibid.2005;294(19):2437-45; ibid.; Ko DT et al., 
"Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed 
intensive-dose and moderate-dose statins."; Preiss D et al., "Risk of incident diabetes with intensive-dose 
compared with moderate-dose statin therapy: a meta-analysis." 
4 
 
diabetes which is significantly contributing to increasing rates of morbidity and mortality 
among Americans.
10
 Diabetes is the seventh leading cause of death in the United States 
with attendant complications such as kidney failure, heart attacks, strokes, and 
amputations.
11
 Diabetes also imposes a substantial economic burden on the US 
population in the form of increased direct and indirect medical costs.
12
  
Several RCTs have examined the association between statins and incident 
diabetes. The Justification for the Use of Statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER) trial was one of the RCTs the FDA used in reaching 
a decision to change the labeling for all statins.
13
 Coincidentally, the results from this 
study also was thought to be influential in the decision by the FDA to expand the labeling 
of statins for use in primary prevention because the rosuvastatin group had a significant 
44% reduction in major coronary events compared to placebo group.
14
 Moreover, a 
somewhat downplayed secondary outcome of the study results also showed that 
rosuvastatin was significantly associated with a 26% increased risk of diabetes.
15
 
                                                 
10 Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of diabetes 
and its burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 
2014. 
11 Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National estimates and 
general information on diabetes and prediabetes in the United States. Atlanta, GA: U.S. Department of 
Health and Human Services, Centers for Disease Control and Prevention; 2011. 
12 American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 
2013;36(4):1033-46. 
13 Ridker PM et al., "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein." 
14 Kaul S, Morrissey RP, and Diamond GA. By jove! What is a clinician to make of JUPITER? Arch Intern 
Med. 2010;170(12):1073-77. 
15 Ridker PM et al., "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein."; ibid. 
5 
 
Similar to the JUPITER study, the Pravastatin in Elderly Individuals at Risk of 
Vascular Disease (PROSPER) study found a 32% increased risk of diabetes associated 
with pravastatin use.
16
 The results from the JUPITER and PROSPER studies were 
consistent with results from other RCTs which showed statins to be associated with 
increased risk of diabetes. While some of these associations were statistically 
significant,
17
 a majority were not statistically significant.
18
 The preponderance of non-
significant results may be due to the fact that the RCTs were not primarily designed to 
measure statin-induced diabetes but were designed to examine the benefit of 
cardiovascular protection provided by statins. Moreover, results from other RCTs showed 
that statins may be associated with a reduced risk (or protective effect) of diabetes rather 
                                                 
16 Shepherd J et al., "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a 
randomised controlled trial." 
17 Koh KK et al., "Atorvastatin causes insulin resistance and increases ambient glycemia in 
hypercholesterolemic patients."; Sabatine MS et al., "High-dose atorvastatin associated with worse 
glycemic control: a PROVE-IT TIMI 22 substudy."; Thongtang N et al., "Effects of maximal atorvastatin 
and rosuvastatin treatment on markers of glucose homeostasis and inflammation." 
18 "Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin 
vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT-LLT)."; Nakamura H et al., "Primary prevention of cardiovascular disease with pravastatin in 
Japan (MEGA Study): a prospective randomised controlled trial."; Sever PS, Dahlof B, Poulter NR, et al. 
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or 
lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid 
Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Ibid.2003;361(9364):1149-58; 
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian 
Simvastatin Survival Study (4S). Ibid.1994;344(8934):1383-9; "MRC/BHF Heart Protection Study of 
cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled 
trial."; Kjekshus J et al., "Rosuvastatin in older patients with systolic heart failure."; Tavazzi L et al., 
"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-
blind, placebo-controlled trial." 
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than being associated with an increased risk.
19
 A majority of these statin protective 
effects were, however, not statistically significant.
20
 
Evidence from meta-analyses of RCTs cited by the FDA,
21
 and other meta-
analyses of RCTs
22
 supports the hypothesis that statins may be associated with a 
moderate increase in risk of diabetes. Statin therapy was significantly associated with a 
9% increased risk of incident diabetes in the 2010 meta-analysis of 19 RCTs by Sattar et 
                                                 
19 Shepherd J et al., "Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group."; Downs JR et al., "Primary 
prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: 
results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study."; "Prevention 
of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad 
range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease 
(LIPID) Study Group."; "Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 
patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI 
Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)."; 
Freeman DJ et al., "Pravastatin and the development of diabetes mellitus: evidence for a protective 
treatment effect in the West of Scotland Coronary Prevention Study." 
20 Shepherd J et al., "Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group."; Downs JR et al., "Primary 
prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: 
results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study."; "Prevention 
of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad 
range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease 
(LIPID) Study Group."; "Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 
patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI 
Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)." 
21 Mills EJ et al., "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-
analysis of 170,255 patients from 76 randomized trials."; Rajpathak SN et al., "Statin therapy and risk of 
developing type 2 diabetes: a meta-analysis."; Sattar N et al., "Statins and risk of incident diabetes: a 
collaborative meta-analysis of randomised statin trials." 
22 Baker WL et al., "Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review 
and meta-analysis."; Coleman CI et al., "The effect of statins on the development of new-onset type 2 
diabetes: a meta-analysis of randomized controlled trials."; Naci H et al., "Comparative tolerability and 
harms of individual statins: A study-level network meta-analysis of 246 955 participants from 135 
randomized controlled trials."; Navarese EP et al., "Meta-analysis of impact of different types and doses of 
statins on new-onset diabetes mellitus."; Preiss D et al., "Risk of incident diabetes with intensive-dose 
compared with moderate-dose statin therapy: a meta-analysis." 
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al.,
23
 the 2011 meta-analysis of 17 RCTs by Mills et al.,
24
 and the 2013 meta-analysis of 
55 RCTs by Naci et al.
25
 Meanwhile, the 2009 meta-analysis of 5 RCTs by Rajpathak et 
al. reported the highest significant increased risk of incident diabetes of 13 percent.
26
 
Evidence from observational studies appears to follow that observed from RCTs 
and meta-analyses of RCTs with respect to the direction and strength of association 
between statin therapy and incident diabetes. The 2012 prospective cohort study by 
Culver et al. showed that statin use was associated with a 47% increased risk of new-
onset diabetes mellitus among postmenopausal women participating in the longitudinal 
Women's Health Initiative (WHI) study.
27
 A 2009 retrospective cohort study that 
examined the effect of statins on fasting plasma glucose in diabetic and nondiabetic 
patient population reported that statin use was significantly associated with a rise in FPG 
in both patient groups.
28
 Two retrospective cohort studies published in 2012 by Wang et 
al.
29
 and Zaharan et al.
30
 reported a 15% and 20% increased risk in diabetes, respectively. 
A more recent retrospective cohort study authored by Danaei et al.
31
 in 2013, reported 
                                                 
23 Sattar N et al., "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin 
trials." 
24 Mills EJ et al., "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-
analysis of 170,255 patients from 76 randomized trials." 
25 Naci H et al., "Comparative tolerability and harms of individual statins: A study-level network meta-
analysis of 246 955 participants from 135 randomized controlled trials." 
26 Rajpathak SN et al., "Statin therapy and risk of developing type 2 diabetes: a meta-analysis." 
27 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative." 
28 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients." 
29 Wang KL et al., "Statins, risk of diabetes, and implications on outcomes in the general population." 
30 Zaharan NL et al., "Statins and risk of treated incident diabetes in a primary care population." 
31 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival." 
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that a 14% increased risk of diabetes was associated with statin users compared to non-
users of statins. 
In general, evidence points to a moderate increase in the risk of diabetes mellitus 
that is associated with statin use in observational studies. While a majority of the studies 
indicates a significant increase in the risk of incident diabetes that is associated with 
statin use,
32
 fewer  studies indicate a non-significant increase in risk,
33
 or a protective 
effect of certain types of statins against diabetes.
34
 
In general, evidence from RCTs, meta-analyses of RCTs, and those from 
observational studies tend to suggest that statin therapy is associated with a moderate 
increase in risk of incident diabetes mellitus.  
The main purpose of the present study is to examine whether the use of statins 
increases the risk of incident diabetes mellitus. This is warranted because current 
evidence linking statin therapy to the development of incident diabetes has been 
inconsistent. While some studies indicate a moderate, statistically significant increase in 
                                                 
32 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative."; Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records 
to evaluate possible bias due to differential survival."; Wang KL et al., "Statins, risk of diabetes, and 
implications on outcomes in the general population."; Zaharan NL et al., "Statins and risk of treated 
incident diabetes in a primary care population."; Sukhija R et al., "Effect of statins on fasting plasma 
glucose in diabetic and nondiabetic patients." 
33 Jick SS and Bradbury BD, "Statins and newly diagnosed diabetes."; Izzo R et al., "Primary prevention 
with statins and incident diabetes in hypertensive patients at high cardiovascular risk." 
34 Carter AA et al., "Risk of incident diabetes among patients treated with statins: population based study."; 
Jick SS and Bradbury BD, "Statins and newly diagnosed diabetes." 
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risk of diabetes with statin therapy,
35
 some indicate that statins reduce the risk of 
diabetes,
36
 while others suggest that the increase in risk is not statistically significant.
37
 
                                                 
35 Koh KK et al., "Atorvastatin causes insulin resistance and increases ambient glycemia in 
hypercholesterolemic patients."; Sabatine MS et al., "High-dose atorvastatin associated with worse 
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randomised statin trials."; Baker WL et al., "Differing effect of statins on insulin sensitivity in non-
diabetics: a systematic review and meta-analysis."; Coleman CI et al., "The effect of statins on the 
development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials."; Naci H et al., 
"Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955 
participants from 135 randomized controlled trials."; Navarese EP et al., "Meta-analysis of impact of 
different types and doses of statins on new-onset diabetes mellitus."; Preiss D et al., "Risk of incident 
diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis."; Culver AL et 
al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative."; 
Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible 
bias due to differential survival."; Wang KL et al., "Statins, risk of diabetes, and implications on outcomes 
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treatment effect in the West of Scotland Coronary Prevention Study."; Shepherd J et al., "Prevention of 
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lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air 
Force/Texas Coronary Atherosclerosis Prevention Study."; "Prevention of cardiovascular events and death 
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Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group."; "Results of the low-
dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do 
stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico)."; Jick SS and Bradbury BD, "Statins and newly 
diagnosed diabetes."; Carter AA et al., "Risk of incident diabetes among patients treated with statins: 
population based study."; Ma T et al., "The long-term effect of statins on the risk of new-onset diabetes 
mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal 
cohort study."; Ma T et al., "Statins and new-onset diabetes: a retrospective longitudinal cohort study." 
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vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
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Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or 
lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid 
Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Ibid.2003;361(9364):1149-58; 
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In addition, a majority of the observational studies examining the association 
between statin use and the development of diabetes were conducted using non-US 
population data. Currently, 12 observational studies have examined the association 
between statins and incident diabetes. Only two of these studies used population data that 
originated from the US.
38
 The other published studies were from Taiwan (4 studies),
39
 
Canada (2 studies),
40
 the United Kingdom (2 studies),
41
 Ireland (1 study),
42
 and Italy (1 
study).
43
 Thus, there is a need to further examine this topic among the US population. 
This is because the US population may be different from other populations in terms of the 
prevalence of risk factors such as overweight, obesity, and cardiovascular diseases that 
                                                                                                                                                 
cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled 
trial."; Kjekshus J et al., "Rosuvastatin in older patients with systolic heart failure."; Tavazzi L et al., 
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38 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients."; 
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et al., "Statins and new-onset diabetes: a retrospective longitudinal cohort study."; Wang KL et al., "Statins, 
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impact of statin on new-onset diabetes in different age groups: a population-based case-control study in 
women from an Asian country." 
40 Carter AA et al., "Risk of incident diabetes among patients treated with statins: population based study."; 
Ko DT et al., "Diabetes mellitus and cardiovascular events in older patients with myocardial infarction 
prescribed intensive-dose and moderate-dose statins." 
41 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival."; Jick SS and Bradbury BD, "Statins and newly diagnosed 
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42 Zaharan NL, Williams D, and Bennett K. Statins and risk of treated incident diabetes in a primary care 
population. Ibid.2013;75(4):1118-24. 
43 Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive patients at high 
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may put people at an increased risk of diabetes, independent of the effects of statins.
44
 
For example, the US has the highest rate of obesity (defined as BMI of 30 or greater – an 
independent risk factor for diabetes and cardiovascular disease) among all high income 
population such as those found in Canada and Europe.
45
 This is in contrast to people from 
East Asia (e.g., Taiwan, China, Japan, etc.) who are known to have mean BMIs that are 
among the lowest in the world.
46
 
Furthermore, this study is needed because a majority of the previous observational 
studies that examined the association between statin therapy and new diabetes did not 
control for important variables such as BMI or obesity,
47
 statin dosages,
48
 and 
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hyperlipidemia or low-density cholesterol level.
49
 These uncontrolled variables may 
confound the association between statin therapy and development of new diabetes.  
The inconsistent findings, few US-based studies, and the weak association linking 
statin therapy to the development of diabetes as shown by previous studies call for further 
investigation using a rigorous methodological and analytical approach. Therefore, the 
purpose of this study is to determine whether the use of statins increases the risk of 
diabetes mellitus using a US database. Thus, this study will compare the incidence of 
diabetes mellitus between statin users and non-statin users using a retrospective cohort 
design.   
                                                 
49 Jick SS and Bradbury BD, "Statins and newly diagnosed diabetes."; Carter AA et al., "Risk of incident 
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retrospective longitudinal cohort study."; Zaharan NL et al., "Statins and risk of treated incident diabetes in 
a primary care population."; Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal 
women in the Women's Health Initiative."; Wang KL et al., "Statins, risk of diabetes, and implications on 
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CHAPTER 2: LITERATURE REVIEW 
2.1 SECTION I: HYPERLIPIDEMIA AND CARDIOVASCULAR 
DISEASE 
2.1.1 Introduction 
Hyperlipidemia, hyperlipemia or hyperlipoproteinemia are terms used to describe 
lipid metabolism disorder where blood levels of artherogenic lipoproteins (most 
especially, LDL-C) are elevated, and where there could be  associated decreased levels of 
protective lipoproteins (e.g., high density lipoprotein cholesterol, HDL-C). These 
terminologies may be confused with dyslipidemia, which refers to abnormal plasma 
lipoprotein level that can be either increased (hyperlipidemia) or decreased 
(hypolipidemia).
50
 However, for this study, hyperlipidemia and dyslipidemia may be used 
interchangeably. 
2.1.2 Etiology of Dyslipidemias 
Most dyslipidemias are hyperlipidemias, and can result from either primary 
(genetic) or secondary disorders of lipid metabolism.
51
 Primary dyslipidemia can  be 
monogenic (single gene defect) or polygenic (multiple genes) in origin, and include 
disorders such as familial lipoprotein deficiency, apoprotein CII deficiency, familial 
hypercholesterolemia, familial apo B-100 deficiency, type III familial, polygenic 
hypercholesterolemia, familial combined hyperlipemia, and familial 
                                                 
50 Eaton CB. Hyperlipidemia. Primary care. 2005;32(4):1027-55. 
51 Angelico F, Baratta F, and Del Ben M. Current ways of treating dyslipidemias to prevent atherosclerosis. 
Ther Apher Dial. 2013;17(2):125-9. 
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hypertriglyceridemia.
52
 Secondary dyslipidemia often results from such causes as 
diabetes mellitus, metabolic syndrome, cholestasis, hypothyroidism, nephrotic syndrome, 
impaired renal function, alcoholism and drug-induced (e.g., use of diuretics, beta 
blockers, and estrogens).
53
 
2.1.3 Lipoprotein Classification 
Cholesterols are fat-like substances in the blood that contain both lipids and 
proteins, thus the term ‘lipoprotein.’54 Lipoproteins are important for cellular metabolism. 
They serve as a transportation vehicle for free fatty acids and plasma cholesterol. They 
are also responsible for several important biological functions that include energy for 
cells and tissues, production of steroid hormone, and bile acid formation. However, 
abnormal lipoprotein metabolism is implicated in the development of atherosclerosis and 
coronary heart disease (CHD), with over 70% of people with CHD also having lipid 
disorders.
55
 
There are five major lipoprotein particles involved with disorders of lipid 
metabolism. These include chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-
                                                 
52 Ibid. 
53 Ibid. 
54 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation. 2002;106(25):3143-421. 
55 Eaton CB, "Hyperlipidemia." 
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density lipoprotein (HDL) cholesterols. Others important lipoproteins include 
chylomicron remnants (partially degraded chylomicrons) and lipoprotein(a).
56
 
Chylomicrons 
Among the lipoprotein particles, chylomicrons have the highest density 
(>0.95g/mL). Chylomicrons transport large amounts of triglycerides (TG). People with 
TG>500mg/dL have elevated amount of the lipoprotein.
57
 
VLDL 
 These are TG-rich lipoproteins with a density of 0.95 – 1.006g/mL. They make up 
10-15% of the total serum cholesterol. People with TG of 150 – 500mg/dL have elevated 
levels of the lipoprotein.
58
 
IDL 
 Intermediate density lipoproteins have a density of 1.006 – 1.019g/mL. They 
transport both TG and cholesterol esters. People with total cholesterol (TC) or TG of 
around 300mg/dL have elevated levels of the lipoprotein.
59
 
LDL 
 Low density lipoproteins (informally called the bad cholesterol) have a density of 
1.019 – 1.063g/mL, and make up 60 – 70% of the total serum cholesterol in the body. 
They transport large amounts of cholesterol esters but smaller amounts of TG. LDL is the 
                                                 
56 Ibid. 
57 Ibid. 
58 Ibid. 
59 Ibid. 
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main lipoprotein implicated in atherosclerotic cardiovascular disease (ASCVD). Levels 
should be less than 100mg/dL in people at high risk of CHD.
60
 
HDL 
 High density lipoproteins (informally called the good cholesterol) have the 
highest density of between 1.063 and 1.21g/mL, and make up about 20 – 30% of the total 
body serum cholesterol. They help remove excess cholesterol from the body and 
transport it to the liver for excretion, hence their anti-atherogenic properties. Levels > 
60mg/dL are believed to be optimal for cardiovascular protection.
61
 
2.1.4 Epidemiology of Hyperlipidemia 
 High levels of LDL-C (defined as level that is at or above LDL-C goal for a 
patient’s cardiovascular risk group, or current use of cholesterol medication) is a major 
risk factor for cardiovascular diseases. Even though Americans have made significant 
progress with regard to controlling their blood levels of total cholesterol over the past 
decade and a half,
62
 the percentage of Americans with high levels of LDL-C still remains 
high. According to data from the 2005 – 2008 National Health and Nutrition Examination 
Survey (NHANES), 71 million (34%) American adults aged 20 years and older had high 
                                                 
60 Ibid. 
61 Ibid. 
62 Carroll MD, Kit BK, and Lacher DA. Total and high-density lipoprotein cholesterol in adults, 2009–
2010. Hyattsville, MD: Centers for Disease Control and Prevention's National Center for Health Statistics, 
Division of Health and Nutrition Examination Surveys; 2012. 
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LDL-C, but only 34 million (48.1%) were treated, and 23 million (33.2%) had their LDL-
C controlled.
63
  
The prevalence of high LDL-C among Americans differs by age, gender, 
race/ethnicity, and insurance status.
64
 The prevalence of high LDL-C is highest among 
those aged 65 years or older (58.2%) compared to those aged 40-64 years (41.2%) and 20 
– 39 years (11.7%). The percentage of males (36.2%) who had high LDL-C is higher than 
that for females (31.0%). Among race/ethnic populations, non-Hispanic whites (34.5%) 
have the highest prevalence of high LDL-C compared to non-Hispanic blacks (30.4%) 
and Mexican-Americans (27.7%). With regard to insurance status among Americans, the 
prevalence of high LDL-C is highest among those with Medicare (58.9%) compared to 
those with public insurance (38.6%), private insurance (27.8%), and the uninsured 
(25.0%).
65
 
2.1.5 Epidemiology and Economic Burden of Cardiovascular Disease 
Data show that about half of Americans (49%) have at least one of the three major 
risk factors (i.e., high LDL-C, high blood pressure, and smoking) responsible for the high 
burden of cardiovascular disease among Americans.
66
 Cardiovascular disease (CVD) is 
the leading cause of death among the various race/ethnic groups in the United States, 
                                                 
63 Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of high levels 
of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008. MMWR. 
2011;60(4):109-14. 
64 Ibid. 
65 Ibid. 
66 Centers for Disease Control and Prevention. Million Hearts: strategies to reduce the prevalence of 
leading cardiovascular disease risk factors in United States. MMWR. 2011;60(36):1248-51. 
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accounting for 600,000 deaths annually (i.e., 1 in every 4 deaths).
67
 The proportion of all 
deaths attributed to heart disease is highest among whites (25.1%) compared to African 
Americans (24.5%), Asians or Pacific Islanders (23.2%), Hispanics (20.8%), and 
American Indians or Alaska Natives (18.0%).
68
 
Currently, 11.3% (26.6 million) of non-institutionalized American adults have 
diagnosed heart disease.
69
 This number is projected to increase to 40.5% (116 million) by 
2030.
70
 CHD (the most common form of CVD) is also the leading cause of death 
worldwide, with an average American having a coronary event (e.g., angina pectoris, 
acute coronary syndrome, silent myocardial ischemia, and sudden cardiac death) 
approximately every 25 seconds, and another dying of these events approximately every 
60 seconds.
71
  
CVD is responsible for 17% of the overall national health expenditures.
72
 This 
cost is projected to increase substantially over the next two decades. The total direct 
medical costs of CVD are projected to triple, from $273 billion in 2010 to $818 billion in 
                                                 
67 Murphy SL, Xu JQ, and Kochanek KD. Deaths: Final data for 2010. Natl Vital Stat Rep. 2013;61(4). 
68 Heron M. Deaths: leading causes for 2008. Ibid.2012;60(6):1-94. 
69 Blackwell DL, Lucas JW, and Clarke TC. Summary health statistics for U.S. adults: National Health 
Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat. 2014;10(260). 
70 Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the 
United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. 
71 Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from 
the American Heart Association. Ibid.2012;125(1):e2-e220. 
72 Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the 
United States: a policy statement from the American Heart Association. Ibid.2011;123(8):933-44. 
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2030, while the indirect costs due to lost productivity are estimated to increase by 61% 
from $172 billion in 2010 to $276 billion in 2030.
73
 
2.1.6 Dyslipidemia and the Risk of Atherosclerotic Cardiovascular 
Disease 
Several risk factors – both lipid and non-lipid – are implicated in the development 
of ASCVD. Lipid risk factors include high levels of LDL-C and TG, and low levels of 
HDL-C. Modifiable non-lipid risk factors include hypertension, cigarette smoking, 
diabetes, metabolic syndrome, overweight and obesity, physical inactivity, and 
atherogenic diets. Non-modifiable, non-lipid risk factors include older age, male sex, and 
family history of premature CHD.
74
 Other currently emerging risk factors considered 
important in the development of ASCVD include lipoprotein remnants, lipoprotein (a), 
small LDL particles, HDL subspecies, apolipoprotein B (apo B), apolipoprotein A-I, 
TC/HDL-C ratio, homocystein, thrombogenic/hemostatic factors, inflammatory markers, 
impaired fasting glucose, and subclinical atherosclerotic diseases such as ankle-brachial 
pressure index (ABI), tests for myocardial ischemia, and tests for atherosclerotic plaque 
burden (i.e., carotid intima medial thickening and coronary calcium).
75
 Of these emerging 
risk factors, apo B occupies a unique position because the presence of apo B in plasma is 
                                                 
73 Ibid. 
74 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Ibid.2002;106(25):3143-421. 
75 Ibid. 
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strongly correlated with the severity of coronary atherosclerosis and CHD events, and it 
is considered the major apolipoprotein residing within every atherogenic lipoprotein.
76
 
Lipid Risk Factors 
As mentioned, the most important lipids connected with the atherosclerotic 
process include high serum levels of LDL-C and TG, and low levels of HDL-C. 
However, LDL-cholesterol is thought to be the main initiating factor for atherosclerosis 
and the development of subsequent ASCVD such as CHD (e.g., CAD and ischemic heart 
disease, IHD) and hypertensive heart disease.
77
 Several epidemiological studies such as 
the Framingham Heart Study,
78
 the Multiple Risk Factor Intervention Trial (MRFIT),
79
 
and the Lipid Research Clinics (LRC) trials,
80
 have all found a direct relationship 
between increased levels of LDL-C (and by implication, TC) and increased rate of 
incident CHD among men and women. In those with established CHD, the rates of 
coronary events such as myocardial infarction (MI) or death from cardiovascular disease 
                                                 
76 Tornvall P, Bavenholm P, Landou C, de Faire U, and Hamsten A. Relation of plasma levels and 
composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery 
disease in young patients with myocardial infarction. Ibid.1993;88(5 Pt 1):2180-9; Sedlis SP, Schechtman 
KB, Ludbrook PA, Sobel BE, and Schonfeld G. Plasma apoproteins and the severity of coronary artery 
disease. Ibid.1986;73(5):978-86; Gotto AM, Jr., Whitney E, Stein EA, et al. Relation between baseline and 
on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Ibid.2000;101:477-84. 
77 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Ibid.2002;106(25):3143-421. 
78 Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, and Kannel WB. Prediction of 
coronary heart disease using risk factor categories. Ibid.1998;97(18):1837-47. 
79 Stamler J, Wentworth D, and Neaton JD. Is relationship between serum cholesterol and risk of premature 
death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the 
Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-8. 
80 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of 
coronary heart disease. Ibid.1984;251(3):351-64; Lipid Research Clinics Program. The Lipid Research 
Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of 
coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74. 
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are increased with increased levels of LDL-C.
81
 Levels of LDL-C above 100mg/dL are 
believed to be atherogenic, with higher levels posing greater risk of ASCVD.
82
 
The Prospective Cardiovascular Munster (PROCAM) study showed that serum 
triglycerides also is an independent risk factor for CHD events, irrespective of serum 
levels of HDL-C or LDL-C.
83
 Similarly, a meta-analysis of 17 population-based 
prospective studies of the association between triglycerides and cardiovascular disease 
showed that elevated serum triglycerides and triglycerides-rich lipoproteins are an 
independent risk factor of CHD.
84
 Factors associated with high TG levels in the body 
include overweight and obesity, physical inactivity, cigarette smoking, excess alcohol 
intake, very high carbohydrate consumption (>60% of total energy intake), other diseases 
(e.g., diabetes, chronic renal failure, nephrotic syndrome), drugs (e.g., corticosteroids, 
protease inhibitors, β-blockers, estrogens), and genetic factors.85 
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Strong epidemiological evidence consistently showed that a low level of serum 
HDL cholesterol is an independent risk factor for CHD.
86
 For instance, a 1 percent 
decrease in serum HDL-C is said to be associated with a 2-3 percent increase in CHD 
risk.
87
 HDL-C is believed, among other mechanisms, to exert its anti-atherogenic effects 
by promoting efflux of cholesterol from atherosclerotic foam cells,
88
 or by inhibiting 
atherogenesis through their antioxidant and anti-inflammatory effects.
89
 Factors 
associated with low serum HDL-C include elevated serum TG, overweight and obesity, 
physical inactivity, cigarette smoking, very high carbohydrate consumption (>60% of 
total energy intake), diabetes, drugs (e.g., β-blockers, anabolic steroids, progestins), and 
genetic factors.
90
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steps 2 and 3. J Lipid Res. 2000;41(9):1495-508; Navab M, Hama SY, Cooke CJ, et al. Normal high 
density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. 
Ibid.:1481-94. 
90 Stone NJ, "Secondary causes of hyperlipidemia."; Chait A and Brunzell JD, "Acquired hyperlipidemia 
(secondary dyslipoproteinemias)."; Krauss RM. Regulation of high density lipoprotein levels. Med Clin 
North Am. 1982;66(2):403-30. 
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2.1.7 Management of Hyperlipidemia 
The following section describes the management of hyperlipidemia based on the 
Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (also known as Adult Treatment Panel III, or ATP III) of the 
National Cholesterol Education Program.
91
 It should be noted, however, that there have 
been some significant changes to the core elements of the ATP III guidelines with the 
recent (December 2013) release of the American College of Cardiology (ACC)/American 
Heart Association (AHA) Guideline on the Treatment of Blood Cholesterol (or the 
ACC/AHA guideline Expert Panel).
92
 The ATP III guideline is used in this discourse 
because the timeline of the study (2003 – 2004) is based on the recommendations of the 
ATP III released in 2001. However, comments [mostly in square brackets] will be 
presented alongside the discourse that highlights the key updates of ATP III that is 
reflected in the ACC/AHA guidelines (colloquially ATP IV). 
Cardiovascular Risk Assessment  
According to the ATP III guidelines, the main concept in the management of 
hyperlipidemia involves the targeting of LDL-C in particular, and engagement in patient 
risk assessment to determine the appropriate lipid goals for the different classes of 
cardiovascular risks [The ATP III uses LDL–C and/or HDL–C levels to target treatment, 
                                                 
91 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA. 2001;285(19):2486-97. 
92 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood 
cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 
Pt B):2889-934. 
24 
 
and evaluates the 10-year cardiovascular risk using the Framingham risk score, while the 
ATP IV guidelines now recommend that appropriate intensity of statin therapy should be 
used to reduce ASCVD risk in those most likely to benefit, and estimates the 10-year 
ASCVD risk using the new Pooled Cohort Equations.
93
] Studies showed that the risk of 
CHD is estimated to be reduced by 1% for every 1% reduction in LDL-C.
94
 This is 
because LDL-C reduction improves cardiovascular protection by increasing the rate of 
plaque regression and stabilization. More aggressive treatment is therefore recommended 
for patients at increased risk than patients at lower CHD risk.  
Other major risk factors, exclusive of LDL-C that modifies LDL goals include: 
family history of premature CHD (i.e., myocardial infarction or sudden death before age 
55 in a first degree relative of the male sex, or before age 65 in a first degree relative of 
the female sex); cigarette smoking; hypertension (systolic and diastolic blood pressure, 
BP ≥140/90 mmHg, or presently taking antihypertensive medication); age ≥45 years in 
men or ≥55 years in women; diabetes mellitus; HDL-C below 40mg/dL in men and 
below 50mg/dL in women.
95
 Table 2.1 summarizes the categories of risk factors 
modifying LDL-C goals in dyslipidemic patients based on the ATP III guideline [ATP IV 
                                                 
93 American College of Cardiology and American Heart Association. ASCVD risk estimator. 2014; 
Available at: 
http://my.americanheart.org/professional/StatementsGuidelines/PreventionGuidelines/Prevention-
Guidelines_UCM_457698_SubHomePage.jsp. Accessed 5/22, 2014. 
94 Cannon CP et al., "Intensive versus moderate lipid lowering with statins after acute coronary 
syndromes."; Pedersen TR et al., "High-dose atorvastatin vs usual-dose simvastatin for secondary 
prevention after myocardial infarction: the IDEAL study: a randomized controlled trial."; Schwartz GG, 
Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute 
coronary syndromes: the MIRACL study: a randomized controlled trial. Ibid.2001;285(13):1711-8. 
95 Angelico F et al., "Current ways of treating dyslipidemias to prevent atherosclerosis."; "Executive 
Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)." 
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guideline now focuses on treatment of blood cholesterol to reduce ASCVD risk. Four 
statin benefit groups were identified (with less focus on treating to LDL-C target) in 
which the potential for an ASCVD risk reduction benefit clearly exceeds the potential for 
adverse effects. The four statin benefit groups are presented in Table 2.2]. 
 
Table 2.1: Categories of Risk that Modify LDL-Cholesterol Goals in the ATP III 
Guideline 
Risk Category Number of Risk Factorsa Target LDL-C (mg/dL) 
Low risk  0 – 1  <160 
Moderate risk >2 <130 
High risk CHD or CHD-risk equivalentb <100 
Very high risk CHD + DM + MetS or ACS <70 
Source: Angelico F, Baratta F, Del Ben M. Current ways of treating dyslipidemias to prevent 
atherosclerosis. Ther Apher Dial. 2013;17(2):125-129. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; CHD, Coronary heart disease; 
MetS, Metabolic syndrome; ACS, Acute coronary syndrome; DM, Diabetes mellitus. 
aRisk factors include family history of premature CHD, cigarette smoking, BP ≥140/85, HDL-
C less than 40mg/dL (men) and 50mg/dL (women). 
bCHD-risk equivalent include ACS, peripheral artery disease, abdominal aortic aneurysm, 
cerebrovascular disease, and DM. 
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Table 2.2: ASCVD Risk Reduction in 4 Statin Benefit Groups in the ATP IV 
Guideline 
Group  Clinical Characteristics 
1 Individuals with clinical ASCVD (acute coronary syndromes, or a history 
of myocardial infarction, stable or unstable angina, coronary or other 
arterial revascularization, stroke, transient ischemic attack, or 
peripheral arterial disease presumed to be of atherosclerotic origin) 
without New York Heart Association (NYHA) class II-IV heart failure or 
receiving hemodialysis 
2 Individuals with primary elevations of LDL–C ≥190 mg/dL 
3 Individuals 40 to 75 years of age with diabetes with LDL-C 70-189 
mg/dL 
4 Individuals without clinical ASCVD or diabetes who are 40 to 75 years of 
age with LDL-C 70-189 mg/dL and an estimated 10-year ASCVD risk of 
7.5% or higher 
Source: Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the 
treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a 
report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. 
 
 
Treatment of Hyperlipidemia 
 ATP III recommends a periodic testing of all adults for dyslipidemia beginning at 
age 20. In the ATP III guideline for the treatment of hyperlipidemia (Table 2.3), LDL-C 
lowering medication is chosen based on patients’ LDL-C level and their CHD risk 
category estimated using the Framingham risk score.
96
 The focus of the new ATP IV 
guideline (Table 2.4), however, is in choosing the appropriate intensity level of statin 
                                                 
96 Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, and Kannel WB. Prediction of 
coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. 
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(defined in Table 2.5) for the reduction of blood cholesterol in the primary and secondary 
prevention of ASCVD in adults. The recommended statin intensity depends on such 
factors as the patient’s age, level of LDL-C, and the presence or absence of diseases such 
as clinical ASCVD and diabetes mellitus.
97
 Rather than using the Framingham risk score 
to determine patient’s CHD risk category, ATP IV now uses a ‘new Pooled Cohort 
Equation’ to estimate the 10-year ASCVD risk in men and women who do not have 
clinical ASCVD.
98
 
In both guidelines, however, the therapeutic management of hyperlipidemia 
involves the use of pharmacological and non-pharmacological strategies. Non-
pharmacological strategies include therapeutic lifestyle changes (TLC) diets, increased 
physical activity, and smoking cessation. Pharmacological strategy involves the use of 
lipid-lowering drugs, especially statins. [ATP IV still recommends therapeutic lifestyle 
modifications as a critical component of health promotion and ASCVD risk reduction, 
both prior to, and in concert with the use of cholesterol-lowering drug therapies].
99
 
                                                 
97 Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines." 
98 American College of Cardiology and American Heart Association, "ASCVD risk estimator". 
99 Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines." 
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Table 2.3: Management of LDL Cholesterol in Persons with Different CHD Risk Categories in the ATP III 
Guideline 
Risk category Patient’s LDL-
C Level 
(mg/dL) 
LDL-C Goal 
(mg/dL) 
Level of LDL-C at 
which to Initiate TLC 
(mg/dL) 
Level of LDL-C at which to 
Initiate LDL-lowering Drugs 
(mg/dL) 
CHD or CHD-risk 
equivalent 
≥130 <100 ≥100 Start drug therapy simultaneously 
with dietary therapy 
100-129 <100 ≥100 Consider drug option 
<100 <100 TLC & emphasize 
weight control and 
physical activity 
LDL-lowering drugs not required 
Multiple (2+) risk 
factors 
10-year risk 
for CHD 
 
>20% <100 ≥100 Start drug therapy simultaneously 
with dietary therapy 
10-20% <130 ≥130 ≥130 
<10% <130 ≥130 ≥160 
0-1 risk factora  <160 ≥160 ≥190b 
Source: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; TLC, Therapeutic lifestyle changes; CHD, Coronary heart disease. 
aMost persons with 0–1 risk factor have a 10-year risk for CHD of <10 percent. 
bDrug therapy is optional for LDL-C of 160–189 mg/dL (after dietary therapy).  
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Table 2.4: Management of Hyperlipidemia to Reduce ASCVD Risk in the ATP IV Guideline  
ASCVD 
Prevention 
Age (years) LDL-C 
(mg/dL) 
Has 
diabetes? 
Has clinical 
ASCVD? 
10-year ASCVD 
risk (%) 
Recommended statin 
intensity 
Primary ≥21 ≥190a No No Not required Highb 
40-75 70-189 Yes No <7.5 Moderatec 
<40 or >75 70-189 Yes No Not specified Not specifiedd 
40-75 70-189 No No ≥7.5 Moderate/Highe 
40-75 70-189 No No 5.0 to <7.5 Moderate/Highe 
Secondary ≤75 Any level No Yes - Highf 
>75 Any level No Yes - Moderate/Highg 
Source: Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. 
Abbreviations: ASCVD, Atherosclerotic cardiovascular disease; LDL-C, Low-density lipoprotein cholesterol. 
aOr has TG≥500mg/dL. 
bEvaluate for secondary causes of hyperlipidemia.Use maximum tolerated statin dose for those intolerant of high-intensity dose. 
Intensify dose to achieve at least a 50% LDL-C reduction. May consider adding a non-statin drug to further lower LDL-C. 
cConsider high-intensity statin if 10-year ASCVD risk is ≥7.5%. 
dEvaluate benefit of ASCVD risk-reduction versus potentials for adverse effects and drug-drug-interactions. Consider patient 
preferences when deciding to initiate, continue, or intensify therapy. 
eEvaluate benefit of ASCVD risk-reduction versus potentials for adverse effects and drug-drug interactions. Consider patient 
preferences. 
fUse moderate-intensity statin if intolerant to high-intensity statin. 
gWhen using high-intensity dose, evaluate benefit of ASCVD risk-reduction versus potentials for adverse effects and drug-drug 
interactions. Consider patient preferences. Continue therapy if tolerated. 
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Table 2.5: Statin Intensity Dosage Levels as Defined in the New ATP IV Guideline 
Statin  Low-Intensity Dose (mg) Moderate-Intensity Dose (mg) High-Intensity Dose (mg) 
Atorvastatin - 10, 20 40-80 
Fluvastatin 20-40 40mg bid, 80 (XL) - 
Lovastatin 20 40 - 
Pitavastatin 1 2-4 - 
Pravastatin 10-20 40, 80 - 
Rosuvastatin - 5, 10 20, 40 
Simvastatin 10 20-40a - 
Approximate % of LDL-C 
lowered by daily dose 
<30% 30% to <50%  ≥ 50% 
Source: Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. 
Abbreviations: bid, twice daily; XL, Extended release dosage form; LDL-C, Low-density lipoprotein cholesterol. 
aAlthough simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by 
the FDA due to the increased risk of myopathy, including rhabdomyolysis. 
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Non-Pharmacological Management 
As mentioned earlier, the ATP IV still recommends the use of non-
pharmacological therapeutic lifestyle changes as a critical component of health promotion 
and ASCVD risk reduction.
100
 Unfortunately, the use of non-pharmacological TLC alone 
is usually not adequate for reaching target lipid levels in many patients, thus necessitating 
the addition of lipid-lowering medications.
101
 TLC regimen that can be used both prior to, 
and in concert with the use of cholesterol-lowering drug therapies include weight 
management, increased physical activity, smoking cessation, and TLC diets that are low 
in sodium, saturated fat and total cholesterol, but high in fiber. Table 2.6 provides a 
summary of the essential components of the NCEP/ATP III-recommended TLC regimen. 
 
 
 
                                                 
100 Ibid. 
101 "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report." 
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Table 2.6: NCEP/ATP III-Recommended Therapeutic Lifestyle Changes (TLC) 
Regimen 
Component Recommendations 
LDL-raising nutrients 
Saturated fatsa <7% of total calories 
Dietary cholesterol <200 mg/day 
Therapeutic options for LDL-lowering 
Plant stanols/sterol 2g per day 
Viscous/soluble fiber 10-25g per day 
Total calories (energy)b Balance energy intake and expenditure to maintain 
desirable body weight/prevent weight gain 
Physical activity 30 minutes of regular moderate intensity activity on 
most, if not all, days of the weekc 
Body weight  10% weight loss goals for overweight persons 
Smoking cessation Employ pharmacological and non-pharmacological 
strategies to smoking cessation 
Macronutrient recommendations for the TLC diet 
Total fat 25% to 35% of total calories 
Polyunsaturated fat ≤10% of total calories 
Monounsaturated fat ≤20% of total calories 
Carbohydratesd 50% to 60% of total calories 
Fiber 20-30 g/day 
Protein ∼15% of total calories 
Source: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 
aTrans fatty acids (partially hydrogenated oils) intake should be kept low. These are found 
in potato chips, other snack foods, margarines and shortenings, and fast-foods. 
bDaily energy expenditure should include at least moderate physical activity. 
cBased on patient’s cardiac status, age and other factors. 
dComplex carbohydrates, including grains (especially whole grains, fruits, and vegetables). 
 
 
 
33 
 
Pharmacological Management 
Currently, five classes of drugs are available for the treatment of dyslipidemia.
102
 
They include: 
 Statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, 
and simvastatin); 
 Bile-acid sequestrants (cholestyramine, colesevelam and colestipol); 
 Fibrates (bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil); 
 Nicotinic acid or niacin; and  
 Ezetimibe.  
The patient's lipid profile, concomitant disease states, and the cost of therapy are 
some of the factors that needed to be considered when choosing drug therapy for the 
patient. Before the new ATP IV guideline was released, the patient’s overall lipid profile 
level (including LDL-C, HDL-C, and TG levels) informed the selection of 
pharmacotherapy using either statin monotherapy or combination therapy of statins and 
non-statin lipid-lowering agents (Table 2.7). [In the new ATP IV guideline, however, the 
selection of the appropriate level of statin intensity needed to prevent ASCVD is 
primarily based on the patient’s LDL-C level, with less emphasis placed on levels of 
HDL-C and TG. Furthermore, the use of non-statin lipid lowering medications may be 
recommended if the ASCVD risk-reduction benefits outweigh the potential for adverse 
                                                 
102 Fischer S, Schatz U, and Julius U. Current standards in diagnosis and therapy of hyperlipoproteinemia. 
Atheroscler Suppl. 2013;14(1):15-8; "Executive Summary of The Third Report of The National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III)." 
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effects: 1) in candidates for statin therapy who are statin-intolerant; and  2) in patients 
with high ASCVD risk (i.e., individuals with clinical ASCVD and age <75 years, 
individuals with baseline LDL-C ≥190mg/dL, and individuals aged 40-75 years with 
diabetes mellitus) who are receiving the maximum tolerated intensity of statin therapy but 
with inadequate therapeutic outcome].
103
 Table 2.8 gives a summary of the advantages 
and disadvantages of currently available lipid-lowering drugs, including their modes of 
action. 
Table 2.7: Lipid-Lowering Drug Selection Process in the ATP III Guideline  
Lipid Profile Monotherapy Combination Therapies 
High LDL-Ca + 
Normal HDLb + 
Normal TGc 
BAS or Niacind or Statin 
 
BAS + Niacind or 
BAS + Statin or 
Statin + Niacind,e 
High LDL-C + 
High TGe 
Intensify LDL-lowering 
therapy 
Statin + Niacind,f or 
Statin + Fibratesf 
High LDL-C + 
High TG (≥500 mg/dL)e 
Consider a combination therapy from Niacin,d Fibrates, 
and Statin 
High TG Niacind or 
Fibrates 
Niacind + Fibrates 
High LDL-C + 
Low HDL-C 
Niacind or 
Statin 
Statin + Niacind,e 
Source: Hyperlipidemia management. Lexicomp Online; 2013. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein 
cholesterol; TG, Triglycerides; BAS, Bile-acid sequestrants. 
aLDL-C <100mg/dL = optimal; 100-129mg/dL = near optimal; 130-159mg/dL = borderline 
high; 160-189mg/dL = high; ≥190mg/dL = very high. 
bHDL-C <40mg/dL = low; ≥60mg/dL = high or optimal. 
cTG <150mg/dL = normal; 150-199mg/dL = borderline high; 200-499mg/dL = high; 
≥500mg/dL = very high. 
dAvoid in diabetics. 
eEmphasize weight reduction and increased physical activity. 
fRisk of myopathy increases with combination. 
 
                                                 
103 Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines." 
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Table 2.8: Advantages, Disadvantages, and Modes of Action of Lipid-Lowering Therapeutic Agents 
Agent Mechanism of Action Advantages Disadvantages 
HMG-CoA reductase 
inhibitors or statins: 
-atorvastatin (Lipitor®) 
-fluvastatin (Lescol®) 
-lovastatin (Mevacor®) 
-pitavastatin (Livalo®) 
-pravastatin 
(Pravachol®) 
-rosuvastatin (Crestor®) 
-simvastatin (Zocor®) 
They inhibit HMG-CoA 
reductase enzyme, 
which is the rate limiting 
step of cholesterol 
synthesis in the liver 
-Produces greatest LDL-C 
reduction 
-Generally well-tolerated 
with convenient once a day 
dosing 
-Proven decrease in CVD 
morbidity and mortality 
Relatively expensive 
Bile acid sequestrants: 
-cholestyramine 
(Questran®) 
-colesevelam (Welchol®) 
-colestipol (Colestid®) 
 
Through disruption of 
bile-acid enterohepatic 
circulation, they prevent 
the reabsorption of bile-
acids from the guta 
-Good choice for those with 
high LDL-C levels 
-Decreases LDL-C up to 
50% when combined with 
a statin 
-Has low potential for 
systemic side effects 
-Good choice for younger 
patients 
-May increase TG 
-High potentials for adverse 
effects and drug interactions 
-Moderately expensive 
-Inconvenient dosing 
Niacin (Niaspan®) 
(also known as vitamin B3 
or nicotinic acid) 
Through their hydroxyl 
carboxylic acid receptor, 
they inhibit lipolysis and 
free fatty acids available 
for liver production of 
TG, VLDL-C and 
consequently LDL-C 
-Good choice for almost any 
lipid abnormality 
-Inexpensive 
-Greatest increase in HDL-C 
-High incidence of adverse effects 
-May adversely affect diabetes 
(with high dose >1.5 g/day) and 
gout 
-Niacin ER may not increase HDL-
C or decrease TG as well as 
immediate release niacin 
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Table 2.8: Advantages, Disadvantages, and Modes of Action of Lipid-Lowering Therapeutic Agents (Cont’d) 
Agent Mechanism of Action Advantages Disadvantages 
Fibric acid derivatives 
-bezafibrate (Bezalip®)b 
-ciprofibrate 
(Modalim®)c 
-clofibrated 
-fenofibrate (Tricor®) 
-gemfibrozil (Lopid®) 
-Induces lipoprotein 
lipolysis 
-Enhances hepatic fatty 
acid uptake and reduction 
of hepatic TG production 
-Causes increased 
removal of LDL particles 
Good choice in patients with 
high TG levels where niacin is 
contraindicated or not well 
tolerated 
Variable effects on LDL-C 
Ezetimibe (Zetia®)  Decreases intestinal 
absorption of cholesterol  
Produces additional 
cholesterol-lowering effects 
when combined with statins 
Effects similar to bile acid 
sequestrants 
Lomitapide (Juxtapid®)e Inhibits the microsomal 
triglyceride transfer 
protein necessary for liver 
assembly and secretion of 
VLDL 
-Decreases LDL-C up to 50% 
when combined with a statin  
-Decrease TG levels 
Produces high incidence of 
gastrointestinal adverse 
effects, especially if used 
with high-fat diet 
Source: Hyperlipidemia management. Lexicomp Online; 2013. 
Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl Coenzyme A; LDL-C, Low-density lipoprotein cholesterol; CVD, 
Cardiovascular disease; TG, Triglycerides; VLDL-C, Very low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein 
cholesterol; ER, Extended release. 
aBile acids are biosynthesized from cholesterol; thus, disruption of bile acid reabsorption will decrease cholesterol levels. 
bCanada brand. Drug is not currently available in the US. 
cGreat Britain brand. Drug is not currently available in the US. 
dDiscontinued in 2002 due to adverse effects. 
eApproved by the FDA in December 2012 as an orphan drug to reduce LDL-C, total cholesterol, and apolipoprotein B in patients 
with homozygous familial hypercholesterolemia. 
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2.2  SECTION II: STATINS  
2.2.1 History  
Early research on statin and cholesterol synthesis was attributed to Drs. Akira 
Endo and Masao Kuroda (who isolated the first non-commercial statin called compactin, 
and later renamed mevastatin, from cultures of the fungi Penicillium citrinum in 1976),
104
 
and two scientists, Drs. Joseph Goldstein and Michael Brown, who were awarded the 
Nobel Prize in Physiology or Medicine in 1985 for their work on cholesterol synthesis 
inhibition and the subsequent development of statin drugs.
105
 Two years later, lovastatin 
was developed by Merck, and became the first statin to be approved by the US Food and 
Drug Administration (FDA) in 1987.
106
 Over the next two and one half decades, the FDA 
granted approval to seven other statins that were either derived from fungi (i.e., 
pravastatin and simvastatin), or were synthetically manufactured (i.e., fluvastatin, 
atorvastatin, cerivastatin, rosuvastatin, and pitavastatin).
107
 All the aforementioned statins 
are currently approved for use in the US except cerivastatin. Cerivastatin (Baycol® and 
Lipobay®) was withdrawn from the US market in August 2001 by the manufacturer, 
Bayer.
108
 The withdrawal was due to several increasing reports of rhabdomyolysis, a 
                                                 
104 Endo A, Kuroda M, and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of 
cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976;29(12):1346-8. 
105 Brown MS, Faust JR, Goldstein JL, Kaneko I, and Endo A. Induction of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive 
inhibitor of the reductase. J Biol Chem. 1978;253(4):1121-8. 
106 Baliga RR. Statin prescribing guide. Vol. ed. Oxford: Oxford University Press, USA; 2010. 
107 Ibid.; Mukhtar RY, Reid J, and Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59(2):239-52. 
108 U.S. Food and Drug Administration. Safety: Baycol (cerivastatin sodium tablets) Aug 2001. 2001; 
Available at: 
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severe form of muscle breakdown that may lead to acute renal failure.
109
 Table 2.9 and 
Table 2.10 present the currently available statins and statin combination products in the 
US, respectively. 
Table 2.9: Currently Available Statins in the United States 
Statin Year 
Approved 
Brand 
Name 
Applicant First 
Generic 
Available 
Other 
Brands 
Lovastatin 1987 Mevacor® Merck  2001 Altoprev® 
Pravastatin 1991 Pravachol® Bristol-
Myers 
Squibb 
2006 NA 
Simvastatin 1991 Zocor® Merck  2006 NA 
Fluvastatin 1993 Lescol® Novartis 2012 NA 
Atorvastatin 1996 Lipitor® Pfizer 2011 NA 
Rosuvastatin 2003 Crestor® AstraZeneca NA NA 
Pitavastatin 2009 Livalo® Kowa Co. NA NA 
Cerivastatin 1998a Baycol®, 
Lipobay® 
Bayer A.G. NA NA 
Source: US Food and Drug Administration. Orange Book: Approved drug products with 
therapeutic equivalence evaluations; 2013.  
aWithdrawn from the US market in 2001. 
  
                                                                                                                                                 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm1722
68.htm. Accessed June 22, 2014. 
109 Lucas RA, Weathersby BB, Rocco VK, Pepper JM, and Butler KL. Rhabdomyolysis associated with 
cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy. 2002;22(6):771-4; Staffa JA, 
Chang J, and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-
40. 
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Table 2.10: Currently Available Statin Combination Products in the United 
States 
Drug Brand Name Generic 
Available? 
Applicant 
Lovastatin + niacin Advicor® No Abbvie 
Simvastatin + sitagliptin Juvisync® No MSD 
Simvastatin + ezetimibe Vytorin® No MSD Intl 
Simvastatin + niacin Simcor® No Abbvie 
Atorvastatin + amlodipine Caduet® Yes Pfizer 
Atorvastatin + ezetimibe Liptruzet® No Merck 
Source: US Food and Drug Administration. Orange Book: Approved drug products with 
therapeutic equivalence evaluations; 2013.  
Abbreviations: MSD, Merck Sharp Dohme.  
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2.2.2 Statin Utilization and Spending in the United States 
In the US, statins are among the most widely prescribed therapeutic class of 
drugs, with simvastatin (86.1 million) and atorvastatin (54.9 million) alone accounting for 
over 140 million dispensed prescriptions in 2012.
110
 Moreover, the best-selling statin 
used to be atorvastatin, marketed as Lipitor®
 
by Pfizer. However, due to the loss of 
Lipitor®
 
patent in November 30, 2011, the US non-discounted spending on atorvastatin 
(Lipitor® included) decreased to $2.3 billion in 2012. This amount is in contrast to $7.7 
billion of non-discounted spending that was attributed to Lipitor® alone in 2011.
111
 
Crestor®, a rosuvastatin brand marketed by AstraZeneca currently has the largest share 
of non-discounted spending, with $5.1 billion in sales in 2012.
112
 
2.2.3 Pharmacokinetic and Pharmacodynamic Properties  
The HMG-CoA (3-hydroxy-3-methylglutaryl Co-enzyme A) reductase inhibitors 
– commonly referred to as statins – have the same pharmacophore, which is a modified 
hydroxyglutaric acid component that is structurally similar to the endogenous substrate 
HMG-CoA on which they exert their effect.
113
 However, modification of the general ring 
structure confers on each statin a unique ring structure and substituents which 
considerably make their physicochemical properties (e.g., solubility, lipophilicity) differ. 
This in turn affects their pharmacokinetics (e.g., bioavailability, tissue distribution, 
                                                 
110 IMS Health Incorporated. Top-line market data. 2013; Available at: 
http://www.imshealth.com/portal/site/ims/menuitem.5ad1c081663fdf9b41d84b903208c22a/?vgnextoid=fbc
65890d33ee210VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed 8/27, 2013. 
111 Ibid. 
112 Ibid. 
113 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol. 2005;19(1):117-25. 
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protein binding, renal excretion, half-life), and pharmacodynamic properties (e.g., 
potency, efficacy, toxicity, adverse effect).
114
 Most statins have a generally low absolute 
bioavailability in the systemic circulation. This is indicative of their extensive first-pass 
metabolism in the liver. However, given that the liver is the target organ for statins, 
efficient first-pass uptake by the liver may be more important than high systemic 
bioavailability for statins to exert their anti-lipemic effects.
115
 Table 2.11 presents a 
summary of the pharmacokinetic properties of currently available statins. 
 
 
 
                                                 
114 Ibid. 
115 Ibid. 
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Table 2.11: Pharmacokinetic Properties of Currently Available Statins 
 Lovastatin Pravastatin Simvastatin Fluvastatin Atorvastatin Rosuvastatin Pitavastatin 
Lipophilicity Lipophilic Hydrophilic Lipophilic Lipophilic Lipophilic Hydrophilic Lipophilic 
Absolute 
bioavailability (%) 
<5 17 <5 24  
29 (ER) 
~14 ~20 51a 
Mean peak plasma 
concentration (hrs) 
2-4  
14 (ER)  
1-5 4 1  
3 (ER) 
1-2 3-5 1 
Onset of action 
(weeks) 
2 1-4 4-6 2-4 2-4 4 1-4 
Optimal time of 
dosing 
Evening (IR)  
Bedtime 
(ER) 
Bedtime Evening Bedtime Any time of 
day 
Any time of 
day 
Any time of 
day 
Effects of food on 
AUC 
Decreased Decreased Not 
significant 
Decreased Not 
significant 
Not  
significant 
Not 
significant 
Protein binding (%) >95 ~50 95 ~98 ≥98 88 >99 
CYP450 
metabolism? 
Isoenzyme 
Yes 
 CYP3A4 
No Yes 
CYP3A4 
Yes 
CYP2C9 
Yes 
CYP3A4 
Yes 
CYP2C9 
Limited  
UGT1A1 
Active metabolites? Yes No Yes Yes Yes Yes No 
Elimination route 
Urine (%) 
Feces (%) 
 
10 
83 
 
20 
70 
 
13 
60 
 
5 
90 
 
<2 
>98 
 
10 
90 
 
15a 
79a 
Half-life (hours) 0.5-3 1.8 0.5-3 <3  
9 (ER) 
~14 ~19 ~12 
Sources: Lexicomp Online; 2013. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol. 2005;19(1):117-125. 
Abbreviations: ER, Extended release tablet or capsule; IR, Immediate release tablet or capsule; AUC, Area under the concentration 
vs. time Curve; CYP450, Cytochrome P-450 enzyme system; UGT, Uridine 5´-diphosphate glucuronosyltransferase enzyme system. 
aEvaluated in oral solution that is not commercially available in the US. 
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2.2.4 Mechanism of Action 
Figure 2.1 graphically summarizes the major sites of action of statin in the 
cholesterol biosynthetic pathway. Statins reduce atherogenic lipoproteins primarily 
through competitive inhibition of HMG-CoA reductase.
116
  HMG-CoA reductase is an 
enzyme necessary for the conversion of HMG-CoA to mevalonate. The inhibition of 
mevalonate production is the rate-limiting step in the synthesis of cholesterol in the liver. 
Statins also exhibit their anti-lipemic actions through several secondary mechanisms of 
action that include “up-regulation” of the LDL-C receptor.117 The LDL-C receptor is the 
membrane receptor which recognizes, binds, and internalizes the circulating 
apolipoproteins which carry apo-B and apo-E on their surface. The LDL-C receptor up-
regulation leads to plasma clearance of cholesterol-rich LDL-C and, to a lesser extent, 
VLDL-C and IDL-C.
118
 Other statin actions include the reduction in hepatic synthesis 
and secretion of TG-rich lipoproteins,
119
 elevation of HDL-C, and inhibition of the 
Rho/Rho Kinase signaling pathway – an action believed to inhibit the development of the 
atherosclerosis process.
120
  
In addition to their anti-lipemic effects, statins also exert beneficial cardiovascular 
effects which are independent of their lipid-lowering effects. These additional properties, 
known as statin pleiotropic effects, are believed to improve endothelial function, stabilize 
                                                 
116 Baliga RR, Statin prescribing guide. 
117 Ibid. 
118 Ibid. 
119 Grundy SM. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia. 
Am J Cardiol. 1998;81(4A):1B-6B. 
120 Baliga RR, Statin prescribing guide. 
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atherosclerotic plaque, improve nitric oxide availability, decrease vascular inflammatory 
responses, and reduce smooth muscle proliferation and cholesterol accumulation.
121
 
Figure 2.1: Inhibition of Cholesterol Synthesis by Statins 
 
 
Source: Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent 
(pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll 
Cardiol. 2005;46(8):1425-1433. 
Abbreviations: HMG CoA, 3-hydroxy-3-methylglutaryl Coenzyme A; PP, pyrophosphate. 
 
                                                 
121 Ibid.; Ray KK, and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) 
effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1425-33. 
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2.2.5 Primary and Secondary Prevention of Cardiovascular Diseases 
Cardiovascular disease (e.g., CAD, CHD, and IHD) – which include a spectrum 
of diagnoses including angina pectoris, myocardial infarction, acute coronary syndrome, 
and sudden cardiac death – is one of the leading causes of death in the world and the 
United States.
122
 The high morbidity and mortality resulting from cardiovascular disease 
impose a heavy economic burden on America, and also negatively impacts the quality of 
life of Americans living with cardiovascular disease (CVD).
123
 
The aim of primary prevention using statins is to prevent the incidence of CHD 
through reduction of the risk factors associated with CHD. In contrast, the aim of 
secondary prevention is to reduce the incidence and prevalence of recurrent CHD in 
people with established CHD.
124
 The prevalence of CHD is high among Americans due 
to a combination of cholesterol-rich diets and CVD risk factors such as hypertension, 
tobacco use, diabetes, obesity, physical inactivity, and increasing age.
125
 
Primary and secondary prevention of dyslipidemia and CVD can be achieved by 
therapeutic lifestyle changes, use of LDL-lowering drugs, or both;
126
 however, differing 
results of LDL-C lowering is achieved depending on the method or combination of 
methods employed.   
                                                 
122 Roger VL et al., "Heart disease and stroke statistics--2012 update: a report from the American Heart 
Association." 
123 Chen J, and Rizzo JA. The economics of cardiovascular disease in the United States. Crit Care Clin. 
2012;28(1):77-88. 
124 "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report." 
125 Graham I et al., "Dyslipidemias in the prevention of cardiovascular disease: risks and causality." 
126 Angelico F et al., "Current ways of treating dyslipidemias to prevent atherosclerosis." 
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2.2.6 Efficacy of Therapeutic Lifestyle Changes  
Serum cholesterol lowering through dietary modification has been demonstrated 
through several primary
127
 and secondary
128
 prevention trials. Overall, these trials showed 
a positive trend of the efficacy of dietary modification to lower serum cholesterol. 
Furthermore, attestation to the effectiveness of lifestyle changes such as smoking 
cessation, increased physical activity, modification of diet, and weight reduction on 
reducing serum cholesterol are the basis for several evidence-based public health 
recommendations and guidelines, including the US Surgeon General’s Reports on Health 
Consequences of Smoking,
129
 Physical Activity Guidelines for Americans,
130
 Clinical 
Guidelines on Overweight and Obesity,
131
 and Dietary Guidelines for Americans.
132
 The 
                                                 
127 Hjermann I, Velve Byre K, Holme I, and Leren P. Effect of diet and smoking intervention on the 
incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy 
men. Lancet. 1981;2(8259):1303-10; Frantz ID, Jr., Dawson EA, Ashman PL, et al. Test of effect of lipid 
lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 1989;9(1):129-
35; Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, and Paavilainen E. Effect of cholesterol-lowering 
diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and 
women. Lancet. 1972;2(7782):835-8; The multiple risk factor intervention trial (MRFIT). A national study 
of primary prevention of coronary heart disease. JAMA. 1976;235(8):825-7. 
128 Ball KP, Hanington E, McAllen PM, et al. Low-fat diet in myocardial infarction: a controlled trial. 
Lancet. 1965;2:501-4; Leren P. The effect of plasma cholesterol lowering diet in male survivors of 
myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl. 1966;466:1-92. 
129 U.S. Department of Health and Human Services. "The Health Consequences of Smoking: A Report of 
the Surgeon General." 941 pages. Atlanta, GA: U.S. Department of Health and Human Services, Centers 
for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 
Office on Smoking and Health, 2004. 
130 U.S. Department of Health and Human Services. "Physical Activity Guidelines for Americans." 76 
pages. Washington, DC., 2008. 
131 National Institutes of Health. "Clinical guidelines on the identification, evaluation, and treatment of 
overweight and obesity in adults - the evidence report." 228 pages. Bethesda, MD: National Heart, Lung 
and Blood Institute, 1998; Clinical guidelines on the identification, evaluation, and treatment of overweight 
and obesity in adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-
209S. 
132 U.S. Department of Agriculture and U.S. Department of Health and Human Services. "Dietary 
Guidelines for Americans." 112 pages. Washington, DC: U.S. Government Printing Ofice, 2010. 
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NCEP/ATP III and the recently released ATP IV guidelines also affirm the validity of 
therapeutic lifestyle changes as the first-line therapy for primary and secondary 
prevention of dyslipidemia and cardiovascular diseases.
133
 
2.2.7 Efficacy of Statins in Primary Prevention 
 Several historic clinical trials have been conducted to examine the efficacy of 
statins and other non-statin lipid lowering drugs. Before the advent of statins, positive, 
but limited trends of major coronary events reduction were achieved by landmark clinical 
trials of non-statin drugs including clofibrate, gemfibrozil, and cholestyramine in the 
World Health Organization clofibrate trial,
134
 the Helsinki Heart Study gemfibrozil 
trials,
135
 and the Lipid Research Clinics cholestyramine trials,
136
 respectively. The 
superiority of statins at reducing LDL-C and relative risks of major coronary events, 
                                                 
133 "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report."; 
Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic 
cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines." 
134 A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from 
the Committee of Principal Investigators. Br Heart J. 1978;40(10):1069-118. 
135 Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in 
middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary 
heart disease. N Engl J Med. 1987;317(20):1237-45; Huttunen JK, Manninen V, Manttari M, et al. The 
Helsinki Heart Study: central findings and clinical implications. Ann Med. 1991;23(2):155-9; Huttunen JK, 
Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J 
Intern Med. 1994;235(1):31-9. 
136 "The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of 
coronary heart disease."; "Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to 
cholesterol lowering." 
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coronary mortality, and all-cause cardiovascular mortality has subsequently been 
demonstrated in several statin primary prevention trials.
137
  
Of the seven currently available statins, the LDL-C lowering efficacies of five 
statins – atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin – have been 
widely studied, while efficacy trials involving fluvastatin and pitavastatin are limited. 
The first major primary prevention statin trial – the West of Scotland Coronary 
Prevention Study (WOSCOPS) – demonstrated that a 40mg daily dose of pravastatin 
given to hypercholesterolemic men aged 45-64 years was able to decrease mean LDL-C 
by 26%; while major coronary events, coronary mortality, and all-cause mortality were 
decreased by 31 percent, 33 percent, and 22 percent, respectively.
138
 
The second major primary prevention statin trial – the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/ TexCAPS) – was not as successful as 
                                                 
137 Shepherd J et al., "Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group."; Downs JR et al., "Primary 
prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: 
results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study."; Major 
outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual 
care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). 
Ibid.2002;288(23):2998-3007; Shepherd J et al., "Pravastatin in elderly individuals at risk of vascular 
disease (PROSPER): a randomised controlled trial."; Sever PS, Dahlof B, Poulter NR, et al. Prevention of 
coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-
average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering 
Arm (ASCOT-LLA): a multicentre randomised controlled trial. Ibid.2003;361(9364):1149-58; Colhoun 
HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in 
type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised 
placebo-controlled trial. Ibid.2004;364(9435):685-96; Knopp RH, d'Emden M, Smilde JG, and Pocock SJ. 
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 
diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-
dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29(7):1478-85; Nakamura H et al., "Primary 
prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised 
controlled trial."; Ridker PM et al., "Rosuvastatin to prevent vascular events in men and women with 
elevated C-reactive protein." 
138 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Ibid.1995;333(20):1301-7. 
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WOSCOP, recording only significant decreases in mean LDL-C and major coronary 
events, but a non-significant difference in the number of coronary mortality between the 
treatment and placebo groups.
139
 In general, results from a majority of the primary 
prevention statin trials provide robust evidence to show that statins have high efficacy at 
reducing atherogenic lipoproteins such as LDL-C, TC, and TG. Statins have also been 
shown to be efficacious at reducing the relative risk for major cardiovascular outcomes 
while minimally increasing the levels of HDL-C, the anti-atherogenic lipoprotein. Table 
2.12 provide a summary of the major (i.e., large number of participants followed up for a 
relatively long period of time) primary prevention trials of statins. Table 2.13 and Table 
2.14 give a summary of the effects of statin treatment and lipid-lowering agents, 
respectively, on lipid profiles.  
                                                 
139 Downs JR et al., "Primary prevention of acute coronary events with lovastatin in men and women with 
average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis 
Prevention Study." 
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Table 2.12: Major Primary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and 
Mortality 
Trials Dates Follow
-up 
(years) 
N Treatment 
Dose/day 
Control  Baseline  
LDL-C 
(mg/dL)a 
LDL-C 
Change 
(%)b 
Major 
Coronary 
Events 
(%)c 
Coronary 
Mortality 
(%) 
All-cause 
Mortality 
(%) 
WOSCOPSd 1989-
1995 
4.9 6,595 Prava 
40mg 
Placebo 192 -26* -31* -32* -22* 
AFCAPS/ 
TexCAPSe 
1990-
1997 
5.2 6,605 Lova 
20-40mg 
Placebo 150 -23* -37* NS NS 
ALLHAT- 
LLTf 
1994-
2002 
4.8 10,355 Prava 
40mg 
Usual 
Care 
146 -29* NS NS NS 
PROSPERg 1997-
2001 
3.2 5,804 Prava 
40mg 
Placebo 147 -34* -15* -24* NA 
ASCOT-
LLAh 
1998-
2002 
3.3 10,305 Atorva 
10mg 
Placebo 132 -32* -36* NS NS 
CARDSi 1997-
2003 
3.9 2,838 Atorva 
10mg 
Placebo 117 -31* -37* NA NS 
MEGAj 1994-
2004 
5.3 7,832 Prava 
10-20mg 
+ diet 
Diet + 
Usual 
Care 
157 -18* -33* NS NS 
ASPENk 1996-
2003 
4.0 2,410 Atorva 
10mg 
Placebo 114 -29* NS NS NA 
JUPITERl 2003-
2008 
1.9 17,802 Rosuva20
mg 
Placebo 108 -49* -44* -47* -20* 
HYRIMm NA 4 568 Fluva 
40mg 
Placebo 150 -22* -0.029# NS NS 
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Table 2.12: Major Primary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and 
Mortality (Cont’d) 
Source:  Kizer JR, Madias C, Wilner B, et al. Relation of different measures of low-density lipoprotein cholesterol to risk of 
coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol. 
2010;105(9):1289-1296; Published articles for each trial results; and TrialResultsCenter.org. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; NS, Not statistically significant; NA, Not applicable; Atorva, 
Atorvastatin; Fluva, Fluvastatin; Lova, Lovastatin; Prava, Pravastatin; Rosuva, Rosuvastatin. 
*Relative risk reduction is statistically significant at p<0.05.  
#Absolute risk reduction is statistically significant at p<0.05. 
aMean baseline LDL-C for the whole group. 
bLDL-C percentage change from baseline to follow-up for treatment only. 
cMajor coronary events include fatal and non-fatal myocardial infarction or stroke, coronary revascularization, coronary artery 
bypass surgery, and unstable angina. 
dShepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 
WOSCOP Study Group. N Engl J Med. 1995;333(20):1301-1307 [WOSCOPS, West of Scotland Coronary Prevention Study: West 
of Scotland and Glasgow, men, hypercholesterolemic, aged 45-64 years]. 
eDowns JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with 
average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622 [AFCAPS/TexCAPS, Air Force/Texas 
Coronary Atherosclerosis Prevention Study: Texas, 2 sites – Lackland Air Force Base in San Antonio and University of North 
Texas Health Science Center in Fort Worth, men aged 45-73 years, and women aged 55-73 years]. 
fMajor outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The 
ALLHAT-LLT. JAMA. 2002;288(23):2998-3007 [ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial: US, Puerto Rico, US Virgin Islands, and Canada, 513 sites, men and women, moderately 
hypercholesterolemic, hypertensive, 55+ years, mean age=66 years]. 
gShepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised 
controlled trial. Lancet. 2002;360(9346):1623-1630 [PROSPER, Pravastatin in Elderly Individuals at Risk of Vascular Disease: 
Scotland, Ireland, and Netherlands, men and women, aged 70-82 years]. 
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Table 2.12: Major Primary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and 
Mortality (Cont’d) 
hSever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who 
have average or lower-than-average cholesterol concentrations, in the ASCOT-LLA: a multicentre randomised controlled trial. 
Lancet. 2003;361(9364):1149-1158 [ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm: United 
Kingdom, men and women, non-dyslipidemic, hypertensive, aged 40-79 years]. 
iColhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes 
in the CARDS: multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696 [CARDS, Collaborative 
Atorvastatin Diabetes Study: United Kingdom & Ireland with 132 sites, 5 Nordic countries, men and women, type 2 diabetic, 
non-hyperlipidemic, aged 40-75 years]. 
jNakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a 
prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163 [MEGA, Management of Elevated Cholesterol in 
the Primary Prevention Group of Adult Japanese: Japan, 924 sites, men and women, hypercholesterolemic, aged 40-70 years]. 
kKnopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in 
subjects with type 2 diabetes: the ASPEN. Diabetes Care. 2006;29(7):1478-1485 [ASPEN, Atorvastatin Study for Prevention of 
Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus: 14 countries, 70 centers, men and women, type 
2 diabetic, low LDL-C, aged 40-75 years]. 
lRidker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein. N Engl J Med. 2008;359(21):2195-2207 [JUPITER, Justification for the Use of Statins in Prevention: an Intervention 
Trial Evaluating Rosuvastatin: 26 countries, 1315 sites, men 50+ years, women 60+ years, high C-reactive protein levels, non-
hyperlipidemic). 
mAnderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid 
intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis. 
2005;178(2):387-397 [HYRIM, Hypertension High Risk Management: Norway, men and women aged 40-74 years with 
hypertension]. 
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Table 2.13: The Effect of Treatment with Different Statins on Lipid Profiles 
 % Change in Lipid Profile 
Statin ↓LDL-C ↓TC ↑HDL-C ↓TG 
Lovastatin 29-48 21-36 7-8 2-13 
Pravastatin 20-30 15-22 3-6 8-13 
Simvastatin 28-46 20-33 5-7 12-18 
Fluvastatin 17-23 13-19 0.9 5-13 
Atorvastatin 37-51 27-39 2-6 20-28 
Rosuvastatin 46-55 33-40 8-10 20-26 
Pitavastatin 39-44 28-32 4-6 14-19 
Source:  Ewang-Emukowhate M, Wierzbicki AS. Lipid-lowering agents. J Cardiovasc 
Pharmacol Ther. 2013. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; TC, Total cholesterol; HDL-C, 
High- density lipoprotein cholesterol; TG, Triglycerides. 
 
Table 2.14: Effects of Different Doses of Lipid-Lowering Agents on Lipid 
Profiles 
Drug 
 
Dose/day 
 
Effect on  
LDL-C 
(%) 
Effect on 
HDL-C 
(%) 
Effect on TG 
(%) 
STATINS 
Atorvastatin 10 mg 
20 mg 
40 mg 
80 mg 
-39 
-43 
-50 
-60 
+6 
+9 
+6 
+5 
-19 
-26 
-29 
-37 
Fluvastatin 20 mg 
40 mg 
80 mg 
-22 
-25 
-36 
+3 
+4 
+6 
-12 
-14 
-18 
Lovastatin 10 mg 
20 mg 
40 mg 
80 mg 
-21 
-24 
-30 
-40 
+5 
+7 
+7 
+9.5 
-10 
-10 
-14 
-19 
Pitavastatin 1 mg 
2 mg 
4 mg 
-32 
-36 
-43 
+8 
+7 
+5 
-15 
-19 
-18 
Pravastatin 10 mg 
20 mg 
40 mg 
80 mg 
-22 
-32 
-34 
-37 
+7 
+2 
+12 
+3 
-15 
-11 
-24 
-19 
 
54 
 
Table 2.14: Effects of Different Doses of Lipid-Lowering Agents on Lipid 
Profiles (Cont’d) 
Drug 
 
Dose/day 
 
Effect on 
LDL-C 
(%) 
Effect on 
HDL-C 
(%) 
Effect on TG 
(%) 
Rosuvastatin 5 mg 
10 mg 
20 mg 
40 mg 
-45 
-52 
-55 
-63 
+13 
+14 
+8 
+10 
-35 
-10 
-23 
-28 
Simvastatin 5 mg 
10 mg 
20 mg 
40 mg 
80 mg 
-26 
-30 
-38 
-41 
-47 
+10 
+12 
+8 
+13 
+16 
-12 
-15 
-19 
-28 
-33 
BILE ACID SEQUESTRANTS 
Cholestyramine 4-24 g -15 to -30 +3 to +5 +0 to +20 
Colesevelam 6 tablets 
7 tablets 
-15 
-18 
+3 
+3 
+10 
+9 
Colestipol 7-30g -15 to -30 +3 to +5 +0 to +20 
FIBRIC ACID DERIVATIVES 
Fenofibrate 67-200 mg -20 to -31 +9 to +14 -30 to -50 
Gemfibrozil 600 mg twice 
daily 
-5 to -10a +10 to +20 -40 to -60 
2-AZETIDINONE 
Ezetimibe 10 mg -15 to -20 +1 to +4 -5 to -8 
OMEGA-3-ACID ETHYL ESTERS 
 4 g +44.5 +9.1 -44.9 
MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN (MTP) INHIBITOR 
Lomitapide 5-60 mg -40 -7 -45 
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Table 2.14: Effects of Different Doses of Lipid-Lowering Agents on Lipid 
Profiles (Cont’d) 
Drug 
 
Dose/day 
 
Effect on 
LDL-C 
(%) 
Effect on 
HDL-C 
(%) 
Effect on TG 
(%) 
COMBINATION PRODUCTS 
Ezetimibe/Simvastatin 10/10 mg 
10/20 mg 
10/40 mg 
10/80 mg 
-45 
-52 
-55 
-60 
+8 
+10 
+6 
+6 
-23 
-24 
-23 
-31 
Niacin/Lovastatin 1000/20 mg 
1000/40 mg 
1500/40 mg 
2000/40 mg 
-30 
-36 
-37 
-42 
+20 
+20 
+27 
+30 
-32 
-39 
-44 
-44 
Niacin/Simvastatin 1000/20 mg 
1000/40 mg 
2000/20 mg 
2000/40 mg 
-12 
-7 
-14 
-5 
+21 
+15 
+29 
+24 
-27 
-23 
-38 
-32 
Source: Hyperlipidemia management. Lexicomp Online; 2013. 
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein 
cholesterol; TG, Triglycerides. 
a
May increase LDL in some patients. 
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2.2.8 Efficacy of Statins in Secondary Prevention  
 People with established CHD are at very high risk for recurrent CVD events.
140
 
Several notably large secondary prevention statin trials provide strong evidence for the 
benefit of cholesterol lowering therapy using statins in persons with established CHD.
141
 
Results from these and other statin trials provide evidence of the efficacy of statins at 
reducing LDL-C, with an accompanied reduction in cardiovascular morbidity, mortality, 
and all-cause mortality. LDL-lowering using statins has been shown to produce 
significant cardiovascular benefit without regard to patients’ gender, age, diabetes, 
smoking, and hypertension status.
142
 In patients with CHD, LDL-lowering has been 
                                                 
140 "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report." 
141 "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the 
Scandinavian Simvastatin Survival Study (4S)."; Sacks FM, Pfeffer MA, Moye LA, et al. The effect of 
pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. 
Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9; Prevention of 
cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range 
of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) 
Study Group. Ibid.1998;339(19):1349-57; "Results of the low-dose (20 mg) pravastatin GISSI Prevenzione 
trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? 
GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto 
Miocardico)."; "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-
risk individuals: a randomised placebo-controlled trial."; Athyros VG, Papageorgiou AA, Mercouris BR, et 
al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in 
secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease 
Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220-8; LaRosa JC et al., "Intensive lipid 
lowering with atorvastatin in patients with stable coronary disease."; Pedersen TR et al., "High-dose 
atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL 
study: a randomized controlled trial."; Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose 
atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59; Search Study 
Collaborative Group, Bowman L, Armitage J, Bulbulia R, Parish S, and Collins R. Study of the 
effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a 
randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007;154(5):815-23; Kjekshus 
J et al., "Rosuvastatin in older patients with systolic heart failure." 
142 Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, and Thorgeirsson G. Cholesterol 
lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup 
analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614-20; Goldberg 
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shown to cause a reduction in the relative risk of stroke,
143
 improvement of angina and 
myocardial perfusion,
144
 and decrease in the need for subsequent coronary 
revascularization.
145
 
                                                                                                                                                 
RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and 
glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the 
cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98(23):2513-9; 
Sacks FM et al., "The effect of pravastatin on coronary events after myocardial infarction in patients with 
average cholesterol levels. Cholesterol and Recurrent Events Trial investigators."; Byington RP, Jukema 
JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of 
clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92(9):2419-25; 
Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, and Lesperance J. Effects of cholesterol 
lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis 
Intervention Trial (CCAIT) substudy. Ibid.:2404-10; Kjekshus J, and Pedersen TR. Reducing the risk of 
coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 
1995;76(9):64C-68C; Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women 
and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian 
Simvastatin Survival Study (4S). Circulation. 1997;96(12):4211-8. 
143 "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease 
and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic 
Disease (LIPID) Study Group."; "Randomised trial of cholesterol lowering in 4444 patients with coronary 
heart disease: the Scandinavian Simvastatin Survival Study (4S)."; Sacks FM et al., "The effect of 
pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. 
Cholesterol and Recurrent Events Trial investigators."; Crouse JR, Byington RP, Hoen HM, and Furberg 
CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997;157(12):1305-10; 
Hebert PR, Gaziano JM, Chan KS, and Hennekens CH. Cholesterol lowering with statin drugs, risk of 
stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278(4):313-21. 
144 Kjekshus J and Pedersen TR, "Reducing the risk of coronary events: evidence from the Scandinavian 
Simvastatin Survival Study (4S)."; Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P. 
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary 
vasomotion. N Engl J Med. 1995;332(8):488-93; Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, 
and van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression 
Growth Evaluation Statin Study (REGRESS). Circulation. 1997;96(2):429-35; Pedersen TR, Kjekshus J, 
Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin 
survival study (4S). Am J Cardiol. 1998;81(3):333-5; Gould AL, Rossouw JE, Santanello NC, Heyse JF, 
and Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 
1998;97(10):946-52. 
145 "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease 
and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic 
Disease (LIPID) Study Group."; The effect of aggressive lowering of low-density lipoprotein cholesterol 
levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass 
grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336(3):153-62; 
"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian 
Simvastatin Survival Study (4S)."; Sacks FM et al., "The effect of pravastatin on coronary events after 
myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial 
investigators."; Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of 
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Table 2.15 provides a summary of the results of major secondary prevention trials 
of statins.  
                                                                                                                                                 
aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post 
coronary artery bypass graft trial. Post CABG Investigators. Circulation. 2000;102(2):157-65. 
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Table 2.15: Major Secondary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and 
Mortality 
Trials Dates Follow-
up 
(years) 
Sample 
Size 
Treatment 
Dose/day 
Control  Baseline  
LDL-C 
(mg/dL)a 
LDL-C 
Change 
(%)b 
Major 
Coronary 
Events 
(%)c 
Coronary 
Mortality 
(%) 
All-cause 
Mortality 
(%) 
4Sd 1988-
1994 
5.4 4,444 Simvastatin 
20-40mg 
Placebo 188 -35* -34* -42* -30* 
CAREe 1989-
1996 
5.0 4,159 Pravastatin 
40mg 
Placebo 139 -30* -25* -24* NS 
LIPIDf 1990-
1997 
6.1 9,014 Pravastatin 
40mg 
Placebo 150 -25* -29* -24* -22* 
GISSI-Pg 1993-
1996 
1.9 4,271 Pravastatin 
20mg 
Usual care 152 -15* NS -40* NS 
HPSh 1994-
2001 
5.0 20,536 Simvastatin 
40mg 
Placebo 131 -41* -26* -17* -12* 
GREACEi 1998-
2001 
3.0 1,600 Atorvastatin 
10-80mg 
Usual care 179 -46* -51* -42* -42* 
LIPSj 1998-
2002 
3.8 1,677 Fluvastatin 
40mg 
Placebo 131 -26* NS NS NS 
TNTk 1998-
2005 
4.9 10,001 Atorvastatin 
80mg 
Atorvastatin 
10mg 
152 -49* -20* -20* NS 
SPARCLl 1998-
2005 
4.9 4,731 Atorvastatin 
80mg 
Placebo 133 -45* NS NS NS 
SEARCHm 1998-
2008 
6.7 12,064 Simvastatin 
80mg 
Simvastatin 
20mg 
97 -11* NS NS NS 
IDEALn 1999-
2005 
4.8 8,888 Atorvastatin 
80mg 
Simvastatin 
20-40mg 
122 -34* -18* NS NS 
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Table 2.15: Major Secondary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and Mortality 
(Cont’d) 
CORONAo 2003-
2007 
2.8 5001 Rosuvastatin 
10mg 
Placebo 137 -45* NS NS NS 
JAPAN-
ACSp 
2005-
2007 
1.0 307 Pitavastatin 
4mg 
Atorvastatin 
20mg 
131 -20* NS NA NA 
Source: Kizer JR, Madias C, Wilner B, et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary 
artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol. 2010;105(9):1289-1296; 
Published articles for each trial results; and TrialResultsCenter.org.  
Abbreviations: LDL-C, Low-density lipoprotein cholesterol; NS, Not statistically significant; NA, Not applicable. 
*Relative risk reduction is statistically significant at p<0.05. 
aMean baseline LDL-C for the whole group. 
bLDL-C percentage change from baseline to follow-up for treatment only. 
cMajor coronary events include fatal and non-fatal myocardial infarction or stroke, coronary revascularization, coronary artery 
bypass surgery, and unstable angina. 
dRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the 4S Group. Lancet. 
1994;344(8934):1383-1389 [4S, Scandinavian Simvastatin Survival Study: 5 Nordic countries, 94 sites, men and women aged 
35-69 years, history of angina pectoris and MI, myocardial infarction]. 
eSacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with 
average cholesterol levels (CARE Trial investigators). N Engl J Med. 1996;335(14):1001-1009 [CARE, Cholesterol and 
Recurrent Events trial: US and Canada, 80 centers, men and women aged 21-75 years, history of acute MI]. 
fPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of 
initial cholesterol levels (LIPID Study Group). N Engl J Med. 1998;339(19):1349-1357 [LIPID, Long-Term Intervention with 
Pravastatin in Ischaemic Disease: Australia and New-Zealand, 87 centers, men and women aged 31-75 years, history of MI and 
unstable angina]. 
gResults of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do 
stopped trials contribute to overall knowledge? GISSI-P Investigators. Ital Heart J. 2000;1(12):810-820 [GISSI-P, Gruppo 
Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Prevenzione: Italy, men and women with history of acute 
MI]. 
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Table 2.15: Major Secondary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and Mortality 
(Cont’d) 
iAthyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program 
goal versus 'usual' care in secondary coronary heart disease prevention (The GREACE study). Curr Med Res Opin. 
2002;18(4):220-228 [GREACE, GREek Atorvastatin and Coronary-heart-disease Evaluation: Greece, men and women, mean 
age of 59 years, history of MI or CHD].  
jSerruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous 
coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-3222 [LIPS, Lescol Intervention Prevention 
Study: Europe, Canada and Brazil, 77 centers, men and women aged 18-80 years, history of angina and silent ischemia with 
first percutaneous coronary intervention]. 
kLaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl 
J Med. 2005;352(14):1425-1435 [TNT, Treating to New Targets clinical trial: 14 countries, 256 centers, men and women aged 
35-75 years, history of chronic coronary artery disease, CAD]. 
lAmarenco P, Bogousslavsky J, Callahan A, III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 
2006;355(6):549-559 [SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels: 25 countries, 130 locations, 
men and women aged 18 years and older, history of stroke or transient ischemia].  
mSearch Study Collaborative Group, Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. SEARCH: characteristics of a randomized 
trial among 12064 myocardial infarction survivors. Am Heart J. 2007;154(5):815-823 [SEARCH, Study of the Effectiveness of 
Additional Reductions in Cholesterol and Homocysteine: UK, 88 centers, men and women aged 18-80 years, history of MI]. 
 nPedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after 
myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445 [IDEAL, Incremental 
Decrease in End Points Through Aggressive Lipid Lowering: 5 Nordic countries, 190 centers, men and women aged 18-80 
years, history of MI]. 
oKjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-
2261 [CORONA, Controlled Rosuvastatin Multinational Study in Heart Failure: 21 countries, 378 centers, men and women 
aged 60 years and older, history of systolic heart failure]. 
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Table 2.15: Major Secondary Prevention Statin Trials and Effects on LDL-C and Cardiovascular Morbidity and Mortality 
(Cont’d) 
pHiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with 
acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin 
versus atorvastatin (JAPAN-ACS study). J Am Coll Cardiol. 2009;54(4):293-302 [JAPAN-ACS, Japan Assessment of Pitavastatin 
and Atorvastatin In Acute Coronary Syndrome: Japan, 33 centers, men and women aged 20 years and older, history of acute 
coronary syndrome]. 
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2.2.9 Efficacy of Statin Dosage Intensity in Primary and Secondary 
Prevention 
The intensity of statin dosing is believed to have a direct relationship with the 
magnitude of the lipid modifying and cardiovascular benefit of statins.
146
 Overall, 
evidence from RCTs indicates that high-intensity statins reduce ASCVD risk more than 
moderate-intensity or low-intensity statins in primary and secondary prevention of 
cardiovascular disease.
147
 For example, the Treating to New Target (TNT) trial 
comparing the efficacy of daily doses of atorvastatin 80mg and 10mg showed significant 
reductions in LDL-C, major coronary events, and coronary mortality in the atorvastatin 
80mg group compared to the atorvastatin 10mg group.
148
 However, the effectiveness of 
intensive statin dosing is more correlated with LDL-C reduction than with improvement 
of cardiovascular outcomes as found in other trials.
149
 
                                                 
146 Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus 
atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-
60; Jones P, Kafonek S, Laurora I, and Hunninghake D. Comparative dose efficacy study of atorvastatin 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the 
CURVES study). Ibid.1998;81(5):582-7; Betteridge J. Pitavastatin - results from phase III & IV. 
Atheroscler Suppl. 2010;11(3):8-14. 
147 Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines." 
148 LaRosa JC et al., "Intensive lipid lowering with atorvastatin in patients with stable coronary disease."; 
ibid. 
149 Armitage J et al., "Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 
12,064 survivors of myocardial infarction: a double-blind randomised trial."; Pedersen TR et al., "High-
dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the 
IDEAL study: a randomized controlled trial." 
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2.2.10 Statin Dosage and Administration  
 Several primary and secondary prevention statin trials have demonstrated 
scientific evidence for usage of statins in various disease conditions. Statins often achieve 
clinical efficacy at different doses, with higher doses achieving greater LDL-C reduction 
but with greater possibility of side effects. The Table 2.16 provides a summary of the 
dosage and administration schedule of currently available statins and statin combination 
products, while Table 2.17 provides a summary of dosage equivalents for statins.  
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Table 2.16: Statin Dosage and Administration 
Statin US Brand 
Names 
FDA-Approved 
Indicationsa 
Starting 
Dose  
(mg/day)b,c 
Maximum 
Dose 
(mg/day)b,c 
Available 
Strength 
(mg)  
Administration 
Considerationsd,e,f 
Lovastatin Mevacor® 
Altoprev® 
 
 
-Primary and 
secondary prevention 
of CAD 
-Primary 
hypercholesterolemia 
-Heterozygous 
familial 
hypercholesterolemia 
in pediatric patients 
(10-17 years) 
20  
20-60 (ER) 
 
80  
60 (ER) 
10, 20, 40 (generic) 
20, 40 (Mevacor®) 
20,40, 60 (ER-
Altoprev®) 
 
-Administer 
immediate release 
tablet with the 
evening meal 
-Administer extended 
release tablet at 
bedtime; do not crush 
or chew. 
Pravastatin Pravachol® 
 
-Primary and 
secondary prevention 
of CAD. 
-Primary 
hypercholesterolemia 
-Heterozygous 
familial 
hypercholesterolemia 
in pediatric patients 
(8-18 years) 
10-80 80 10, 20, 40, 80 
(generic) 
20, 40, 80 
(Pravachol®) 
-May be taken without 
regard to meals 
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Table 2.16: Statin Dosage and Administration (Cont’d) 
Statin US 
Brand 
Names 
FDA-Approved 
Indicationsa 
Starting 
Dose 
(mg/day)b,c 
Maximum 
Dose 
(mg/day)b,c 
Available 
Strength 
(mg)  
Administration 
Considerationsd,e,f 
Simvastatin Zocor® 
 
-Secondary 
prevention of CHD to 
reduce morbidity, 
mortality and stroke 
-Primary 
hypercholesterolemia 
-Homozygous familial 
hypercholesterolemia 
-Heterozygous 
familial 
hypercholesterolemia  
5-40 80g 5, 10, 20, 40, 80 
(generic and 
Zocor®) 
-May be taken without 
regard to meals 
-Better taken in the 
evening 
 
Fluvastatin Lescol® 
Lescol-
XL® 
-Primary and 
secondary prevention 
of CAD 
-Primary 
hypercholesterolemia 
(heterozygous familial 
and non-familial) 
-Mixed dyslipidemia 
-Heterozygous 
familial 
hypercholesterolemia 
in pediatric patients 
(10-16 years) 
-Diabetic dyslipidemia 
20 80 (XL) 
40mg bid  
20, 40 (generic and 
Lescol®) 
80 (Lescol-XL®) 
-May be taken without 
regard to meals (food 
reduces rate but not 
the extent of 
absorption) 
-Should be given 2 
hours after a bile-acid 
sequestrants or niacin  
-Do not break, chew, or 
crush extended release 
tablets; do not open 
capsules 
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Table 2.16: Statin Dosage and Administration (Cont’d) 
Statin US Brand 
Names 
FDA-Approved 
Indicationsa 
Starting 
Dose 
(mg/day)b,c 
Maximum 
Dose 
(mg/day)b,c 
Available 
Strength 
(mg)  
Administration 
Considerationsd,e,f 
Atorvastatin Lipitor® 
 
-Primary and 
secondary prevention 
of CAD 
-Primary 
hypercholesterolemia 
(heterozygous familial 
and non-familial) 
-Heterozygous familial 
hypercholesterolemia 
in pediatric patients 
(10-17 years) 
10-80 80 10, 20, 40, 80 
(generic and 
Lipitor®) 
May be taken 
without regard to 
meals at any time of 
day 
 
 
Rosuvastatin Crestor® 
 
-Primary and 
secondary prevention 
of CAD 
-Primary 
hypercholesterolemia 
-Increase HDL-C 
-Primary 
dysbetalipoproteinemia 
-Homozygous familial 
hypercholesterolemia 
-Heterozygous familial 
hypercholesterolemia 
in pediatric patients 
(10-17 years) 
5-40 40 5, 10, 20, 40 
(Crestor®) 
May be taken 
without regard to 
meals at any time of 
day 
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Table 2.16: Statin Dosage and Administration (Cont’d) 
Drug/ 
Statin 
US Brand 
Names 
FDA-Approved 
Indicationsa 
Starting 
Dose 
(mg/mg 
per day)b,c 
Maximum 
Dose 
(mg/mg 
per day)b,c 
Available 
Strength 
(mg/mg)  
Administration 
Considerationsd,e,f 
Pitavastatin Livalo® 
 
-Primary 
hyperlipidemia   
-Mixed dyslipidemia 
2 4 1, 2, 4 (Livalo®) May be administered 
with or without food 
and taken without 
regard to time of day 
Statin Combination Formulations 
 Niacin/ 
Lovastatin 
 
Advicor® (See lovastatin) 
 
500/20 2000/40 500/20, 750/20, 
1000/20, 1000/40 
(Advicor®)h 
Should be taken at 
bedtime with a low-
fat snack; Swallowed 
whole; do not crush 
or chew 
Ezetimibe/ 
Simvastatin 
Vytorin® (See simvastatin) 10/10-40 10/80g 10/10, 10/20, 
10/40, 10/80 
(Vytorin®) 
(See simvastatin) 
Should be taken ≥2 
hours before or ≥4 
hours after 
administration of a 
bile acid sequestrant 
Niacin/ 
Simvastatin 
Simcor® (See simvastatin) 500/20-40 2000/40 500/20, 500/40, 
750/20, 1000/20, 
1000/40 
(Simcor®)h 
(See 
Niacin/Lovastatin) 
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Table 2.16: Statin Dosage and Administration (Cont’d) 
Drug/ 
Statin 
US Brand 
Names 
FDA-Approved 
Indicationsa 
Starting 
Dose 
(mg/mg 
per day)b,c 
Maximum 
Dose 
(mg/mg 
per day)b,c 
Available 
Strength 
(mg/mg)  
Administration 
Considerationsd,e,f 
Statin Combination Formulations (Cont’d) 
Sitagliptin/ 
Simvastatin 
Juvisync® (See simvastatin) 
-Type 2 diabetes 
100/40 NA 50/10, 50/20, 
50/40, 100/10, 
100/20, 100/40 
(Juvisync®) 
(See simvastatin) 
Administer in the 
evening. Do not split 
or divide tablet 
Amlodipine/ 
Atorvastatin 
Caduet® (See atorvastatin) 
-Hypertension 
-Chronic stable angina 
-Prinzmetal's angina  
5-10/10-80 10/80 2.5/10, 2.5/20, 
2.5/40, 5/10, 5/20, 
5/40, 5/80, 10/10, 
10/20, 10/40, 
10/80 (generic and 
Caduet®) 
(See atorvastatin) 
Ezetimibe/ 
Atorvastatin 
Liptruzet® (See atorvastatin) 10/10-80 10/80 10/10, 10/20, 
10/40, 10/80 
(Liptruzet®) 
(See atorvastatin) 
Administer ≥2 hours 
before or ≥4 hours 
after bile acid 
sequestrants 
Source: Lexicomp Online, 2013. US Food and Drug Administration. National Drug Code query-active ingredient, 2013. 
Abbreviations: FDA, US Food and Drug Administration; LDL-C, Low-density lipoprotein cholesterol; XL or ER, Extended release tablet or 
capsule; CAD, Coronary artery disease; CHD, Coronary heart disease; NA, Information is not available. 
aUse in indications is to reduce blood levels of total cholesterol, LDL-C, apolipoprotein B, and triglyceride. 
bDoses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient 
response; adjustments should be made at intervals of 4 weeks or more. 
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Table 2.16: Statin Dosage and Administration (Cont’d) 
cAll adult dosing information; dosage forms are immediate release unless otherwise stated. 
dAvoid large quantities of grapefruit juice (>1 quart/day) and red yeast rice (contains an estimated 2.4 mg lovastatin per 600 mg rice). 
eConsumption of large amounts of ethanol may increase the risk of liver damage with statins. 
fSt. John's wort may decrease the bioavailability of statins; avoid. 
gIf patient is unable to achieve LDL-C goal using the 40 mg dose of simvastatin, increasing to 80 mg dose is not recommended. Instead, 
switch patient to an alternative LDL-C-lowering treatment providing greater LDL-C reduction. 
hAll niacin doses are in extended release form. 
 
 
 
Table 2.17: Statin Dosage Equivalency in Patients with Hypercholesterolemia* 
Dose  
Level 
Fluvastatin 
(mg) 
Pravastatin 
(mg) 
Lovastatin 
(mg) 
Pitavastatin 
(mg) 
Simvastatin 
(mg) 
Atorvastatin 
(mg) 
Rosuvastatin 
(mg) 
 % LDL-C 
Reduction 
1 20 10 10     15-20 
2 40 20 20  5-10   21-29 
3 80-XL 40-80 40 1-2 20 10  30-38 
4   80 4 40 20 5-10 39-47 
5     80 40 20 48-54 
6      80 40 55-59 
Source: Texas Diabetes Council. Lipid algorithm for type 1 and type 2 diabetes mellitus in adults; 2011.  
*Information not completely based on head to head comparison. 
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2.2.11 Complications, Contraindications, and Adverse Effects 
Statins are generally well tolerated and are believed to have minimal adverse 
effects.
150
 However, statin-associated adverse events including elevations of liver 
enzymes, myopathies, and rhabdomyolysis demands special monitoring and clinical 
considerations.
151
 Discontinuation and/or reduction of the statin dose usually lead to 
resolution of these side effects.
152
 Recently, however, debate has focused on the possible, 
negative long-term effects of statin treatment on cognitive decline,
153
 colorectal cancer 
risk,
154
 and diabetes mellitus.
155
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cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials."; Rajpathak 
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mellitus: a review of the literature. Can J Cardiol. 2012;28(5):581-9; Jukema JW, Cannon CP, de Craen AJ, 
Westendorp RG, and Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll 
Cardiol. 2012;60(10):875-81; Kaski JC. High dose statin treatment and new onset diabetes. Cardiovascular 
drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 
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2012; Preiss D, and Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr 
Opin Lipidol. 2011;22(6):460-6; Preiss D, and Sattar N. Pharmacotherapy: Statins and new-onset diabetes--
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Muscle Toxicity and Elevation of Liver Enzymes 
 Despite their cardiovascular benefit in primary and secondary prevention of CVD, 
statins as a therapeutic class are associated with clinically significant muscle problems 
that include: (1) myopathy (i.e., a general term referring to any disease of muscles); (2) 
myalgia (i.e., muscle ache or weakness without creatine kinase elevation); (3) myositis 
(i.e., muscle symptoms with increased creatine kinase levels); and (4) rhabdomyolysis 
(i.e., muscle symptoms with marked creatine kinase elevation that is substantially greater 
than 10 times the upper limit of normal, and with creatinine elevation that is accompanied 
by brown urine and urinary myoglobin).
156
 Cerivastatin (Baycol® and Lipobay®) was 
withdrawn from the US market on August 8, 2001 as a result of severe incidences of 
rhabdomyolysis.
157
 
Several conditions increase the risk of statin-induced myopathy. These include 
patient-related factors and factors related to drug interactions. Patient-related risk factors 
include advanced age – especially for people 80 years of age or greater, female gender, 
having a low body mass index, strenuous exercise, surgery requiring high metabolic 
demands, and disease conditions such as impaired renal or liver function, 
hypothyroidism, diabetes mellitus, biliary tract obstruction, and inflammatory or inherited 
                                                                                                                                                 
the important questions. Nat Rev Cardiol. 2012;9(4):190-2; Sattar N, and Taskinen MR. Statins are 
diabetogenic--myth or reality? Atheroscler Suppl. 2012;13(1):1-10. 
156 Pasternak RC et al., "ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins." 
157 U.S. Food and Drug Administration, "Safety: Baycol (cerivastatin sodium tablets) Aug 2001". 
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metabolic muscle defects (e.g., McArdle’s disease and carnitine palmityl transferase II 
deficiency).
158
 
The risk of myopathy also is increased with heavy alcohol consumption and in 
drug abuse (e.g., cocaine, amphetamines, and heroin); and when statins are co-
administered with grapefruit juice (greater than 1 quart per day), other lipid-lowering 
drugs (especially gemfibrozil, fibrates, and niacin), and drugs metabolized through the 
cytochrome P-450 3A4 enzyme system: macrolide antibiotics (e.g., azithromycin and 
erythromycin), antifungals (e.g., fluconazole and ketoconazole), protease inhibitors (e.g., 
amprenavir and indinavir), nefazodone, amiodarone, calcium antagonists (e.g., verapamil 
and diltiazem), and warfarin.
159
 
 Despite the clinical seriousness of statin-induced myopathies, lower incidences of 
myopathies appeared to have been reported by RCTs of statins compared to reports from 
observational studies. For example, major statin trials such as the Heart Protection Study 
(HPS), WOSCOPS and the Scandinavian Simvastatin Survival Study (4S) have reported 
myopathy incidences of 0.11%, 0.12%, and 0.27%, respectively.
160
 In contrast, higher 
incidences of statin-induced myopathy, ranging from 5-10%, have been reported in 
                                                 
158 Rallidis LS, Fountoulaki K, and Anastasiou-Nana M. Managing the underestimated risk of statin-
associated myopathy. Int J Cardiol. 2012;159(3):169-76. 
159 Ibid. 
160 Shepherd J et al., "Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group."; "Randomised trial of 
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observational studies.
161
 The lower incidences of myopathies reported in RCTs might be 
due to strict criteria required for trial participation, such as the initial exclusion, from 
statin trials, of patients with increased risk factors for myopathy (e.g., patients with 
histories of muscle symptoms, creatine kinase (CK) elevations, and renal or liver 
diseases).
162
 Nevertheless, recent evidence from a meta-analysis of 246,955 participants 
from 135 RCTs which evaluated the comparative tolerability and harms of statins in 
subjects with and without CVD indicated that statins users were not different than 
controls in terms of myalgia, CK elevation, and discontinuation of therapy due to adverse 
events.
163
 Another meta-analysis of 35 randomized statin trials has confirmed similar 
observation.
164
 
The most common clinical symptoms of myopathy ranges from mild muscle 
fatigue and pains to symptoms such as diffuse muscle pains, weakness, low back pain, 
proximal muscle pain and aching, or the flu-like symptom manifestation of 
rhabdomyolysis – the rarest form of myopathy requiring hospitalization of the patient.165 
However, reported incidence of rhabdomyolysis is low (~3.2/100,000 person years), with 
                                                 
161 Nichols GA, and Koro CE. Does statin therapy initiation increase the risk for myopathy? An 
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163 Naci H et al., "Comparative tolerability and harms of individual statins: A study-level network meta-
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164 Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of 
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165 Antons KA, Williams CD, Baker SK, and Phillips PS. Clinical perspectives of statin-induced 
rhabdomyolysis. Am J Med. 2006;119(5):400-9. 
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incidence having the potential to increase by almost 12 times when statins are combined 
with gemfibrozil.
166
 
Mechanism 
The mechanism of statin-induced myopathy is unclear, but has been attributed to 
instability of cell membranes caused by a decreased cholesterol synthesis and/or 
decreased ubiquinone (Coenzyme Q10 or CoQ10) production, a process considered 
essential for mitochondrial electron transport.
167
 CoQ10 supplementation is believed to 
mitigate myopathy-related complaints, but there is insufficient evidence to support its 
usefulness in alleviating statin-induced myopathies.
168
 
Management 
Myopathies and rhabdomyolysis are serious statin adverse effects warranting an 
immediate discontinuation of the statin therapy or a significant reduction of the statin 
dose.
169
 Because several factors could cause an increased serum CK levels, routine 
measurement of CK is considered not helpful in detecting rare cases of statin-induced 
myopathy; instead, CK levels are recommended to be measured upon a patient’s report of 
unexplained or new muscle pain, tenderness, or weakness, or the evidence of a brown 
urine. When the level of serum CK are greater than 10,000 Units/L, patients should be 
                                                 
166 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
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placed on high fluid intake to avoid azotemia and kidney damage. Upon continued 
evaluation and treatment, the muscle pain and high CK levels may dissipate within a few 
days, with full recovery expected within a week. Because of the possibility of drug 
interaction-induced myopathies, a review of the patient’s medication list is necessary to 
remove the offending drug before statin therapy is re-instated. Re-introduction of the 
statin therapy should be done at a lower dose, or by switching to an alternate statin with 
better adverse effect profile.
170
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2.3 SECTION III: DIABETES MELLITUS 
2.3.1 Introduction 
 Diabetes mellitus is a group of metabolic diseases in which there is increased 
level of blood sugar (hyperglycemia) which results from defects in insulin secretion, 
insulin action, or both.
171
 Hyperglycemia is defined as serum glucose level > 180 mg/dL 
that persists for more than 2 hours.
172
 The two major forms of diabetes mellitus occur 
because of an absolute lack of insulin production which is a result of an auto-immune 
destruction of the insulin-producing pancreatic β-cells (type 1 diabetes), or because 
individuals are not able to efficiently use the normal insulin secreted by their pancreatic 
β-cells (type 2 diabetes).173 Either form of diabetes results in high blood sugar levels 
(hyperglycemia), which produces the classical symptoms of frequent urination 
(polyuria), increased thirst (polydipsia), and increased hunger (polyphagia).
174
 Diabetes 
mellitus is a chronic illness requiring constant medical care that includes patient self-
management, education, and support to prevent acute complications such as 
hypoglycemia, and to reduce the risk of long-term complications such as retinopathy and 
diabetic neuropathy.
175
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2.3.2 Epidemiology 
Almost 350 million people are affected by diabetes worldwide, with increasing 
prevalence in the United States.
176
 According to the 2009 – 2012 National Health and 
Nutrition Examination Survey estimates applied to 2012 US Census data, the Centers for 
Disease Control and Prevention (CDC) reported that 28.9 million (12.3%) Americans 
aged 20 years and older have diagnosed diabetes, while another 86 million (37%) have 
prediabetes – a preclinical condition associated with increased risk of diabetes, heart 
disease and stroke.
177
 These 2014 National Diabetes Statistics Report has since surpassed 
those released in 2010 which puts the numbers of diagnosed diabetes and prediabetes 
among Americans aged 20 years and older at 25.6 million (11.3%) and 79 million (35%), 
respectively.
178
 The report indicates that diabetes prevalence has increased since 2010, 
but incidence has decreased slightly from 1.9 million people who were newly diagnosed 
with diabetes in 2010,
179
 to 1.7 million in 2012.
180
 A CDC estimate of data from the 
National Health Interview Survey (NHIS) put the age-adjusted incidence of diabetes 
among Americans at 7.6 per 1000 population.
181
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As mentioned above, the percentage of the population with diagnosed diabetes 
continues to rise, with one study projecting that as many as a third of US adults could 
have diabetes by 2050 if the current trends continue.
182
 What makes diabetes a 
particularly more frightening pandemic is that nearly 28 percent of those with diabetes 
(approximately 8 million Americans) are unaware of their disease.
183
 This makes 
unmanaged diabetes a major killer disease that is accompanied by serious complications 
such as kidney failure, cardiovascular diseases, amputations, and blindness – conditions 
contributing significantly to the overall health care cost of the nation.
184
 
2.3.3 Economic Burden 
Diabetes imposes a substantial burden on the US economy in the forms of 
increasing direct medical cost of diabetes treatment, and in indirect medical cost due to 
lost productivity from work-related absenteeism, chronic disability and premature 
mortality.
185
 The society also pays a high intangible cost in the form of reduced quality of 
life, and pain and suffering of the patients, their families, and friends.
186
 
Diabetes-associated treatment cost has increased by 41% since 2007, from $174 
billion to an estimated $245 billion in 2012, accounting for a large portion of the total US 
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healthcare cost.
187
 Even though people with diabetes comprise less than 10% of the total 
US population,
188
 expenditures associated with diabetes accounts for more than 20% of 
the total health care cost, with diabetics incurring an average medical expenditure of 
approximately $13,700 annually. This expenditure is approximately 2.3 times higher than 
what would have been in the absence of diabetes.
189
 
Diabetes is the seventh leading cause of death in the US, with risk of mortality 
doubling for people with diabetes compared to people of similar age without diabetes. 
Diabetics, compared to people without diabetes, are also at increased risk of suffering 
from complications such as heart attacks, stroke, high blood pressure, kidney failure, 
blindness and amputations of feet and legs.
190
 The combined cost of hospital inpatient 
care and prescription medications to treat these complications alone stands at almost $150 
billion in 2012.
191
 Therefore, a better understanding of the economic and social cost of 
diabetes should be a major motivation to reduce its prevalence and burden. 
2.3.4 Classification  
According to the American Diabetes Association, diabetes can be classified into 
four major categories. These include type 1 diabetes, type 2 diabetes, gestational diabetes, 
and diabetes resulting from other causes.
192
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Type 1 diabetes (also known as insulin dependent diabetes or juvenile diabetes) 
results from an auto-immune destruction of the insulin-secreting pancreatic β-cells, 
leading to absolute insulin deficiency.
193
 It is a metabolic disorder affecting about 5 to 10 
percent of people who are diabetic, with diagnoses often occurring before the age of 
thirty.
194
 
People with type 2 diabetes (also known as non-insulin dependent diabetes or 
adult-onset diabetes) have a relative insulin deficiency in spite of their relatively 
functioning pancreatic β-cells. The deficiency is due to a combination of metabolic 
processes that includes peripheral tissue insulin resistance, defective insulin secretion, 
and increased hepatic glucose output.
195
 Type 2 diabetes is a genetically mediated 
metabolic disease in which the majority of cases is associated with unhealthy lifestyle, 
often progressing to insulin dependence after eight to ten years of onset.
196
 
Approximately 90 to 95 percent of people with diabetes have type 2 diabetes.
197
  
Gestational diabetes is discovered during pregnancy. It is usually not considered 
overt diabetes because it is transitory, with blood sugar often returning to normal levels 
postpartum. This condition is more prevalent among African Americans, Hispanic 
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Americans, American Indians, and among women with obesity and family history of 
diabetes.
198
 
Other types of diabetes are identified by other specific causes. These causes 
include genetic defects of pancreatic β-cells and insulin functions, diseases (e.g., cystic 
fibrosis), drug or chemical associated with HIV/AIDS treatment, or diabetes associated 
with after-effects of organ transplantation.
199
 
2.3.5 Etiology  
Environmental and genetic factors play significant roles in the etiology of both 
type 1 and type 2 diabetes mellitus.
200
 Genetic influence explains why the risk of 
developing type 1 diabetes in a person increases by 10-20 times those of the general 
population if that person’s immediate relative (i.e., parent, brother, sister, son or 
daughter) has type 1 diabetes.
201
 Similarly, the likelihood of someone having type 2 
diabetes is three times the risk for the general population if one of the parents has type 2 
diabetes. This risk increases to fourfold if both parents have the disease.
202
 
The influence of environmental factors in the etiology of type 1 diabetes explains 
why the probability that one member of a monozygotic (genetically identical) twin will 
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have type 1 diabetes is less than 40% if the other member of the twin has the disease.
203
 
The increased incidence of type 1 diabetes among population groups that moved from a 
low to a high incidence region further supports the influence of environmental factors in 
the etiology of type 1 diabetes.
204
 
The epidemic of type 2 diabetes mellitus among Americans has been attributed to 
increasing rates of environmental factors such as overweight, obesity, inadequate 
physical activity, and sedentary lifestyle.
205
 Because obesity increases insulin resistance, 
overweight and obese individuals are therefore especially at greater risk for type 2 
diabetes.
206
 
Moreover, genetic factors may explain why individuals with identical 
environmental risk exposure may or may not develop diabetes.
207
 This epidemiological 
observation is exemplified by variance in the prevalence of diabetes among diverse ethnic 
groups sharing a common environment. For example, the Pima Indians of Arizona have 
the highest reported prevalence of diabetes (40%) of any population in the world.
208
 This 
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is despite sharing a similar unhealthy, high-caloric diet and sedentary lifestyles with the 
wider US population who has a prevalence of diabetes of 9.3 percent.
209
 
2.3.5.1 Drug-induced Diabetes Mellitus 
Apart from the influence of genetics and environmental factors, many therapeutic 
agents can precipitate new onset diabetes especially when pre-existing risk factors are 
also present. The impairment of glucose metabolism and deterioration of glucose control 
is also especially pronounced when diabetogenic drugs are taken by those with existing 
diabetes. Diabetogenic medications act mainly by either increasing insulin resistance, or 
by inhibiting insulin secretion. Widely used drug therapeutic classes that are considered 
moderately diabetogenic include thiazide diuretics,
210
 β-blockers,211 antipsychotic 
agents,
212
 antidepressants,
213
 and statins. Other drugs, used for special indications, and 
which are considered more strongly diabetogenic include glucocorticoids (especially 
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prednisolone and dexamethasone),
214
 and immunosuppressive agents (especially 
tacrolimus and cyclosporine).
215
 
2.3.6 Pathophysiology 
Three distinct pathophysiologic processes can be attributed to the development of 
type 2 diabetes. These include resistance to insulin action in the peripheral tissue, 
defective insulin secretion, and increased hepatic glucose output.
216
 Insulin resistance is 
believed to be the first step in the development of diabetes. Elevated levels of free fatty 
acids and pro-inflammatory cytokines – both secondary to weight gain and obesity – 
causes insulin resistance, thereby decreasing cellular transport of glucose, and increasing 
both hepatic glucose output and fat metabolism. This processes triggers increased 
production of insulin by pancreatic beta cells in order to maintain glucose homeostasis. 
The sustained hyperglycemia leads to dysfunction and subsequent death of the beta cells, 
causing insulin production to be insufficient to counteract the increased plasma glucose 
concentration.
217
 
The pathophysiology of type 1 diabetes involves the autoimmune destruction of 
the pancreatic beta cells.
218
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2.3.7 Demographic Risk Factors  
Non-modifiable demographic factors such as male gender, older age, and certain 
race/ethnicity put people at increased risk of diabetes.
219
 
According to the CDC’s National Diabetes Statistics Report of 2014 which 
utilized data from the 2009 – 2012 NHIS, the prevalence of diagnosed and undiagnosed 
diabetes (type 1 or type 2) among adults aged 20 years and older was higher among men 
(13.6% or 15.5 million) compared to women (11.2% or 13.4 million).
220
 A higher 
proportion of people with diabetes was also seen among people aged 65 years and older 
(25.9%) compared to those aged 45 – 64 years (16.2%), or 20 – 44 years (4.1%).221 
 After adjustment for age differences, and using data from the 2010 – 2012 NHIS 
and the 2012 Indian Health Service’s National Patient Information Reporting System, the 
CDC reports that the proportion of people with diagnosed diabetes among American 
Indians/Alaska Natives (15.9%) was higher compared to the proportion of people with 
diagnosed diabetes among non-Hispanic blacks (13.2%), Hispanics (12.8%), Asian-
Americans (9.0%) and non-Hispanic whites (7.6%).
222
 
2.3.8 Signs, Symptoms, and Complications 
The hallmark symptoms of diabetes are polydipsia (excessive thirst), polyuria 
(frequent urination), and polyphagia (increased hunger) which are related to the 
                                                 
219 Centers for Disease Control and Prevention, "National Diabetes Statistics Report: Estimates of diabetes 
and its burden in the United States, 2014." 
220 Ibid. 
221 Ibid. 
222 Ibid. 
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hyperglycemia.
223
 Diabetic patients are often asymptomatic for many years after which a 
gradual progression of symptoms and chronic complications of the disease sets in.
224
 
Other symptoms that may be present at diagnosis include irritability, fatigue, skin 
wounds, blurred vision, and vaginal infections.
225
 
Acute complications of diabetes include hypoglycemia (abnormally low blood 
sugar level between 50-60 mg/dL), diabetic ketoacidosis (acute shortage of insulin, 
common in type 1 than type 2 diabetes), and hyperglycemic hyperosmolar syndrome 
(characterized by an altered sense of awareness of sensation, perception and 
interpretation of the surrounding). Chronic complications of diabetes are related to the 
cardiovascular and renal systems which significantly impair the activity of daily living, 
and include macrovascular complications (cerebrovascular disease, coronary heart 
disease, and peripheral vascular disease), and microvascular complications (retinopathy, 
nephropathy, and neuropathy).
226
 
2.3.9 Diagnosis 
Diabetes is diagnosed by a variety of laboratory methods, including through the 
fasting plasma glucose (FPG), the 2-hour value of the 75-g oral glucose tolerance test 
(OGTT), random plasma glucose (RPG), and glycated or glycosylated hemoglobin A1c 
(A1C). Diagnosis through the A1C method – endorsed by an International Expert 
Committee on diabetes (which includes the American Diabetes Association) – is the 
                                                 
223 Hilaire ML, and Woods TM. Type 2 diabetes: A focus on new guidelines. Formulary. 2013;48(2):55. 
224 American Diabetes Association, "Standards of medical care in diabetes--2014." 
225 Ali N, Diabetes and you: A comprehensive, holistic approach. 
226 Ibid. 
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preferable and more accurate method due to convenience (because fasting is not 
required), and stability (A1C estimates the average blood glucose level over the past 2-3 
months).
227
 Furthermore, AIC is a strong predictor for subsequent development of 
diabetes,
228
 and for complications arising from diabetes.
229
 
Routine testing to detect type 2 diabetes and prediabetes is recommended in 
asymptomatic adults of any age who are overweight or obese, and who have one or more 
additional risk factor for diabetes (Table 2.19). Prediabetics are intermediate group of 
people with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) who do 
not currently meet the criteria for clinical diagnosis of diabetes, but have an increased 
risk of developing full diabetes in the future.  
In accordance with adult testing recommendations, and because the incidence of 
diabetes among US adolescents has substantially increased within the past decade,
230
 
routine testing within the health care setting should be initiated – beginning at age 10 – in 
asymptomatic children who are at increased risk of type 2 diabetes (i.e., who are 
                                                 
227 Sacks DB, Arnold M, Bakris GL, et al. Position statement executive summary: guidelines and 
recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes 
Care. 2011;34(6):1419-23. 
228 Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. 
Ibid.2010;33(7):1665-73; Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and 
cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-11; Ackermann RT, Cheng YJ, 
Williamson DF, and Gregg EW. Identifying adults at high risk for diabetes and cardiovascular disease 
using hemoglobin A1c National Health and Nutrition Examination Survey 2005-2006. Am J Prev Med. 
2011;40(1):11-7. 
229 The effect of intensive treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial 
Research Group. N Engl J Med. 1993;329(14):977-86; Stratton IM, Adler AI, Neil HA, et al. Association 
of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): 
prospective observational study. BMJ. 2000;321(7258):405-12. 
230 Dabelea D, D'Agostino RB, Jr., Mayer-Davis EJ, et al. Testing the accelerator hypothesis: body size, 
beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care. 2006;29(2):290-4. 
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overweight, have a family history of type 2 diabetes, belong to races/ethnicity with 
increased risk of diabetes, have signs or conditions associated with insulin resistance 
[acanthosis nigricans, hypertension, hyperlipidemia, etc.], and have a maternal history of 
GDM during the child’s gestation).231 
In type 1 diabetes, clinical-based routine testing is currently not recommended for 
low-risk asymptomatic individuals, but screening (through measurement of islet 
autoantibodies) should be considered in individuals who have relatives with type 1 
diabetes.
232
 
Table 2.18 summarizes the diagnostic methods and cut-off values in diabetes and 
prediabetes, while Table 2.19 summarizes the recommended steps that should guide 
testing of type 2 diabetes in asymptomatic adults. 
 
 
 
 
 
 
 
 
                                                 
231 American Diabetes Association. Standards of medical care in diabetes--2014. Ibid.2014;37 Suppl 
1:S14-80. 
232 Ibid. 
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Table 2.18: Criteria for the Diagnosis of Diabetes and Prediabetes in Adults 
Criteria Diabetes Prediabetes Comments 
A1C  ≥6.5% 5.7-6.4% The test should be performed in a 
laboratory using a method that is 
NGSP certified and standardized to 
the DCCT assaya 
OR 
FPG  ≥126 mg/dL 
(7.0 mmol/L) 
100-125 mg/dL 
(5.6-6.9 
mmol/L) 
Fasting is defined as no caloric 
intake for at least 8 hoursa 
OR 
2-hour 
plasma 
glucose 
during an 
OGTT 
≥200 mg/dL 
(11.1 
mmol/L) 
 
140-199 mg/dL 
(7.8-11 
mmol/L) 
The test should be performed as 
described by the WHO, using a 
glucose load containing the 
equivalent of 75 g anhydrous 
glucose dissolved in watera 
OR 
RPG 
 
≥200mg/dL 
(11.1 
mmol/L) 
NA In patients with classic symptoms of 
hyperglycemia or hyperglycemic 
crisis 
Source: American Diabetes Association. Standards of medical care in diabetes—2014. 
Diabetes Care. 2014;37(Supplement 1):S14-S80. 
Abbreviations: A1C, Glycated hemoglobin A1C; NGSP, National Glycohemoglobin 
Standardization Program; DCCT, Diabetes Control and Complications Trial; FPG, Fasting 
plasma glucose; OGTT, Oral glucose tolerance test; WHO, World Health Organization; RPG, 
Random plasma glucose. 
aIn the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.  
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Table 2.19: Diabetes Risk Factors and Criteria for Testing for Type 2 Diabetes 
in Asymptomatic Adults 
A Testing should be considered in all adults who are overweight (BMI ≥25 
kg/m2)a and who have additional risk factors 
Risk factors: 
1. Physical inactivity 
2. First-degree relative with diabetes 
3. High-risk race/ethnicity (e.g., African American, Latino, Native American, 
Asian American, Pacific Islander) 
4. Women who delivered a baby weighing >9 lb or were diagnosed with GDM 
5. Hypertension (≥140/90 mmHg or on therapy for hypertension) 
6. HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride 
level >250 mg/dL (2.82 mmol/L) 
7. Women with polycystic ovary syndrome 
8. A1C ≥5.7% or presence of prediabetes 
9. Presence of other clinical conditions associated with insulin resistance (e.g., 
severe obesity, acanthosis nigricans)b 
10. History of CVD 
B In the absence of the above criteria, testing for diabetes should begin at age 45 
years. 
C If results are normal, testing should be repeated at least at 3-year intervals, 
with consideration of more frequent testing depending on initial results (e.g., 
those with prediabetes should be tested yearly) and risk status. 
Source: American Diabetes Association. Standards of medical care in diabetes—2014. 
Diabetes Care. 2014;37(Supplement 1):S14-S80. 
Abbreviations: BMI, Body mass index; GDM, Gestational diabetes mellitus; HDL, High-
density lipoprotein; A1C; Glycated hemoglobin A1C; CVD, Cardiovascular disease. 
aAt-risk BMI may be lower in some ethnic groups. 
bAcanthosis nigricans is a brown to black, poorly defined, velvety hyperpigmentation of 
the skin usually found in body folds such as the posterior and lateral folds of the neck, 
armpits, groin, navel, and forehead. 
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2.3.10 Prevention of Diabetes 
Several RCTs have demonstrated the efficacy of intensive lifestyle modification 
and use of pharmacological agents (especially metformin) at significantly decreasing the 
rate of onset of type 2 diabetes in people at high risk of developing the disease.
233
 Long-
term follow-up of three particularly large studies of lifestyle intervention has shown 
sustained reduction in the rate of conversion from prediabetes to diabetes. The China Da 
Qing Diabetes Prevention Study showed a 43% risk reduction of diabetes at 20 years,
234
 
while the Finish Diabetes Prevention Study,
235
 and the US Diabetes Prevention Program 
Outcomes Study,
236
 respectively, showed a 43% risk reduction at 7 years, and a 34% risk 
reduction at 10 years of utilizing TLC. Of the therapeutic agents (e.g., metformin, α-
glucosidase inhibitors, orlistat, and thiazolinediones) considered useful in the prevention 
of diabetes, long-term use of metformin has been shown to be particularly safe and 
tolerable,
237
 and cost-effective.
238
 
                                                 
233 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with 
lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403; Tuomilehto J, Lindstrom J, 
Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with 
impaired glucose tolerance. Ibid.2001;344(18):1343-50; Pan XR, Li GW, Hu YH, et al. Effects of diet and 
exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes 
Study. Diabetes Care. 1997;20(4):537-44; Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar 
AD, and Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and 
metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). 
Diabetologia. 2006;49(2):289-97. 
234 Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the 
China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-9. 
235 Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes 
by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Ibid.2006;368(9548):1673-9. 
236 Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss 
in the Diabetes Prevention Program Outcomes Study. Ibid.2009;374(9702):1677-86. 
237 Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention 
Program Outcomes Study. Diabetes Care. 2012;35(4):731-7. 
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In type 1 diabetes, clinical trial interventions using agents such as rituximab
239
 
and abatacept
240
 are believed to be showing promising efficacy at slowing down the 
destruction of β-cells in individuals with evidence of recent-onset autoimmunity. 
2.3.11 Therapeutic Management  
Diabetes management should be patient specific and should involve 
collaborations from an interdisciplinary health care team that includes nurses, dieticians, 
physicians, and pharmacists.
241
 Treatment strategy should involve taking into account the 
individual patient’s comorbid conditions, ability to adhere to prescribed medications, and 
the cost associated with a chosen therapeutic option.
242
 
The goals of controlling blood glucose are to avoid acute symptoms of 
hypoglycemia, avoid instability in blood glucose levels, and to prevent or delay the 
development of diabetes complications without adversely affecting quality of life.
243
 
Once a patient is diagnosed with type 2 diabetes, lifestyle modifications including 
diet, weight loss (if needed), and exercise are encouraged. Metformin monotherapy 
should be started at, or soon after diagnosis unless contraindicated. The guidelines 
recommend checking A1C after 3 months of therapy, with the possibility of adding a 
                                                                                                                                                 
238 The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-
to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723-30. 
239 Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and 
preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-52. 
240 Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-
onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412-9. 
241 Hilaire ML and Woods TM, "Type 2 diabetes: A focus on new guidelines." 
242 Ibid. 
243 Ibid. 
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second antidiabetic agent if therapy is not at goal. Possible second-line agents include 
sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, and insulin.
244
 
The recommended pharmacological treatment with insulin therapy in most people 
with type 1 diabetes involves three approaches: 1) the use of multiple dose insulin 
injections or continuous subcutaneous insulin infusion therapy; 2) matching of prandial 
(with meal) insulin to carbohydrate intake, pre-prandial blood glucose, and anticipated 
activity; and 3) the use of insulin analogs (e.g., insulin glargine, insulin lispro, insulin 
aspart, etc.) in individuals experiencing problems with hypoglycemia.
245
 
Recommendations for the management of type 2 diabetes, as jointly issued by the 
American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes are presented in Table 2.20. Table 2.21 summarizes the FDA- approved 
medications (excluding insulin) that are currently available for treating type 2 diabetes. 
  
                                                 
244 Ibid. 
245 American Diabetes Association, "Standards of medical care in diabetes--2014." 
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Table 2.20: Recommendations for the Management of Type 2 Diabetes 
1. Metformin, if not contraindicated and if tolerated, is the preferred initial 
pharmacological agent for type 2 diabetes 
 
2. In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or 
elevated blood glucose levels or A1C, consider insulin therapy, with or without 
additional agents, from the outset 
 
3. If noninsulin monotherapy at maximal tolerated dose does not achieve or 
maintain the A1C target over 3–6 months, add a second oral agent, a glucagon-
like peptide-1 (GLP-1) receptor agonist, or insulina 
 
4. A patient-centered approach should be used to guide choice of pharmacological 
agents. Considerations include efficacy, cost, potential side effects, effects on 
weight, comorbidities, hypoglycemia risk, and patient preferences 
 
5. Due to the progressive nature of type 2 diabetes, insulin therapy is eventually 
indicated for many patients with type 2 diabetes 
Source: American Diabetes Association. Standards of medical care in diabetes—2014. 
Diabetes Care. 2014;37(Supplement 1):S14-S80. 
aSecond-line oral agents include sulfonylureas, thiazolidinediones, and dipeptidylpeptidase-
4 (DPP-4) inhibitors.  
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Table 2.21: FDA-Approved Oral Medications Used in the Treatment of Type 2 Diabetes* 
Class Mechanism of 
Action 
Drug Brand Name Available 
Strength 
(mg)# 
Dosing^ 
Alpha-
glucosidase 
inhibitorsa 
Competitively blocks 
alpha-glucosidase 
enzyme, resulting in 
the slowing down  of 
intestinal breakdown 
of carbohydrate and 
starch into glucose 
Acarbose Precose® 25, 50, 100 
(Generic and Precose®) 
Initial: 25 mg TID 
Max: 100 mg TID 
Miglitol Glyset® 25, 50, 100 
(Glyset®) 
Initial: 25-50 mg TID  
Max: 100 mg TID 
Biguanidesb -Inhibits hepatic 
glycogenolysis and 
gluconeogenesis 
-Enhances insulin 
sensitivity in muscle 
and fat 
Metformin 
 
Glucophage® 
Glucophage 
XR® 
Fortamet®(ER) 
Glumetza® 
(ER) 
 
500, 850, 1000 (Generic 
and Glucophage®) 
500, 750, 1000 (Generic 
XR) 
500, 750 (Glucophage 
XR®) 
500, 1000 (Fortamet® 
and Glumetza®) 
Initial: 500 mg BID or 
850 mg QD  
(XR=500 mg QD) 
Max: 2550 mg QD 
(XR=2000 mg QD) 
 
Meglitinidesc They stimulate 
pancreatic insulin 
secretion 
Nateglinide Starlix® 60, 120 
(Generic and Starlix®) 
Initial: 120 mg TID 
Max: 120 mg TID 
Repaglinide Prandin® 0.5, 1, 2 
(Generic and Prandin®) 
Initial: 0.5-4 mg QD 
Max: 16 mg QD 
Sulfonylureas 
1st 
generationd 
They stimulate 
pancreatic insulin 
secretion 
Chlorpropamide NA 100, 250 (Generic) Initial: 250 mg QD 
Max: 750 mg QD 
Tolbutamide NA 500 (Generic) Initial: 1-2g QD 
Max: 3g QD 
Tolazamide NA 250, 500 (Generic) Initial: 100-250 mg 
QD 
Max: 1g QD 
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Table 2.21: FDA-Approved Oral Medications Used in the Treatment of Type 2 Diabetes (Cont’d)* 
Class Mechanism of Action Drug Brand Name Available 
Strength 
(mg)# 
Dosing^ 
Sulfonylureas 
2nd generatione 
They stimulate 
pancreatic insulin 
secretion 
Glipizide Glucotrol® 
Glucotrol XL® 
GlipiZIDE XL® 
5, 10 (Generic and 
Glucotrol) 
2.5, 5, 10 (Generic ER, 
GlipiZIDE XL® and 
Glucotrol XL®) 
Initial: 5 mg QD  
(XL=5-10 mg QD) 
Max: 15-40 mg QD 
(XL=20 mg QD) 
Glibenclamide 
(Glyburide) 
Diabeta® 
Glynase® 
1.25, 1.5, 2.5, 3, 5, 6 
(Generic) 
1.25, 2.5, 5 (Diabeta®) 
1.5, 3, 6 (Glynase®) 
Initial: 1.25-5 mg QD 
Max: 20 mg QD 
Glimepiride Amaryl® 1, 2, 4 (Generic and 
Amaryl®) 
Initial: 1-2 mg QD 
Max: 8 mg QD 
Thiazolidinedi-
ones  
(Glitazones)f 
Enhances insulin 
sensiti- vity in muscle 
and fat by increasing 
glucose trans- porter 
expression 
Rosiglitazone Avandia® 2, 4, 8 (Avandia®) Initial: 4 mg QD 
Max: 8 mg QD 
Pioglitazone Actos® 15, 30, 45 (Generic and 
Actos®) 
Initial: 15-30 mg QD 
Max: 45 mg QD 
Bile acid 
sequestrants 
-May reduce hepatic 
insulin resistance 
leading to reduction in 
hepatic glucose 
production 
-May reduce intestinal 
glucose absorption 
Colesevelam Welchol® 625, 3750 (Welchol®) 
  
Initial: 6 tab (3.75g) 
QD 
Or 3 tab (1.875g) BID 
Max: 3.75g QD 
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Table 2.21: FDA-Approved Oral Medications Used in the Treatment of Type 2 Diabetes (Cont’d)* 
Class Mechanism of Action Drug Brand Name Available 
Strength 
(mg)# 
Dosing^ 
Amylin analog -Decreases 
postprandial glucagon 
secretion and hepatic 
glucose production 
-Slows gastric emptying 
which leads to feelings 
of satiety 
Pramlintide SymlinPen 60® 
SymlinPen 
120® 
 
1500 mcg/1.5mL   
2700 mcg/2.7mL  
(SubQ solutions) 
 
Initial: 60 mcg QD, 
SubQ 
Max: 120 mcg QD, 
SubQ 
Dipeptidyl 
peptidase-4 
(DPP-4) 
inhibitorsg 
Inhibits breakdown of 
endogenous incretins 
resulting in increased 
secretion of insulin and 
decreased secretion of 
glucagon 
Sitagliptin Januvia® 25, 50, 100 (Januvia®) 100 mg QD 
Saxagliptin Onglyza® 2.5, 5 (Onglyza®) 2.5-5 mg QD 
Linagliptin Tradjenta® 5 (Tradjenta®) 5 mg QD 
Alogliptin Nesina® 6.25, 12.5, 25 (Nesina®) 25 mg QD 
Glucagon-like 
peptide-1 
(GLP-1) 
agonistsh 
 
-Stimulate GLP-1 
recept- ors, which 
increases insulin 
production in response 
to high blood glucose 
levels  
-Inhibit postprandial 
glucagon release and 
slow gastric emptying 
Exenatide Bydureon®  
Byetta 10 MCG 
Pen®  
Byetta 5 MCG 
Pen®  
2mg (Bydureon®, SubQ 
suspension) 
10 mcg/0.04mL (Byetta 
10 MCG Pen®, SubQ 
solution) 
5 mcg/0.02mL (Byetta 5 
MCG Pen®, SubQ 
solution) 
5-10 mcg BID 
(ER: 2mg once weekly) 
Liraglutide Victoza® 18 mg/3mL 
(SubQ solution) 
 
Initial: 0.6-1.2 mg QD 
Max: 1.8 mg QD 
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Table 2.21: FDA-Approved Oral Medications Used in the Treatment of Type 2 Diabetes (Cont’d)* 
Class Mechanism of Action Drug Brand Name Available 
Strength 
(mg)# 
Dosing^ 
Dopamine 
agonist 
Increases insulin sensitivity as 
a result of hypothalamic 
regulatory changes in 
metabolism 
Bromocriptin Cycloset® 
 
0.8 (Cycloset®) Initial: 0.8 mg QD 
Max: 4.8 mg QD 
Sources: Lexicomp Online; 2013. US Food and Drug Administration. National Drug Code query-active ingredient; 2013. Hilaire ML, 
Woods TM. Type 2 diabetes: A focus on new guidelines. Formulary. 2013;48(2):55. 
Abbreviations: QD, Daily; BID, Twice daily; TID, Three times daily; Max, Maximum; XR/ER/XL, Extended release tablet or capsule; 
NA, Not available; SubQ, Subcutaneously. 
^All dosing are for adults. 
#All dosage forms are immediate release tablets or capsules, unless otherwise stated. 
*Several combination products exist, including pioglitazone/metformin, rosiglitazone/metformin, glipizide/metformin, 
glyburide/metformin, sitagliptin/metformin, linagliptin/metformin, saxagliptin/metformin, repaglinide/metformin, 
rosiglitazone/glimepiride, and pioglitazone/glimepiride. 
aIncludes voglibose (research product of Takeda Pharma; not yet FDA-approved). 
bIncludes phenformin, buformin (both withdrawn from the market due to toxic effects), and proguanil (not FDA-approved for 
diabetes but indicated as an antimalarial). 
cInclude mitiglinide (not yet FDA-approved for treating type 2 diabetes). 
dIncludes carbutamide and acetohexamide (both discontinued in the United States). 
eIncludes gliclazide, glibornuride, gliquidone, glisoxepide, and glycopyramide (either outdated, discontinued, or not presently 
available in the United States). 
fIncludes troglitazone (withdrawn from the market due to drug-induced hepatitis), netoglitazone, rivoglitazone, and ciglitazone 
(experimental agents). 
gIncludes vildagliptin (marketed in the European Union), dutogliptin, gemigliptin (both under development), and anagliptin 
(marketed in Japan). 
hIncludes albiglutide and taspoglutide (both under development).  
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2.3.12 Glycemic Control 
Optimization of glycemic control is a central strategy in the management of 
diabetic nephropathy, retinopathy, and neuropathy. Lowering A1C to below or around 
7% has been shown to reduce microvascular complications of diabetes, and if 
implemented soon after the diagnosis of diabetes, is associated with long-term reduction 
in macrovascular disease.
246
 However, the target A1C should be chosen such that 
hypoglycemia and other adverse events of treatment are significantly minimized.
247
 The 
importance of intensive glycemic control at delaying the onset of, or slowing down the 
progression of diabetic nephropathy,
248
 diabetic retinopathy,
249
 and diabetic 
neuropathy,
250
 has been elucidated by several studies. However, CVD – a more common 
cause of death in populations with diabetes than microvascular complications – is less 
clearly impacted by levels of hyperglycemia, or by the intensity of glycemic control.
251
 
                                                 
246 Ibid. 
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Several reasons may be responsible for the inability to reach target glycemic 
control in people with diabetes. More successful outcomes may be achieved by a 
reassessment of factors including the patient’s income, health literacy, distress associated 
with the disease, depression, and competing demands, especially those related to family 
responsibilities and dynamics.
252
 Other strategies that may be employed to enhance 
patient compliance and achieve more glycemic control include culturally appropriate and 
enhanced diabetes self-management education and support, co-management with a 
diabetes team, referral to a medical social worker for assistance with insurance coverage, 
or change in pharmacological therapy.
253
 Initiation of, or increase in patient self-
monitoring of blood glucose, utilization of continuous glucose monitoring, frequent 
contact with the patient, or referral to a mental health professional or physician with 
special expertise in diabetes may also be useful.
254
 
2.3.13 Management of Diabetes Comorbidities 
In addition to achieving a desirable glycemic control, special attention should be 
given to cardiovascular and lipid management in people with diabetes. Other 
management considerations should also include antiplatelet management (using aspirin 
75–162 mg/day),255 smoking cessation therapy,256 management of diabetes-associated 
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disease conditions such as diabetic foot ulcer,
257
 hearing impairment,
258
 obstructive sleep 
apnea,
259
 fatty liver disease,
260
 low testosterone in men,
261
 periodontal disease,
262
 certain 
cancers (e.g., liver, pancreas, colorectal, and breast),
263
 fractures,
264
 cognitive 
impairment,
265
 and depression.
266
 
Cardiovascular Management  
CVD is a macrovascular complication of diabetes. It is the major cause of 
morbidity and mortality in people with diabetes, contributing substantially to the direct 
and indirect medical cost associated with diabetes treatment.
267
 Moreover, the two 
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common conditions coexisting with diabetes (i.e., hypertension and dyslipidemia) are risk 
factors for CVD, with diabetes itself being an independent CVD risk factor.
268
 
A blood pressure goal of <140/<80mmHg is recommended for people with 
comorbid diabetes and hypertension.
269
 Studies indicate that people with diabetes have 
better cardiovascular outcomes and reduced mortality when their BP is less than 
115/75mmHg, whereas a systolic blood pressure above 120mmHg is a recipe for long-
term end-stage renal disease (ESRD).
270
 
The management of people with comorbid hypertension and diabetes often 
involve a combination of non-pharmacological and pharmacological therapeutic options. 
Non-pharmacological management should include therapeutic lifestyle changes such as 
weight loss through physical exercise, moderation of alcohol consumption, smoking 
cessation, and the implementation of the Dietary Approaches to Stop Hypertension 
(DASH) dietary pattern (including increased intake of fruits and vegetables, and 
reduction of salt).
271
 Significant cardiovascular outcomes has been achieved, and therapy 
for patients with comorbid diabetes and hypertension is optimal when the first choice 
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therapeutic agent includes either an angiotensin converting enzyme (ACE) inhibitor or an 
angiotensin receptor blocker (ARB).
272
 
Nevertheless, multiple drug therapy (using two or more agents at maximal doses) 
is generally required to achieve blood pressure targets in this group of patients.
273
 Table 
2.22 summarizes the major classes of drugs used in treating hypertension in people with 
diabetes. 
Table 2.22: FDA-Approved Medications Used in the Treatment of Hypertension 
in Patients with Diabetes 
Drug Brand Name Available Strength (mg)# 
ACE-Inhibitorsa 
Benazepril Lotensin® 5, 10, 20, 40 (Generic) 
10, 20, 40 (Lotensin®) 
Captopril NA 12.5, 25, 50, 100 
Enalapril Vasotec® 
Epaned® 
2.5, 5, 10, 20 (Generic and Vasotec®) 
150mL of 1mg/mL (Epaned®) 
Fosinopril NA 10, 20, 40 
Lisinopril Prinivil® 
Zestril® 
5, 10, 20 (Prinivil®) 
2.5, 5, 10, 20, 30, 40 (Generic and Zestril®) 
Moexipril Univasc® 7.5, 15 (Generic and Univasc®) 
Perindopril Aceon® 2, 4, 8 (Generic) 
4, 8 (Aceon®) 
Quinapril Accupril® 5, 10, 20, 40 (Generic and Accupril®) 
Ramipril Altace® 1.25, 2.5, 5, 10 (Generic and Altace®) 
Trandolapril Mavik® 1, 2, 4 (Generic and Mavik®) 
ARBs 
Azilsartan Edarbi® 40, 80 (Edarbi®) 
Candesartan Atacand® 4, 8, 16, 32 (Generic and Atacand®) 
Eprosartan Teveten® 600 (Generic), 400, 600 (Teveten®) 
                                                 
272 Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine 
Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes 
Care. 1998;21(4):597-603; Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, and Schrier RW. 
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-
insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645-52; Schrier RW, Estacio 
RO, Mehler PS, and Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 
2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007;3(8):428-38. 
273 American Diabetes Association, "Standards of medical care in diabetes--2014." 
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Table 2.22: FDA-Approved Medications Used in the Treatment of 
Hypertension in Patients with Diabetes (Cont’d) 
Drug Brand Name Available Strength (mg)# 
ARBs cont’d 
Irbesartan Avapro® 75, 150, 300 (Generic and Avapro®) 
Losartan Cozaar® 25, 50, 100 (generic and Cozaar®) 
Olmesartan Benicar® 5, 20, 40 (Benicar®) 
Telmisartan Micardis® 20, 40, 80 (Micardis®) 
Valsartan Diovan® 40, 80, 160, 320 (Diovan®) 
Calcium Channel Blockers (Dihydropyridine)b 
Amlodipine Norvasc® 2.5, 5, 10 (Generic and Norvasc®) 
Clevidipine Cleviprex®  0.5 mg/mL (50 mL, 100 mL)(Cleviprex®) 
Felodipine Plendil® 2.5, 5, 10 (Generic and Plendil®) 
Isradipine Dynacirc® CR 2.5, 5 (Generic) 
5, 10 (Dynacirc CR®) 
Nicardipine Cardene IV® 
Cardene SR® 
20, 30 (Generic) 
30, 60 (Cardene SR®) 
20 mg (200 mL), 40 mg (200 mL)(Cardene IV®) 
2.5 mg/mL (10 mL)(Generic and Cardene IV®) 
Nifedipine Adalat CC® 
Afeditab CR® 
Nifediac CC® 
Nifedical XL® 
Procardia® 
Procardia XL® 
10 (Procardia®) 
10, 20 (Generic) 
30, 60 (Nifedical XL®, Nifediac CC®, Afeditab CR®) 
30, 60, 90 (Generic ER, Procardia XL®, Adalat CC®) 
90 (Nifediac CC®) 
Nimodipine Nymalize® 30 (Generic) 
60 mg/20 mL (473 mL)(Nymalize®) 
Nisoldipine Sular® 8.5, 17, 20, 25.5, 30, 34, 40 (Generic) 
8.5, 17, 34 (Sular®) 
Source: Lexicomp Online; 2013. US Food and Drug Administration. National Drug Code 
query-active ingredient; 2013.  
Abbreviations: FDA, Food and Drug Administration; ACE, Angiotensin Converting Enzyme; 
ARB, Angiotensin Receptor Blocker; NA, Not Available; IV, Intravenous. 
#All dosage forms are oral immediate release tablets or capsules, unless otherwise stated. 
CR, SR, CC, CR, and XL are extended or controlled release dosage forms. 
aClass includes cilazapril, imidapril, and zofenopril (marketed internationally but not 
currently approved for use in the United States). 
bClass members not currently marketed in the US includes aranidipine, azelnidipine, 
barnidipine, benidipine, cilnidipine, efonidipine, lacidipine, lercanidipine, manidipine, 
nilvadipine, nitrendipine, and pranidipine. 
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Lipid Management 
Patients with diabetes have an increased prevalence of lipid abnormalities that can 
contribute to their high risk of CVD.
274
 Annual screening for dyslipidemia is encouraged 
by the ADA to achieved an LDL-C and TG goals of <100mg/dL and <150mg/dL, 
respectively. An HDL-C goals of >40 mg/dL (men) or >50 mg/dL (women) is desired; 
however, the main goal of therapy is focused on reducing LDL-C levels.
275
 Treatment of 
diabetic dyslipidemia is usually achieved with a combination of lifestyle modifications 
and pharmacotherapy using statins and other lipid-lowering agents. Unless 
contraindicated, statins should be started, regardless of initial LDL-C levels, in all type 2 
diabetic patients that are aged 40 years and older and with at least one cardiovascular risk 
factor (e.g., family history of CVD, hypertension, smoking, dyslipidemia, and 
albuminuria).
276
 [The new ATP IV guideline recommends using a moderate intensity 
statin in individuals 40 – 75 years of age with diabetes who have LDL-C of 70-189 
mg/dL. A high intensity statin should be considered in this group of patients if the 10-
year ASCVD risk is ≥ 7.5%. Meanwhile, consideration should be given to patient 
preferences, evaluation of the ASCVD risk-reduction benefit versus potentials for 
adverse effects, and drug-drug-interactions when deciding to initiate, continue, or 
intensify therapy in those less than 40 years or those older than 75 years].
277
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Several clinical trials have demonstrated the effectiveness of statins at reducing 
LDL-C levels and improving cardiovascular outcomes in both primary and secondary 
prevention, including among the diabetic sub-population.
278
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2.4 SECTION IV: STATINS AND INCIDENT DIABETES 
MELLITUS  
2.4.1 Introduction 
Statins are generally well tolerated and are believed to have minimal adverse 
effects.
279
 However, some of the most common adverse effects associated with statin 
therapy include myopathies, elevation of liver enzymes, and very rarely, 
rhabdomyolysis.
280
 Discontinuation or reduction in the dose of statin treatment usually 
leads to resolution of these adverse effects.
281
 For many years, however, there has been 
debate as to whether statins are indeed as safe as reported in clinical trials.
282
  
Recently, the US FDA have expanded the warning section of the label for all 
statins to suggest an increased risk of incident diabetes mellitus as a result of increases in 
glycosylated hemoglobin (A1C) and fasting plasma glucose (FPG).
283
 Recent evidence 
also suggests that the use of statins can result in an increased risk for the development of 
diabetes, possibly through modification of glucose homeostasis.
284
 Meanwhile, the 
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mechanism by which statins have differential effects on glucose homeostasis still remain 
unclear;
285
 however, statins are thought to worsen glycemic control and increase fasting 
plasma glucose and insulin resistance, thereby possibly leading to diabetes mellitus.
286
 
Only a few observational studies have evaluated the association between statin 
use and the risk of new onset diabetes. Results from these studies have also been 
inconsistent. To date, only twelve population-based observational studies have examined 
the association between statin therapy and incidence of diabetes.
287
 These observational 
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studies included eight retrospective cohort studies,
288
 two prospective cohort studies,
289
 
and two case-control studies.
290
 Overall, the strength of association linking statin therapy 
to incident diabetes in RCTs, meta-analyses of RCTs and observational studies is weak or 
moderate. Moreover, other evidence indicates a protective effect of statins on diabetes. 
The section below evaluates the available evidence linking statin therapy to increased risk 
of incident diabetes. Evidences from randomized control trials, meta-analyses of RCTs, 
and observational studies are examined. 
2.4.2 Randomized Control Trials 
Several major (i.e., recruiting large number of participants and with follow-up 
period greater than 1 year) placebo-controlled statin trials in primary,
291
 and secondary 
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prevention,
292
 suggests a moderate association (i.e., increase in risk that is less than 50%) 
between statin therapy and increased risk of incident diabetes. Similar results were seen 
in trials comparing intensive and moderate statin doses
293
 (See Table 2.23). While the 
results of some of the earlier trials published between 1995 and 2000 demonstrated a non-
statistically significant, moderately protective effect of statin therapy on incident diabetes 
(as observed in the WOSCOP,
294
 AFCAPS/TexCAPS,
295
 LIPID,
296
 and GISSI-P 
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trials
297
), the majority of later studies, albeit with a mixture of statistical significance and 
non-significance, showed a tendency for statins to be associated with an increased odds 
of diabetes. These increased odds of diabetes ranged from 3 percent, observed in the 4S 
study,
298
 to 32 percent, recorded in the PROSPER study.
299
 
In particular, the results of the PROSPER study,
300
 published in 2002, and similar 
findings by the JUPITER study,
301
 published in 2008, showed that  pravastatin and 
rosuvastatin were significantly associated with relatively large increase in the odds of 
diabetes of 32 percent and 26 percent, respectively. These later findings kick-started a 
series of discussions about the safety of statins and the need to weigh the benefit of 
cardiovascular protection against the risk of incident diabetes from statin use. In 
combination with other evidence, the FDA was prompted to take action, resulting to a 
change in the labeling of all statins, in February 2012, to include risk of increases in 
HbA1c and/or fasting plasma glucose that could lead to drug-induced diabetes 
mellitus.
302
 
The incidences of diabetes reported by the results of the aforementioned RCTs - 
which primarily examined statins’ beneficial effects on cardiovascular outcomes in 
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primary and secondary prevention trials – has prompted other investigators, through 
meta-analyses of RCTs and observational studies, to either confirm or reject the 
hypothesis that statins are associated with increased risk of statin-induced diabetes.  
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Table 2.23: Incident Diabetes Reported in Major Randomized Controlled Trials of Statins 
Trials Statin 
(dose per day) 
Control Total 
N 
Non-DM at 
baseline 
(%) 
Number 
(statin) 
Number 
(control)  
New 
DM 
cases 
New 
DM 
(statin) 
New DM 
(control) 
Odds Ratio  
(95% C.I.) 
WOSCOPSa Pravastatin 
40mg 
Placebo 6,595 5,974 (91) 2,999 2,975 168 75 93 0.79  
(0.58-1.10) 
AFCAPS/ 
TexCAPSb 
Lovastatin 
20-40mg 
Placebo 6,605 6,211 (94) 3,094 3,117 146 72 74 0.98 
(0.70-1.38) 
ALLHAT- 
LLTc 
Pravastatin 
40mg 
Usual 
Care 
10,355 6,087 (59) 3,017 3,070 450 238 212 1.15 
(0.95-1.41) 
PROSPERd Pravastatin 
40mg 
Placebo 5,804 5,023 (87) 2,510 2,513 292 165 127 1.32 
(1.03-1.69) 
ASCOT-
LLAe 
Atorvastatin  
10mg 
Placebo 10,305 7,773 (75) 3,910 3,863 288 154 134 1.14 
(0.89-1.46) 
MEGAf Pravastatin 
10-20mg 
+ diet 
Diet + 
Usual 
Care 
7,832 6,086 (78) 3,013 3,073 336 172 164 1.07 
(0.86-1.35) 
JUPITERg Rosuvastatin 
20mg 
Placebo 17,802 17,802 
(100) 
8,901 8,901 486 270 216 1.26 
(1.04-1.51) 
HPSh Simvastatin 
40mg 
Placebo 20,536 14,573 
(72) 
7,291 7,282 628 335 293 1.15 
(0.98-1.35) 
4Si Simvastatin 
20-40mg 
Placebo 4444 4242 (95) 2116 2126 391 198 193 1.03 
(0.84-1.28) 
LIPIDj Pravastatin 
40mg 
Placebo 9014 6997 (78) 3496 3501 264 126 138 0.91 
(0.71-1.71) 
CORONAk Rosuvastatin 
20mg 
Placebo 5011 3534 (71) 1771 1763 188 100 88 1.14 
(0.84-1.55) 
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Table 2.23: Incident Diabetes Reported in Major Statin Randomized Controlled Trials (Cont’d) 
Trials Statin 
Dose/day 
Control Total 
N 
Non-DM at 
baseline 
(%) 
Number 
(statin) 
Number 
(control)  
New 
DM 
cases 
New 
DM 
(statin) 
New DM 
(control) 
Odds Ratio  
(95% C.I.) 
GISSI-HFl Rosuvastatin 
10mg 
Placebo 4,574 3,378 (74) 1,660 1,718 440 225 215 1.10 
(0.89-1.35) 
GISSI-Pm Pravastatin 
20mg 
Usual 
care 
4,271 3,460 (81) 1,743 1,717 201 96 105 0.89 
(0.67-1.20) 
Intensive Dose vs. Moderate Dose Statin Trials 
 Intensive statin dose/ 
Moderate statin dose  
(dose per day) 
Total 
N 
Non-DM at 
baseline 
(%) 
Number 
(ISD) 
Number 
(MSD) 
New 
DM 
cases 
New 
DM 
(ISD) 
New DM 
(MSD) 
Odds Ratio  
(95% C.I.) 
PROVE 
IT-TIMI 
22n 
Atorvastatin 80mg/ 
pravastatin 40mg 
4,162 3,395 (82) 1,707 1,688 200 101 99 1.01 
(0.76-1.34) 
A to Zo 
 
Simvastatin 40mg, 
Simvastatin 80mg/ 
placebo, 
simvastatin 20mg 
4,497 3,504 (78) 1768 1,736 112 65 47 1.37 
(0.94-2.01) 
TNTp Atorvastatin 80mg/ 
atorvastatin 10mg 
10,001 7,595 (76) 3,798 3,797 776 418 358 1.19 
(1.02-1.38) 
IDEALq Atorvastatin 80mg/ 
simvastatin 20mg or 
simvastatin 40mg 
8,888 7,461 (84) 3,737 3,724 449 240 209 1.15 
(0.95-1.40) 
SEARCHr Simvastatin 80mg/ 
simvastatin 20mg 
12,064 10,797 
(89) 
5,398 5,399 1,212 625 587 1.07 
(0.95-1.21) 
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Table 2.23: Incident Diabetes Reported in Major Statin Randomized Controlled Trials (Cont’d) 
Sources:  Navarese EP, Swiatkiewicz I, Sukiennik A, et al. Meta-analysis of impact of different types and doses of statins on new-
onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123. Preiss D, Sabatine MS, Braunwald E, et al. Risk of incident diabetes with 
intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-2564. Sattar N, Preiss D, 
Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 
2010;375(9716):735-742. 
Abbreviations: N, Sample size; DM, Diabetes mellitus; C.I., Confidence interval; ISD, Intensive statin dose; MSD, Moderate statin 
dose. 
aShepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 
WOSCOPS Group. N Engl J Med. 1995;333(20):1301-1307 [WOSCOPS, West of Scotland Coronary Prevention Study]. 
bDowns JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with 
average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622 [AFCAPS/TexCAPS, Air Force/Texas 
Coronary Atherosclerosis Prevention Study]. 
cMajor outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The 
ALLHAT-LLT. JAMA. 2002;288(23):2998-3007 [ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial]. 
dShepherd J, Blauw GJ, Murphy MB, et al. (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630 
[PROSPER, Pravastatin in Elderly Individuals at Risk of Vascular Disease]. 
eSever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who 
have average or lower-than-average cholesterol concentrations, in the ASCOT-LLA: a multicentre randomised controlled trial. 
Lancet. 2003;361(9364):1149-1158 [ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm]. 
fNakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a 
prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163 [MEGA, Management of Elevated Cholesterol in 
the Primary Prevention Group of Adult Japanese]. 
gRidker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive 
protein. N Engl J Med. 2008;359(21):2195-2207 [JUPITER, Justification for the Use of Statins in Prevention: an Intervention 
Trial Evaluating Rosuvastatin]. 
hMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-
controlled trial. Lancet. 2002;360(9326):7-22 [HPS, Heart Protection Study]. 
iRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the 4S. Lancet. 1994;344(8934):1383-
1389 [4S, Scandinavian Simvastatin Survival Study]. 
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Table 2.23: Incident Diabetes Reported in Major Statin Randomized Controlled Trials (Cont’d) 
jPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of 
initial cholesterol levels. The LIPID Study Group. N Engl J Med. 1998;339(19):1349-1357 [LIPID, Long-Term Intervention with 
Pravastatin in Ischaemic Disease]. 
kKjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-
2261 [CORONA, Controlled Rosuvastatin Multinational Study in Heart Failure]. 
lTavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a 
randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-1239 [GISSI-HF, Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure: Italy, double-blind trial of 3.9 years follow-up conducted in 
326 centers, men and women aged 18 years and older with symptomatic heart failure with average age of 68 years]. 
mResults of the low-dose (20 mg) pravastatin GISSI-P trial in 4271 patients with recent myocardial infarction: do stopped trials 
contribute to overall knowledge? GISSI-P Investigators. Ital Heart J. 2000;1(12):810-820 [GISSI-P, Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico Prevenzione]. 
nCannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. 
N Engl J Med. 2004;350(15):1495-1504 [PROVE IT-TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22: Double-blind trial conducted in 8 countries and 349 centers with a mean follow-up 
of 2 years, men and women with acute coronary syndrome]. 
ode Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute 
coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-1316 [A to Z, Aggrastat to Zocor trial: Double-blind 
trial conducted in 322 centers of 41 countries, men and women with acute coronary syndrome aged 21-80 years with baseline 
LDL-C of 112 mg/dL]. 
pLaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl 
J Med. 2005;352(14):1425-1435 [TNT, Treating to New Targets clinical trial]. 
qPedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after 
myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445 [IDEAL, Incremental 
Decrease in End Points Through Aggressive Lipid Lowering]. 
rArmitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 
12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-1669 [SEARCH, 
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine]. 
 
118 
 
2.4.3 Meta-Analysis of RCTs 
Shortly after the publication of the 2008 JUPITER study that showed pravastatin 
was associated with a 26 percent increase in the odds of new onset diabetes, Rajpathak et 
al. (2009) published the results of a meta-analysis of six RCTs, comprising WOSCOPS, 
HPS, ASCOT-LLA, LIPID, CORONA, and, of course, JUPITER, to investigate the 
hypothesis that statin therapy is associated with increased risk of diabetes.
303
 Their results 
showed that statin use was associated with a 13 percent significant increase in diabetes 
risk (RR=1.13, C.I.=1.03-1.23, p=0.008), with no evidence of heterogeneity across trials 
when the WOSCOP trial (which originally showed a protective effect of statin against 
diabetes) was excluded from the analyses. Upon inclusion of the WOSCOP trial, a non-
significant increase of 6 percent in diabetes risk (RR=1.06, 95% C.I.=0.93-1.25, p=0.38) 
was associated with statin use, with evidence of heterogeneity across trials.  
The results of subsequent meta-analyses has shown an overall tendency of statin 
therapy to be associated with an increased risk in diabetes, with one meta-analysis 
recording a non-statistically significant increase of diabetes or worsening of insulin 
sensitivity,
304
 while others showed a statistically significant increased risk of diabetes.
305
 
For example, Mills et al. (2011) investigated the risk of statin-associated incident diabetes 
                                                 
303 Rajpathak SN et al., "Statin therapy and risk of developing type 2 diabetes: a meta-analysis." 
304 Baker WL et al., "Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review 
and meta-analysis." 
305 Navarese EP et al., "Meta-analysis of impact of different types and doses of statins on new-onset 
diabetes mellitus."; Mills EJ et al., "Efficacy and safety of statin treatment for cardiovascular disease: a 
network meta-analysis of 170,255 patients from 76 randomized trials."; Preiss D et al., "Risk of incident 
diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis."; Sattar N et al., 
"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials." 
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in a meta-analysis of 17 large RCTs comprising 111,003 participants. Study results 
showed that the odds of incident diabetes increased by 9 percent in statin users compared 
to controls (OR=1.09, 95% C.I.=1.02-1.16), with little heterogeneity between trials.
306
 
Similarly, a meta-analyses of 13 large RCTs comprising 91, 140 patients by Sattar 
et al. (2010) showed that statin therapy was associated with a 9 percent increase in the 
odds of  incident diabetes (OR=1·09, 95% C.I.=1·02–1·17), with little heterogeneity 
between trials.
307
 A sub-analyses of the association between the individual statins and 
incident diabetes showed that rosuvastatin (3 RCTs) was associated with the highest 
increase in diabetes odds of 18 percent, while atorvastatin (1 RCT), simvastatin (2 
RCTs), and pravastatin (6 RCTs) were associated with a 14 percent, 11 percent, and 3 
percent increase in the odds of incident diabetes, respectively. Moreover, lovastatin (1 
RCT) was associated with a 2 percent protective effect. 
A more recent meta-analysis of 55 RCTs comprising 113,698 patients conducted 
by Naci et al. (2013) also showed that statin therapy was associated with a 9 percent 
increase in the odds of incident diabetes compared to controls (OR=1.09, 95% C.I.=1.02-
1.16), with little heterogeneity between trials, and with no statistically detectable 
differences between individual statins in terms of diabetes mellitus incidence.
308
 
                                                 
306 Mills EJ et al., "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-
analysis of 170,255 patients from 76 randomized trials." 
307 Sattar N et al., "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin 
trials." 
308 Naci H et al., "Comparative tolerability and harms of individual statins: A study-level network meta-
analysis of 246 955 participants from 135 randomized controlled trials." 
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However, another recent meta-analysis of 17 RCTs comprising 113,394 patients 
by Navarese et al. (2013) showed a mixed result with respect to the type and daily dose of 
statin used.
309
 Though not statistically significant, pravastatin 40mg was shown to be 
associated with the lowest increase in the odds of new onset diabetes compared with 
placebo (OR=1.07, 95% C.I.=0.86 – 1.30), while rosuvastatin 20mg was found to be 
associated with the highest increase in the odds of new onset diabetes when compared 
with placebo (OR=1.25, 95% C.I.=0.82 – 1.90). The overall results of this meta-analysis 
indicated a  non-statistically significant protective effect, or a non-statistically significant 
increase in the odds of diabetes associated with different types and doses of statin, with 
odds ratio ranging from 0.9-1.25 (i.e.,10 percent reduction in the odds of diabetes to 25 
percent increase in the odds of diabetes). 
In summary, evidence from meta-analysis of RCTs leaned towards statins being 
significantly associated with a moderate increase in risk of diabetes. 
2.4.4 Observational Studies  
Since the FDA’s announcement of safety labeling changes to all statins in 
February 2012, ten observational studies have been published that tested the hypothesis 
of whether increased risk of incident diabetes is associated with statin therapy. These 
studies examined the association between incident diabetes and statins as a class, as well 
as the effects of various types and doses of statins on the risk of incident diabetes. The 
observational studies that were published after the statin labeling changes included seven 
                                                 
309 Navarese EP et al., "Meta-analysis of impact of different types and doses of statins on new-onset 
diabetes mellitus." 
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retrospective cohort studies,
310
 two prospective cohort studies,
311
 and one case-control 
study.
312
 Five of these aforementioned studies examined the effects of statins as a class 
on incident diabetes. Four of the five studies concluded that statins were significantly 
associated with increased risk of new onset diabetes,
313
 whereas one study found a non-
significant increase in risk.
314
 
Moreover, two studies conducted before the statin labeling change concluded that 
statins were generally associated with an increased risk of incident diabetes.
315
 A 2009 
retrospective cohort study found fasting plasma glucose to be significantly increased 
among statin users compared to non-users,
316
 whereas a 2004 case-control study found a 
non-statistically significant increased risk of incident diabetes with statin use.
317
 
                                                 
310 Ko DT et al., "Diabetes mellitus and cardiovascular events in older patients with myocardial infarction 
prescribed intensive-dose and moderate-dose statins."; Danaei G et al., "Statins and risk of diabetes: an 
analysis of electronic medical records to evaluate possible bias due to differential survival."; Carter AA et 
al., "Risk of incident diabetes among patients treated with statins: population based study."; Zaharan NL et 
al., "Statins and risk of treated incident diabetes in a primary care population."; Wang KL et al., "Statins, 
risk of diabetes, and implications on outcomes in the general population."; Ma T et al., "Statins and new-
onset diabetes: a retrospective longitudinal cohort study."; Ma T et al., "The long-term effect of statins on 
the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: 
a retrospective longitudinal cohort study." 
311 Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive patients at high 
cardiovascular risk."; Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women 
in the Women's Health Initiative." 
312 Chen CW et al., "Differential impact of statin on new-onset diabetes in different age groups: a 
population-based case-control study in women from an Asian country." 
313 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival."; Zaharan NL et al., "Statins and risk of treated incident diabetes 
in a primary care population."; Wang KL et al., "Statins, risk of diabetes, and implications on outcomes in 
the general population."; Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal 
women in the Women's Health Initiative." 
314 Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive patients at high 
cardiovascular risk." 
315 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients."; Jick 
SS and Bradbury BD, "Statins and newly diagnosed diabetes." 
316 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients." 
317 Jick SS and Bradbury BD, "Statins and newly diagnosed diabetes." 
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In addition to examining the risk of incident diabetes in statins as a class, some of 
these observational studies also examined whether certain types and doses of statins are 
associated or not associated with increased risk of incident diabetes. Evidence from the 
observational studies suggested that simvastatin and atorvastatin had the greatest 
potential to be significantly associated with increased risk of incident diabetes, while 
fluvastatin and lovastatin had the least potential to be significantly associated with an 
increased risk. Pravastatin and rosuvastatin appears to have moderate potential to be 
significantly associated with increased risk. None of the observational studies evaluated 
the association of pitavastatin and incident diabetes.  
With respect to statin doses and its association with incident diabetes, a 2013 
retrospective cohort study found no significant difference in the proportion of patients on 
intensive dose statin and those on moderate dose statin that had new onset diabetes.
318
 
Overall, the evidence from observational studies appears to indicate that statins 
are generally associated with a moderate increased risk of incident diabetes, with a 
majority of statins recording a statistically significant increase in risk, while a minority 
recorded a non-statistically significant increase in risk. Some statins showed both a 
statistically significant and a statistically non-significant protective effect against 
diabetes. Table 2.24 summarizes the study characteristics and results of observational 
studies examining the association between statin use and reports of incident diabetes, 
while Table 2.25 summarizes the relative risk (i.e., hazard ratio and odds ratio), including 
                                                 
318 Ko DT et al., "Diabetes mellitus and cardiovascular events in older patients with myocardial infarction 
prescribed intensive-dose and moderate-dose statins." 
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the statistical significance of the relative risk (i.e., Table 2.26) of the association between 
different types of statins and incident diabetes that are reported in observational studies.  
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Table 2.24: Incident Diabetes Reported in Observational Studies 
 Title Study cohort Region Outcomes Statistical Analysis Results 
RETROSPECTIVE COHORT 
Ko, 
2013a 
Diabetes mellitus 
and cardiovascular 
events in older 
patients with 
myocardial 
infarction prescribed 
intensive-dose and 
moderate-dose 
statins 
17,080 
hospitalized 
patients with MI, 
8540 matched 
pairs, mean 
age=78 years 
Canada NOD 
compared 
between 
patients 
prescribed IDS 
vs. MDS 
Kaplan-Meier 
survival curves 
between the two 
group were 
compared using 
stratified log rank 
test 
At 5 years, no 
significant difference 
in the proportion of 
IDS patients (13.6%) 
and MDS patient 
(13%) that  had NOD 
(p=0.19) 
Danaei, 
2013b 
Statins and risk of 
diabetes: an analysis 
of electronic medical 
records to evaluate 
possible bias due to 
differential survival 
285,864 men and 
women aged 50-
84 years without 
DM 
United 
Kingdom 
Incident T2D 
between statin 
initiators and 
non-initiators 
Estimated the 
observational analog 
of ITT hazard ratio of 
DM for initiators vs. 
non-initiators by 
fitting a Cox model 
Statin initiation was 
significantly 
associated with 
increased risk of 
T2D. HR=1.14 (95% 
C.I.=1.10-1.19) 
Carter, 
2013c 
Risk of incident 
diabetes among 
patients treated with 
statins: population 
based study 
471,250 patients, 
median age=73 
years, 54% 
women 
Canada Incident 
diabetes 
between other 
statins and 
pravastatin 
Time to event 
analyses using Cox 
proportional hazard 
regression to 
estimate relation 
between use of statin 
and incident diabetes 
Compared to 
pravastatin, there 
was significant 
increased risk of 
NOD with 
atorvastatin, 
rosuvastatin, and 
simvastatin; but not 
with fluvastatin or 
lovastatin 
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Table 2.24: Incident Diabetes Reported in Observational Studies (Cont’d) 
 Title Study cohort Region Outcomes Statistical Analysis Results 
RETROSPECTIVE COHORT (Cont’d) 
Ma, 
2012d 
The long-term effect 
of statins on the risk 
of new-onset 
diabetes mellitus in 
elderly Taiwanese 
patients with 
hypertension and 
dyslipidaemia: a 
retrospective 
longitudinal cohort 
study 
15,637 elderly 
hypertensive and 
dyslipidemic 
patients, 65-80 
years, mean 
age=75 years, 
57% women 
Taiwan Effect of 
statins on the 
development 
of NOD 
compared to 
non-users 
Cox regression model 
to estimate time to 
development of  NOD 
for each statin 
Compared to non-
users, there was 
significant increased 
risk of NOD with 
lovastatin and 
simvastatin; 
significant decreased 
risk with 
atorvastatin and 
rosuvastatin; and no 
difference in risk 
with fluvastatin and 
pravastatin 
Zaharan, 
2012e 
Statins and risk of 
treated incident 
diabetes in a 
primary care 
population 
239,628 patients 
who received 
statin 
monotherapy 
Ireland  Incident 
diabetes 
between 
statin users 
and non-users 
Time to NOD was 
compared between 
statin users and non-
users using the Cox 
proportional hazard 
regression model 
Statin use was 
associated with a 
significant increased 
risk of NOD 
(HR=1.20, 95% 
C.I.=1.17-1.23) 
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Table 2.24: Incident Diabetes Reported in Observational Studies (Cont’d) 
 Title Study cohort Region Outcomes Statistical Analysis Results 
RETROSPECTIVE COHORT (Cont’d) 
Ma, 
2012f 
Statins and new-
onset diabetes: A 
retrospective 
longitudinal cohort 
study 
16,027 patients 
with 
hypertension and 
dyslipidemia aged 
20-84 years, 
mean age=60 
years, 54% 
women 
Taiwan Effect of 
statins on the 
development 
of NOD 
compared to 
non-users 
Cox regression model 
to estimate time to 
development of  NOD 
for each statin 
Compared to non-
users, there was 
significant increased 
risk of NOD with 
pravastatin; 
significant decreased 
risk with fluvastatin, 
rosuvastatin and 
lovastatin; and no 
difference in risk 
with atorvastatin 
and simvastatin 
Wang, 
2012g 
Statins, risk of 
diabetes, and 
implications on 
outcomes in the 
general population 
42,060 men and 
women aged ≥45 
years and ≥55 
years, 
respectively 
Taiwan Incident 
diabetes 
between statin 
users and non-
users 
-Kaplan-Meier 
survival curves 
between statin users 
and non-users  were 
compared using 
stratified log rank test 
-Cox regression 
model to estimate 
time to development 
of  NOD between 
statin users and non-
users 
-Cumulative 
incidence of diabetes 
were significantly 
higher in statin users 
(22.7%) compared 
to non-users 
(20.8%)(p<0.001) 
-NOD significantly 
increased with statin 
use (HR=1.15, 95% 
C.I.=1.08-1.22) 
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Table 2.24: Incident Diabetes Reported in Observational Studies (Cont’d) 
 Title Study cohort Region Outcomes Statistical Analysis Results 
RETROSPECTIVE COHORT (Cont’d) 
Sukhija, 
2009h 
Effect of statins on 
fasting plasma 
glucose in diabetic 
and nondiabetic 
patients 
345,417 patients, 
mean age=61 
years, 94% males, 
6% diabetic 
USA 
Veterans 
Affairs 
Effect of 
statins on FPG 
in nondiabetic 
and diabetic 
patients 
Multiple regression 
to compare 
difference in  FPG 
change between 
statin users and non-
users  
FPG significantly 
increased in statin 
users compared to 
non-users  among 
diabetic (p<0.0001) 
and non-diabetic 
populations 
(p<0.0001) 
PROSPECTIVE COHORT 
Izzo, 
2013i 
Primary prevention 
with statins and 
incident diabetes in 
hypertensive 
patients at high 
cardiovascular risk 
4,750 
hypertensive, non-
diabetic patients, 
mean age=59 
years, 58% men 
Italy Risk of 
incident DM 
with statin use 
Hazard functions for 
incident DM were 
generated by Cox 
regression analysis 
comparing 
participants taking 
or not taking statins 
Statins were not 
significantly  
associated with 
increased risk of 
incident DM 
(HR=1.03, 95% 
C.I.=0.79-1.35) 
Culver, 
2012j 
Statin use and risk 
of diabetes mellitus 
in postmenopausal 
women in the WHI 
153,840 
postmenopausal 
women aged 50-
79 years, mean 
age=63 years 
USA 
40 
centers 
Risk of 
incident DM 
with statin use 
Cox proportional 
hazards model used 
to estimate HRs of 
DM by statin 
medication use 
Statin use was 
significantly 
associated with 
increased risk in 
incident DM 
(HR=1.48, 95% 
C.I.=1.38-1.59) 
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Table 2.24: Incident Diabetes Reported in Observational Studies (Cont’d) 
 Title Study cohort Region Outcomes Statistical Analysis Results 
CASE-CONTROL 
Chen, 
2013k 
Differential impact 
of statin on new-
onset diabetes in 
different age 
groups: a 
population-based 
case-control study 
in women from an 
Asian country 
1065 female 
patients with 
NOD and 10650 
matched-controls, 
mean age=61 
years 
Taiwan  Risk of 
incident DM 
with statin use 
Multiple logistic 
regression to 
examine whether 
statin use was an 
independent risk 
factor of NOD 
Increased risk of DM 
was associated with 
use of atorvastatin, 
rosuvastatin, 
simvastatin, and 
pravastatin compared 
to non-users. 
Jick, 
2004l 
Statins and newly 
diagnosed diabetes 
588 cases and 
2063 matched 
controls aged 30-
79 years, mean 
age of 59 years, 
51% male 
United 
Kingdom 
Odds of 
incident DM 
with statin use 
Conditional logistic 
regression 
Statins were not 
significantly 
associated with 
increased risk of DM 
(OR=1.1, 95% 
C.I.=0.8-1.4) 
Abbreviations: MI, Myocardial infarction; NOD, New-onset diabetes; IDS, Intensive-dose statin; MDS, Moderate-dose statin; DM, 
Diabetes mellitus; T2D, Type 2 diabetes; ITT, Intention-to-treat; HR, Hazard ratio; C.I., Confidence interval; FPG, Fasting plasma 
glucose; WHI, Women’s Health Initiative. 
aKo DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, Tu JV. Diabetes mellitus and cardiovascular events in older patients 
with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 
2013;6(3):315-322. 
bDanaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical 
records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236. 
cCarter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with 
statins: population based study. BMJ. 2013;346:f2610. 
dMa T, Chang MH, Tien L, Liou YS, Jong GP. The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly 
Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging. 
2012;29(1):45-51. 
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Table 2.24: Incident Diabetes Reported in Observational Studies (Cont’d) 
eZaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 
2013;75(4):1118-1124. 
fMa T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 
2012;34(9):1977-1983. 
gWang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 
2012;60(14):1231-1238. 
hSukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig 
Med. 2009;57(3):495-499. 
iIzzo R, de Simone G, Trimarco V, et al. Primary prevention with statins and incident diabetes in hypertensive patients at high 
cardiovascular risk. Nutr Metab Cardiovasc Dis. 2013;23(11):1101-1106. 
jCulver AL, Merriam PA, Rahilly-Tierny C, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative. Arch Intern Med. 2012;172(2):144. 
kChen CW, Chen TC, Huang KY, Chou P, Chen PF, and Lee CC. Differential impact of statin on new-onset diabetes in different age 
groups: a population-based case-control study in women from an Asian country. PLoS One. 2013;8(8):e71817. 
lJick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58(3):303-309. 
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Table 2.25: Summary of the Association between Different Types of Statins 
and Incident Diabetes Reported in Observational Studies 
Study Statin Adjusted HR (95% C.I.) 
RETROSPECTIVE COHORT 
Danaei, 2013a Atorvastatin  1.22 (1.12-1.32) 
Fluvastatin 1.02 (0.69-1.50) 
Pravastatin 1.01 (0.84-1.21) 
Rosuvastatin 1.11 (0.89-1.38) 
Simvastatin  1.14 (1.09-1.20) 
Carter, 2013b Atorvastatin  1.22 (1.15-1.29) 
Fluvastatin 0.95 (0.81-1.11) 
Lovastatin 0.99 (0.86-1.14) 
Rosuvastatin 1.18 (1.10-1.26) 
Simvastatin  1.10 (1.04-1.17) 
 Ma, 2012c Atorvastatin  0.77 (0.72-0.83) 
Fluvastatin 1.00 (0.87-1.16) 
Lovastatin 1.36 (1.24-1.48) 
Pravastatin 1.07 (0.94-1.23) 
Rosuvastatin 0.66 (0.52-0.83) 
Simvastatin  1.30 (1.14-1.47) 
Zaharan, 2012d Atorvastatin  1.25 (1.21-1.28) 
Fluvastatin 1.04 (0.91-1.18) 
Pravastatin 1.02 (0.98-1.06) 
Rosuvastatin 1.42 (1.33-1.52) 
Simvastatin  1.14 (1.06-1.23) 
Ma, 2012e Atorvastatin  1.15 (0.96-1.35) 
Fluvastatin 0.46 (0.33-0.61) 
Lovastatin 0.70 (0.59-0.83) 
Pravastatin 1.30 (1.13-1.56) 
Rosuvastatin 0.54 (0.39-0.76) 
Simvastatin  1.11 (0.92-1.32) 
PROSPECTIVE COHORT 
Culver, 2012f Atorvastatin  1.61 (1.26-2.06) 
Fluvastatin 1.61 (1.35-1.92) 
Lovastatin 1.35 (1.19-1.55) 
Pravastatin 1.63 (1.43-1.87) 
Simvastatin  1.41 (1.25-1.61) 
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Table 2.25: A Summary of the Association between Different Types of Statins 
and Incident Diabetes Reported in Observational Studies (Cont’d) 
Study Statin Adjusted OR (95% C.I.) 
CASE-CONTROL 
Chen, 2013g Atorvastatin  2.80 (1.74-4.49) 
Pravastatin 3.41 (1.66-7.04) 
Rosuvastatin 4.69 (2.78-7.92) 
Simvastatin  4.09 (2.52-6.64) 
Jick, 2004h Pravastatin 0.70 (0.40-1.20) 
Simvastatin 1.00 (0.70-1.30) 
Abbreviations: HR, Hazard ratio; OR, Odds ratio; C.I., Confidence interval. 
aDanaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of 
diabetes: an analysis of electronic medical records to evaluate possible bias due to 
differential survival. Diabetes Care. 2013;36(5):1236 [Reference = non-statin users: 
adjusted for age, sex, LDL-C, HDL-C, BMI, systolic BP, alcohol use, smoking, medications 
such as antihypertensives, NSAIDs, β-blockers, hormone replacement therapy, steroids, 
antidepressants, immunosuppressants, chemotherapy, and medical conditions 
including COPD, atrial fibrillation, depression, hypothyroidism, osteoporosis, psoriasis, 
rheumatoid arthritis, and chronic pancreatitis]. 
bCarter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident 
diabetes among patients treated with statins: population based study. BMJ. 
2013;346:f2610 [Reference = pravastatin: adjusted for age, sex, year of cohort entry, 
recent acute coronary syndrome, chronic coronary artery disease, Charlson score, 
previous use of thiazide, nitroglycerin, angiotensin receptor blocker, β-blocker, 
hormones and analogues]. 
cMa T, Chang MH, Tien L, Liou YS, Jong GP. The long-term effect of statins on the risk of new-
onset diabetes mellitus in elderly Taiwanese patients with hypertension and 
dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging. 2012;29(1):45-51 
[Reference = non-statin users: adjusted for age, sex, concomitant medication usage 
(aspirin, diuretics, β-blockers, calcium channel blockers, ACE-inhibitors, ARBs, α-
blockers, and vasodilators), and mean dose of statin]. 
dZaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a 
primary care population. Br J Clin Pharmacol. 2013;75(4):1118-1124 [Reference = non-
statin users: adjusted for gender, age group, prescriptions for oral corticosteroids, 
antipsychotics, antihypertensives, nitrates, and lipid lowering agents such as ezetimibe, 
omega-3, fibrates, niacin]. 
eMa T, Tien L, Fang C-L, Liou Y-S, Jong G-P. Statins and new-onset diabetes: a retrospective 
longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983 [Reference = non-statin 
users: adjusted for age, sex, concomitant medications such as aspirin, diuretics, β-
blockers, calcium channel blockers, ACE-inhibitors, ARBs, α-blockers, and vasodilators, 
and mean dose of statin]. 
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Table 2.25: A Summary of the Association between Different Types of Statins 
and Incident Diabetes Reported in Observational Studies (Cont’d) 
fCulver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in 
postmenopausal women in the Women's Health Initiative. Arch Intern Med. 
2012;172(2):144-152 [Reference = non-statin users: adjusted for age, race/ethnicity, 
education, cigarette smoking, BMI, physical activity, alcohol intake, energy intake, family 
history of DM, hormone therapy use, study arms, and self-report of CVD at baseline]. 
gChen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-
onset diabetes in different age groups: a population-based case-control study in women 
from an asian country. PLoS One. 2013;8(8):e71817 [Reference = non-statin users: 
adjusted for gender, diseases such as hypertension, CHD, diabetes, hyperlipidemia, 
atrial fibrillation, CKD, obesity, PAD, medications such as non-statin lipid lowering 
drugs, aspirin, ACE-Is, TG-lowering medications, hormone therapy, SES, geographic 
region, and urbanization level of residence].  
hJick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 
2004;58(3):303-309 [Reference = non-statin users: adjusted for BMI, hypertension, 
steroid use, smoking, and number of GP visits within 3 years preceding the index date. 
Matched on gender, age, practice area of physician, index date, and length of history of 
patients in the database].  
 
Table 2.26: A Summary of Table 2.25 Showing the Statistical Significance of the 
Hazard Ratios and Odds Ratios of the Association between Different Statin 
Types and Incident Diabetes Obtained from Observational Studies 
Statin Increased Risk Protective Effect 
Significant Not-
significant 
Significant Not-
significant 
Atorvastatin ***** * *  
Fluvastatin * ** * ** 
Lovastatin **  * * 
Pravastatin *** ***  * 
Rosuvastatin *** * **  
Simvastatin ****** *  * 
Sub-total  20 8 5 5 
Total 28 10 
*One count of observational study in which the stated statin showed increased risk 
or protective effect. 
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2.5 SECTION V: STUDY RATIONALE, STUDY PURPOSE, 
STUDY OBJECTIVES AND HYPOTHESES, AND STUDY AIMS 
2.5.1 Study Rationale  
The benefits of statins in both primary and secondary prevention of 
cardiovascular diseases are well documented in several studies. The recent change to 
statin labeling by the FDA to suggest an increased risk of diabetes through increases in 
A1C and plasma glucose level have prompted several investigators to assess the 
hypothesis of whether statins are truly diabetogenic. Most of the evidence from RCTs, 
meta-analyses of RCTs, and observational studies suggests that statins are moderately 
associated with increased risk; however, results of these associations are not consistent. 
While a majority of the results (with a mixture of statistical and non-statistical 
significance) indicates a moderate increase in risk, some studies suggest a protective 
effect of statins on diabetes.  
Due to the inconsistency in the results obtained from previous studies, this 
observational study was conducted to further confirm or reject the hypothesis that statins 
are associated with increased risk of diabetes mellitus. In addition, this study was being 
undertaken because the majority of published observational studies examining the 
association between statin therapy and incident diabetes were carried out using non-US 
data. Even more importantly, several of the observational studies failed to account for the 
influence of certain important variables such as obesity, statin dosage intensity, and 
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hyperlipidemia that may confound the association between statin therapy and the 
development of incident diabetes.  
Overall, the results from this study will provide further evidence as to the 
diabetogenic nature of statins. This information may provide additional guidance to 
clinicians in their decision to continue to use statins in patients with comorbid 
hypertension, dyslipidemia and cardiovascular diseases who are at high risk of 
developing diabetes.   
2.5.2 Study Purpose 
This study has two primary purposes. The first purpose of this study was to 
examine whether the development of incident diabetes differed between two exposure 
groups (i.e., between statin users or the exposed group and non-statin users or the 
unexposed group). The second purpose of this study was to examine whether the 
development of incident diabetes differed by the intensity of the statin dosage (i.e., 
intensive-dose statin vs. moderate-dose statin) to which subjects were exposed. 
Both of these study purposes were accomplished by using two statistical 
approaches suitable for a retrospective cohort design. First, this study used survival 
analysis to compare the survival time (i.e., time between first drug use and the first 
diagnosis of diabetes) between statin users and non-statin users, between users of each 
statin type and non-statin users, and between intensive-dose statin users and moderate-
dose statin users. Second, this study used a binary logistic regression analysis to compare 
incidence of diabetes mellitus between statin users and non-statin users, between users of 
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each statin type and non-statin users, and between intensive-dose statin users and 
moderate-dose statin users. 
Both of these analyses were conducted while controlling for demographic 
variables (i.e., age and gender) and clinical covariates (i.e., hyperlipidemia, obesity, 
hypertension, statin medication adherence, diabetogenic medications, and Charlson 
comorbidity index [CCI] score) that were appropriate for each statistical analysis. 
2.5.3 Study Objectives and Hypotheses 
The present study has 12 objectives. The specific study objectives with 
hypotheses for each objective are as follows: 
Objective 1: To assess whether demographic characteristics (i.e., age and gender) differ 
between statin users and non-statin users.  
H1a:  Statin users will have a significantly higher mean age compared to non-
statin users. 
H1b: There is a significant association between exposure group (i.e., statin users 
and non-statin users) and gender. 
Objective 2:  To assess whether hyperlipidemia diagnosis differs between statin users 
and non-statin users.  
H2: The proportion of statin users with a hyperlipidemia diagnosis will be 
significantly higher compared to that of non-statin users.  
Objective 3: To assess whether obesity diagnosis differs between statin users and non-
statin users. 
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H0(3): There is no significant difference in the proportion of statin users and non-
statin users who have an obesity diagnosis. 
Objective 4: To assess whether hypertension diagnosis differs between statin users and 
non-statin users. 
H4: The proportion of statin users with a hypertension diagnosis will be 
significantly higher compared to that of non-statin users. 
Objective 5: To assess whether the mean number of prescriptions for all diabetogenic 
medications and the mean number of prescriptions for each diabetogenic medication (i.e., 
thiazide diuretics, β-blockers, antipsychotics, antidepressants, immunosuppressants, and 
glucocorticoids) differ between statin users and non-statin users.  
H0(5a): There is no significant difference in the mean number of prescriptions for 
all diabetogenic medications between statin users and non-statin users. 
H0(5b): There is no significant difference in the mean number of thiazide diuretic 
prescriptions for statin users and non-statin users. 
H0(5c): There is no significant difference in the mean number of β-blocker 
prescriptions for  statin users and non-statin users. 
H0(5d): There is no significant difference in the mean number of antipsychotic 
prescriptions for statin users and non-statin users. 
H0(5e): There is no significant difference in the mean number of antidepressant 
prescriptions for statin users and non-statin users. 
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H0(5f): There is no significant difference in the mean number of 
immunosuppressant prescriptions for statin users and non-statin users.. 
H0(5g): There is no significant difference in the mean number of glucocorticoid 
prescriptions for statin users and non-statin users. 
Objective 6: To compare the mean CCI score between statin users and non-statin users.  
H0(6): There is no significant difference in the mean CCI score between statin 
users and non-statin users. 
Objective 7: To assess whether medication adherence (using MPR) differs among users 
of each statin type, and between intensive-dose statin users and moderate-dose statin 
users. 
H0(7a): There is no significant difference in mean medication possession ratio 
(MPR) among users of each statin type. 
H7b: The mean medication possession ratio (MPR) will be significantly lower 
among intensive-dose statin users compared to moderate-dose statin users. 
Objective 8 (Survival Analysis – Log-rank test and Kaplan-Meier Curves): To 
assess whether survival times (i.e., time to occurrence of diabetes) differ between statin 
users and non-statin users, among users of each statin type, and between intensive-dose 
statin users and moderate-dose statin users.  
H8a: Statin users will have a shorter survival time compared to non-statin users. 
H0(8b): There is no significant difference in the mean survival time among users 
of each statin type. 
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H8c: Intensive-dose statin users will have a shorter survival time compared to 
moderate-dose statin users. 
Objective 9 (Survival Analysis – Cox Regression): To assess whether survival times 
differ between statin users and non-statin users, and between users of each statin type and 
non-statin users, while controlling for demographic variables (i.e., age and gender), and 
clinical covariates (i.e., hyperlipidemia, obesity, hypertension, diabetogenic medication 
use, and CCI score). 
H9a: Statin users will have a significantly shorter survival time compared to 
non-statin users while controlling for age, gender, and clinical covariates. 
H9b: Atorvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
H9c: Fluvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
H9d: Lovastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
H9e: Pravastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
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H9f: Rosuvastatin users will have a significantly shorter survival time 
compared to non-statin users while controlling for age, gender, and 
clinical covariates. 
H9g: Simvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
Objective 10 (Survival Analysis – Cox Regression):   To assess whether survival times 
differ between intensive-dose statin users and moderate-dose statin users, while 
controlling for demographic variables (i.e., age and gender), and clinical covariates (i.e., 
hyperlipidemia, obesity, hypertension, medication adherence, diabetogenic medication 
use, and CCI score). 
H10: Intensive-dose statin users will have a significantly shorter survival time 
compared to moderate-dose statin users while controlling for age, gender, 
and clinical covariates. 
Objective 11 (Binary Logistic Regression):   To assess whether incidence of diabetes 
differs between statin users and non-statin users, and between users of each statin type 
and non-statin users, while controlling for demographic variables (i.e., age and gender), 
and clinical covariates (i.e., hyperlipidemia, obesity, hypertension, diabetogenic 
medication use, and CCI score). 
H11a: The proportion of statin users with incident diabetes will be significantly 
higher compared to that of non-statin users.  
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H11b: The proportion of statin users with incident diabetes will be significantly 
higher than that of non-statin users while controlling for age, gender and 
clinical covariates. 
H11c: The proportion of atorvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
H11d: The proportion of fluvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
H11e: The proportion of lovastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
H11f: The proportion of pravastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
H11g: The proportion of rosuvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
H11h: The proportion of simvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
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Objective 12 (Binary Logistic Regression):   To assess whether incidence of diabetes 
differs between intensive-dose statin users and moderate-dose statin users, while 
controlling for demographic variables (i.e., age and gender), and clinical covariates (i.e., 
hyperlipidemia, obesity, hypertension, medication adherence, diabetogenic medication 
use, and CCI score). 
H12: The proportion of intensive-dose statin users with incident diabetes will be 
significantly higher than that of moderate-dose statin users while 
controlling for age, gender and clinical covariates. 
2.5.4 Study Aims 
The 12 study objectives presented above are summarized by the following four 
study aims: 
Aim 1: To compare the demographic (i.e., age and gender) and clinical 
characteristics (i.e., hyperlipidemia, obesity, hypertension, diabetogenic medication use, 
and CCI score) between statin users and non-statin users (Objectives 1 – 6). 
Aim 2:  To compare medication adherence among users of each statin type, and 
between intensive-dose statin users and moderate-dose statin users (Objective 7). 
Aim 3: Using survival analysis, to compare time to diabetes (or survival time) 
between statin users and non-statin users, between users of each statin type and non-statin  
users, and between intensive-dose statin users and moderate-dose statin users (Objectives 
8 – 10). 
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Aim 4: Using binary logistic regression analysis, to compare incidence of diabetes 
between statin users and non-statin users, between users of each statin type and non-statin 
users, and between intensive-dose statin users and moderate-dose statin users (Objectives 
11 & 12). 
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CHAPTER 3: METHODOLOGY 
3.1 CHAPTER OVERVIEW 
 This section provides a detailed description of the study design (i.e., study 
population, study timeline, formation of the retrospective study cohorts, inclusion and 
exclusion criteria), data source (description of the MarketScan® data elements, coding of 
the diagnosis and procedure codes in the MarketScan® database), sample size 
calculation, study variables and the data analysis procedures. 
3.2 INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL 
 The study protocol submission was granted an IRB waiver by the Office of 
Research Support of The University of Texas at Austin’s Institution Review Board 
because a secondary analysis of de-identified data does not meet the criteria to be 
considered human subjects research. 
3.3 STUDY DESIGN 
 The study utilized a retrospective cohort design using an administrative claims 
database containing patients’ pharmacy and medical claims to answer the research 
question of whether statin therapy was associated with an increased risk of diabetes 
incidence. Other investigators have used a retrospective cohort design (with survival 
analysis
319
 and binary logistic regression analysis
320
 procedures) to assess the association 
between drug exposure and incident diabetes in observational studies. 
                                                 
319 Carter AA et al., "Risk of incident diabetes among patients treated with statins: population based 
study."; Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
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3.3.1 Study Population 
The base population for this study consisted of patients in the MarketScan 
database period of January 1, 2003 and December 31, 2004.  
The following inclusion/exclusion criteria applied to the study population: 
 Aged 20 – 63 years at index date (the index date for the statin and the non-statin 
groups was defined as the date of the first prescription claim for a statin or a non-
statin drug, starting from July 1, 2003. In other words, the index drugs were 
identified within the index period of July 1, 2003 and January 1, 2004).  
 Did not have a diagnosis of diabetes mellitus (ICD-9-CM codes 250.xx) in the 
pre-index period (the pre-index period for the statin and the non-statin groups was 
defined as a period of six months before the statin or the non-statin drug index 
dates). The six months of pre-index period was to ensure only incident diabetes 
cases were being measured; 
 Continuously enrolled during the pre-index period and for at least one year after 
the index date; 
 Patients who were 65 years and older were excluded due to the possibility of dual 
eligibility for private/public insurance and Medicare, and the consequent 
possibility of incomplete information. 
                                                                                                                                                 
possible bias due to differential survival."; Ko DT et al., "Diabetes mellitus and cardiovascular events in 
older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins."; Wang KL 
et al., "Statins, risk of diabetes, and implications on outcomes in the general population."; Zaharan NL et 
al., "Statins and risk of treated incident diabetes in a primary care population." 
320 Khoza S. "Use of antidepressant agents and the incidence of type 2 diabetes mellitus: A methodological 
comparison." Dissertation, The University of Texas at Austin, 2011. 
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3.3.2 Study Timeline 
 The overall timeframe for the study was the MarketScan data period between 
January 1, 2003 and December 31, 2004. Subjects were eligible for study inclusion if 
they had continuous enrollment during the pre-index period and also had a minimum 
continuous enrollment period of 12 months after the index medication. Subjects were 
allowed to enter the statin or the non-statin cohort any time from July 1, 2003, the earliest 
index date, until January 1, 2004, the latest index date. Subjects may therefore have 
different index dates and follow-up periods due to the open nature of the cohort entry. 
However, each index date was preceded by a six months of pre-index period for the 
purpose of excluding subjects with previous diagnosis of diabetes or previous use of the 
index medication. Subjects were allowed to exit either the statin or the non-statin cohort 
by a diagnosis of diabetes or by reaching the end of the study period without a diagnosis 
of diabetes. 
Figure 3.1 illustrates the study timeline where one scenario depicts an ideal 
situation in which the index date was July 1, 2003 (Scenario 1), while the others 
(Scenarios 2 & 3) depict the follow-up and study inclusiveness of two subjects with 
different enrollment and index dates. The end of the study period (i.e., Dec 31, 2004) 
represented the enrollment end dates for all three scenarios. 
146 
 
Figure 3.1: Study Timeline 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Jan 1, 
2003 
July 1, 
2003 
Jan 1, 
2004 
Dec 31, 
2004 
SCENARIO 2:  
Subject was 
included in study 
cohort 
Pre-index 
period 
Pre-index period 
 
Earliest index 
date 
End of study period 
Apr 1, 
2003 
Oct 1, 
2003 
Jul 31, 
2004 
Index date Cohort exit: 
diabetes diagnosis 
SCENARIO 1: 
General study 
timeline 
Latest index date 
Index period 
147 
 
Figure 3.1: Study Timeline (cont’d) 
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3.3.3 Retrospective Cohort Design 
3.3.3.1 Overview 
Cohort studies are longitudinal, observational studies that follow a group of 
people with shared characteristics, called ‘a cohort,’ through a defined period of time in 
order to observe a given outcome of interest at the end of the observation period.
321
 
Cohort studies can be performed prospectively (looking from the present to the future), or 
retrospectively (looking from the past to the present).
322
 The measure of association in a 
cohort design is often expressed as a risk ratio called the relative risk (RR).
323
 
The retrospective cohort design (also known as historic cohort study) is a cohort 
study sub-type where medical records of patients that were collected in the past are now 
being analyzed in the present with the aim of establishing and comparing two groups of 
people (i.e., the exposed and unexposed) on an outcome of interest. The two cohorts, who 
should be free of the disease of interest at baseline, are then ‘followed-up’ (i.e., from the 
receipt of the index medication to the end of the observation period) in order to determine 
their relative risk of developing the outcome of interest (here, diabetes).
324
  
3.3.3.2 Formation of Cohorts 
 In the retrospective cohort design, two cohorts of patients were formed from the 
retrospective data. The first cohort, called statin users (or the exposed group) were those 
                                                 
321 Euser AM, Zoccali C, Jager KJ, and Dekker FW. Cohort studies: prospective versus retrospective. 
Nephron Clin Pract. 2009;113(3):c214-7. 
322 Ibid. 
323 Ibid. 
324 Ibid. 
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patients who received a statin medication; while the second cohort, called non-statin 
users (or the unexposed group) were those patients who did not receive any statin 
medication. These two cohorts of people were then ‘followed up’ to determine their 
relative risk of developing incident diabetes.  
Cohort 1: Statin Users  
 Statin users (or the exposed group) were those who received any statin medication 
including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin 
(pitavastatin is not included because it was approved after 2004, the study endpoint). The 
presence of any of these medications was determined using the FDA’s National Drug 
Code (NDC) (see section 3.4.4 for the full description of the NDC code).  
Because new users of statin drugs (i.e., no statin use in the six months prior to the 
first statin prescription claim) was desired in the cohort, the index date for statin users 
was defined as the date of the first prescription claim for any statin, starting from July 1, 
2003. Thus, the earliest index date for any statin user was July 1, 2003, while the latest 
index date was January 1, 2004. This translated to an index period of between July 1, 
2003 and January 1, 2004. Moreover, due to the open enrollment nature of the cohort, 
subjects had different index dates. The statin user cohort was then followed until they 
exited the cohort. Cohort exit (or end of follow-up) was defined as the occurrence of one 
of the following, whichever occurred first: (i) manifestation of the outcome of interest 
(i.e., diabetes); or (ii) reaching the end of the study period (i.e., December 31, 2004) 
without manifesting the outcome of interest.  
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Cohort 2: Non-Statin Users 
 The non-statin users were defined as subjects who did not receive a statin 
prescription during the observation period. The non-statin users as defined in this study 
have been used as the unexposed group in previous observational studies examining the 
association between statin therapy and incidence of diabetes mellitus.
325
  
Similar to the statin users, non-statin users were identified within the index period 
of July 1, 2003 and January 1, 2004. This cohort was also followed until: (i) 
manifestation of diabetes; or (ii) end of follow-up period (December 31, 2004) without 
manifestation of diabetes. 
3.3.3.3 Inclusion/Exclusion Criteria 
 In addition to the eligibility criteria set for the whole study population, the 
following additional sets of inclusion/exclusion criteria were set for statin users (cohort 1) 
and non-statin users (cohort 2): 
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Cohort 1: Statin Users 
 Received at least one statin prescription for atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin, or simvastatin.
326
 
 New statin user (i.e., had no prescription for a statin medication in the six months 
before the index date. The earliest index date was July 1, 2003); 
 Did not fill a statin prescription that was combined with any of the non-statin lipid 
lowering agents such as bile-acid sequestrants (cholestyramine, colesevelam and 
colestipol), fibrates (bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil), 
nicotinic acid or niacin, and ezetimibe; 
In addition, subjects who switched the index statin type to a different statin type 
were analyzed based on the intention-to-treat principle, while subjects who switched 
the index statin dosage intensity to a different dosage intensity level were analyzed 
based on whether they ever received an intensive-dose statin during the observation 
period, or whether they received a moderate-dose statin throughout the observation 
period. 
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Cohort 2: Non-Statin Users  
 Not a statin user (i.e., did not fill prescription for any statin drug during the 
observation period). 
 Did not fill prescription for a statin that is combined with any of the non-statin 
lipid lowering agents.  
3.3.3.4 Statistical Methodology 
 The retrospective cohort design was analyzed using two different statistical 
methods. Survival analysis was used when the dependent variable of interest (i.e., 
survival time) is continuous in nature. This analysis strategy had been used in previous 
retrospective cohort designs that examined the association between drug exposure and 
incident diabetes mellitus.
327
 A binary logistic regression analysis was used when the 
dependent variable of interest (incidence of diabetes: yes/no) is binary or dichotomous in 
nature. This alternate strategy for analyzing a retrospective cohort design had been used 
in a study that examined the association between antidepressant exposure and incident 
type 2 diabetes.
328
 
3.3.3.4.1 Survival Analysis 
Survival analysis is a statistical procedure used in modeling data that contains 
censored data on the outcome variable of interest. The outcome variable of interest is 
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called the survival time. It is defined as the time (in days, weeks, months, or years) from 
when an individual is exposed to the factor of interest (e.g., statins) until an event (e.g., 
diabetes) occurs. The survival time gives the time that an individual has ‘survived’ over 
some follow-up period after an exposure of interest. The event is often referred to as a 
‘failure’ because the event of interest usually is death, disease incidence, or some other 
negative individual experience. However, some survival times may be positive event, 
such as the time to return to work after an elective surgical procedure.
329
 
In order to fully understand survival analysis, it is desirable to give a brief 
description of the key concepts, statistical procedures and notations associated with 
survival analysis. These include: (i) analytical problems such as “censoring,” a concept 
that is primarily the distinguishing feature of survival analysis; (ii) mathematical concepts 
such as the survival function and the hazard function; and (iii) analytical methods such as 
the Kaplan-Meier estimator, the log-rank test, and the Cox proportional hazards 
regression (and its assumptions), tools that are used in comparing the survival experience 
of two or more groups.
330
 
Censoring 
Most survival analyses must consider a key analytical problem called censoring. 
Censoring occurs when we have some information about individual survival time but we 
do not know the survival time exactly. For a prospective cohort study, censoring may 
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occur when a person does not experience the event before the study ends, or when a 
person is lost to follow-up during the study period. In a retrospective cohort study design, 
censoring may mean discontinuation of an exposure of interest before the person 
experiences the event of interest.
331
 
A table of survival data should contain a variable indicating censorship (0) or 
failure (1). Thus, a person who does not fail (i.e., does not get the event during the 
observation period), must have been censored either before or at the end of the study. 
Although data can be left-censored (i.e., the true survival time is less than or equal to the 
observed survival time), or assume some other forms of censoring; however, most 
survival data are right-censored.
332
 Right censoring means that the true survival time is 
equal to or greater than the observed survival time. In other words, it means the complete 
survival time interval, which is unknown, has been cut-off at the right side of the 
observed survival time interval. This is the whole point of conducting survival analysis: 
to estimate the true survival time. 
The Survival Function 
 The survival function, denoted by S(t), gives the probability that a person survives 
longer than some specified time t. In other words, S(t) gives the probability that the 
random variable T exceeds the specified time t. The capital T is the random variable for a 
person’s survival time. Its possible values include all nonnegative numbers (i.e., T ≥ 0). 
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The small letter t denotes any specific value of interest for the random variable T.
333
 For 
example, if we are interested in evaluating whether a person survives more than 5 years 
after undergoing cancer therapy, small t equals 5; we then ask whether capital T exceeds 
5. Thus, the main purpose of the survival function is to help in estimating the survival 
probabilities for the different values of the observed survival time t.
334
 
 The survival function has the following theoretical characteristics: 
(i) they are nonincreasing; that is, they decrease as t increases; 
(ii) at time t = 0, S(t) = S(0) = 1. This means that the probability of surviving past the 
beginning of the study (when no one has experienced the event yet) is 1; 
(iii) at time t = ∞, S(t) = S(∞) = 0. This means that, theoretically, if the study period 
increased without limit, eventually nobody would survive, and the survival curve would 
eventually fall to zero.
335
  
The Hazard Function 
 The hazard function, denoted by h(t), gives the instantaneous potential per unit 
time for the event to occur, given that the individual has survived up to time t.
336
 In 
contrast to the survival function which focuses on ‘not failing,’ the hazard function 
focuses on ‘failing;’ that is, on the event occurring. In mathematical terms, the hazard 
function (Figure 3.2) is written as: 
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Figure 3.2: The Hazard Function 
 
h(t)= lim
∆𝑡→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡)
∆𝑡
 
In words, the hazard function translates to: h(t) equals the limit, as ∆t approaches 
zero, of a conditional probability statement about survival, divided by ∆t, where ∆t 
denotes a small interval in time. The conditional probability (the numerator) gives the 
probability that a person’s survival time, T, will lie in the interval between t and t + ∆t, 
given that the survival time is greater than or equal to t.
337
 
 The hazard function has the following attributes: 
(i) it is always nonnegative; that is, it is equal to or greater than zero; 
(ii) it is a rate rather than a probability; 
(iii) it has no upper bound (i.e., it can assume values from zero up to infinity). 
The nature of the hazard function can be constant over time (exponential model), 
increasing over time (increasing Weibull), decreasing over time (decreasing Weibull), or 
a mixture of increasing and decreasing function over time (log-normal).
338
 Even though 
the survival function is more naturally appealing for analyzing survival data (as S(t) 
directly describes the survival experience of a study cohort); however, the hazard 
                                                 
337 Ibid. 
338 Ibid. 
157 
 
function is of particular interest because it is the vehicle by which mathematical modeling 
of survival data is carried out (e.g., the Cox proportional hazards regression model).
339
  
The Kaplan-Meier Method and Survival Curves 
The Kaplan-Meier (KM) method is used in estimating and graphing survival 
curves. The estimated survival probabilities are computed using a product limit formula 
of the ordered survival times.
340
 The KM estimator of the survival function at time t is 
given by the equation in Figure 3.3.  
Figure 3.3: The Kaplan-Meier Estimator 
 
?̂?(𝑡) = ∏
𝑛𝑖 − 𝑑𝑖
𝑛𝑖
𝑡(𝑖)≤t
 
where: 
?̂?(𝑡) = the estimated survival function; 
∏
𝑛𝑖−𝑑𝑖
𝑛𝑖
𝑡(𝑖)≤t
 = product of all the estimated probabilities of surviving past time 𝑡(𝑖) 
given the subject has made it to time 𝑡(𝑖); 
𝑛𝑖  = the number of subjects at risk at time 𝑡(𝑖); 
𝑑𝑖 = the number of observed events at time 𝑡(𝑖); 
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𝑛𝑖−𝑑𝑖
𝑛𝑖
 = the estimated probability of surviving past time 𝑡(𝑖) given the subject has 
made it to time 𝑡(𝑖).341 
For example, suppose we have 10 subjects in a cohort, where the first subject with 
survival time t(1) = 3 is censored, but the second and third subjects at t(2) = 7, and t(3) = 8 
had events. What is the KM estimator at t = 7, where survival time is in days? 
Solution: Since both t(1) and t(2) are less than or equal to t = 7, there will be two terms in 
the product: 
?̂?(7) = ∏
𝑛𝑖 − 𝑑𝑖
𝑛𝑖
𝑡(𝑖)≤7
=  
10 − 0
10
×
9 − 1
9
=
10
10
∗
8
9
=
8
9
=
8 ∗ 100%
9
= 88.9% 
Thus, 88.9% of the subjects (i.e., 8.89 persons out of the 10 subjects that started the 
cohort) survived past the 7
th
 day.
342
 
The Log-Rank Test 
The log-rank test (also known as the Mantel-Cox test) is a non-parametric test that 
can be used in evaluating whether or not the estimates of survival function for two or 
more groups at each observed event time are statistically equivalent.
343
 It is an 
appropriate statistical test for survival data that are right-skewed and censored. The test 
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statistic has approximately a chi-square distribution with g − 1 degrees of freedom, 
where g denotes the number of groups being compared.344 
The Cox Proportional Hazards (PH) Model 
 Unlike the KM estimator and the log-rank test which cannot accommodate 
controls for confounding variables, the Cox proportional hazards model (or the Cox 
model) is a regression-type model used for comparing the survival experience of two 
groups while adjusting for the possible confounding and/or interaction effects of other 
covariates.
345
 The Cox model is particularly useful because of its robustness. This implies 
that a reasonably good estimate of regression coefficients and hazard ratios (i.e., the 
hazard for one group divided by the hazard of another group) can be obtained without 
specifying the nature of the baseline hazard function.
346
  
Apart from using it to obtain regression coefficients and relative risks (or hazard 
ratios), the Cox model can also be used to obtain survival curves for each treatment 
groups that are adjusted for the effects of covariates. These adjusted survival curves are 
unlike those obtained from the KM estimator survival curves which do not adjust for the 
effects of covariates.
347
 
 The Cox model (Figure 3.4) is usually written in terms of the hazard function. 
This model gives an expression for the hazard at time t for an individual with a given 
specification of a set of explanatory (independent) variables denoted by 𝑋𝑖. 
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Figure 3.4: The Cox PH Model 
 
ℎ(𝑡, 𝑋) = ℎ0(𝑡)𝑒
∑ 𝛽𝑖𝑋𝑖
𝑝
𝑖=1  
OR 
ℎ(𝑡, 𝑋) = ℎ0(𝑡)𝑒𝑥𝑝[𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ +𝛽𝑝𝑋𝑝] 
The Cox model says that the hazard at time t is the product of two quantities: 
ℎ0(𝑡) = the baseline hazard function; and 
𝑒∑ 𝛽𝑖𝑋𝑖
𝑝
𝑖=1  = the exponential expression e to the linear sum of 𝛽𝑖𝑋𝑖, where this sum is 
over the 𝑝 explanatory 𝑋𝑖 variables (i.e., 𝑋𝑖 = 𝑋1, 𝑋2, 𝑋3, … 𝑋𝑝); and 𝛽𝑖 is the regression 
coefficient for the corresponding 𝑋𝑖 variable (i.e., 𝛽𝑖 = 𝛽1, 𝛽2, 𝛽3, … 𝛽𝑝).  
The Hazard Ratio 
 The hazard ratio (HR) is a ratio of the hazard function of the active group (𝑋𝑎) 
compared to the hazard function of the reference group (𝑋𝑏). It is the unit by which the 
relative risks of an outcome of interest between two groups are expressed in survival 
analysis. It is analogous to the relative risk in multiple regression, and the odds ratio in 
logistic regression.
348
 The estimated hazard ratio is given by the formula in Figure 3.5. 
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Figure 3.5: The Hazard Ratio 
 
𝐻𝑅 =
ℎ(𝑡, 𝑋𝑎)
ℎ(𝑡, 𝑋𝑏)
 
where: 
ℎ(𝑡, 𝑋𝑎) = the hazard function for the active group at time t;  
ℎ(𝑡, 𝑋𝑏) = the hazard function for the reference group at time t, while controlling for 
other explanatory variables.
349
 
The Proportional Hazards Assumption 
 An important feature of the Cox PH model is that the hazard function is assumed 
to be constant over time. In other words, the survival curve of the two groups being 
compared should have the same shape and remain parallel over time.
350
 This property is 
known as the proportional hazards assumption. In other not to violate the proportionality 
assumption therefore, the explanatory variables are assumed not to change over time (i.e., 
they should be time-independent). However, the Cox model can still accommodate time-
dependent variables but such model will no longer satisfy the PH assumption except an 
interaction term is included in the model (however, the inclusion of an interaction term 
makes the independent contributing effects of the explanatory variables more difficult to 
explain).
351
 It is noteworthy that although variables such as age and weight may change 
over time, it may be appropriate to treat such variables as time-independent variables in 
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the analysis if their effect on survival risk depends essentially on the value at only one 
measurement (i.e., on their baseline values).
352
 In this situation, the proportional hazards 
assumption is not violated. 
There are three general approaches for assessing the PH assumption. These 
include a graphical procedure, a goodness-of-fit testing procedure, and a procedure that 
involves the use of time-dependent covariates.
353
 
The graphical approach involves either a comparison of the estimated log-log KM 
survivor curves over the levels of the variable being investigated (parallel curves indicate 
that the PH assumption is satisfied), or comparing the observed with predicted survivor 
curves (the observed and predicted survival curves are plotted on the same graph. If the 
two curves are close, then the PH assumption is reasonable). The drawback regarding the 
use of the graphical approach is the subjective decision regarding whether the curves are 
parallel. A second disadvantage is the difficulty in evaluating the PH assumption for 
several variables simultaneously.
354
 
A second approach for assessing the PH assumption involves the goodness-of-fit 
tests. This approach is more appealing than the graphical approach because the chi-square 
statistics and the p-value computed for each variable in the model – while adjusting for 
the effect of other variables – can be used for making more objective decision. A large, 
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non-significant p-value (i.e., a p-value that is greater than the nominal p-value, say 
p>0.01) suggests that the PH assumption is reasonable.
355
 
 The third approach for assessing the PH assumption involves the use of time-
dependent covariates. This method involves the inclusion of an interaction term (i.e., the 
product) of the time-independent variable being assessed (e.g., age) and some function of 
time (time=survival time). A p-value obtained that is less than the p-value used in 
assessing statistical significance suggests that the PH assumption is not met.
356
 However, 
addition into the regression model of any time-dependent covariate that violates the PH 
assumption means that the method for ‘diagnosing the disease is also the cure.’357 In 
other words, when a time-dependent covariate that does not satisfy the PH assumption is 
controlled for in a model, this means that the proportionality of hazard assumption is no 
longer violated for that variable.
358
 The choice of which function of time to use (i.e., 
whether 𝑓(𝑡) equals 𝑡 or ln 𝑡) is not clear cut, and it is possible that different choices may 
result in different conclusions about whether the PH assumption is violated or not.
359
 
However, some researchers use the natural log of time (ln 𝑡) to avoid large numerical 
values that may arise from multiplying the predictor variable by 𝑡 rather than ln 𝑡.360 
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3.3.3.4.2 Binary Logistic Regression 
 The binary logistic regression model (or the logit model) was the second 
statistical procedure (the first being survival analysis) that was used to analyze the 
retrospective cohort design. The overall direction of the association between statin 
therapy and incident diabetes should remain the same irrespective of the analysis method 
used within the retrospective cohort design. The logistic regression model was 
appropriate because it allowed evaluation of the effects of the primary explanatory 
variable (i.e., statin users vs. non-statin users, which can be binary or categorical) on the 
binary outcomes variable (i.e., incidence of diabetes: yes/no), while controlling for the 
effects of other confounding variables (which can be continuous, binary, or 
categorical).
361
 
 The logit model for the odds of having incident diabetes for any given subject is 
given by the following equation in Figure 3.6.
362
 
Figure 3.6: The Logistic Regression Model 
 
𝑙𝑜𝑔 (
𝑃
1 − 𝑃
) = 𝛽0 + ∑ 𝛽𝑖𝑋𝑖
𝐾
𝑖=1
 
𝑙𝑜𝑔 (
𝑃
1 − 𝑃
) = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + ⋯ + 𝛽𝐾𝑋𝐾 
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𝑃
1 − 𝑃
= 𝑒𝛽0+𝛽1𝑋1+𝛽2𝑋2+𝛽3𝑋3+⋯+𝛽𝐾𝑋𝐾 
where: 
𝑃
1−𝑃
 = the odds of incident diabetes; 
𝑃 = the probability of having incident diabetes; 
1 − 𝑃 = the probability of NOT having incident diabetes; 
𝛽0 = intercept; 
∑ 𝛽𝑖𝑋𝑖
𝐾
𝑖=1  = product of the regression coefficient 𝛽𝑖 and the corresponding 
explanatory variable 𝑋𝑖, summed over values of 𝑖 ranging from 1 to K.363 
3.3.3.4.3  The Odds Ratio 
The odds ratio (OR) is a ratio of the odds of the event happening in the active 
group compared to the odds of the event happening in the reference group. It is the unit 
by which the relative risks of an outcome of interest between two groups are expressed in 
logistic regression analysis.
364
 
For example, assuming the exposure variable (coded as 1=statin users and 0=non-
statin users) in Figure 3.6 is represented by the explanatory variable 𝑋1, then the odds 
ratio (OR) comparing the odds of incident diabetes among statin users relative to the odds 
of incident diabetes among non-statin users (assuming no interaction effects, and 
controlling for other explanatory variables 𝑋2 − 𝑋𝐾) is given by: 
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𝑂𝑅 = 𝑒𝛽1 
where: 
𝑒𝛽1= exponentiation of 𝛽1 (the regression coefficient of the exposure variable 𝑋1) to base 
𝑒.365 
 For example, if the OR = 2.5 at a significance level of p<0.05, this is interpreted 
as: the odds of incident diabetes among statin users is 2.5 times the odds of incident 
diabetes among non-statin users, controlling for other variables. In simple terms, it means 
statin therapy is significantly associated with incident diabetes.  
3.4 DATA SOURCE 
This retrospective claims analysis utilized data from the Truven Health 
MarketScan® Commercial Claims & Encounters Database (also known as the Thomson 
Reuters MarketScan® Commercial Claims and Encounters Database, or the 
MarketScan® Database) for the period of 2003 to 2004.
366
 The data were provided as 
part of the Thomson Reuters MarketScan Dissertation Support Program. 
The MarketScan Commercial Claims and Encounters Database consists of 
employer- and health plan-sourced data containing medical and prescription data for 
several million individuals annually, including employees, their spouses, and dependents 
who are covered by employer-sponsored private health insurance. These private health 
plans include fee-for-service (FFS) plans, preferred provider organizations (PPO), 
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exclusive provider organizations (EPO), point of service plans (POS), indemnity plans, 
and health maintenance organizations (HMO).
367
 
The MarketScan claims database is one of the largest proprietary databases in the 
US with over 170 million unique patients since 1995 and with 56 million covered lives in 
the most recent full data year.
368
 One limitation of the MarketScan database is that it is a 
convenience sample; however, it has a large enough sample size that allows for the 
creation of a nationally representative data sample of Americans with employer-
sponsored health insurance in all 50 states of the US and Puerto Rico.
369
 Health care 
claims from the MarketScan Database are sourced mainly from large employers. 
Medium and small firms are underrepresented.
370
 
The 2003 and 2004 MarketScan data used for this project had a combined 
enrollment of over 11 million unique individuals who are 20 – 64 years old. Table 3.1 
summarizes the annual enrollment demographics (e.g., age group, gender, region, and 
health plan) of the 2003 and 2004 MarketScan Commercial Claims and Encounters 
Database. 
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Table 3.1: Demographic Characteristics of the MarketScan Data 
DEMOGRAPHICS 2003 2004 
Age Group Percent Percent 
0 – 17 25.63 25.59 
18 – 34 22.88 21.95 
35 – 44 16.74 16.29 
45 – 54 18.90 19.34 
55 – 64 15.78 16.84 
65 and older 0.08 - 
Gender   
Male 47.39 47.49 
Female 52.61 52.51 
Region   
Northeast 11.89 11.20 
North Central 26.99 26.63 
South  39.49 41.59 
West 20.38 19.15 
Unknown 1.25 1.43 
Health Plan   
Employer 100.00 100.00 
Source: Truven Health Analytics MARKETSCAN® Commercial Claims & Encounters 
Enrollment Annual Summary – 2003 & 2004 Version 5.0 Data Quality Reports. 
 
3.4.1 Data Quality Control 
 Data quality controls to ensure reasonableness against norms are routinely 
conducted during the MarketScan Database creation.
371
 Examples of reasonableness 
checks include diagnosis against age, diagnosis against sex, and charges against payment. 
Validity checks are conducted for selected fields, including diagnosis codes, procedure 
codes, service dates, sex, and age, to compare recorded values to lists of possible valid 
values for those fields.
372
 Additional enhancement to the data control include comparing 
                                                 
371 Truven Health Analytics. Truven Health MarketScan Research Databases: Commercial Claims and 
Encounters Medicare Supplemental data year 2011 edition. 2012:21-23. 
372 Ibid. 
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diagnosis and procedure codes to codes that were in effect at that time and editing them if 
necessary, and creating a common synthetic patient identifier so that patients can be 
tracked over years and across different files while ensuring patient confidentiality.
373
 
3.4.2 Data Elements 
The MarketScan® Database consists of demographic, medical, health plans, 
financial, drug, and enrollment information for employees, their spouses and dependents 
who are covered by employer-sponsored private health insurance.
374
 Medical claims are 
linked to outpatient prescription drug claims and person-level enrollment information 
through a unique enrollee identifier across files and across years of data.
375
 
The data elements extracted from the MarketScan Database included 
demographic information (patient de-identified unique ID, age, and gender); inpatient and 
out-patient medical information (diagnosis codes, major diagnostic category, principal 
procedure code, secondary diagnosis codes [up to 14], secondary procedure codes [up to 
14], diagnosis-related group); drug information (national drug codes, therapeutic class, 
days of medication supplied, prescription refill number, and therapeutic group number); 
and enrollment information (date enrollment start, date enrollment end, enrollment 
indicator month 1 – 12, enrollment months, and member days month 1 – 12). A full 
description of the MarketScan data elements is presented in Table 3.2.  
 
                                                 
373 Ibid. 
374 Hansen LG and Chang S, "White Paper. Health research data for the real world: The MarketScan 
Databases." 
375 Ibid. 
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Table 3.2: Description of the MarketScan Data Elements  
Variable Type Long Name Description Valid Content 
Outpatient Prescription Drugs File 
AGEa Num Age of Patient Patient age in years at the time of service Each character = 0-9 
DAYSUPP Num Days Supply The number of days of drug therapy 
covered by this prescription 
Each character = 0-9 
DOBYRa Num Patient Birth Year Year of patient birth CCYYc 
ENROLIDa Num Enrollee ID A unique 3-11 digit number identifying each 
enrollee in the data file 
Each character = 0-9 
NDCNUM Char National Drug Code The full 11 digits of FDA registered number Each character = 0-9; 
FDA’s 10-digit NDC 
codes zero- filled to 11 
characters 
REFILL Num Refill Number A number indicating whether this is the 
original prescription (0), or the refill 
number (1, 2, 3, etc.) 
Each character = 0-9 
SEXa Char Gender of Patient Gender of the patient  1=Male, 2=Female 
SVCDATEb Num Date Service Incurred Date of inpatient or outpatient service or 
date prescription was filled 
mmddyy10.d 
THERCLS Num Therapeutic Class A 3-digit code that indicates the 
therapeutic/pharmacologic category of the 
drug product 
Each character = 0-9 
THERGRP Char Therapeutic Group A 2-digit code that further aggregates the 
THERCLS values 
Each character = 0-9 
WGTKEYa Num MarketScan National 
Weight Link 
An integer key linking to national weight 
values for the record 
1-72, Missing 
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Table 3.2: Description of the MarketScan Data Elements (cont’d) 
Variable Type Long Name Description Valid Content 
YEARa Num Date Year Incurred The calendar year during which the service 
was rendered, the admission began, or the 
population was eligible 
CCYY 
Enrollment Information File 
DTEND Num Date Enrollment End End date of continuous enrollment period mmddyy10. 
DTSTART Num Date Enrollment Start Start date of continuous enrollment period mmddyy10. 
ENRIND1 
through 
ENRIND12 
Num Enrollment Indicator 
Month 1 
through 
Enrollment Indicator 
Month 12 
A flag which indicates that an individual 
was enrolled in the specified month 
0=Not enrolled  
1=Enrolled 
ENRMON Num Enrollment Months Total number of months during the year in 
which an individual was enrolled 
1-12 
MEMDAY1 
through  
MEMDAY12 
Num Member Days Month 1  
through 
Member Days Month 12 
The number of days an individual was 
enrolled during the specified month 
Each character = 0-9 
MEMDAYS Num Member Days The number of member days an enrollee 
was enrolled 
Each character = 0-9 
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Table 3.2: Description of the MarketScan Data Elements (cont’d) 
Variable Type Long Name Description Valid Content 
Inpatient Services and Outpatient Services Files 
DX1  
through 
DX15 
Char Diagnosis 1 
through 
Diagnosis 15 
The principal diagnosis and up to 14 
secondary diagnosis codes as recorded on 
the service records 
 
PDX Char Principal Diagnosis Principal diagnosis explains the main 
reason for an admission; usually the 
discharge diagnosis 
 
PPROC Char Principal Procedure Principal procedure is the procedure 
performed during an admission that had 
the greatest influence on which DRG was 
assigned to the admission 
 
PROC1 
through 
PROC15 
Char Procedure 1  
through 
Procedure 15 
The principal procedure (PROC1) and up to 
14 other procedures as recorded 
chronologically on the service record. 
 
TSVCDAT Num Date Service Ending The end date for a service mmddyy10.  
Source: Truven Health Analytics. 2011 Truven Health MarketScan Commercial Claims and Encounters Medicare Supplementation 
and Coordination of Benefit data dictionary. Ann Arbor, MI. 2012. 
Abbreviations: Num, Numeric; Char, Character; FDA, Food and Drug Administration; DRG, Diagnosis Related Group. 
aThese variables are present within the Outpatient Prescription Drug file, the Enrollment Information file, and the Outpatient 
Services and Inpatient Services files. 
bVariable absent in the Enrollment Information file, but present in the Outpatient Prescription Drug file and the Outpatient 
Services and Inpatient Services files. 
cA date format showing a two-digit century and year (e.g., 2004; where CC is 20 and YY is 04). 
dmmddyy10. is a SAS date format. For example, December 23, 2003 will be displayed as 12/23/2003 using this format. 
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3.4.3 Diagnosis and Procedure Codes in the MarketScan Data 
Diagnosis Codes 
The diagnosis codes in MarketScan data used the ICD-9-CM classification 
system.
376
 The diagnosis codes are three to five characters in length (Table 3.3). The first 
character was alphanumeric (0 – 9, E or V), while characters two to five were numeric or 
blank. In MarketScan data, the decimal point was implied between the third and fourth 
digit of the code. 
Table 3.3: ICD-9-CM Diagnosis Codes in MarketScan Data  
ICD-9-CM MarketScan Data Value 
390 390 (followed by 2 spaces) 
012.1 0121 (followed by 1 space) 
223.89 22389 
Source: Truven Health Analytics. Truven Health MarketScan Research Databases: 
Commercial Claims and Encounters Medicare Supplemental data year 2011 edition. Ann 
Arbor, MI. 2012:21-23. 
 
 
 
 
 
 
 
 
                                                 
376 Truven Health Analytics, "Truven Health MarketScan Research Databases: Commercial Claims and 
Encounters Medicare Supplemental data year 2011 edition." 
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Procedure Codes 
The ICD-9-CM procedure codes (found on hospital claims) are three to four digits 
in length and are all numeric (Table 3.4). There was an implied decimal between the 
second and third digits in the MarketScan data value. The ICD-9-CM procedure codes 
used in the MarketScan data are five characters in length. 
Table 3.4: ICD-9-CM Procedure Codes in MarketScan Data  
ICD-9-CM MarketScan Data Value 
13.9 139 (followed by 2 spaces) 
13.19 1319 (followed by 1 space) 
Source: Truven Health Analytics. Truven Health MarketScan Research Databases: 
Commercial Claims and Encounters Medicare Supplemental data year 2011 edition. Ann 
Arbor, MI. 2012:21-23. 
 
3.4.4 The National Drug Code in the MarketScan Data 
The FDA’s National Drug Code is a unique 10-digit, 3-segment code (with the 4-
4-2, 5-3-2, or the 5-4-1 configuration) that serves as a universal product identifier for 
drugs.
377
 The first segment (assigned by the FDA), is called the labeler code. A labeler is 
any firm that manufactures (including repackers or relabelers), or distributes (under its 
own name) the drug. The second segment, called the product code, identifies the strength, 
dosage form, and formulation of a drug. The third segment, called the package code, 
identifies the package sizes and types. Both the product code and the package code are 
assigned by the drug firm.
378
 
                                                 
377 U.S. Food and Drug Administration. National Drug Code directory. 2014; Available at: 
http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm. Accessed July 1, 2014. 
378 Ibid. 
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 The NDC number within the MarketScan data was an 11-digit, 5-4-2 
configuration code obtained by padding with zeroes, in the appropriate places, the FDA’s 
10-digit NDC codes (Table 3.5).
379
 The NDC codes used to identify all drugs in this 
study were obtained from the already standardized, 11-digit, 5-4-2 configured FDA’s 
NDC codes published by the RED BOOK Online®.
380
 The RED BOOK Online® (and 
Micromedex® 2.0 through which it was accessed) are brand products of Truven Health 
Analytics, the owner of the MarketScan data. 
Table 3.5: NDC Codes in the MarketScan Data  
FDA’s NDC Configuration MarketScan Data’s 5-4-2 Format 
4-4-2: XXXX-XXXX-XX 0XXXX-XXXX-XX 
5-3-2: XXXXX-XXX-XX XXXXX-0XXX-XX 
5-4-1: XXXXX-XXXX-X XXXXX-XXXX-0X 
Source: Truven Health Analytics. Truven Health MarketScan Research Databases: 
Commercial Claims and Encounters Medicare Supplemental data year 2011 edition. Ann 
Arbor, MI. 2012:61. 
  
                                                 
379 Truven Health Analytics, "Truven Health MarketScan Research Databases: Commercial Claims and 
Encounters Medicare Supplemental data year 2011 edition." 
380 Truven Health Analytics. RED BOOK online search. 2014; Available at: 
http://www.micromedexsolutions.com.ezproxy.lib.utexas.edu/micromedex2/librarian/ND_T/evidencexpert/
ND_PR/evidencexpert/CS/620D43/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/E495
C2/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.FindRedBook. 
Accessed July 1, 2014. 
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3.5 SAMPLE SIZE CALCULATION 
 The sample size required for the retrospective cohort design was determined from 
five parameters. These include:  
 The tolerable type I error rate or alpha: this two-tailed alpha was be set at 0.01. 
Sample size sensitivities was conducted for alpha=0.05. 
 The tolerable type II error rate (β): this was conventionally set at 0.2 to result in a 
minimum level of power of 80% (i.e., 1-β) in order to be able to detect differences 
between two groups if one truly existed. 
 The minimum effect size (i.e., the relative risk of disease in the exposed population): 
based on results from five retrospective cohort studies that evaluated the association 
between statin therapy and incidence of diabetes, the average relative risk of diabetes 
in patients exposed to different statin types compared to non-users of statins was 1.17 
(note: average was for those with RR > 1, see Table 2.25).
381
 Similarly, the average 
relative risk of diabetes in patients exposed to statins as a class compared to 
unexposed subjects was 1.17 in two retrospective cohort studies.
382
 The average 
relative risk obtained from two prospective cohort studies that examined the 
                                                 
381 Carter AA et al., "Risk of incident diabetes among patients treated with statins: population based 
study."; Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival."; Ma T et al., "The long-term effect of statins on the risk of new-
onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective 
longitudinal cohort study."; Ma T et al., "Statins and new-onset diabetes: a retrospective longitudinal cohort 
study."; Zaharan NL et al., "Statins and risk of treated incident diabetes in a primary care population." 
382 Wang KL et al., "Statins, risk of diabetes, and implications on outcomes in the general population."; 
Zaharan NL et al., "Statins and risk of treated incident diabetes in a primary care population." 
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association between statin use and incidence of diabetes was 1.26.
383
 A relative risk 
of 1.25 was assumed for this study, with sample size sensitivities calculated for 
relative risks of 1.50 and 1.75. 
 The expected incidence of the disease in the unexposed population: the 2011 age-
adjusted incidence of diabetes among US adults aged 18 – 76 years was 7.6 per 1,000 
persons (or 0.76% or 0.0076). This incidence value was used because the MarketScan 
Database is assumed to be fairly representative of the entire US population.
384
 
Sample size sensitivity analyses were conducted for incidence values of 0.005 and 
0.01. 
 The number of the unexposed subjects to be included in the study for each exposed 
subjects: this was set at a one-to-one ratio (1:1).  
An estimate of the sample size required for the retrospective cohort design was 
estimated from an online calculator for calculating sample size for a cohort study.
385
 
Sample size estimates from this online tool yielded approximately the same values when 
                                                 
383 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative."; Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive 
patients at high cardiovascular risk." 
384 Hansen LG and Chang S, "White Paper. Health research data for the real world: The MarketScan 
Databases." 
385 Sergeant E. Epitools epidemiological calculators: sample size for a cohort study. 2014; Available at: 
http://epitools.ausvet.com.au/content.php?page=cohortSS. Accessed 12/10, 2014. 
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validated against estimates from the Strom and Kimmel sample size table 
386
 which used 
the Schlesselman formula (Figure 3.7) for calculating sample sizes in cohort studies.
387
 
Figure 3.7: Sample Size Formula for Cohort Design 
 
𝑵 =
𝟏
[𝒑(𝟏 − 𝑹)]𝟐
[𝒁𝟏−𝜶/𝟐√(𝟏 +
𝟏
𝑲
) 𝑼(𝟏 − 𝑼) + 𝒁𝟏−𝜷√(𝒑𝑹(𝟏 − 𝑹𝒑) +
𝒑(𝟏 − 𝒑)
𝑲
)]
𝟐
 
where: 
𝑁 = Number of sample size required for the exposed group; 
𝑝 = Incidence of diabetes within the unexposed group (7.6/1000 = 0.0076); 
𝑅 = The minimum relative risk of diabetes among the exposed compared to the 
unexposed (1.25; sample size sensitivities was calculated for 𝑅 = 1.50 and 𝑅 = 1.75). 
𝛼 = Type I error rate (0.01; sample size sensitivities was calculated for 𝛼 = 0.05); 
β = Type II error rate (0.2); 
𝑍1−𝛼/2 and 𝑍1−𝛽 = unit normal deviates corresponding to α and β (Note: α was 
divided by 2 because two-tailed tests were assumed; β or power is typically one-
tailed; 𝑍1−𝛼/2 = 𝑍0.975 = 1.96; while 𝑍1−𝛽 = 𝑍0.8 = 0.84). 
𝐾 = ratio of number of unexposed subjects to the number of exposed subjects 
(1/1=1); 
                                                 
 
 
387 Schlesselman JJ. Sample size requirements in cohort and case-control studies of disease. Am J 
Epidemiol. 1974;99(6):381-4. 
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𝑈 =
𝐾𝑝+𝑝𝑅
𝐾+1
.  
Given the above parameters, and using the online sample size tool (sample size 
values cannot be estimated for relative risk < 1 using this online tool), the number of 
subjects required for the exposed group (i.e., statin users) was 54,843. An equal number 
was required for the unexposed group (i.e., non-statin users). Thus, the total sample size 
required for the retrospective cohort design was 109,686.  Table 3.6 shows an estimation 
of the sample sizes required when the values of 𝛼 (type I error), 𝑝 (incidence in the 
unexposed group) and 𝑅 (relative risk to be detected) are varied. 
Table 3.6: Sample Sizes for Cohort Studiesa 
𝜶 Incidence in the 
unexposed group 
Relative risk to be detected 
1.25 1.50 1.75 
0.01 0.005 83,610 23,207 11,336 
0.0076 54,843 15,216 7,429 
0.01 41,566 11,528 5,626 
 
0.05 0.005 56,191 15,596 7,618 
0.0076 36,858 10,226 4,993 
0.01 27,935 7,747 3,781 
Source: Sergeant E. Epitools epidemiological calculators: sample size for a cohort study. 
2014 
 [𝛽 = 0.2 (80% 𝑃𝑜𝑤𝑒𝑟), 𝑒𝑥𝑝𝑜𝑠𝑒𝑑: 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑟𝑎𝑡𝑖𝑜 = 1: 1 ] 
aThe sample size shown is the number needed among the exposed group. 
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3.6 STUDY VARIABLES 
 This section describes all the relevant available study variables – both the primary 
predictor variable of interest (exposure group, statin types, and statin dosage intensity), 
and the clinical covariates that was controlled for in the investigation of the association 
between statin exposure and the occurrence of incident diabetes. 
3.6.1 Study Model 
Figure 3.8 illustrates the study model (containing the dependent and independent 
variables) for the retrospective cohort design. 
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Figure 3.8: Study Model for the Retrospective Cohort Design 
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Primary Predictor Variables 
 
1. Exposure group: statin users 
vs. non-statin users 
2. Statin type 
3. Statin dosage intensity 
Demographic variables 
 
1. Age 
2. Gender 
 
 
Clinical variables 
 
1. Hyperlipidemia 
2. Obesity 
3. Hypertension 
4. Medication adherence (MPR) 
5. Diabetogenic medication use 
6. Charlson comorbidity index score 
 
 
 
 
 
 
 
Dependent Variables 
1. Survival time 
(continuous: survival 
analysis) 
 
2. Diabetes mellitus 
(yes/no: binary logistic 
regression) 
.  
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3.6.2 Dependent Variables 
I. Survival Time 
 Survival time was defined as the duration of time (in months) from when a subject 
was first exposed to the index medication to the first date of diabetes diagnosis. 
II. Incidence of Diabetes 
 The occurrence of diabetes incidence was defined as the first date a subject was 
diagnosed with a new case of diabetes after exposure to the index medication. Incident 
diabetes was identified using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) diagnostic codes 250.xx (diabetes mellitus). To 
ensure that subjects with only incident cases of diabetes were included in the cohort, the 
retrospective cohort design required that subjects do not have a diagnosis of diabetes in 
the pre-index period (a period of six months before the index date). In other words, 
subjects with previous cases of diabetes (or prevalent cases of diabetes) were excluded 
from the cohorts.  
3.6.3 Independent Variables 
 In order to have a high confidence of inferring or not inferring that statin therapy 
was associated with new diabetes mellitus, it was important that certain confounding 
variables be controlled for in the statistical analyses. Confounding variables that were 
controlled for included demographic variables (i.e., age and gender), and clinical 
covariates (i.e., hyperlipidemia, obesity, hypertension, statin medication adherence, 
diabetogenic medications, and CCI score).  
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The operational definitions of the available independent variables are discussed in 
the following section. 
3.6.3.1 Primary Predictor Variables 
 The primary predictor variables included exposure group, statin types, and statin 
dosage intensity. 
I. Exposure Group 
 Subjects who were initially free of diabetes were divided into two exposure group 
cohorts: statin users and non-statin users.  
(a) Statin Users 
Statin users were defined as those that had at least one prescription for any of the 
statins available within the 2003-2004 MarketScan Database.
388
 These statins included 
atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Pitavastatin 
was not included because it was approved in 2009, five years after the study endpoint.  
(b) Non-Statin Users 
 Non-statin users were defined as subjects who did not receive prescription for any 
statin, including statins that existed in any combined dosage form with other drugs 
throughout the observation period. This definition has been used in previous 
                                                 
388 Carter AA et al., "Risk of incident diabetes among patients treated with statins: population based 
study."; Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival."; Ma T et al., "Statins and new-onset diabetes: a retrospective 
longitudinal cohort study."; Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and 
nondiabetic patients." 
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observational studies that examined the association between statin therapy and incidence 
of diabetes mellitus.
389
  
II. Statin Type 
 In addition to examining the overall association of statins (as a class) and 
incidence of diabetes, users of each statin type were also compared to non-statin users in 
order to determine their relative risk of incident diabetes. For the purpose of this study, 
six statin types were considered. They included atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin, and simvastatin.  
III. Statin Dosage Intensity 
 A meta-analysis of five RCTs suggested that intensive-dose statin therapy was 
associated with higher risk of incident diabetes compared to moderate-dose statin 
therapy.
390
 Statin doses were dichotomized into: 1 = intensive dose and 0 = moderate 
dose (reference category). These doses are defined in Table 3.7 by type of statin. 
 
 
 
                                                 
389 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival."; Ma T et al., "The long-term effect of statins on the risk of new-
onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective 
longitudinal cohort study."; Ma T et al., "Statins and new-onset diabetes: a retrospective longitudinal cohort 
study."; Zaharan NL et al., "Statins and risk of treated incident diabetes in a primary care population."; 
Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health 
Initiative."; Chen CW et al., "Differential impact of statin on new-onset diabetes in different age groups: a 
population-based case-control study in women from an Asian country."; Jick SS and Bradbury BD, "Statins 
and newly diagnosed diabetes." 
390 Preiss D et al., "Risk of incident diabetes with intensive-dose compared with moderate-dose statin 
therapy: a meta-analysis." 
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Table 3.7: Moderate vs. Intensive Statin Dosages 
Statin  Moderate Dose (mg) Intensive Dose (mg) 
Atorvastatin 10, 20 40, 80 
Fluvastatin 20, 40, 80 - 
Pravastatin 10, 20, 40, 80 - 
Lovastatin 10, 20, 40, 60 - 
Rosuvastatin 5, 10 20, 40 
Simvastatin 5, 10, 20, 40 80 
Source: Texas Diabetes Council. Lipid algorithm for type 1 and type 2 diabetes mellitus in 
adults; 2011. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-
dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 
2011;305(24):2556-2564. 
 
3.6.3.2 Demographic Variables 
I. Age 
 Age is an independent risk factor for diabetes mellitus.
391
 Age is a continuous 
variable that was defined as the age (in years) when subjects received their first index 
medication. 
II. Gender 
 Among the US adult population aged 20 years or older, the prevalence of diabetes 
was higher among males compared to females.
392
 Gender is a dichotomous variable that 
was coded as 1 = male and 0 = female (reference category). 
                                                 
391 American Diabetes Association, "Standards of medical care in diabetes--2014." 
392 Centers for Disease Control and Prevention, "National Diabetes Statistics Report: Estimates of diabetes 
and its burden in the United States, 2014." 
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3.6.3.3 Clinical Covariates 
I. Hyperlipidemia 
 Due to the problem of confounding by indication (i.e., the possibility that 
hyperlipidemia – the indication for which statins are used – was responsible for the 
association between statin therapy and incident diabetes, and not the statin itself), it was 
necessary to control for hyperlipidemia diagnosis. Hyperlipidemia is a risk factor for 
metabolic syndrome and cardiovascular diseases,
393
 which are in turn risk factors for 
diabetes mellitus.
394
 The hyperlipidemia (or hyperlipidemia diagnosis) variable was 
identified by ICD-9-CM codes 272.0 (pure hypercholesterolemia: high TC), 272.1 (pure 
hypertriglyceridemia: high TG), 272.2 (mixed hyperlipidemia: high LDL-C, high TG, 
and low HDL-C), and 272.4 (other and unspecified hyperlipidemia).
395
 Hyperlipidemia is 
a dichotomous variable that was coded as 1 = hyperlipidemia present, and 0 = 
hyperlipidemia absent (reference category). 
 
 
 
 
                                                 
393 Wilson PW et al., "Prediction of coronary heart disease using risk factor categories."; "The Lipid 
Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart 
disease."; "Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial 
results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering." 
394 Carr MC, and Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: 
Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin 
Endocrinol Metab. 2004;89(6):2601-07. 
395 ICD9Data.com: disorders of lipoid metabolism.  Available at: 
http://www.icd9data.com/2014/Volume1/240-279/270-279/272/default.htm. Accessed June 17, 2014. 
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II. Obesity 
The epidemic of gestational and type 2 diabetes in the US has been attributed to 
increasing rates of overweight and obesity.
396
 Because obesity increases insulin 
resistance, overweight and obese individuals are therefore especially at greater risk for 
diabetes.
397
 The obesity (or obesity diagnosis) variable was identified using ICD-9-CM 
codes 278.00 (obesity, unspecified) and 278.01 (morbid obesity).
398
 Obesity is a 
dichotomous variable that was coded as 1 = obesity present, and 0 = obesity absent 
(reference category).  
III. Hypertension 
 Hypertension (or high blood pressure) is an independent risk factor for diabetes 
mellitus.
399
 The hypertension (or hypertension diagnosis) variable was identified using 
ICD-9-CM codes 401.0 (malignant essential hypertension), 401.1 (benign essential 
hypertension), and 401.9 (unspecified essential hypertension). Hypertension is a 
dichotomous variable that was coded as 1 = hypertension present, and 0 = hypertension 
absent (reference category).  
 
 
 
                                                 
396 Kirkman MS et al., "Diabetes in older adults."; Lawrence JM et al., "Trends in the prevalence of 
preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of 
pregnant women, 1999-2005." 
397 Norris SL et al., "Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a 
review." 
398 "ICD9Data.com: disorders of lipoid metabolism". 
399 American Diabetes Association, "Standards of medical care in diabetes--2014." 
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IV. Medication Adherence 
 Medication adherence (a proxy for estimating drug exposure and compliance with 
medication dosage regimen) was estimated using the medication possession ratio 
(MPR).
400
 MPR as defined as the total number of days of medication supplied during a 
defined period of time divided by the length of therapy.
401
 The length of therapy (the 
denominator of MPR) was defined as the number of days elapsed between the first and 
the last prescription fill dates.
402
 With the denominator defined this way, the numerator is 
now redefined as the total number of days of medication supplied before the last fill date 
(the number of days supply for the last prescription is not added to the numerator).
403
 
MPR is a continuous variable that was computed by the formula in Figure 3.9. 
MPR values greater than 1 (or 100%) were truncated to 100%. 
Figure 3.9: Medication Possession Ratio (MPR) 
 
𝑀𝑃𝑅 =  
𝑆𝑢𝑚 𝑜𝑓 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑜𝑓 𝑅𝑥 𝑠𝑢𝑝𝑝𝑙𝑖𝑒𝑑 (𝑚𝑖𝑛𝑢𝑠 𝑙𝑎𝑠𝑡 𝑅𝑥 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦) 
𝑆𝑢𝑚 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑓𝑖𝑟𝑠𝑡 𝑅𝑥 𝑎𝑛𝑑 𝑙𝑎𝑠𝑡 𝑅𝑥 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒𝑠
 
 
 
 
 
                                                 
400 Fairman KA, and Motheral B. Evaluating medication adherence: which measure is right for your 
program. J Manag Care Pharm. 2000;6(6):502. 
401 Richhariya A. "Impact of Medicare Part D on adherence and persistence to statin medications for Texas 
dual-eligible beneficiaries." Thesis, The University of Texas at Austin, 2010. 
402 Ibid. 
403 Ibid. 
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V. Diabetogenic Medication Use 
In assessing the association between statin use and incidence of diabetes, it was 
important to account for the potential confounding effect of certain drugs and agents that 
have been shown to independently increase the risk of diabetes. These drugs included 
thiazide diuretics,
404
 β-blockers,405 antipsychotic agents,406 antidepressants,407 
glucocorticoids (especially prednisolone and dexamethasone),
408
 and immunosuppressive 
agents (especially tacrolimus and cyclosporine).
409
 
The diabetogenic medication variable is a continuous variable that was obtained 
by summing the number of prescriptions for all diabetogenic medications filled during 
the observation period for any of the above diabetogenic medications. A prescription fill 
was defined as a 30-day supply of the diabetogenic medication. 
 
 
 
 
                                                 
404 Zillich AJ et al., "Thiazide diuretics, potassium, and the development of diabetes: A quantitative 
review."; Elliott WJ and Meyer PM, "Incident diabetes in clinical trials of antihypertensive drugs: a 
network meta-analysis." 
405 Kuti EL et al., "The development of new-onset type 2 diabetes associated with choosing a calcium 
channel blocker compared to a diuretic or beta-blocker."; Bangalore S et al., "A meta-analysis of 94,492 
patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus." 
406 Holt RI and Peveler RC, "Association between antipsychotic drugs and diabetes." 
407 Khoza S et al., "Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case-control 
study." 
408 Kwon S and Hermayer KL, "Glucocorticoid-induced hyperglycemia." 
409 Penfornis A and Kury-Paulin S, "Immunosuppressive drug-induced diabetes."; Vincenti F et al., 
"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with 
cyclosporine versus tacrolimus." 
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VI. Charlson Comorbidity Index Score 
 Comorbidity is the co-occurrence of two or more disease conditions in a patient. 
Because the epidemiological design (retrospective cohort) used for this study does not 
involve randomization of subjects into groups, it was necessary to control for the baseline 
clinical conditions between the exposed and unexposed groups. Failure to control for 
baseline comorbid conditions may confound the relationship between the exposure of 
interest (statins) and occurrence of incident diabetes.  
The CCI is a tool originally developed by Mary E. Charlson, MD to estimate the 
prognostic impact or risk of mortality associated with two or more comorbid conditions 
in patients.
410
 The CCI is a weighted index (higher weight is assigned to more severe 
condition) that was calculated by summing the weights (i.e., 1, 2, 3, or 6) assigned to a 
set of diagnostic conditions and/or procedures (identified using the ICD-9-CM diagnostic 
and procedure codes) that were present at or prior to the start of the index medication use. 
For example, a patient with comorbid conditions of congestive heart failure (1), ulcer (1), 
leukemia (2), and liver disease (3) had a CCI score of 7.  
The Dartmouth-Manitoba adaptation of the CCI (Table 3.8) was used for this 
study.
411
 It was preferred over other CCI variants, such as the Deyo
412
 and the 
                                                 
410 Charlson ME, Pompei P, Ales KL, and MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. 
411 Romano PS, Roos LL, and Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-9; discussion 81-90. 
412 Deyo RA, Cherkin DC, and Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative databases. Ibid.1992;45(6):613-9. 
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D’Hoore,413 because it incorporated ICD-9-CM procedure codes in addition to its more 
comprehensive ICD-9-CM diagnostic codes.  
 
                                                 
413 D'Hoore W, Bouckaert A, and Tilquin C. Practical considerations on the use of the Charlson 
comorbidity index with administrative data bases. Ibid.1996;49(12):1429-33. 
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Table 3.8: The Dartmouth-Manitoba Adaptation of the Charlson Comorbidity Index Diagnostic Categories and 
ICD-9-CM Codes  
Clinical Conditions Weights Dartmouth-Manitoba ICD-9-CM codes 
Myocardial infarction 1 410.xx, 412 
Congestive heart failure 1 402.01, 402.11, 402.91, 425.x, 428.x, 429.3 
Peripheral vascular disease 1 440.x, 441.x, 442.x, 443.1 – 443.9, 447.1, 785.4,  
38.13 – 38.14(P), 38.16(P), 38.18(P), 38.33 – 38.34(P), 38.36(P), 
38.38(P), 38.43 – 38.44(P), 38.46(P), 38.48(P), 39.22 – 39.26(P), 
39.29(P)# 
Cerebrovascular disease 1 362.34, 430 – 436, 437 – 437.1, 437.9, 438, 781.4, 784.3, 997.0,  
38.12(P), 38.42(P) 
Dementia 1 290.x, 331 – 331.2 
Chronic pulmonary disease 1 415.0, 416.8 – 416.9, 491.x – 494, 496 
Rheumatologic disease 1 710.x, 714.x 
Peptic ulcer disease 1 531.xx – 534.xx 
Mild liver disease 1 571.2, 571.5 – 571.6, 571.8 – 571.9 
Hemiplegia or Paraplegia 2 342.x, 344.x 
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Table 3.8: The Dartmouth-Manitoba Adaptation of the Charlson Comorbidity Index Diagnostic Categories and 
ICD-9-CM Codes (cont’d) 
Clinical Conditions Weights Dartmouth-Manitoba ICD-9-CM codes 
Renal disease 2 585 – 586, V42.0, V45.1, V56.x*, 
39.27(P), 39.42(P), 39.93 – 39.95(P), 54.98(P) 
Any malignancy 
Lymphoma 
Leukemia 
2 140.x – 171.x, 174.x – 195.x, 200.xx – 208.x, 273.0, 273.3, V10.46, 
60.5(P), 62.4 – 62.41(P) 
Moderate or severe liver disease 3 572.2 – 572.4, 456.0 – 456.2x,  
39.1(P), 42.91(P)^ 
Metastatic solid tumor 6 196.x – 199.x^ 
AIDS 6 042.x – 044.x 
Source: Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing 
perspectives. J Clin Epidemiol. 1993;46(10):1075-1079. 
#ICD-9-CM codes with (P) following them describes procedures rather than diagnoses (Vol. III). 
*ICD-9-CM codes with a ‘V’ before them are classified under the “Supplementary Classification of Factors Influencing Health Status 
and Contact with Health Services” of the ICD-9-CM diagnostic categories. 
^These comorbidities take precedence over less severe comorbidities involving the same organ system. 
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 Table 3.9 summarizes the study variables (both dependent and independent 
variables) for the retrospective cohort design, while Table 3.10 summarizes the 
operational definitions of all study variables. 
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Table 3.9: Summary of Study Variables in the Retrospective Cohort Design 
Dependent variables Independent variables 
1. Survival time 
2. Incidence of diabetes 
 
Primary predictor variables: 
1. Exposure group (statin users vs. non-statin users) 
2. Statin type (atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin, and simvastatin) 
3. Statin dosage intensity (intensive-dose vs. moderate-
dose) 
 
Demographic variables: 
1. Age 
2. Gender 
 
Clinical covariates: 
1. Hyperlipidemia 
2. Obesity 
3. Hypertension 
4. Medication adherence (MPR) 
5. Diabetogenic medications 
6. CCI score 
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Table 3.10: Summary of Operational Definitions of Study Variables 
 OPERATIONAL DEFINITION MEASUREMENT LEVEL 
DEPENDENT VARIABLES 
Survival time (or time to 
occurrence of diabetes) 
The period (in months) between the first date of the index 
medication and the diagnosis of diabetes, or the period between the 
index date and the end of study period (if there was no occurrence 
of diabetes) 
Continuous 
Incidence of diabetes A diagnosis of diabetes after exposure to the index medication. 
Identified using ICD-9-CM codes 250.xx 
1=diagnosed with diabetes 
0=not diagnosed with diabetes 
Dichotomous 
INDEPENDENT VARIABLES 
Exposure group The nature of drug a subject was exposed to at index date: 
1=Exposed to statin 
0=Not exposed to statin (reference) 
Dichotomous 
Statin type The type of statin a subject was exposed to at index: 
1=Atorvastatin  
2=Fluvastatin 
3=Lovastatin 
4=Pravastatin  
5=Rosuvastatin 
6=Simvastatin  
Nominal 
Statin dosage intensity Intensiveness of the statin therapy received during the observation 
period: 
1= intensive-dose statin (received an intensive-dose statin at any 
time during the observation period) 
0=moderate-dose statin (reference: received a moderate-dose 
statin throughout the observation period) 
Dichotomous 
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Table 3.10: Summary of Operational Definitions of Study Variables (cont’d) 
Age Age of each subject (in years) at the index date Continuous 
Gender Gender of subjects at index date: 
1=Male 
0=Female (reference) 
Dichotomous 
Hyperlipidemia Presence or absence of a hyperlipidemia diagnosis at or before 
index: 
1=present 
0=absent (reference) 
Dichotomous 
Obesity Presence or absence of an obesity diagnosis at or before index: 
1=present 
0=absent (reference) 
Dichotomous 
Hypertension Presence or absence of a hypertension diagnosis at or before index: 
1=present 
0=absent (reference) 
Dichotomous 
Medication adherence Estimated using the medication possession ratio (MPR) defined as: 
𝑺𝒖𝒎 𝒐𝒇 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒐𝒇 𝑹𝒙 𝒔𝒖𝒑𝒑𝒍𝒊𝒆𝒅 (𝒎𝒊𝒏𝒖𝒔 𝒍𝒂𝒔𝒕 𝑹𝒙 𝒅𝒂𝒚𝒔 𝒔𝒖𝒑𝒑𝒍𝒚) 
𝑺𝒖𝒎 𝒐𝒇 𝒅𝒂𝒚𝒔 𝒃𝒆𝒕𝒘𝒆𝒆𝒏 𝒇𝒊𝒓𝒔𝒕 𝑹𝒙 𝒂𝒏𝒅 𝒍𝒂𝒔𝒕 𝑹𝒙 𝒇𝒊𝒍𝒍 𝒅𝒂𝒕𝒆𝒔
 
Continuous 
Diabetogenic medication usea 
 
Sum of all/each diabetogenic medication prescriptions filled at pre- 
and post-index:  
1 prescription fill= 30-day supply of a diabetogenic medication 
filled during the observation period (observation period was 
defined as the period between the start of the pre-index period and 
the cohort exit) 
continuous 
CCI score The sum of weights related to each comorbid condition before or at 
index 
Continuous 
aDiabetogenic medication  variables included thiazide diuretics, β-blockers, antipsychotics, antidepressants, immunosuppressants 
and glucocorticoids.
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3.7 DATA ANALYSIS PROCEDURES 
Data manipulation and analyses was performed using SAS
®
 for Windows
®
 
version 9.3 (SAS Institute, Cary, NC) and IBM SPSS Statistics Version 21 (SPSS Inc, 
Chicago, IL).  
 Preliminary analysis (using the minimum and maximum function) was used to 
identify problematic observations (i.e., outliers) that may impact the study results. In 
addition, appropriate preliminary analyses (e.g., normality, chi-square assumptions, 
multicollinearity, and proportionality of hazards regression) were performed to assess the 
validity of assumptions associated with each of the statistical analyses conducted. 
Appropriate non-parametric test (e.g., Mann-Whitney U median test) was used for 
analysis of univariate t-test procedures where the normality assumption was violated for 
the continuous dependent variable.  
T-tests were used to compare two groups on a continuous dependent variable 
(Hypotheses 1a, 5, 6, and 7b). Chi-square tests were used to examine the association 
between two independent variables that have two or more levels within them (Hypotheses 
1b, 2, 3, 4, and 11a). The analysis of variance (ANOVA) procedure was used to compare 
two or more groups on a continuous dependent variable (Hypotheses 7a). The log-rank 
test was used to test the equality of the survival functions of two or more groups on a 
continuous, censored dependent variable (i.e., survival time) (Hypotheses 8a-c). The 
Kaplan-Meier curve was used to graph and compare the survival function of two or more 
groups on a continuous, censored dependent variable (i.e., survival time) (Hypotheses 8a-
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c). The Cox proportional hazards regression was used to compare two groups on a 
continuous, censored dependent variable (i.e., survival time) while controlling for 
covariates (Hypotheses 9a-g and 10). The binary logistic regression analysis was used to 
compare two groups on a dichotomous dependent variable while controlling for 
covariates (Hypotheses 11b-h and 12).  
All analyses were two-tailed with a significance level set at p<0.01. Table 3.11 
below summarizes all the analyses conducted, including the corresponding study aims, 
hypothesis, dependent variables (DV), independent variables (IV), and measurement 
levels of both DV and IV.  
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
AIM 1: TO COMPARE THE DEMOGRAPHIC (I.E., AGE AND GENDER), AND CLINICAL CHARACTERISTICS (I.E., 
HYPERLIPIDEMIA, OBESITY, HYPERTENSION,  DIABETOGENIC MEDICATION USE, AND CCI SCORE) BETWEEN STATIN 
USERS AND NON-STATIN USERS (OBJECTIVES 1 – 6) 
Objective 1: To assess whether 
demographic characteristics 
(i.e., age and gender) differs 
between statin users and non-
statin users 
 
H1a: Statin users will have a 
significantly higher mean age 
compared to non-statin users 
Age Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous t-test 1 
H1b: There is a significant 
association between the 
exposure group (i.e., statin 
users and non-statin users) and 
gender 
Gender: 
Male vs. Female 
Dichotomous 
 
Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Chi-square 
test 
1 
Objective 2: To assess whether 
hyperlipidemia diagnosis differs 
between statin users and non-
statin users 
 
H2: The proportion of statin 
users with a hyperlipidemia 
diagnosis will be significantly 
higher compared to that of non-
statin users 
Hyperlipidemia: 
Yes/No 
Dichotomous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Chi-square 
test 
1 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
Objective 3: To assess 
whether obesity diagnosis 
differs between statin users 
and non-statin users  
 
H0(3): There is no significant 
difference in the proportion of 
statin users and non-statin 
users who have an obesity 
diagnosis 
Obesity: 
Yes/No 
Dichotomous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Chi-square 
test 
1 
Objective 4: To assess 
whether hypertension 
diagnosis differs between 
statin users and non-statin 
users 
 
H(4): The proportion of statin 
users with a hypertension 
diagnosis will be significantly 
higher compared to that of 
non-statin users 
Hypertension: 
Yes/No 
Dichotomous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Chi-square 
test 
1 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
Objective 5: To assess whether 
the mean number of prescriptions 
for all diabetogenic medications 
and the mean number of 
prescriptions for each 
diabetogenic medication (i.e., 
thiazide diuretics, β-blockers, 
antipsychotics, antidepressants, 
immunosuppressants, and 
glucocorticoids) differs between 
statin users and non-statin users 
 
H0(5): There is no significant 
difference in the mean number of 
prescriptions for all diabetogenic 
medications between statin users 
and non-statin users 
Number of 
prescriptions 
for all 
diabetogenic 
medications 
Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous t-test 1 
H0(5b-g): There is no significant 
difference in the mean number  of 
prescriptions for each 
diabetogenic medication (i.e., 
thiazide diuretics [H0(5b)], β-
blockers [H0(5c)], antipsychotics 
[H0(5d)], antidepressants[H0(5e)], 
immunosuppressants [H0(5f)], and 
glucocorticoids [H0(5g)]) between 
statin users and non-statin users 
Number of 
prescriptions 
for each 
diabetogenic 
medication 
Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous t-test 6 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
Objective 6:  To compare the 
mean CCI score between statin 
users and non-statin  users 
 
H0(6): There is no significant 
difference in the mean CCI 
score between statin users and 
non-statin users 
CCI score Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous t-test 1 
AIM 2: TO COMPARE MEDICATION ADHERENCE AMONG USERS OF EACH STATIN TYPE, AND BETWEEN INTENSIVE-DOSE 
STATIN USERS AND MODERATE-DOSE STATIN USERS (OBJECTIVE 7) 
Objective 7: To assess 
whether medication adherence 
(using MPR) differs between 
users of each statin type, and 
between intensive-dose statin 
users and moderate-dose 
statin users 
 
H0(7a): There is no significant 
difference in mean medication 
possession ratio (MPR) among 
users of each statin type 
 
MPR Continuous 
 
Statin type: 
Atorvastatin vs. 
Fluvastatin vs. 
Lovastatin vs. 
Pravastatin vs. 
Rosuvastatin vs. 
Simvastatin 
Nominal ANOVA 1 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
H7b:  The mean medication 
possession ratio (MPR) will be 
significantly lower among 
intensive-dose statin users 
compared to moderate-dose 
statin users 
MPR Continuous 
 
Statin dosage 
intensity: 
Intensive-dose 
vs. 
Moderate-dose 
Dichotomous t-test 1 
AIM 3: SURVIVAL ANALYSIS – TO COMPARE TIME TO DIABETES (SURVIVAL TIME) BETWEEN STATIN USERS AND NON-
STATIN USERS, BETWEEN USERS OF EACH STATIN TYPE AND NON-STATIN USERS, AND BETWEEN INTENSIVE-DOSE 
STATIN USERS AND MODERATE-DOSE STATIN USERS (OBJECTIVES 8 – 10) 
Objective 8: To assess 
whether survival times differ 
between statin users and non-
statin users, among users of 
each statin type, and between 
intensive-dose statin users 
and moderate-dose statin 
users 
 
H8a: Statin users will have a 
significantly shorter survival 
time compared to non-statin 
users 
Survival time Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Log-rank test 
Kaplan-Meier 
curves 
1 
1 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
H0(8b): There is no significant 
difference in the mean survival 
time among  users of each 
statin type 
 
Survival time Continuous Statin type: 
Atorvastatin vs. 
Fluvastatin vs. 
Lovastatin vs. 
Pravastatin vs. 
Rosuvastatin vs. 
Simvastatin 
Nominal Log-rank test 
Kaplan-Meier 
curves 
1 
1 
H8c:  Intensive-dose statin 
users will have a shorter 
survival time compared to 
moderate-dose statin users 
 
Survival time Continuous Statin dosage 
intensity: 
Intensive-dose 
vs. 
Moderate-dose 
Dichotomous Log-rank test 
Kaplan-Meier 
curves 
1 
1 
Objective 9: To assess 
whether  survival time differs 
between statin users and non-
statin users, and between 
users of each statin type and 
non-statin users, while 
controlling for age, gender, and 
clinical covariatesa  
 
H9a: Statin users will have a 
significantly shorter survival 
time compared to non-statin 
users while controlling for age, 
gender, and clinical covariatesa 
Survival time Continuous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Cox 
proportional 
hazards 
regression 
1 
aClinical covariates include hyperlipidemia, obesity, hypertension,  diabetogenic medication use, and CCI score.  
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
H9b-g: Users of each statin type 
(i.e., atorvastatin [H9b], 
fluvastatin [H9c], lovastatin 
[H9d], pravastatin [H9e], 
rosuvastatin [H9f], and 
simvastatin [H9g]) will have a 
significantly shorter survival 
time compared to non-statin 
users while controlling for age, 
gender, and clinical covariatesa 
 
Survival time Continuous -Atorvastatin vs. 
non-statin users; 
-Fluvastatin vs. 
non-statin users; 
-Lovastatin vs. 
non-statin users; 
-Pravastatin vs. 
non-statin users; 
-Rosuvastatin vs. 
non-statin users; 
-Simvastatin vs. 
non-statin users 
Nominal Cox 
proportional 
hazards 
regression 
6 
Objective 10 :   To assess 
whether survival times differ 
between intensive-dose statin 
users and moderate-dose 
statin users, while controlling 
for age, gender, and clinical 
covariatesb 
      
H10: Intensive-dose statin users 
will have a significantly shorter 
survival time compared to 
moderate-dose statin users 
while controlling for age, 
gender, and clinical covariatesb 
Survival time Continuous Statin dosage 
intensity: 
Intensive-dose vs. 
Moderate-dose 
Dichotomous Cox 
proportional 
hazards 
regression 
1 
bClinical covariates include hyperlipidemia, obesity, hypertension, diabetogenic medication use, CCI score, and medication 
adherence.  
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
AIM 4: LOGISTIC REGRESSION – TO COMPARE INCIDENCE OF DIABETES BETWEEN STATIN USERS AND NON-STATIN 
USERS,  BETWEEN USERS OF EACH STATIN TYPE AND NON-STATIN USERS, AND BETWEEN  INTENSIVE-DOSE STATIN 
USERS AND MODERATE-DOSE STATIN USERS (OBJECTIVES 11 & 12) 
Objective 11: To assess 
whether incidence of diabetes 
differs between statin users 
and non-statin users, and 
between users of each statin 
type and non-statin users, 
while controlling for age, 
gender, and clinical covariatesa  
 
H11a: The proportion of statin 
users with incident diabetes 
will be significantly higher 
than that of non-statin users 
Incidence of 
diabetes: 
Yes/No 
Dichotomous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Chi-square 
test 
1 
H11b: The proportion of statin 
users with incident diabetes 
will be significantly higher 
than that of non-statin users 
while controlling for age, 
gender and clinical covariatesa 
Incidence of 
diabetes: 
Yes/No 
Dichotomous Exposure group: 
statin users vs. 
non-statin users 
Dichotomous Binary 
logistic 
regression 
1 
aClinical covariates include hyperlipidemia, obesity, hypertension,  diabetogenic medication use, and CCI score. 
  
208 
 
Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
H11c-h: The proportion of each 
user of statin type  (i.e., 
atorvastatin [H11c], fluvastatin 
[H11d], lovastatin [H11e], 
pravastatin [H11f], rosuvastatin 
[H11g], and simvastatin [H11h]) 
that has incident diabetes will 
be significantly higher than 
that of  non-statin users while 
controlling for age, gender, and 
clinical covariatesa 
Incidence of 
diabetes: 
Yes/No 
Dichotomous Users of each 
statin type vs. 
non-statin users: 
-Atorvastatin vs. 
non-statin users; 
-Fluvastatin vs. 
non-statin users; 
-Lovastatin vs. 
non-statin users; 
-Pravastatin vs. 
non-statin users; 
-Rosuvastatin vs. 
non-statin users; 
-Simvastatin vs. 
non-statin users 
Nominal Binary 
logistic 
regression 
6 
aClinical covariates include hyperlipidemia, obesity, hypertension,  diabetogenic medication use, and CCI score. 
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Table 3.11: Summary of Study Aims, Objectives, Hypotheses, Study Variables, and Analyses Procedures (cont’d) 
Objectives/Hypothesis Dependent 
Variable 
Nature of 
Variable 
Independent 
Variable 
Nature of 
Variable 
Statistical 
Procedure 
# of 
Tests/ 
Models 
Objective 12:   To assess 
whether incidence of diabetes 
differs between intensive-dose 
statin users and moderate-
dose statin users, while 
controlling for age, gender, and 
clinical covariatesb 
      
H12: The proportion of 
intensive-dose statin users 
with incident diabetes will be 
significantly higher than that of 
moderate-dose statin users 
while controlling for age, 
gender, and clinical covariatesb 
Incidence of 
diabetes: 
Yes/No 
Dichotomous Statin dosage 
intensity: 
Intensive-dose 
vs. 
Moderate-dose 
Dichotomous Binary 
logistic 
regression 
1 
aClinical covariates include hyperlipidemia, obesity, hypertension,  diabetogenic medication use, and CCI score. 
bClinical covariates include hyperlipidemia, obesity, hypertension, diabetogenic medication use, CCI score, and medication 
adherence. 
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CHAPTER 4: RESULTS 
This chapter provides detailed descriptions of the study results, including the 
selection criteria and sample size requirements for the statin user and the non-statin 
cohorts, description of preliminary data analyses (i.e., procedures used to assess the 
validity of assumptions associated with each statistical analysis conducted), description 
of the study results structured by study objectives and corresponding hypotheses, and a 
summary of the study hypotheses tested.  
4.1 PATIENT SELECTION CRITERIA AND SAMPLE SIZE 
The study population consisted of 116,224 subjects who were aged 20 – 63 years 
at index date. They were followed from the earliest index date of July 1, 2003 until they 
had a diagnosis of diabetes or reached the end of the study period (December 31, 2004) 
without having diabetes diagnosis. The study population (N=116,224) was composed of 
an equal proportions of statin users (N=58,112) and non-statin users (N=58,112).  
The sample sizes for the two cohorts met the a priori sample size requirements of 
N=54,843 for each group, or a total sample size of N=109,686 (given the following 
parameters: alpha=0.01, power=80%, effect size or relative risk of diabetes among statin 
users=1.25, incidence of diabetes among the unexposed=7.6 per 1,000 population, and 
number of the unexposed subjects to be included in the study for each exposed 
subject=1:1).  
The statin user cohorts were: (i) subjects aged 20 – 63 years when they filled their 
first prescription for any statin medication including atorvastatin, fluvastatin, lovastatin, 
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pravastatin, rosuvastatin, and simvastatin; (ii) new statin users (i.e., did not have any 
statin prescription in the six months before the index date. The earliest index date was 
July 1, 2003. The index statin drug cases were selected within the index period of July 1, 
2003 and January 1, 2004); (iii) subjects who did not fill a statin prescription that was 
combined with any of the non-statin lipid lowering agents; (iv) subjects who did not have 
a diabetes diagnosis during the six months of pre-index period; and (v) subjects who were 
continuously enrolled during the six months of pre-index period and for at least a year 
after the index date.  
The non-statin user cohort were subjects who: (i) were aged 20 – 63 years when 
they filled their first prescription for any non-statin medication; (ii) did not receive any 
statin prescription; (iii) had index drug cases that were selected within a similar index 
period of July 1, 2003 and January 1, 2004 as statin users (for subjects with multiple drug 
cases, the first prescription date represented the index drug case); (iv) did not have a 
diagnosis of diabetes in the six months of pre-index period; and (v) were continuously 
enrolled during the six months of pre-index period and for at least a year after the index 
date. 
Figures 4.1 and 4.2 describe the inclusion/exclusion criteria used in selecting both 
the statin user cohort and the non-statin user cohort, respectively.  
212 
 
Figure 4.1: Inclusion/Exclusion Criteria for the Statin Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unique number of patients using lipid-lowering agents (N=1,223,169): aged 20-63 
at index 
Excluded (N=220,032): users of non-statin drugs 
Statin users (N=1,003,137) 
Excluded (N=902,962): index statin drug cases did 
not fall within the index period of July 1, 2003 and 
January 1, 2004 
 
New statin users (N=100,175) 
Excluded (N=25,027): not continuously enrolled 
during the six months of pre-index period and for 
at least a year after the index date 
Excluded (N=17,036): had diabetes in the six 
months of pre-index period 
New statin users without pre-index diabetes (N=83,139) 
Statin user cohort (N=58,112) 
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Figure 4.2: Inclusion/Exclusion Criteria for the Non-statin Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*A simple random sampling (without replacement) of exactly N=58,112 from N=391,124. 
Non-unique total observation for non-statin users (N=158,260,446) 
 
Excluded (N=157,544,397): duplicate cases and 
index drug cases that did not fall within the index 
period of July 1, 2003 and January 1, 2004 
 
Unique, non-statin index drug cases (N=716,049) 
 
Excluded (N=14,607): aged <20 or >63 at index  
 
Non-statin users aged 20 – 63 years at index (N=701,442) 
 
Excluded (N=300,856): not continuously enrolled 
during the six months of pre-index period and for 
at least a year after the index date 
Excluded (N=9,462): had diabetes in the six 
months of pre-index period 
 
Non-statin users without pre-index diabetes (N=691,980) 
Non-statin user cohort (N=391,124) 
 
Non-statin user cohort (N=58,112)* 
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4.2 PRELIMINARY DATA ANALYSIS PROCEDURES 
Preliminary analysis involved examining out-of-range data values and assessing 
the assumptions associated with each statistical analysis conducted. Out-of-range data 
values were examined using the minimum and maximum functions. Out-of-range data 
values were set to system missing. Normality assumptions (and the Levene’s test of 
equality of variance) were examined on continuous dependent variables such as age, 
number of prescriptions for all/each diabetogenic medication(s), CCI score, and MPR. 
The sample size assumption was examined for each chi-square analysis. Multicollinearity 
diagnostics (using VIF and/or Tolerance values) were examined for all predictor 
variables in each Cox regression and/or logistic regression model. The proportionality of 
hazards assumption was examined for each Cox regression model.  
4.2.1 Normality 
The normality assumption was examined for all continuous dependent variables 
(DV) such as age (hypothesis 1a), number of prescriptions for all/each diabetogenic 
medication(s) (hypotheses 5a-g), CCI score (hypothesis 6), and MPR (hypotheses 7a and 
7b). These variables were the DVs in univariate parametric tests such as t-test and 
ANOVA. A formal test of normality was not used to assess the normality assumption due 
to sensitivity of such tests to large sample sizes.
414
 However, the normality assumption 
                                                 
414 Lumley T, Diehr P, Emerson S, and Chen L. The importance of the normality assumption in large 
public health data sets. Annu Rev Public Health. 2002;23:151-69. 
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was considered not violated if the absolute values of the skewness and kurtosis were not 
in excess of 2.
415
 
In addition to the normality tests, the Levene’s test of equality of variance was 
also assessed. In instances where the p-value associated with the Levene’s test of equality 
of variance was less than 0.01 (i.e., significant), the value of the t-test for equality of 
means (and the associated degrees of freedom) corresponding to when equal variances 
between groups is not assumed was reported. 
In all cases where the normality assumption was violated for the continuous 
dependent variable, the parametric t-test or ANOVA procedures were still conducted 
because of their robustness to violations of the normality assumption.
416
 However, in 
such instances of normality assumption violations,  appropriate non-parametric tests were 
also conducted (Mann-Whitney U median test and the Kruskal-Wallis test are the non-
parametric equivalents of an independent samples t-test and ANOVA, respectively). The 
results of both the parametric and non-parametric tests were reported if a DV violates the 
normality assumption. Parametric tests were favored because the descriptive statistics 
(i.e., mean and standard deviation) were more informative than the descriptive statistics 
for non-parametric tests (the median value of each of the DVs that violated the normality 
assumption was zero for the two groups being compared). 
                                                 
415 Curran PJ, West SG, and Finch JF. The robustness of test statistics to nonnormality and specification 
error in confirmatory factor analysis. Psychol Methods. 1996;1(1):16-29. 
416 Lumley T et al., "The importance of the normality assumption in large public health data sets." 
216 
 
As mentioned earlier, the normality assumption was considered not violated if the 
absolute values of the skewness and kurtosis were not in excess of 2. Thus, the normality 
assumption was not violated for age (skewness= -0.64 and kurtosis= -0.49) and MPR 
(skewness= -0.89 and kurtosis= -0.29), but was violated for number of prescriptions for 
all/each diabetogenic medication(s) (absolute values of the skewness and kurtosis ranged 
from 3.16 – 64.76 and 11.48 – 5,429.19, respectively), and CCI score (skewness=8.15 
and kurtosis=80.35). 
See Appendix A for the full descriptive statistics and graphs associated with the 
evaluation of the normality assumption for all continuous dependent variables. 
4.2.2 Chi-square Assumptions 
 Unless otherwise indicated, 0 cells (0.0%) had an expected count less than 5 for 
all chi-square tables reported in the results. The chi-square method assumes that a dataset 
is reasonably large and that tables are densely populated and well balanced (tables are 
unbalanced if more than 20% of the cells have an expected count less than 5). In such 
cases, a Fisher’s exact test may be more appropriate for the analysis. Only one chi-square 
table was unbalanced, where 2 cells (33.3%) had an expected count of less than 5. 
Furthermore, all groups being compared were assumed to be independent of each other. 
4.2.3 Multicollinearity 
 Multicollinearity occurs when two or more predictor variables (e.g., X1, X2, and 
X3) are inter-correlated. Multicollinearity diagnostics could help assess which two or 
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more predictor variables are redundant with respect to one another (and thus help in 
deciding whether to retain or remove one or more of such variables from the model).  
The multicollinearity diagnostic values were obtained by running a series of 
multiple regression analyses among all the predictor variables in each Cox regression 
model (hypotheses 9a-g and 10) and each logistic regression model (hypotheses 11b-h 
and 12). Because the predictor variables in each Cox regression model were also 
duplicated for each logistic regression model, a total of eight multiple regression 
multicollinearity diagnostic models were run. The number of multiple regression models 
corresponded to the number of main predictor variables of interest examined by the Cox 
and logistic regression analyses. These eight predictor variables of interest included 
‘Exposure’ (statin users vs. non-statin users); ‘Atorvastatin’ (atorvastatin users vs. non-
statin users); ‘Fluvastatin’ (fluvastatin users vs. non-statin users); ‘Lovastatin’ (lovastatin 
users vs. non-statin users); ‘Pravastatin’ (pravastatin users vs. non-statin users); 
‘Rosuvastatin’ (rosuvastatin users vs. non-statin users); ‘Simvastatin’ (simvastatin users 
vs. non-statin users); and ‘Intensive’ (intensive-dose statin users vs. moderate-dose statin 
users). Other predictor variables that formed part of each multiple regression analyses 
included gender, hyperlipidemia, obesity, hypertension, number of prescriptions for all 
diabetogenic medications, CCI score, and MPR (Note: MPR was included only in the 
model containing the ‘Intensive’ variable). Because a continuous variable is required as 
the dependent variable in a multiple regression, age was used as the dependent variable in 
all multiple regression models (Note: one additional multiple regression model [Table 
218 
 
4.1b] evaluated the multicollinearity diagnostics for the variable ‘Age’ by making CCI 
score the dependent variable). 
Evidence of multicollinearity was assumed if the Tolerance value for any variable 
was less than 0.1, or if the variance inflation factor (VIF) value for any of the variable 
was in excess of 10 [VIF = 1/Tolerance].
417
  
There was no evidence of multicollinearity among the variables as shown by 
Tolerance values that ranged from 0.558 (‘Exposure’) to 0.999 (‘Obesity’). Tables 4.1 – 
4.8 show the full result of the Tolerance and VIF values for each variable in the 
multicollinearity diagnostics. 
Table 4.1a: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Statin Use and Incident Diabetes 
Variable Tolerance VIF 
Exposure (statin) 0.640 1.564 
Gender (male) 0.989 1.011 
Hyperlipidemia 0.761 1.313 
Obesity 0.998 1.002 
Hypertension 0.855 1.170 
Diabetogenic medications 0.849 1.177 
CCI score 0.970 1.031 
DV=age 
 
 
 
 
 
 
 
                                                 
417 Kutner M, Nachtsheim C, and Neter J. In Applied linear regression models. New York, NY: McGraw-
Hill/Irwin, 2004. 
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Table 4.1b: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Statin Use and Incident Diabetes 
Variable Tolerance VIF 
Exposure (statin) 0.558 1.792 
Age 0.736 1.358 
Gender (male) 0.989 1.011 
Hyperlipidemia 0.759 1.318 
Obesity 0.997 1.003 
Hypertension 0.850 1.177 
Diabetogenic medications 0.852 1.174 
DV=CCI score 
 
 
Table 4.2: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Atorvastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Atorvastatin 0.603 1.657 
Gender (male) 0.991 1.009 
Hyperlipidemia 0.723 1.383 
Obesity 0.998 1.002 
Hypertension 0.841 1.190 
Diabetogenic medications 0.838 1.194 
Comorbidity index 0.969 1.032 
DV=age 
 
 
Table 4.3: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Fluvastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Fluvastatin 0.850 1.176 
Gender (male) 0.991 1.009 
Hyperlipidemia 0.893 1.120 
Obesity 0.999 1.001 
Hypertension 0.922 1.084 
Diabetogenic medications 0.932 1.073 
CCI score 0.990 1.010 
DV=age 
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Table 4.4: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Lovastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Lovastatin 0.821 1.217 
Gender (male) 0.992 1.008 
Hyperlipidemia 0.929 1.076 
Obesity 0.992 1.008 
Hypertension 0.910 1.099 
Diabetogenic medications 0.863 1.159 
CCI score 0.989 1.011 
DV=age 
 
Table 4.5: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Pravastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Pravastatin 0.696 1.436 
Gender (male) 0.991 1.009 
Hyperlipidemia 0.805 1.242 
Obesity 0.999 1.001 
Hypertension 0.867 1.154 
Diabetogenic medications 0.862 1.160 
CCI score 0.975 1.025 
DV=age 
 
 
Table 4.6: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Rosuvastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Rosuvastatin 0.767 1.305 
Gender (male) 0.991 1.009 
Hyperlipidemia 0.832 1.202 
Obesity 0.999 1.001 
Hypertension 0.895 1.117 
Diabetogenic medications 0.910 1.099 
CCI score 0.988 1.012 
DV=age 
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Table 4.7: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Simvastatin Use and Incident Diabetes 
Variable Tolerance VIF 
Simvastatin 0.632 1.582 
Gender (male) 0.994 1.006 
Hyperlipidemia 0.773 1.294 
Obesity 0.998 1.002 
Hypertension 0.844 1.185 
Diabetogenic medications 0.826 1.211 
CCI score 0.960 1.042 
DV=age 
 
 
Table 4.8: Tolerance and VIF to test Multicollinearity among Predictor 
Variables in the Cox and Logistic Regression Models Evaluating the Association 
between Intensive-dose Statin Use and Incident Diabetes 
Variable Tolerance VIF 
Dosage Intensity (intensive-dose) 0.990 1.010 
Gender (male) 0.976 1.024 
Hyperlipidemia 0.992 1.008 
Obesity 0.999 1.001 
Hypertension 0.974 1.027 
Diabetogenic medications 0.931 1.075 
CCI score 0.986 1.014 
Medication possession ratio 0.971 1.029 
DV=age 
 
4.2.4 Proportionality of Hazards Assumption 
An important feature of the Cox proportional hazard (Cox PH) model is that the 
hazard ratio (for any variable) comparing the hazard of one group to the hazard of 
another group is constant over time (i.e., hazard ratio is independent of time).  
As mentioned in section 3.3.3.4.1 (survival analysis – the proportional hazards 
assumption), there are three general approaches for assessing the PH assumption. These 
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include a graphical procedure, a goodness-of-fit testing procedure, and a procedure that 
involves the use of time-dependent covariates.
418
 
 The third approach (a procedure that involves the use of time-dependent 
covariates) was employed in this dissertation because the p-value computed for each 
time-dependent covariate in the model – while adjusting for the effect of other variables – 
can be used for making more objective decision as opposed to the use of graphical 
methods. Time-dependent covariates were obtained by multiplying each independent 
variable in the model by the natural log of survival time. The PH assumption is not met 
for any time-dependent covariate with a p-value less than 0.01 (See Appendix B for an 
SPSS syntax example that can be used to run a Cox regression model with multiple time-
dependent covariates). 
The PH assumption was satisfied for all the major predictor variables of interest. 
These variables included ‘Exposure’ (statin users vs. non-statin users); ‘Atorvastatin’ 
(atorvastatin users vs. non-statin users); ‘Fluvastatin’ (fluvastatin users vs. non-statin 
users); ‘Lovastatin’ (lovastatin users vs. non-statin users); ‘Pravastatin’ (pravastatin users 
vs. non-statin users); ‘Rosuvastatin’ (rosuvastatin users vs. non-statin users); 
‘Simvastatin’ (simvastatin users vs. non-statin users); and ‘Intensive’ (intensive-dose 
statin users vs. moderate-dose statin users).  
However, the PH assumption was not satisfied for some variables, including some 
variables that were measured at baseline. Because variables such as age and gender were 
                                                 
418 Kleinbaum DG and Klein M, "Evaluating the proportional hazards assumption." 
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defined at index (i.e., they were baseline values with single measurement at a single point 
in time), it was surprising that the PH assumption was not satisfied for them in some 
models. This means that the PH assessment considered age and gender as time-dependent 
variables. As a result of this observation, the PH assessment was considered not 
reasonable in all instances. Thus, the proportionality of hazards assumption was ignored 
and assumed not to be violated in all Cox regression models, and these were presented as 
the primary results (note again: the PH assumption was not violated for all the main 
predictor variables of interest). 
Ignoring a violation of the PH assumption has been likened to suppressing, or not 
controlling for, the interaction of a variable of interest with time in regression models – a 
phenomenon that is known to be common among many researchers.
419
 One author 
believed that a suppression of the PH assumption might be reasonable: (i) if the 
researcher does not have a strong theoretical interest in those interactions, (ii) when there 
is no reason to believe that the interactions with time are so strong that it would be 
misleading to suppress them, and (iii) due to the impracticality of testing for all possible 
2-way interactions in models with moderately large number of variables.
420
  
When a violation of the PH assumption is suppressed for a variable, it is 
acceptable to consider the coefficient estimate (and HRs) of such variables as an ‘average 
effect’ over the range of times that is observed in the data.421  
                                                 
419 Allison PD, "Cox models with non-proportional hazards." 
420 Ibid. 
421 Ibid. 
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However, sensitivity analyses of the hazards ratios (while controlling for variables 
that did not satisfy the PH assumption) were conducted. The hazard ratios (and 99% 
confidence interval of the hazard ratios) for the sensitivity analyses were presented 
alongside those of the primary results. The magnitude of the hazard ratios increased when 
time-dependent covariates were controlled for in all Cox regression models (the specifics 
of each variable that failed to satisfy the PH assumption test is discussed in section 4.5 of 
the results).  
Appendix C shows the full model results of the sensitivity analyses when time-
dependent covariates were controlled for in all Cox regression models.  
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4.3 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS  
 The current study had four study aims. The first aim of the study was to compare 
the descriptive statistics (mean, median, minimum, maximum, frequency, and percent) of 
demographic (i.e., age and gender) and clinical (i.e., hyperlipidemia, obesity, 
hypertension, number of prescriptions for all/each diabetogenic medication(s), and CCI 
score) variables between statin users and non-statin users (objectives 1 – 6). The main 
purpose of objectives 1 – 6 was to examine if statin users and non-statin users differed 
significantly on any of these demographic and clinical variables. A significant difference 
or association on any of the variable(s) warranted controlling for such variable(s) in the 
regression models (Cox regression and logistic regression) that was used to examine the 
differential risk of incident diabetes between statin users and non-statin users.  
Furthermore, the second aim of the study was to compare MPR among users of 
each statin type and between intensive-dose statin users and moderate-dose statin users 
(objective 7). The third (objectives 8 – 10) and fourth (objectives 11 and 12) study aims 
primarily compared survival time and incidence of diabetes between statin users and non-
statin users using Cox regression and logistic regression models, respectively. These 
study aims are further discussed in sections 4.4 – 4.6.  
The first and second study aims are mainly descriptive in nature and are presented 
in this section. The study results are organized by study objectives and corresponding 
hypotheses. 
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4.3.1 Demographic Variables 
 Objective 1 examined whether statin users and non-statin users differed 
significantly on demographic characteristics. Age and gender were the only demographic 
information available in the MarketScan data used for this project. Race/ethnicity 
information is an important demographic variable that would have been ideal to control 
for but was not available in the data.  
Objective 1: To assess whether demographic characteristics (i.e., age and gender) 
differed between statin users and non-statin users. 
4.3.1.1 Age 
 Age is a continuous variable that was defined as the age (in years) when subjects 
received their first index medication. Mean age was compared between statin users and 
non-statin users. In addition, the association between exposure status (i.e., statin users vs. 
non-statin users) and age was examined by categorizing age into four groups (i.e., 20 – 
34, 35 – 44, 45 – 54, and 55 – 63). 
H1a:  Statin users will have a significantly higher mean age compared to non-
statin users. 
Table 4.9 shows the descriptive statistics of age between statin users and non-
statin users. The age at index ranged from 20 to 63 years for statin users, while age at 
index ranged from 20 to 62 years for non-statin users. The table shows that the mean age 
(SD) for the study population (N=116,224) was 46.4 (11.6) while the median age was 49 
years. An independent samples t-test showed that mean age was significantly higher 
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among statin users (52.2, SD=7.8) compared to non-statin users (40.6, SD=11.9) 
(t=197.2; df=100,418.5; p<0.0001). [Conclusion: alternative hypothesis H1a was 
supported]. 
Table 4.9: Descriptive Statistics of Age for Statin Users and Non-statin Users 
Agea Statin Users Non-statin Users Study Population 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
52.2 (7.8) 
54 
20 
63 
58,112 
40.6 (11.9) 
41 
20 
62 
58,112 
46.4 (11.6) 
49 
20 
63 
116,224 
t-test (t=197.2; df=100,418.5; p<0.0001) 
aWeighted mean (SD) age for statin users, non-statin users, and the study population are 
53.3 (7.1), 42.0 (11.9), and 48.1 (11.1), respectively.  
MarketScan weights: MarketScan person-level national weights (included as a weight 
variable in the data) were constructed utilizing weight estimates from the Household 
Component of the Medical Expenditure Panel Survey (MEPS). MEPS’s weights accounts for 
demographic variables that includes region (Northeast, North Central, South, West); age (0 
– 17, 18 – 44, 45 – 64); and sex (male, female). The MarketScan weight is the ratio of MEPS-
based estimates in the different age/sex/region categories and the MarketScan number in 
the same category. 
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Age Categories 
Table 4.10 shows the age group distribution for statin users and non-statin users. 
A chi-square test showed that there was a significant association of exposure status (i.e., 
statin users vs. non-statin users) and age categories (χ2 = 27,715.5; df=3; p<0.0001). The 
majority of statin users (83.6%, N=48,573) were aged 45 years and above while the 
majority of non-statin users (59.6%, N=34,613) were aged below 45 years. 
Table 4.10: Frequency and Percent of Statin Users and Non-statin Users by Age 
Group 
Age Group Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
20 – 34 
35 – 44 
45 – 54 
55 – 63 
1,728 (3.0) 
7,811 (13.4) 
21,909 (37.7) 
26,664 (45.9) 
18,747 (32.3) 
15,866 (27.3) 
15,167 (26.1) 
8,332 (14.3) 
20,475 (17.6) 
23,677 (20.4) 
37,076 (31.9) 
34,996 (30.1) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 27,715.5; df=3; p<0.0001 
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Age and Dosage Intensity 
A sub-analysis among the statin user group (N=58,112) showed that mean age 
was not significantly different between intensive-dose statin users (52.0, SD=7.9) and 
moderate-dose statin users (52.3, SD=7.8) (t=2.5; df=58,110; p=0.011). When stratified 
by age categories, a chi-square test shows that there was no significant association of 
statin dosage intensity (i.e., intensive-dose statin users vs. moderate-dose statin users) and 
age categories (χ2 = 2.70; df=3; p=0.44). The proportion of intensive-dose statin users 
(83.1%, N=5,153) and moderate-dose statin users (83.7%, N=43,420) who were 45 years 
and above was similar. 
Table 4.11 shows the descriptive statistics of age for intensive-dose and moderate-
dose statin users, while Table 4.12 shows the age group distribution for intensive-dose 
and moderate-dose statin users. 
Table 4.11: Descriptive Statistics of Age for Intensive-dose and Moderate-dose 
Statin Users 
Age Intensive-dose  Moderate-dose  Statin Users  
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
52.0 (7.9) 
53 
20 
63 
6,205 
52.3 (7.8) 
54 
20 
63 
51,907 
52.2 (7.8) 
54 
20 
63 
58,112 
t-test (t=2.5; df=58,110; p=0.011) 
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Table 4.12: Frequency and Percent of Intensive-dose and Moderate-dose 
Statin Users by Age Group 
Age Group Intensive-dose  
N (%) 
Moderate-dose  
N (%) 
Statin Users  
N (%) 
20 – 34 
35 – 44 
45 – 54 
55 – 63 
198 (3.2) 
854 (13.8) 
2,355 (38.0) 
2,798 (45.1) 
1,530 (2.9) 
6,957 (13.4) 
19,554 (37.7) 
23,866 (46.0) 
1,728 (3.0) 
7,811 (13.4) 
21,909 (37.7) 
26,664 (45.9) 
Total 6,205 (100.0) 51,907 (100.0) 58,112 (100.0) 
χ2 = 2.7; df=3; p=0.44 
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4.3.1.2 Gender 
 Gender is a dichotomous variable (1=male, 0=female) that was defined as the sex 
of each subject when they received the index medication.  
H1b: There is a significant association between the exposure group (i.e., statin 
users and non-statin users) and gender. 
 Table 4.13 shows gender distribution for statin users and non-statin users. The 
majority (51.1%, N=59,421) of the study population were males. A chi-square analysis 
showed that there was a significant association of exposure group (i.e., statin users vs. 
non-statin users) and gender (χ2 = 41.7; df=1; p<0.0001). The proportion of statin users 
that are males (50.2%, N=29,160) was higher compared to the proportion of statin users 
that are females (49.8%, N=28,952). Similarly, the proportion of non-statin users that are 
males (52.1%, N=30,261) was higher compared to the proportion of non-statin users that 
are females (47.9%, N=27,851). [Conclusion: hypothesis H1b was supported]. 
Table 4.13: Frequency and Percent of Statin Users and Non-statin Users by 
Gender 
Gendera Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Male 
Female 
29,160 (50.2) 
28,952 (49.8) 
30,261 (52.1) 
27,851 (47.9) 
59,421 (51.1) 
56,803 (48.9) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 41.7; df=1; p<0.0001 
aWeighted values: the proportion of statin users and non-statin users that are males are 
30.3% (N=812,956) and 29.9% (N=685,917), respectively. The proportion of the study 
population that are males and females are 30.1% (N=1,498,873) and 69.9% (N=3,480,394), 
respectively. 
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4.3.2 Clinical Variables 
 Objectives 2 – 6 examined whether statin users and non-statin users differed on 
certain clinical characteristics that are considered important risk factors for diabetes 
mellitus. These clinical characteristics include the presence or absence of hyperlipidemia 
(objective 2), obesity (objective 3), and hypertension (objective 4), number of 
prescriptions for all/each diabetogenic medication(s) (objective 5), and the CCI score 
(objective 6). Other clinical variables that would have been important to control for but 
were not available in the MarketScan data include family history of diabetes, physical 
activity level, cholesterol level (HDL-C, LDL-C, TG), height and weight data (thus 
BMI), and presence or absence of prediabetes.   
4.3.2.1 Hyperlipidemia 
Hyperlipidemia (or hyperlipidemia diagnosis) is a dichotomous variable that was 
defined as the presence or absence of at least one hyperlipidemia diagnosis at or before 
the index date. The hyperlipidemia diagnosis variable was identified using ICD-9-CM 
codes 272.0 (pure hypercholesterolemia: high TC), 272.1 (pure hypertriglyceridemia: 
high TG), 272.2 (mixed hyperlipidemia: high LDL-C, high TG, and low HDL-C), and 
272.4 (other and unspecified hyperlipidemia).  
Objective 2:  To assess whether hyperlipidemia diagnosis differed between statin users 
and non-statin users.  
H2: The proportion of statin users with a hyperlipidemia diagnosis will be 
significantly higher compared to that of non-statin users.  
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Table 4.14 shows hyperlipidemia diagnosis distribution for statin users and non-
statin users. For the total study population, 28.0% (N=35,516) had a diagnosis of 
hyperlipidemia. A chi-square analysis showed that there was a significant difference in 
the proportion of statin users and non-statin users with a hyperlipidemia diagnosis (χ2 = 
27,526.9; df=1; p<0.0001). The proportion of statin users with a hyperlipidemia diagnosis 
(49.8%, N=28,953) was higher compared to the proportion of non-statin users with a 
hyperlipidemia diagnosis (6.1%, N=3,563). [Conclusion: hypothesis H2 was 
supported].  
Table 4.14: Frequency and Percent of Statin Users and Non-statin Users by 
Hyperlipidemia Diagnosis 
Hyperlipidemia Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
28,953 (49.8) 
29,159 (50.2) 
3,563 (6.1) 
54,549 (93.9) 
32,516 (28.0) 
83,708 (72.0) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 27,526.9; df=1; p<0.0001 
 
4.3.2.2 Obesity 
 Obesity (or obesity diagnosis) is a dichotomous variable that was defined as the 
presence or absence of at least one obesity diagnosis at or before the index date. The 
obesity diagnosis variable was identified using ICD-9-CM codes 278.00 (obesity, 
unspecified) and 278.01 (morbid obesity).  
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Objective 3: To assess whether obesity diagnosis differed between statin users and non-
statin users. 
H0(3): There is no significant difference in the proportion of statin users and non-
statin users who have an obesity diagnosis. 
Table 4.15 shows obesity diagnosis distribution for statin users and non-statin 
users. For the total study population, 0.6% (N=753) had a diagnosis of obesity. A chi-
square analysis showed that there was a significant difference in the proportion of statin 
users and non-statin users with an obesity diagnosis (χ2 = 206.4; df=1; p<0.0001). The 
proportion of statin users with an obesity diagnosis (1.0%, N=573) was higher compared 
to the proportion of non-statin users with an obesity diagnosis (0.3%, N=180). 
[Conclusion: Null hypothesis H0(3) was rejected]. 
Table 4.15: Frequency and Percent of Statin Users and Non-statin Users by 
Obesity Diagnosis 
Obesity Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
573 (1.0) 
57,539 (99.0) 
180 (0.3) 
57,932 (99.7) 
753 (0.6) 
115,471 (99.4) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 206.4; df=1; p<0.0001 
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4.3.2.3 Hypertension 
 Hypertension (or hypertension diagnosis) is a dichotomous variable that was 
defined as the presence or absence of at least one hypertension diagnosis at or before the 
index date. The hypertension diagnosis variable was identified using ICD-9-CM codes 
401.0 (malignant essential hypertension), 401.1 (benign essential hypertension), and 
401.9 (unspecified essential hypertension). 
Objective 4: To assess whether hypertension diagnosis differed between statin users 
and non-statin users. 
H4: The proportion of statin users with a hypertension diagnosis will be 
significantly higher compared to that of non-statin users. 
Table 4.16 shows hypertension diagnosis distribution for statin users and non-
statin users. For the total study population, 17.5% (N=20,348) had a diagnosis of 
hypertension. A chi-square analysis showed that there was a significant difference in the 
proportion of statin users and non-statin users with a hypertension diagnosis (χ2 = 
14,257.5; df=1; p<0.0001). The proportion of statin users with a hypertension diagnosis 
(30.8%, N=17,909) was higher compared to the proportion of non-statin users with a 
hypertension diagnosis (4.2%, N=2,439). [Conclusion: alternative hypothesis H4 was 
supported]. 
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Table 4.16: Frequency and Percent of Statin Users and Non-statin Users by 
Hypertension Diagnosis 
Hypertension Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
17,909 (30.8) 
40,203 (69.2) 
2,439 (4.2) 
55,673 (95.8) 
20,348 (17.5) 
95,876 (82.5) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 14,257.5; df=1; p<0.0001 
 
4.3.2.4 Diabetogenic Medication Use 
 Objective 5 examined whether statin users and non-statin users differed in the 
mean number of prescriptions for all/each diabetogenic medication(s) they received. If 
one group was exposed to a higher amount of diabetogenic drugs, then that group may be 
more predisposed to have an increased risk of diabetes that is independent of the effects 
of statin use. Thus, the number of prescriptions for all/each diabetogenic medication(s) 
received by statin users and non-statin users was compared and accounted for in all 
regression analyses. 
The ‘number of prescriptions for all diabetogenic medications’ is a continuous 
variable that was obtained by summing the number of days supplied for all diabetogenic 
medications during the observation period (the observation period was defined as the 
time between the start of the pre-index period and the date of diabetes diagnosis or the 
end of the study period if there was no occurrence of diabetes). These diabetogenic 
medication variables (identified using the therapeutic class ‘THERCLS’ variable) 
included thiazide diuretics, beta-blockers, antipsychotics, antidepressants, 
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immunosuppressants, and glucocorticoids. One prescription fill was defined as a 30-day 
supply of the diabetogenic medication.  
Furthermore, the ‘number of prescriptions for each diabetogenic medication’ is a 
continuous variable that was obtained by summing the number of days supplied for each 
diabetogenic medication during the observation period. One prescription fill was also 
defined as a 30-day supply of the diabetogenic medication. 
Objective 5: To assess whether the mean number of prescriptions for all diabetogenic 
medications and the mean number of prescriptions for each diabetogenic medication 
differed between statin users and non-statin users. 
4.3.2.4.1 Number of prescriptions for all diabetogenic medications  
H0(5a): There is no significant difference in the mean number of prescriptions for 
all diabetogenic medications between statin users and non-statin users. 
Table 4.17 shows the descriptive statistics of ‘number of prescriptions for all 
diabetogenic medications’ for statin users and non-statin users.  
The mean (SD) number of prescriptions for all diabetogenic medications for the 
study population (N=116,224) was 3.2 (7.1). An independent samples t-test showed that 
the mean number of prescriptions received for all diabetogenic medications by statin 
users (5.7, SD=9.0) was significantly higher than that received by non-statin users (0.8, 
SD=3.0) (t=123.3; df=71,250.0; p<0.0001).  
Because the ‘number of prescriptions for all diabetogenic medications’ variable 
was not normally distributed, an independent samples Mann-Whitney U median test also 
238 
 
showed that the median (and the distribution of the median) number of prescriptions for 
all diabetogenic medications was not the same across levels of the exposure group 
(p<0.0001). Thus, there was a significant difference in the mean (or median) number of 
prescriptions for all diabetogenic medications received by statin users and non-statin 
users. [Conclusion: null hypothesis H0(5a) was rejected]. 
Table 4.17: Descriptive Statistics of Number of Prescriptions for All 
Diabetogenic Medications for Statin Users and Non-statin Users  
Number of prescriptions 
for all diabetogenic 
medicationsa 
Statin Users Non-statin Users Study 
Population 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
5.66 (8.97) 
0 
0 
107 
58,112 
0.82 (3.04) 
0 
0 
71 
58,112 
3.24 (7.12) 
0 
0 
107 
116,224 
t-test (t=123.3; df=71,250; p<0.0001) 
aOne prescription is equivalent to a 30-day supply of all diabetogenic medications filled over 
the observation period. 
 
 
Categorized ‘number of prescriptions for all diabetogenic medications’ 
Table 4.18 shows the distribution for the categorized ‘number of prescriptions for 
all diabetogenic medications’ for statin users and non-statin users. A chi-square test 
showed that there was a significant association of exposure status (i.e., statin users vs. 
non-statin users) and the ‘number of prescriptions for all diabetogenic medications’ 
categories (χ2 = 17,069.4; df=3; p<0.0001). The majority of statin users (55.3%, 
N=32,112) and non-statin users (87.7%, N=50,979) did not receive any diabetogenic 
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medication prescription. However, the proportion of statin users with at least one 
diabetogenic medication prescription (44.7%, N=26,000) was higher compared to the 
proportion of non-statin users with at least one diabetogenic medication prescription 
(12.3%, N=7,133). 
Table 4.18: Frequency and Percent of Statin Users and Non-statin Users by 
Number of Prescriptions for All Diabetogenic Medications 
Number of 
prescriptions for all 
diabetogenic 
medicationsa 
 Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population  
N (%) 
0 
1 – 5 
6 – 10 
>10 
32,112 (55.3) 
6,224 (10.7) 
5,832 (10.0) 
13,944 (24.0) 
50,979 (87.7) 
3,945 (6.8) 
1,645 (2.8) 
1,543 (2.7) 
83,091 (71.5) 
10,169 (8.7) 
7,477 (6.4) 
15,487 (13.3) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 17,069.4; df=3; p<0.0001 
aOne prescription is equivalent to a 30-day supply of all diabetogenic medications filled over 
the observation period. 
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4.3.2.4.2 Number of prescriptions for each diabetogenic medication 
H0(5b-g): There is no significant difference in the mean number of prescriptions for 
each diabetogenic medication (i.e., thiazide diuretics [H0(5b)], β-blockers 
[H0(5c)], antipsychotics [H0(5d)], antidepressants[H0(5e)], 
immunosuppressants [H0(5f)], and glucocorticoids [H0(5g)]) between statin 
users and non-statin users. 
Table 4.19 shows the descriptive statistics of ‘number of prescriptions for each 
diabetogenic medication’ for statin users and non-statin users. Independent samples t-
tests in Table 4.19 shows that the mean number of prescriptions for each diabetogenic 
medication (except those of glucocorticoids) was significantly higher among statin users 
compared to non-statin users.  
Because the distributions of ‘number of prescriptions for each diabetogenic 
medication’ variables were not normal, independent samples Mann-Whitney U median 
tests also showed that the median (and the distributions of the median) number of 
prescriptions for thiazides, beta-blockers, antipsychotics, antidepressants, and 
immunosuppressants were significantly (p<0.0001) different across levels of the exposure 
group (i.e., statin users and non-statin users). However, the median (and the distribution 
of the median) number of prescriptions for glucocorticoids was not significantly different 
(p=0.098) between statin users and non-statin users.  
Thus, there was a significant difference in the mean (or median) number of 
prescriptions for each diabetogenic medication received by statin users and non-statin 
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users (except those of glucocorticoids). [Conclusion: null hypotheses H0(5b-f) were 
rejected, but null hypothesis H0(5g) was not rejected]. 
Table 4.19: Descriptive Statistics of Number of Prescriptions for Each 
Diabetogenic Medication for Statin Users and Non-statin Users  
Number of prescriptions for 
each diabetogenic medicationa 
Statin Users Non-statin Users 
Thiazide diuretics 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
0.73 (2.85) 
0 
0 
37 
58,112 
 
0.11 (0.97) 
0 
0 
20 
58,112 
t-test (t=49.7; df=71,268.6; p<0.0001) 
Beta-blockers 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
2.23 (4.94) 
0 
0 
38 
58,112 
 
0.02 (1.46) 
0 
0 
25 
58,112 
t-test (t=94.3; df=68,237.6; p<0.0001) 
Antipsychotics 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
0.12 (1.32) 
0 
0 
50 
58,112 
 
0.02 (0.45) 
0 
0 
27 
58,112 
t-test (t=17.5; df=71,251; p<0.0001) 
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Table 4.19: Descriptive Statistics of Number of Prescriptions for Each 
Diabetogenic Medication for Statin Users and Non-statin Users (cont’d) 
Number of prescriptions for 
each diabetogenic medication 
Statin Users Non-statin Users 
Antidepressants 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
2.52 (5.82) 
0 
0 
94 
58,112 
 
0.47 (2.13) 
0 
0 
69 
58,112 
t-test (t=79.9; df=73,426.3; p<0.0001) 
Immunosuppressants 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
0.05 (1.11) 
0 
0 
64 
58,112 
 
0.005 (0.241) 
0 
0 
29 
58,112 
t-test (t=10.3; df=63,611.2; p<0.0001) 
Glucocorticoids 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
 
0.004 (0.102) 
0 
0 
9.93 
58,112 
 
0.002 (0.077) 
0 
0 
9.50 
58,112 
t-test (t=2.4; df=108,817; p=0.016) 
aOne prescription is equivalent to a 30-day supply of each diabetogenic medication filled 
over the observation period. 
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Categorized ‘number of prescriptions for each diabetogenic medication’ 
Table 4.20 shows the distribution of the categorized ‘number of prescriptions for 
each diabetogenic medication’ for statin users and non-statin users. A chi-square test 
showed that there was a significant association of exposure status (i.e., statin users vs. 
non-statin users) and the ‘number of prescriptions for each diabetogenic medication’ 
categories for each diabetogenic medication except glucocorticoids. 
The majority of statin users and non-statin users, respectively, did not receive any 
prescription for thiazide diuretics (91.3% vs. 98.1%), beta-blockers (78.2% vs. 96.8%), 
antipsychotics (98.6% vs. 99.7%), antidepressants (75.5% vs. 91.7%), 
immunosuppressants (99.6% vs. 99.9%), and glucocorticoids (99.90% vs. 99.94%). 
However, the proportion of statin users who received at least one diabetogenic 
medication prescription was higher compared to the proportion of non-statin users who 
received at least one diabetogenic medication prescription, respectively, for thiazide 
diuretics (8.7% vs. 1.9%), beta-blockers (21.8% vs. 3.1%), antipsychotics (1.4% vs. 
0.4%), antidepressants (24.6% vs. 8.3%), and immunosuppressants (0.40% vs. 0.06%). 
However, the proportion of statin users (0.10%, N=56) and non-statin users (0.06%, 
N=33) who received at least one glucocorticoid prescription was similar.  
  
244 
 
Table 4.20: Frequency and Percent of Statin Users and Non-statin Users by 
Number of Prescriptions for Each Diabetogenic Medication 
Number of 
prescriptions for each 
diabetogenic 
medicationa 
 Statin Users 
N (%) 
Non-statin Users 
N (%) 
Total  
N (%) 
Thiazide diuretics 
0 
1 – 5 
6 – 10 
>10 
 
53,073 (91.3) 
1,828 (3.1) 
1,424 (2.5) 
1,787 (3.1) 
 
57,034 (98.1) 
624 (1.1) 
280 (0.5) 
174 (0.3) 
 
110,107 (94.7) 
2,452 (2.1) 
1,704 (1.5) 
1,961 (1.7) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 2,828.5; df=3; p<0.0001 
Beta-blockers 
0 
1 – 5 
6 – 10 
>10 
 
45,459 (78.2) 
2,886 (5.0) 
3,443 (5.9) 
6,324 (10.9) 
 
56,263 (96.8) 
872 (1.5) 
484 (0.8) 
493 (0.8) 
 
101,722 (87.5) 
3,758 (3.2) 
3,927 (3.4) 
6,817 (5.9) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 9,444.1; df=3; p<0.0001 
Antipsychotics 
0 
1 – 5 
6 – 10 
>10 
 
57,324 (98.6) 
328 (0.6) 
171 (0.3) 
289 (0.5) 
 
57,909 (99.7) 
127 (0.2) 
44 (0.1) 
32 (0.1) 
 
115,233 (99.1) 
455 (0.4) 
215 (0.2) 
321 (0.3) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 372.5; df=3; p<0.0001 
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Table 4.20: Frequency and Percent of Statin Users and Non-statin Users by 
Number of Prescriptions for Each Diabetogenic Medication (cont’d) 
Number of 
prescriptions for each 
diabetogenic 
medicationa 
 Statin Users 
N (%) 
Non-statin Users 
N (%) 
Total  
N (%) 
Antidepressants 
0 
1 – 5 
6 – 10 
>10 
 
43,846 (75.5) 
4,581 (7.9) 
3,480 (6.0) 
6,205 (10.7) 
 
53,290 (91.7) 
2,996 (5.2) 
1,064 (1.8) 
762 (1.3) 
 
97,136 (83.6) 
7,577 (6.5) 
4,544 (3.9) 
6,967 (6.0) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 6,786.7; df=3; p<0.0001 
Immunosuppressants 
0 
1 – 5 
6 – 10 
>10 
 
57,887 (99.60) 
61 (0.10) 
46 (0.10) 
118 (0.20) 
 
58,077 (99.94) 
17 (0.03) 
7 (0.01) 
11 (0.02) 
 
115,964 (99.78) 
78 (0.10) 
53 (0.05) 
129 (0.10) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 142.6; df=3; p<0.0001 
Glucocorticoids 
0 
1 – 5 
6 – 10 
 
58,056 (99.90) 
53 (0.09) 
3 (0.01) 
 
58,079 (99.94) 
30 (0.05) 
3 (0.01) 
 
116,135 (99.92) 
83 (0.07) 
6 (0.01) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 6.4b; df=2; p=0.04  
aOne prescription is equivalent to a 30-day supply of each diabetogenic medication filled 
over the observation period. 
b2 cells (33.3%) had an expected count less than 5. The minimum expected count was 3. 
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4.3.2.5 Charlson Comorbidity Index Score 
 The CCI score is a continuous weighted (higher weight is assigned to more severe 
conditions) variable that was calculated by summing the weights (i.e., 1, 2, 3, or 6) 
assigned to a set of diagnostic conditions and/or procedures (identified using the ICD-9-
CM diagnostic and procedure codes) that were present at or prior to the start of the index 
medication use. For example, a patient with comorbid conditions of congestive heart 
failure (1), ulcer (1), leukemia (2), and liver disease (3) will have a CCI score of 7. The 
higher the CCI score for a patient, the higher the risk of mortality associated with such 
two or more comorbid conditions in the patient. Because diabetes is often comorbid with 
other diseases such as coronary heart disease, individuals with higher CCI scores might 
have increased risk of diabetes. Therefore, the CCI score was controlled for in all 
regression models examining the risk of diabetes between statin users and non-statin 
users. 
Objective 6: To compare the mean CCI score between statin users and non-statin users.  
H0(6): There is no significant difference in the mean CCI score between statin 
users and non-statin users. 
Table 4.21 shows the descriptive statistics of CCI scores for statin users and non-
statin users. The mean (SD) CCI score for the study population (N=116,224) was 0.15 
(0.73). An independent samples t-test showed that the mean CCI score was significantly 
higher among statin users (0.25, SD=0.94) compared to non-statin users (0.04, SD=0.39) 
(t=48.6; df=78,093.9; p<0.0001).  
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Because the CCI score variable was not normally distributed, an independent 
samples Mann-Whitney U median test also showed that the median CCI score (and the 
distribution of the median CCI score) was not the same across levels of the exposure 
group (p<0.0001). Thus, there was a significant difference in the mean (or median) CCI 
score between statin users and non-statin users. [Conclusion: null hypothesis H0(6) was 
rejected]. 
Table 4.21: Descriptive Statistics of Charlson Comorbidity Index Score for 
Statin Users and Non-statin Users 
Charlson Comorbidity 
Index Score 
Statin Users Non-statin Users Study Population 
Mean (SD) 
Median 
Minimum 
Maximum 
Number of cases 
0.25 (0.94) 
0 
0 
15 
58,112 
0.04 (0.39) 
0 
0 
11 
58,112 
0.15 (0.73) 
0 
0 
15 
116,224 
t-test (t=48.6; df=78,093.9; p<0.0001) 
 
Categorized ‘Charlson Comorbidity Index Score’ 
Table 4.22 shows the distribution of the categorized CCI score for statin users and 
non-statin users. A chi-square test showed that there was a significant association of 
exposure status (i.e., statin users vs. non-statin users) and the CCI score categories (χ2 = 
4,667; df=3; p<0.0001). The majority of statin users (87.1%, N=50,631) and non-statin 
users (97.7%, N=56,792) had zero CCI scores. However, the proportion of statin users 
with CCI scores of one or more (12.9%, N=7,481) was higher compared to the proportion 
of non-statin users with CCI scores of one or more (2.3%, N=1,320).  
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Table 4.22: Frequency and Percent of Statin Users and Non-statin Users by 
Charlson Comorbidity Index Score Categories 
CCI score categories  Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population  
N (%) 
0 
1 – 5 
6 – 10 
>10 
50,631 (87.1) 
6,794 (11.7) 
678 (1.2) 
9 (0.015) 
56,792 (97.7) 
1,212 (2.1) 
107 (0.2) 
1 (0.002) 
107,423 (92.4) 
8,006 (6.9) 
785 (0.7) 
10 (0.009) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 4,667; df=3; p<0.0001 
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4.3.3 Medication Possession Ratio (Medication Adherence) 
 The second aim of the study was to compare medication adherence (using the 
medication possession ratio) among users of each statin type (objective 7, hypothesis 7a) 
and between intensive-dose statin users and moderate-dose statin users (objective 7, 
hypothesis 7b). MPR is a continuous variable (for the purpose of all regression analyses) 
that was defined as the sum of number of days of statin prescription supplied (minus the 
number of days supplied for the last statin prescription) divided by the sum of days 
between the first and last statin prescription fill dates.  
For descriptive purposes, statin users were also categorized into those who were 
adherent (MPR ≥80%) or not adherent (MPR<80%) with their statin medications (Note: 
MPR values greater than 100% were truncated to 100%). MPR is a measure of 
medication adherence, with higher MPR values indicating higher adherence or 
compliance with the statin medication. MPR was compared among users of six statin 
types (i.e., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin), 
as well as between intensive-dose statin users and moderate dose statin users.  
Objective 7: To assess whether medication adherence (using MPR) differed among 
users of each statin type, and between intensive-dose statin users and moderate-dose 
statin users. 
4.3.3.1 Statin Types and Medication Adherence 
H0(7a): There is no significant difference in mean MPR among users of each statin 
type. 
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Table 4.23 shows the descriptive statistics of MPR (in percent) by statin type and 
the frequency and percent of use of each statin type. The table shows that the most 
frequently prescribed statins were atorvastatin (50.7%, N=29,474) and simvastatin 
(23.1%, N=13,415), while the least prescribed statin was fluvastatin (3.1%, N=1,799). 
 The mean (SD) MPR among all statin users (N=50,557) was 75.0 (25.3). A one-
way ANOVA showed that there was at least one significant difference in mean MPR 
among users of each statin type (F=29.1; df=5; p<0.0001). Mean MPR was highest 
among lovastatin users (79.6, SD=24.2) but decreased, consecutively, among rosuvastatin 
(76.5, SD=23.9), atorvastatin (74.8, SD=25.3), pravastatin (74.5, SD=25.5), and 
simvastatin (74.3, SD=25.6) users. Fluvastatin users (72.8, SD=26.4) had the lowest 
mean MPR. Thus, there was at least one significant difference in mean MPR among users 
of each statin type. [Conclusion:  null hypothesis H0(7a) was rejected]. 
Post-hoc Analysis 
There are 15 possible two-way multiple comparisons in a group with six different 
statin types (i.e., number of comparison =𝑁(𝑁 − 1) 2⁄ , where 𝑁 equals the number of 
levels in the group). A post-hoc multiple comparison analysis indicated that mean MPR 
was significantly higher for lovastatin users (79.6) compared to rosuvastatin (76.5, 
p<0.0001), atorvastatin (74.8, p<0.0001), pravastatin (74.5, p<0.0001), simvastatin (74.3, 
p<0.0001), and fluvastatin (72.8, p<0.0001) users. In addition, mean MPR was 
significantly higher for rosuvastatin users (76.5) compared to simvastatin (74.3, p=0.001) 
and fluvastatin (72.8, p<0.0001) users. All the other eight possible two-way multiple 
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comparisons of the mean MPRs were not statistically different (i.e., p≥0.01) from each 
other. 
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Table 4.23: Descriptive Statistics of Medication Possession Ratio by Types of Statin  
Type of Statin Mean (SD) Median Minimum Maximum N (%)a N (%)b 
Lovastatin 
Rosuvastatin 
Atorvastatin 
Pravastatin 
Simvastatin 
Fluvastatin 
79.6 (24.2) 
76.5 (23.9) 
74.8 (25.3) 
74.5 (25.5) 
74.3 (25.6) 
72.8 (26.4) 
90.4 
84.1 
82.9 
82.6 
82.3 
81.1 
0.2 
4 
3 
3 
0.4 
3 
100 
100 
100 
100 
100 
100 
3,329 (6.6) 
2,608 (5.2) 
25,948 (51.3) 
5,472 (10.8) 
11,677 (23.1) 
1,523 (3.0) 
4,054 (7.0) 
2,987 (5.1) 
29,474 (50.7) 
6,383 (11.0) 
13,415 (23.1) 
1,799 (3.1) 
Statin users 75.0 (25.3) 83.3 0.2 100 50,557 (100.0) 58,112 (100.0) 
ANOVA (F=29.1; df=5; p<0.0001) 
aTotal N was less than 58,112 because of missing values for MPR. MPR values were missing for cases with only one prescription of 
the statin filled (MPR numerator and denominator=0), or if two or more prescriptions filled, one or more number of days supply 
was zero or negative (MPR numerator=0 or negative). MPRs with negative or zero values were set to missing. 
bFrequency and percent of statin use (by statin type) without regard to missing MPR values. 
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Statin Types and Adherence 
Table 4.24 shows the frequency and percent of users of each statin type 
categorized as non-adherent (MPR<80) or adherent (MPR≥80). A chi-square test showed 
that there was a significant difference in the proportion of users of each statin type who 
were adherent or not adherent with their medications (χ2 = 96.4; df=5; p<0.0001).  
The table shows that the majority (54.2%, N=27,412) of all statin users were 
adherent with their medications. The proportion of users of each statin type who were 
adherent with their medication was highest among lovastatin users (62%, N=2,065) and 
lowest among fluvastatin users (52.3%, N=796).  
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Table 4.24: Frequency and Percent of Users of Each Statin Type by Adherence Status 
 Atorvastatin 
N (%) 
Fluvastatin 
N (%) 
Lovastatin 
N (%) 
Pravastatin 
N (%) 
Rosuvastatin 
N (%) 
Simvastatin 
N (%) 
Statin Users 
N (%) 
Adherenta 
Non-adherentb 
13,961 (53.8) 
11,987 (46.2)  
796 (52.3) 
727 (47.7) 
2,065 (62.0) 
1,264 (38.0) 
2,929 (53.5) 
2,543 (46.5) 
1,461 (56.0) 
1,147 (44.0) 
6,200 (53.1) 
5,477 (46.9) 
27,412 (54.2) 
23,145 (45.8) 
Total 25,948 
(100.0) 
1,523  
(100.0) 
3,329  
(100.0) 
5,472  
(100.0) 
2,608  
(100.0) 
11,677 
(100.0) 
50,557c 
(100.0) 
(χ2 = 96.4; df=5; p<0.0001) 
aMPR≥80%. 
bMPR<80%. 
cTotal N was less than 58,112 because of missing values for MPR. MPR values were missing for cases with only one prescription of 
the statin filled (MPR numerator and denominator=0), or if two or more prescriptions filled, one or more number of days supply 
was zero or negative (MPR numerator=0 or negative). MPRs with negative or zero values were set to missing. 
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4.3.3.2 Dosage Intensity and Medication Adherence 
H7b: The mean medication possession ratio (MPR) will be significantly lower 
among intensive-dose statin users compared to moderate-dose statin users. 
Table 4.25 shows the frequency and percent of intensive-dose and moderate-dose 
statin users depending on how dosage intensity was defined per study protocol. For this 
study, intensive-dose statin use was defined as the use of at least one intensive-dose statin 
at any time during the observation period, while moderate-dose statin use was defined as 
the use of a moderate-dose statin throughout the observation period. Intensive-dose 
statins included atorvastatin 40 and 80mg, rosuvastatin 20 and 40mg, and simvastatin 
80mg. Moderate-dose statins included atorvastatin 10 and 20mg, rosuvastatin 5 and 
10mg, simvastatin 5, 10, 20, and 40mg, and all doses of fluvastatin, pravastatin, and 
lovastatin.  
Table 4.25 shows that the proportions of statin users who were categorized as 
using intensive-dose statins increased from 5.6% (N=3,272) to 10.7% (N=6,205) when 
intensive-dose statin use was defined as the use of at least one intensive-dose statin at any 
time during the observation period rather than the use of an intensive-dose statin at the 
index date. Nevertheless, the majority (89.3%, N=51,907) of statin users were still 
prescribed a moderate statin dose.  
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Table 4.25: Frequency and Percent of Intensive-dose and Moderate-dose 
Statin Users Based on Definition of Dosage Intensity 
Dosage Intensity N (%)a N (%)b 
Intensive-dosec 
Moderate-dosed 
3,272 (5.6) 
54,840 (94.4) 
6,205 (10.7) 
51,907 (89.3) 
Total 58,112 (100.0) 58,112 (100.0) 
aDosage intensity defined based on whether subjects received intensive-dose or moderate 
dose statin at index date (intention-to-treat). 
bIntensive-dose users defined as receiving at least one intensive-dose statin at any time 
during the observation period. Moderate-dose users defined as receiving only a moderate-
dose statin throughout the observation period. 
cIntensive-dose statins include atorvastatin 40 and 80mg, rosuvastatin 20 and 40mg, and 
simvastatin 80mg. 
dModerate-dose statins include atorvastatin 10 and 20mg, rosuvastatin 5 and 10mg, 
simvastatin 5, 10, 20, and 40mg, and all doses of fluvastatin, pravastatin, and lovastatin. 
 
Furthermore, Table 4.26 shows the descriptive statistics of MPR (in percent) for 
intensive-dose and moderate-dose statin users. Among statin users (N=50,557), an 
independent samples t-test showed that mean MPR was significantly lower among 
intensive-dose statin users (70.7., SD=26.4) compared to moderate-dose statin users 
(75.6, SD=25.1) (t=13.3; df=7,175.8; p<0.0001). [Conclusion: alternative hypothesis 
H7b was supported]. 
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Table 4.26: Descriptive Statistics of Medication Possession Ratio by Statin 
Dosage Intensity  
Dosage Intensity Mean (SD) Median Min Max N (%) 
Intensive-dosea 
Moderate-doseb 
70.7 (26.3) 
75.6 (25.1) 
76.4 
84.0 
0.4 
0.2 
100 
100 
5,767 (11.4) 
44,790 (88.6) 
Statin users 75.0 (25.3) 83.3 0.2 100 50,557c (100.0) 
t-test (t=13.3; df=7,175.8; p<0.0001) 
aIntensive-dose statins include atorvastatin 40 and 80mg, rosuvastatin 20 and 40mg, and 
simvastatin 80mg. 
bModerate-dose statins include atorvastatin 10 and 20mg, rosuvastatin 5 and 10mg, 
simvastatin 5, 10, 20, and 40mg, and all doses of fluvastatin, pravastatin, and lovastatin. 
cTotal N was less than 58,112 because of missing values for MPR. MPR values were missing 
for cases with only one prescription of the statin filled (MPR numerator and 
denominator=0), or if two or more prescriptions filled, one or more number of days supply 
was zero or negative (MPR numerator=0 or negative). MPRs with negative or zero values 
were set to missing. 
 
Dosage Intensity and Adherence  
Table 4.27 shows the frequency and percent of intensive-dose and moderate-dose 
statin users when they were categorized as non-adherent (MPR<80) or adherent 
(MPR≥80) with their medications. A chi-square test showed that there was a significant 
difference in the proportion of intensive-dose and moderate-dose statin users who were 
adherent or not adherent with their medications (χ2 = 176.3; df=1; p<0.0001). The 
proportion of moderate-dose statin users who were adherent with their medications 
(55.3%, N=24,758) was higher compared to the proportion of intensive-dose statin users 
who were adherent with their medications (46.0%, N=2,654).  
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Table 4.27: Frequency and Percent of Intensive-dose and Moderate-dose 
Statin Users by Adherence Status 
 Intensive-dose 
N (%) 
Moderate-dose  
N (%) 
Statin Users 
N (%) 
Adherenta 
Non-adherentb 
2,654 (46.0) 
3,113 (54.0) 
24,758 (55.3) 
20,032 (44.7) 
27,412 (54.2) 
23,145 (45.8) 
Total 5,767 (100.0) 44,790 (100.0) 50,557c (100.0) 
(χ2 = 176.3; df=1; p<0.0001) 
a
Intensive-dose statins include atorvastatin 40 and 80mg, rosuvastatin 20 and 40mg, and 
simvastatin 80mg. 
b
Moderate-dose statins include atorvastatin 10 and 20mg, rosuvastatin 5 and 10mg, 
simvastatin 5, 10, 20, and 40mg, and all doses of fluvastatin, pravastatin, and lovastatin. 
cTotal N was less than 58,112 because of missing values for MPR. MPR values were missing 
for cases with only one prescription of the statin filled (MPR numerator and 
denominator=0), or if two or more prescriptions filled, one or more number of days supply 
was or negative (MPR numerator=0 or negative). MPRs with negative or zero values were 
set to missing. 
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4.4 SURVIVAL ANALYSIS (KM Curves and Log-rank Test) 
 Kaplan-Meier curves (and log-rank tests of the curves) were used to compare the 
survival time (and the estimated survival probability over time) between statin users and 
non-statin users (objective 8, hypothesis 8a). Survival time is a continuous variable that 
was defined as the time between the receipt of the index medication and manifestation of 
diabetes (for those that had the event), or the time between receipt of the index 
medication and the end of the study period (for those that reached the end of the study 
period without manifesting diabetes).  
Survival times (and the estimated survival probabilities over time) were also 
compared among users of each statin type (objective 8, hypothesis 8b), and between 
intensive-dose statin users and moderate-dose statin users (objective 8, hypothesis 8c). A 
group with the shorter survival time (or with the shorter survival probability over time, or 
with its KM survival curve situated below that of its comparator’s KM survival curve) 
may be more likely to have the outcome of interest (diabetes).  
The KM survival curves and the log-rank tests of the curves are univariate 
procedures that compare the survival experience of two or more groups without 
controlling for any confounding variable. Controlling for confounding variable(s) while 
comparing the survival experience of two groups was achieved using the Cox 
proportional hazards regression models discussed in the next section (section 4.5). 
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Objective 8: To assess whether survival times (i.e., time to diabetes) differed between 
statin users and non-statin users, among users of each statin type, and between intensive-
dose statin users and moderate-dose statin users. 
4.4.1 Statin Users and Survival Time 
H8a: Statin users will have a shorter survival time compared to non-statin users. 
Table 4.28 shows the KM survival estimates and the descriptive statistics of the 
observed survival times for statin users and non-statin users. The table shows that the 
proportion of statin users with the event (9.8%, N=5,678) was higher compared to the 
proportion of non-statin users with the event (3.3%, N=1,915). In addition, the estimated 
mean survival time (in months) for statin users (16.92, standard error, SE=0.02) was 
shorter compared to that of non-statin users (17.67, SE=0.01).  
Furthermore, Figure 4.3 shows two Kaplan-Meier survival curves comparing the 
survival probability against time for statin users and non-statin users. The log-rank test 
comparing the distribution of the two survival curves showed that statin users had a 
significantly shorter survival probability over time compared to non-statin users (χ2 = 
2,022.8; df=1; p<0.0001).  
From Figure 4.3, the respective 6-month and 12-month survival probabilities for 
statin users (95.5% and 91.8%) were lower compared to those for non-statin users (98.7 
and 97.3%). At 18-months, the survival probability for statin users fell to 0.89 (i.e., 89% 
of statin users survived past 18 months without having diabetes) compared to 96.3% of 
non-statin users that survived past 18 months without having diabetes. Thus, statin users 
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had a shorter survival time (and shorter survival probabilities over time) compared to 
non-statin users. [Conclusion: alternative hypothesis H8a was supported]. 
Table 4.28: Survival Probability and Mean Survival Time for Statin Users and 
Non-statin Users 
 Statin Users Non-statin Users 
Kaplan-Meier estimates 
Mean (SE) survival timea 
6-month survival probabilityb 
12-month survival probabilityb 
18-month survival probabilityb 
 
16.92 (0.02) 
95.5 
91.8 
89.0 
 
17.67 (0.01) 
98.7 
97.3 
96.3 
Observed survival time 
Mean (SD) 
Median 
Minimum 
Maximum 
 
14.32 (3.27) 
14.82 
0.03 
18.04 
 
14.98 (2.40) 
15.24 
0.03 
18.04 
Number of cases with event (%) 
Number of cases censored (%)c 
5,678 (9.8) 
52,434 (90.2) 
1,915 (3.3) 
56,197 (96.7) 
Total number of cases (%) 58,112 (100.0) 58,112 (100.0) 
Abbreviations: Standard Error, SE; Standard Deviation, SD. 
aKaplan-Meier estimate of the mean survival time and standard error of the population 
mean survival time (in months). 
bThis is the proportion of subjects that survived (i.e., did not have the event) past the stated 
month (in percent). 
cThose censored do not have the event by end of study period. 
 
 
262 
 
Figure 4.3: Graph Comparing the Survival Probability Curves of Statin Users and Non-statin Users 
 
 
Log-rank test χ2 = 2,022.8; df=1; p<0.0001 
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ADDENDUM 
Incidence Density Rate: Statin users vs. non-statin users 
Appendix D shows the weighted and unweighted incidence density rates and the 
cumulative incidence of diabetes by statin use. From Table D.1 in Appendix D, the 
unweighted diabetes incidence density rate for statin users (6.82 per 1,000 person-
months) was higher compared to that for non-statin users (2.2 per 1,000 person-months). 
This means that if 1,000 statin users were followed for one month, 6.82 new cases of 
diabetes will be recorded. This rate is higher compared to the 2.2 new cases of diabetes 
that will be recorded if 1,000 non-statin users were followed for one month. 
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4.4.2 Statin Types and Survival Time 
H0(8b): There is no significant difference in mean survival time among users of 
each statin type. 
Table 4.29 shows the KM survival estimates and the descriptive statistics of the 
observed survival times among users of each statin type. The table shows that the 
proportion of those with the event (i.e., diabetes) was highest among lovastatin users 
(13.9%, N=564) and lowest among rosuvastatin users (8.1%, N=242). In addition, the 
estimated mean survival time (in months) was shortest among rosuvastatin users (15.51, 
SE=0.06) and increased, consecutively, among lovastatin (16.41, SE=0.07), fluvastatin 
(16.84, SE=0.09), and simvastatin (16.84, SE=0.03) users. Atorvastatin (17.01, SE=0.02) 
and pravastatin (17.01, SE=0.04) users had the longest estimated mean survival time 
[Note: having a shorter survival time means getting the event early]. 
Furthermore, Figure 4.4 shows six Kaplan-Meier survival curves comparing the 
survival probabilities against time among users of each statin type. The log-rank test 
comparing the distribution of the six survival curves showed that at least one of the 
survival curves significantly differed from  another (χ2 = 110.8; df=5; p<0.0001).  
From Figure 4.4, the proportion of statin users that survived past six months 
appeared similar for atorvastatin (95.8%), fluvastatin (95.0%), pravastatin (95.8%), 
rosuvastatin (95.8%), and simvastatin (95.1%) users. In contrast, a lower proportion of 
lovastatin users (93.0%) survived past six months. Furthermore, the 12-month survival 
probability appeared significantly lower for lovastatin users (88.5%) compared to 
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fluvastatin and simvastatin users (91%), pravastatin users (92.3%), and atorvastatin and 
rosuvastatin users (92.5%). Similarly, at 18-months, the survival probability was lowest 
for lovastatin users (84.1%) compared to fluvastatin and simvastatin users (88.5%), 
atorvastatin users (89.6%), and pravastatin users (89.8%). Rosuvastatin users had a 
survival probability of 88.8% at 16.4 months (their maximally observed survival time). 
Thus, there was at least one significant difference in mean survival time (and survival 
probabilities over time) among users of each statin type. [Conclusion: null hypothesis 
H0(8b) was rejected]. 
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Table 4.29: Survival Probability and Mean Survival Times for Statin Types 
 Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin 
Kaplan-Meier estimates 
Mean (SE) survival timea 
6-month SPb 
12-month SPb 
18-month SPb 
 
17.01 (0.02) 
95.8 
92.5 
89.6 
 
16.84 (0.09) 
95.0 
91.0 
88.5 
 
16.41 (0.07) 
93.0 
88.5 
84.1 
 
17.01 (0.04) 
95.8 
92.3 
89.8 
 
15.51 (0.06) 
95.8 
92.5 
(88.8)c 
 
16.84 (0.03) 
95.1 
91.0 
88.5 
Observed survival time  
Mean (SD) 
Median 
Minimum 
Maximum 
 
14.41 (3.19) 
14.95 
0.03 
18.04 
 
14.45 (3.38) 
15.18 
0.03 
18.04 
 
13.92 (3.74) 
14.59 
0.03 
18.04 
 
14.62 (3.22) 
15.24 
0.03 
18.04 
 
12.99 (2.53) 
13.34 
0.03 
16.36 
 
14.37 (3.39) 
15.01 
0.03 
18.04 
Events, N (%) 
Censored, N (%)d 
2,690 (9.1) 
26,784 (90.9) 
192 (10.7) 
1,607 (89.3) 
564 (13.9) 
3,490 (86.1) 
587 (9.2) 
5,796 (90.8) 
242 (8.1)  
2,745 (91.9) 
1403 (10.5)  
12,012 (89.5) 
Total, N (%) 29,474 (100.0) 1,799 (100.0) 4,054 (100.0) 6,383 (100.0) 2,987 (100.0) 13,415 (100.0) 
Abbreviations: SE, Standard Error; SD, Standard Deviation; SP, Survival Probability. 
aKaplan-Meier estimate of the mean survival time (in months) and standard error of the population mean survival time. 
bThis is the proportion of subjects that survived (i.e., did not have the event) past the stated month (in percent). 
c88.8% of rosuvastatin users survived past 16.36 months (their maximum survival time). 
dThose censored do not have the event (i.e., diabetes) by end of study period. 
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Figure 4.4: Graph Comparing the Survival Probability Curves of Different Statin Types 
 
  
Log-rank test χ2 = 110.8; df=5; p<0.0001 
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4.4.3 Statin Dosage Intensity and Survival Time 
H8c: Intensive-dose statin users will have a shorter survival time compared to 
moderate-dose statin users. 
Table 4.30 shows the KM survival estimates and the descriptive statistics of the 
observed survival times between intensive-dose statin users and moderate-dose statin 
users. The table shows that the proportion of intensive-dose statin users with the event 
(13.4%, N=831) was higher compared to the proportion of moderate-dose statin users 
with the event (9.3%, N=4,847). In addition, the estimated mean survival time (in 
months) for intensive-dose statin users (16.51, standard error, SE=0.05) was shorter 
compared to that of moderate-dose statin users (16.97, SE=0.02).  
Furthermore, Figure 4.5 shows two Kaplan-Meier survival curves comparing the 
survival probability against time for intensive-dose statin users and moderate-dose statin 
users. The log-rank test comparing the distribution of the two survival curves showed that 
intensive-dose statin users had a significantly shorter survival probability over time 
compared to moderate-dose statin users (χ2 = 101.4; df=1; p<0.0001).  
From Figure 4.5, the respective 6-month and 12-month survival probabilities for 
intensive-dose statin users (93.8% and 88.8%) were lower compared to those for 
moderate-dose statin users (95.7% and 92.2%). At 18-months, the survival probability for 
intensive-dose statin users fell to 85.2% (i.e., 85.2% of intensive-dose statin users 
survived past 18 months without having diabetes) compared to 89.5% of moderate-dose 
statin users that survived past 18 months without having diabetes. Thus, intensive-dose 
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statin users had a shorter survival time (and shorter survival probabilities over time) 
compared to moderate-dose statin users. [Conclusion: alternative hypothesis H8c was 
supported]. 
Table 4.30: Survival Probability and Mean Survival Time for Intensive-dose 
and Moderate-dose Statin Users 
 Intensive-dose Moderate-dose 
Kaplan-Meier estimates 
Mean (SE) survival timea 
6-month survival probabilityb 
12-month survival probabilityb 
18-month survival probabilityb 
 
16.51 (0.05) 
93.8 
88.8 
85.2 
 
16.97 (0.02) 
95.7 
92.2 
89.5 
Observed survival time  
Mean (SD) 
Median 
Minimum 
Maximum 
 
14.12 (3.67) 
14.85 
0.03 
18.04 
 
14.34 (3.22) 
14.82 
0.03 
18.04 
Number of cases with event (%) 
Number of cases censored (%)c 
831 (13.4) 
5,374 (86.6) 
4,847 (9.3) 
47,060 (90.7) 
Total number of cases (%) 6,205 (100.0) 51,907 (100.0) 
Abbreviations: Standard Error, SE; Standard Deviation, SD. 
aKaplan-Meier estimate of the mean survival time and standard error of the population 
mean survival time (in months). 
bThis is the proportion of subjects that survived (i.e., did not have the event) past the stated 
month (in percent). 
cThose censored do not have the event by end of study period. 
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Figure 4.5: Graph Comparing the Survival Probability Curves of Intensive-Dose and Moderate-Dose Statin Users 
 
 
 
Log-rank test χ2 = 101.4; df=1; p<0.0001 
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ADDENDUM 
Incidence Density Rate: Intensive-dose statin users vs. moderate-dose statin 
users 
Appendix D shows the weighted and unweighted incidence density rate and 
cumulative incidence of diabetes by statin use. From Table D.1, the unweighted diabetes 
incidence density rate for intensive-dose statin users (9.48 per 1,000 person-months) was 
higher compared to that for moderate-dose statin users (6.51 per 1,000 person-months). 
This means that if 1,000 intensive-dose statin users were followed for one month, 9.48 
new cases of diabetes will be recorded. This rate is higher compared to the 6.51 new 
cases of diabetes that will be recorded if 1,000 moderate-dose statin users were followed 
for one month. 
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4.5 SURVIVAL ANALYSIS (Cox Regression) 
 The preceding section (section 4.4) compared, among other things, the survival 
experience of statin users and non-statin users (using KM curves and log-rank test) 
without controlling for confounding variables that may increase the risk of diabetes in 
one group versus the other. Because of the need to control for confounding factors such 
as demographic (age and gender) and clinical characteristics (hyperlipidemia, obesity, 
hypertension, use of diabetogenic medications, and CCI score), this section utilized the 
Cox proportional hazards regression (or the Cox regression) to compare the hazard of 
diabetes between statin users and non-statin users (objective 9, hypothesis 9a), between 
users of each statin type and non-statin users (objective 9, hypothesis 9b-g), and between 
intensive-dose statin users and moderate-dose statin users (objective 10, hypothesis 10). 
 The hazard ratio (HR) gives an estimate of the hazard of diabetes in the active 
group (i.e., statin users and users of each statin type) relative to that of the reference 
group (i.e., non-statin users). HRs greater than 1.0 indicate that the hazard of diabetes (or 
the risk of diabetes) among the active group is higher than the hazard of diabetes among 
the reference group. 
In addition to the main Cox regression models examining the association of statin 
use and incidence of diabetes while controlling for all covariates, three additional 
sensitivity analyses were carried out (on each original Cox regression model) to examine 
how the hazard ratios were influenced by: (i) controlling for time-dependent covariates 
(i.e., independent variables that violated the proportionality of hazards assumption), (ii) 
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not controlling for the obesity variable in the model (due to low prevalence of obesity 
among the study population compared to that of the adult US population), and (iii) not 
controlling for any of the covariates (i.e., unadjusted models).  
The hazard ratios (and 99% confidence intervals of the HRs) of the sensitivity 
analyses results were presented alongside those of the main results. Appendices C, E, and 
F also give a visual summary of the sensitivity analyses of the hazard ratios when 
significant time-dependent covariates were controlled for, when none of the covariates 
were controlled for, and when obesity was not controlled for, respectively. 
Objective 9: To assess whether survival times differed between statin users and non-
statin users, and between users of each statin type and non-statin users, while controlling 
for demographic variables (i.e., age and gender), and clinical covariates (i.e., 
hyperlipidemia, obesity, hypertension, diabetogenic medication use [i.e., number of 
prescriptions for all diabetogenic medications], and CCI score). 
4.5.1 Statin Users  
H9a: Statin users will have a significantly shorter survival time compared to 
non-statin users while controlling for age, gender, and clinical covariates. 
The estimated mean survival time (in months) for statin users (16.92, SE=0.02) 
was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.31 shows the results of the Cox regression model comparing survival time 
between statin users and non-statin users while controlling for covariates. The overall 
model was statistically significant (χ2=4,036.8; df=8; p<0.0001). This means that at least 
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one of the predictor variables was significantly associated with the dependent variable 
(survival time). 
Compared to no statin use, and controlling for covariates, statin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=2.752; 99% 
C.I.=2.535 – 2.987; p<0.0001]. In other words, the hazard of incident diabetes for statin 
users was 2.752 times the hazard of incident diabetes for non-statin users. When 
significant time-dependent covariates specific to this model (i.e., gender, hyperlipidemia, 
hypertension, and diabetogenic medications) were controlled for in a separate model, the 
hazard of incident diabetes for statin users increased, and was 2.812 times those of non-
statin users [HR=2.812; 99% C.I.=2.590 – 3.052; p<0.0001]. However, when the obesity 
variable was not controlled for in a separate model, the hazard ratio comparing statin 
users to non-statin users increased marginally and remained significant [HR=2.765; 99% 
C.I.=2.548 – 3.002; p<0.0001]. [Conclusion: alternative hypothesis H9a was 
supported].  
275 
 
Table 4.31: Cox Regression Model Comparing Survival Time between Statin Users and Non-statin Users while 
Controlling for Covariates (N=116,224) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina 1.012 0.032 1009.438 p<0.0001 2.752 2.535 2.987 
Age 0.032 0.001 525.357 p<0.0001 1.033 1.029 1.036 
Gender: Maleb -0.064 0.023 7.675 0.006 0.938 0.884 0.996 
Hyperlipidemia -0.423 0.026 260.766 p<0.0001 0.655 0.612 0.701 
Obesity 0.573 0.101 31.929 p<0.0001 1.773 1.366 2.302 
Hypertension 0.344 0.027 164.668 p<0.0001 1.410 1.316 1.511 
Diabetogenic medications -0.049 0.002 555.108 p<0.0001 0.953 0.948 0.958 
CCI score 0.131 0.009 201.689 p<0.0001 1.140 1.114 1.168 
Model Parameters: χ2=4,036.8; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., gender, hyperlipidemia, 
hypertension, and diabetogenic medications) were controlled for in a separate model, the hazard ratio comparing statin users to 
non-statin users increased and remained significant [HR=2.812; 99% C.I.: 2.590 – 3.052; p<0.0001].  
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
statin users to non-statin users increased and remained significant [HR=3.089; 99% C.I.=2.886 – 3.307; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing statin users 
to non-statin users increased marginally and remained significant [HR=2.765; 99% C.I.=2.548 – 3.002; p<0.0001].
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4.5.2 Atorvastatin 
H9b: Atorvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
The estimated mean survival time (in months) for atorvastatin users (17.01, 
SE=0.02) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.32 shows the results of the Cox regression model comparing survival time 
between atorvastatin users and non-statin users while controlling for covariates. The 
overall model was statistically significant (χ2=2,637.1; df=8; p<0.0001). This means that 
at least one of the predictor variables was significantly associated with the dependent 
variable (survival time).  
Compared to no statin use, and controlling for covariates, atorvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=2.425; 99% 
C.I.=2.200 – 2.673; p<0.0001]. In other words, the hazard of incident diabetes for 
atorvastatin users was 2.425 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., gender, 
hyperlipidemia, and diabetogenic medications) were controlled for in a separate model, 
the hazard of incident diabetes for atorvastatin users increased, and was 2.474 times those 
of non-statin users [HR=2.474; 99% C.I.=2.244 – 2.727; p<0.0001]. However, when 
obesity was not controlled for in another separate model, the hazard ratio comparing 
atorvastatin users to non-statin users increased marginally and remained significant 
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[HR=2.430; 99% C.I.=2.204 – 2.678; p<0.0001]. [Conclusion: alternative hypothesis 
H9b was supported]. 
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Table 4.32: Cox Regression Model Comparing Survival Time between Atorvastatin Users and Non-statin Users 
while Controlling for Covariates (N=87,586) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Atorvastatina 0.886 0.038 548.135 p<0.0001 2.425 2.200 2.673 
Age 0.033 0.002 402.828 p<0.0001 1.034 1.029 1.038 
Gender: Maleb -0.061 0.030 4.226 0.04 0.941 0.872 1.016 
Hyperlipidemia -0.387 0.036 113.303 p<0.0001 0.679 0.618 0.746 
Obesity 0.365 0.157 5.396 0.02 1.441 0.961 2.159 
Hypertension 0.409 0.037 122.561 p<0.0001 1.505 1.369 1.656 
Diabetogenic medications -0.044 0.003 238.879 p<0.0001 0.957 0.950 0.964 
CCI score 0.152 0.012 155.046 p<0.0001 1.164 1.128 1.201 
Model Parameters: χ2=2,637.1; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., gender, hyperlipidemia, and 
diabetogenic medications) were controlled for in a separate model, the hazard ratio comparing atorvastatin users to non-statin 
users increased and remained significant [HR=2.474; 99% C.I.=2.244 – 2.727; p<0.0001].  
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
atorvastatin users to non-statin users increased and remained significant [HR=2.871; 99% C.I.=2.658 – 3.101; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing atorvastatin 
users to non-statin users increased marginally and remained significant [HR=2.430; 99% C.I.=2.204 – 2.678; p<0.0001]. 
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4.5.3 Fluvastatin 
H9c: Fluvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
The estimated mean survival time (in months) for fluvastatin users (16.84, 
SE=0.09) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.33 shows the results of the Cox regression model comparing survival time 
between fluvastatin users and non-statin users while controlling for covariates. The 
overall model was statistically significant (χ2=855.2; df=8; p<0.0001). This means that at 
least one of the predictor variables was significantly associated with the dependent 
variable (survival time).  
Compared to no statin use, and controlling for covariates, fluvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=2.064; 99% 
C.I.=1.647 – 2.586; p<0.0001]. In other words, the hazard of incident diabetes for 
fluvastatin users was 2.064 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., age and 
diabetogenic medications) were controlled for in a separate model, the hazard of incident 
diabetes for fluvastatin users increased, and was 2.072 times those of non-statin users 
[HR=2.072; 99% C.I.=1.653 – 2.599; p<0.0001]. However, when obesity was not 
controlled for in another separate model, the hazard ratio comparing fluvastatin users to 
non-statin users increased marginally and remained significant [HR=2.067; 99% 
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C.I.=1.649 – 2.589; p<0.0001]. [Conclusion: alternative hypothesis H9c was 
supported]. 
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Table 4.33: Cox Regression Model Comparing Survival Time between Fluvastatin Users and Non-statin Users 
while Controlling for Covariates (N=59,911) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Fluvastatina 0.725 0.088 68.452 p<0.0001 2.064 1.647 2.586 
Age 0.036 0.002 305.844 p<0.0001 1.037 1.032 1.043 
Gender: Maleb -0.044 0.044 1.006 0.316 0.957 0.855 1.071 
Hyperlipidemia -0.041 0.073 0.312 0.576 0.960 0.795 1.159 
Obesity 0.202 0.334 0.364 0.546 1.224 0.517 2.895 
Hypertension 0.653 0.072 83.119 p<0.0001 1.921 1.598 2.310 
Diabetogenic medications -0.032 0.007 23.627 p<0.0001 0.968 0.952 0.985 
CCI score 0.167 0.027 38.321 p<0.0001 1.182 1.103 1.267 
Model Parameters: χ2=855.2; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., age and diabetogenic medications) 
were controlled for in a separate model, the hazard ratio comparing fluvastatin users to non-statin users increased and remained 
significant [HR=2.072; 99% C.I.=1.653 – 2.599; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
fluvastatin users to non-statin users increased and remained significant [HR=3.354; 99% C.I.=2.760 – 4.076; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing fluvastatin 
users to non-statin users increased marginally and remained significant [HR=2.067; 99% C.I.=1.649 – 2.589; p<0.0001]. 
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4.5.4 Lovastatin 
H9d: Lovastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
The estimated mean survival time (in months) for lovastatin users (16.41, 
SE=0.02) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.34 shows the results of the Cox regression model comparing survival time 
between lovastatin users and non-statin users while controlling for covariates. The overall 
model was statistically significant (χ2=1,896; df=8; p<0.0001). This means that at least 
one of the predictor variables was significantly associated with the dependent variable 
(survival time).  
Compared to no statin use, and controlling for covariates, lovastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=3.413; 99% 
C.I.=2.949 – 3.951; p<0.0001]. In other words, the hazard of incident diabetes for 
lovastatin users was 3.413 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., gender and 
diabetogenic medications) were controlled for in a separate model, the hazard of incident 
diabetes for lovastatin users increased, and was 3.501 times those of non-statin users 
[HR=3.501; 99% C.I.=3.025 – 4.051; p<0.0001]. However, when obesity was not 
controlled for in another separate model, the hazard ratio comparing lovastatin users to 
non-statin users increased marginally and remained significant [HR=3.455; 99% 
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C.I.=2.988 – 3.997; p<0.0001]. [Conclusion: alternative hypothesis H9d was 
supported]. 
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Table 4.34: Cox Regression Model Comparing Survival Time between Lovastatin Users and Non-statin Users 
while Controlling for Covariates (N=62,166) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Lovastatina 1.228 0.057 466.996 p<0.0001 3.413 2.949 3.951 
Age 0.037 0.002 344.885 p<0.0001 1.038 1.033 1.043 
Gender: Maleb -0.053 0.040 1.701 0.192 0.949 0.855 1.053 
Hyperlipidemia -0.175 0.064 7.442 0.006 0.839 0.712 0.990 
Obesity 0.462 0.185 6.208 0.013 1.587 0.985 2.558 
Hypertension 0.600 0.062 92.797 p<0.0001 1.821 1.552 2.138 
Diabetogenic medications -0.057 0.006 105.323 p<0.0001 0.944 0.931 0.958 
CCI score 0.154 0.024 41.181 p<0.0001 1.166 1.097 1.241 
Model Parameters: χ2=1,896.4; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., gender and diabetogenic 
medications) were controlled for in a separate model, the hazard ratio comparing lovastatin users to non-statin users increased 
and remained significant [HR=3.501; 99% C.I.=3.025 – 4.051; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
lovastatin users to non-statin users increased and remained significant [HR=4.521; 99% C.I.=3.996 – 5.115; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing lovastatin 
users to non-statin users increased marginally and remained significant [HR=3.455; 99% C.I.=2.988 – 3.997; p<0.0001].
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4.5.5 Pravastatin 
H9e: Pravastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
The estimated mean survival time (in months) for pravastatin users (17.01, 
SE=0.04) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.35 shows the results of the Cox regression model comparing survival time 
between pravastatin users and non-statin users while controlling for covariates. The 
overall model was statistically significant (χ2=1,334.7; df=8; p<0.0001). This means that 
at least one of the predictor variables was significantly associated with the dependent 
variable (survival time).  
Compared to no statin use, and controlling for covariates, pravastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=1.889; 99% 
C.I.=1.620 – 2.202; p<0.0001]. In other words, the hazard of incident diabetes for 
pravastatin users was 1.889 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., gender, 
hyperlipidemia, and diabetogenic medications) were controlled for in a separate model, 
the hazard of incident diabetes for pravastatin users increased, and was 1.905 times those 
of non-statin users [HR=1.905; 99% C.I.=1.633 – 2.222; p<0.0001]. However, when 
obesity was not controlled for in another separate model, the hazard ratio comparing 
pravastatin users to non-statin users increased marginally and remained significant 
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[HR=1.890; 99% C.I.=1.621 – 2.203; p<0.0001]. [Conclusion: alternative hypothesis 
H9e was supported]. 
. 
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Table 4.35: Cox Regression Model Comparing Survival Time between Pravastatin Users and Non-statin Users 
while Controlling for Covariates (N=64,495) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Pravastatina 0.636 0.060 113.865 p<0.0001 1.889 1.620 2.202 
Age 0.037 0.002 349.844 p<0.0001 1.038 1.033 1.044 
Gender: Maleb -0.061 0.040 2.304 0.129 0.941 0.848 1.043 
Hyperlipidemia -0.139 0.060 5.313 0.021 0.870 0.745 1.016 
Obesity 0.185 0.290 0.406 0.524 1.203 0.570 2.536 
Hypertension 0.629 0.059 112.723 p<0.0001 1.876 1.610 2.185 
Diabetogenic medications -0.043 0.005 71.124 p<0.0001 0.958 0.945 0.971 
CCI score 0.172 0.020 74.894 p<0.0001 1.187 1.128 1.249 
Model Parameters: χ2=1,334.7; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., gender, hyperlipidemia, and 
diabetogenic medications) were controlled for in a separate model, the hazard ratio comparing pravastatin users to non-statin 
users increased and remained significant [HR=1.905; 99% C.I.=1.633 – 2.222; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
pravastatin users to non-statin users increased and remained significant [HR=2.859; 99% C.I.=2.532 – 3.228; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing pravastatin 
users to non-statin users increased marginally and remained significant [HR=1.890; 99% C.I.=1.621 – 2.203; p<0.0001]. 
 
 
288 
 
4.5.6 Rosuvastatin 
H9f: Rosuvastatin users will have a significantly shorter survival time 
compared to non-statin users while controlling for age, gender, and 
clinical covariates. 
The estimated mean survival time (in months) for rosuvastatin users (15.51, 
SE=0.06) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.36 shows the results of the Cox regression model comparing survival time 
between rosuvastatin users and non-statin users while controlling for covariates. The 
overall model was statistically significant (χ2=926.6; df=8; p<0.0001). This means that at 
least one of the predictor variables was significantly associated with the dependent 
variable (survival time).  
Compared to no statin use, and controlling for covariates, rosuvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=1.615; 99% 
C.I.=1.307 – 1.996; p<0.0001]. In other words, the hazard of incident diabetes for 
rosuvastatin users was 1.615 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., gender and 
diabetogenic medications) were controlled for in a separate model, the hazard of incident 
diabetes for rosuvastatin users increased, and was 1.665 times those of non-statin users 
[HR=1.665; 99% C.I.=1.348 – 2.057; p<0.0001]. However, when obesity was not 
controlled for in another separate model, the hazard ratio comparing rosuvastatin users to 
non-statin users increased marginally and remained significant [HR=1.621; 99% 
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C.I.=1.311 – 2.003; p<0.0001]. [Conclusion: alternative hypothesis H9f was 
supported]. 
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Table 4.36: Cox Regression Model Comparing Survival Time between Rosuvastatin Users and Non-statin Users 
while Controlling for Covariates (N=61,099) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Rosuvastatina 0.480 0.082 34.043 p<0.0001 1.615 1.307 1.996 
Age 0.036 0.002 303.255 p<0.0001 1.037 1.031 1.042 
Gender: Maleb -0.062 0.043 2.057 0.152 0.940 0.841 1.051 
Hyperlipidemia -0.006 0.070 0.008 0.930 0.994 0.829 1.191 
Obesity 0.571 0.278 4.205 0.040 1.770 0.864 3.627 
Hypertension 0.725 0.068 113.620 p<0.0001 2.064 1.733 2.459 
Diabetogenic medications -0.030 0.006 23.941 p<0.0001 0.971 0.955 0.986 
CCI score 0.187 0.024 61.725 p<0.0001 1.206 1.134 1.282 
Model Parameters: χ2=926.6; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., gender and diabetogenic 
medications) were controlled for in a separate model, the hazard ratio comparing rosuvastatin users to non-statin users increased 
and remained significant [HR=1.665; 99% C.I.=1.348 – 2.057; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
rosuvastatin users to non-statin users increased and remained significant [HR=2.777; 99% C.I.=2.328 – 3.313; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing rosuvastatin 
users to non-statin users increased marginally and remained significant [HR=1.621; 99% C.I.=1.311 – 2.003; p<0.0001]. 
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4.5.7 Simvastatin 
H9g: Simvastatin users will have a significantly shorter survival time compared 
to non-statin users while controlling for age, gender, and clinical 
covariates. 
The estimated mean survival time (in months) for simvastatin users (16.84, 
SE=0.03) was shorter compared to that of non-statin users (17.67, SE=0.01). 
Table 4.37 shows the results of the Cox regression model comparing survival time 
between simvastatin users and non-statin users while controlling for covariates. The 
overall model was statistically significant (χ2=2,283.0; df=8; p<0.0001). This means that 
at least one of the predictor variables was significantly associated with the dependent 
variable (survival time).  
Compared to no statin use, and controlling for covariates, simvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [HR=2.567; 99% 
C.I.=2.284 – 2.884; p<0.0001]. In other words, the hazard of incident diabetes for 
simvastatin users was 2.567 times the hazard of incident diabetes for non-statin users. 
When significant time-dependent covariates specific to this model (i.e., hyperlipidemia 
and diabetogenic medications) were controlled for in a separate model, the hazard of 
incident diabetes for simvastatin users increased, and was 2.622 times those of non-statin 
users [HR=2.622; 99% C.I.=2.334 – 2.946; p<0.0001]. However, when obesity was not 
controlled for in another separate model, the hazard ratio comparing simvastatin users to 
non-statin users increased marginally and remained significant [HR=2.574; 99% 
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C.I.=2.291 – 2.892; p<0.0001]. [Conclusion: alternative hypothesis H9g was 
supported]. 
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Table 4.37: Cox Regression Model Comparing Survival Time between Simvastatin Users and Non-statin Users 
while Controlling for Covariates (N=71,527) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Simvastatina 0.943 0.045 433.518 p<0.0001 2.567 2.284 2.884 
Age 0.036 0.002 392.325 p<0.0001 1.037 1.032 1.042 
Gender: Maleb -0.011 0.035 0.101 0.75 0.989 0.904 1.082 
Hyperlipidemia -0.295 0.047 39.105 p<0.0001 0.745 0.660 0.841 
Obesity 0.655 0.187 12.309 p<0.0001 1.926 1.190 3.116 
Hypertension 0.478 0.047 104.066 p<0.0001 1.612 1.429 1.819 
Diabetogenic medications -0.049 0.004 168.956 p<0.0001 0.952 0.943 0.962 
CCI score 0.128 0.015 70.020 p<0.0001 1.136 1.092 1.182 
Model Parameters: χ2=2,283.0; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., hyperlipidemia and diabetogenic 
medications) were controlled for in a separate model, the hazard ratio comparing simvastatin users to non-statin users increased 
and remained significant [HR=2.622; 99% C.I.=2.334 – 2.946; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
simvastatin users to non-statin users increased and remained significant [HR=3.299; 99% C.I.=3.014 – 3.612; p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing simvastatin 
users to non-statin users increased marginally and remained significant [HR=2.574; 99% C.I.=2.291 – 2.892; p<0.0001]. 
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4.5.8 Dosage Intensity 
Objective 10: To assess whether survival times differed between intensive-dose statin 
users and moderate-dose statin users, while controlling for demographic variables (i.e., 
age and gender), and clinical covariates (i.e., hyperlipidemia, obesity, hypertension, 
diabetogenic medication use, CCI score, and medication adherence). 
H10: Intensive-dose statin users will have a significantly shorter survival time 
compared to moderate-dose statin users while controlling for age, gender, 
and clinical covariates. 
The estimated mean survival time (in months) for intensive-dose statin users 
(16.51, SE=0.05) was shorter compared to that of moderate-dose statin users (16.97, 
SE=0.02). 
Table 4.38 shows the results of the Cox regression model comparing survival time 
between intensive-dose statin users and moderate-dose statin users while controlling for 
covariates. The overall model was statistically significant (χ2=1,286.7; df=9, p<0.0001). 
This means that at least one of the predictor variables was significantly associated with 
the dependent variable (survival time).  
Compared to moderate-dose statin use, and controlling for covariates, intensive-
dose statin use was significantly associated with increased risk of incident diabetes 
mellitus [HR=1.525; 99% C.I.=1.378 – 1.686; p<0.0001]. In other words, the hazard of 
incident diabetes for intensive-dose statin users was 1.525 times the hazard of incident 
diabetes for moderate-dose statin users. When significant time-dependent covariates 
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specific to this model (i.e., age, gender, hyperlipidemia, hypertension, and diabetogenic 
medications) were controlled for in a separate model, the hazard of incident diabetes for 
intensive-dose statin users increased, and was 1.540 times those of moderate-dose statin 
users [HR=1.540; 99% C.I.=1.393 – 1.704; p<0.0001]. However, when obesity was not 
controlled for in another separate model, the hazard ratio comparing intensive-dose statin 
users to moderate-dose statin users increased marginally and remained significant 
[HR=1.526; 99% C.I.=1.379 – 1.688; p<0.0001]. [Conclusion: alternative hypothesis 
H10 was supported].  
Table 4.39 is a summary of Tables 4.31 – 4.38 that gives a visual comparison of 
the strength of association (i.e., hazard ratios) of statin use and incident diabetes. 
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Table 4.38: Cox Regression Model Comparing Survival Time between Intensive-dose Statin Users and 
Moderate-dose Statin Users while Controlling for Covariates (N=50,557) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Dosage intensity: 
Intensive-dosea 
0.422 0.039 116.165 p<0.0001 1.525 1.378 1.686 
Age 0.026 0.002 156.593 p<0.0001 1.026 1.021 1.031 
Gender: Maleb -0.104 0.029 13.196 p<0.0001 0.901 0.837 0.970 
Hyperlipidemia -0.500 0.029 297.859 p<0.0001 0.607 0.563 0.654 
Obesity 0.584 0.113 26.814 p<0.0001 1.794 1.341 2.399 
Hypertension 0.287 0.030 92.918 p<0.0001 1.333 1.234 1.439 
Diabetogenic medications -0.053 0.002 547.188 p<0.0001 0.948 0.943 0.954 
CCI score 0.119 0.010 128.276 p<0.0001 1.126 1.096 1.157 
Adherence (MPR)c 0.024 0.056 0.183 0.669 1.024 0.887 1.183 
Model Parameters: χ2=1,286.7; df=9, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Moderate-dose statin users. 
bReference=Female. 
cAdherence evaluated using the medication possession ratio, MPR. 
Sensitivity Analysis I: When significant time-dependent covariates specific to this model (i.e., age, gender, hyperlipidemia, 
hypertension, and diabetogenic medications) were controlled for in a separate model, the hazard ratio comparing intensive-dose 
statin users to moderate-dose statin users increased and remained significant [HR=1.540; 99% C.I.=1.393 – 1.704; p<0.0001]. 
Sensitivity Analysis II: When none of the model covariates were controlled for in a separate model, the hazard ratio comparing 
intensive-dose statin users to moderate-dose statin users decreased and remained significant [HR=1.456; 99% C.I.=1.322 – 1.604; 
p<0.0001]. 
Sensitivity Analysis III: When obesity was not controlled for in another separate model, the hazard ratio comparing intensive-
dose statin users to moderate-dose statin users increased marginally and remained significant [HR=1.526; 99% C.I.=1.379 – 1.688; 
p<0.0001]. 
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Table 4.39: A Summary of Tables 4.31 – 4.38 Showing the Statistical Significance of the Hazard Ratios of the 
Association between Statin Use and Incident Diabetes (Cox Regression) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.012 0.032 1009.438 p<0.0001 2.752 2.535 2.987 
Atorvastatina,c 0.886 0.038 548.135 p<0.0001 2.425 2.200 2.673 
Fluvastatina,c 0.725 0.088 68.452 p<0.0001 2.064 1.647 2.586 
Lovastatina,c 1.228 0.057 466.996 p<0.0001 3.413 2.949 3.951 
Pravastatina,c 0.636 0.060 113.865 p<0.0001 1.889 1.620 2.202 
Rosuvastatina,c 0.480 0.082 34.043 p<0.0001 1.615 1.307 1.996 
Simvastatina,c 0.943 0.045 433.518 p<0.0001 2.567 2.284 2.884 
Intensive-dose statinb,d 0.422 0.039 116.165 p<0.0001 1.525 1.378 1.686 
[Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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4.6 LOGISTIC REGRESSION ANALYSIS 
 In the preceding section (i.e., section 4.5), two groups were compared on a 
dependent variable that was continuous in nature (i.e., survival time). The purpose of this 
section was to conduct an alternate analysis, using logistic regression, when the 
dependent variable is dichotomous in nature (i.e., presence or absence of incident 
diabetes). The magnitude of the risk ratios (i.e., hazard ratios) obtained from the Cox 
regression analyses and those of the logistic regression analyses (i.e., odds ratios) were 
then compared for consistency. Like the hazard ratio which compares the hazard of 
diabetes in the active group versus the hazard of diabetes in the reference group, the odds 
ratio (OR) also compares the odds of diabetes in the active group (i.e., statin users and 
users of each statin type) versus the odds of diabetes in the reference group (i.e., non-
statin users). ORs greater than 1.0 indicate that the odds of diabetes (or the risk of 
diabetes) among the active group is higher than the odds of diabetes among the reference 
group. 
 Thus, the aim of this logistic regression section, while controlling for 
demographic and clinical covariates, was to compare the incidence of diabetes between 
statin users and non-statin users (objective 11, hypothesis 11b), between users of each 
statin type and non-statin users (objective 11, hypotheses 11c-h), and between intensive-
dose statin users and moderate-dose statin users (objective 12, hypothesis 12). 
 In addition to the main logistic regression models examining the association of 
statin use and incidence of diabetes while controlling for all covariates, two additional 
299 
 
sensitivity analyses were carried out (on each original logistic regression model) to 
examine how the odds ratios were influenced by: (i) not controlling for the obesity 
variable in the model (due to low prevalence of obesity among the study population 
compared to that of the adult US population), and (ii) not controlling for any of the 
covariates (i.e., unadjusted models). The odds ratios (and 99% confidence intervals of the 
ORs) of the sensitivity analyses results were then presented alongside those of the main 
results. Appendices E and F also give a visual summary of the sensitivity analyses of the 
odds ratios when none of the covariates were controlled for, and when obesity was not 
controlled for, respectively. 
Objective 11: To assess whether incidence of diabetes differed between statin users and 
non-statin users, and between users of each statin type and non-statin users, while 
controlling for demographic variables (i.e., age and gender), and clinical covariates (i.e., 
hyperlipidemia, obesity, hypertension, diabetogenic medication use, and CCI score). 
4.6.1 Statin Users 
H11a: The proportion of statin users with incident diabetes will be significantly 
higher compared to that of non-statin users.  
Table 4.40 shows incident diabetes distribution for statin users and non-statin 
users. Among the study population (N=116,224), 6.5% (or N=7,593) had incident 
diabetes. An unadjusted chi-square analysis showed that the proportion of statin users 
with incident diabetes (9.8%, N=5,678) was higher compared to the proportion of non-
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statin users with incident diabetes (3.3%, N=1,915) (χ2 = 1,995.2; df=1; p<0.0001). 
[Conclusion: alternative hypothesis H11a was supported]. 
Table 4.40: Frequency and Percent of Statin Users and Non-statin Users by 
Incident Diabetes 
Diabetes Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
5,678 (9.8) 
52,434 (90.2) 
1,915 (3.3) 
56,197 (96.7) 
7,593 (6.5) 
108,631 (93.5) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 1,995.2; df=1; p<0.0001 
 
 
H11b: The proportion of statin users with incident diabetes will be significantly 
higher than that of non-statin users while controlling for age, gender and 
clinical covariates. 
Alternative hypothesis 11a was accepted and showed that the proportion of statin 
users with incident diabetes was higher than the proportion of non-statin users with 
incident diabetes. In addition, Table 4.41 shows the results of the binary logistic 
regression model comparing the odds of incident diabetes between statin users and non-
statin users while controlling for covariates. The overall model was statistically 
significant (χ2=3,775.2; df=8, p<0.0001). This means that at least one of the predictor 
variables was significantly associated with the dependent variable (incident diabetes). 
Furthermore, the p-value (p=0.216) associated with the Hosmer-Lemeshow goodness of 
fit test was greater than 0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for all covariates, statin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=2.824; 99% 
C.I.=2.594 – 3.074; p<0.0001]. In other words, the odds of incident diabetes for statin 
users were 2.824 times the odds of incident diabetes for non-statin users. However, when 
obesity was not controlled for in another separate model, the odds ratio comparing statin 
users to non-statin users increased marginally and remained significant [OR=2.838; 99% 
C.I.=2.607 – 3.089; p<0.0001]. [Conclusion: alternative hypothesis H11b was 
supported]. 
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Table 4.41: Logistic Regression Model Comparing Incident Diabetes between Statin Users and Non-statin Users 
while Controlling for Covariates (N=116,224) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Statina 1.038 0.033 993.897 p<0.0001 2.824 2.594 3.074 
Age 0.033 0.001 531.678 p<0.0001 1.034 1.030 1.038 
Gender: Maleb -0.071 0.024 8.437 0.004 0.932 0.875 .992 
Hyperlipidemia -0.451 0.028 264.644 p<0.0001 0.637 0.593 .684 
Obesity 0.597 0.111 28.773 p<0.0001 1.817 1.364 2.420 
Hypertension 0.359 0.029 157.286 p<0.0001 1.431 1.330 1.541 
Diabetogenic medications -0.049 0.002 524.305 p<0.0001 0.952 0.947 .957 
CCI score 0.148 0.011 185.437 p<0.0001 1.160 1.128 1.192 
Constant -4.740 0.070 4,553.366 p<0.0001 0.009 - - 
Model Parameters: χ2=3,775.2; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
statin users to non-statin users increased and remained significant [OR=3.178; 99% C.I.=2.963 – 3.408; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing statin users to 
non-statin users increased marginally and remained significant [OR=2.838; 99% C.I.=2.607 – 3.089; p<0.0001]. 
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4.6.2 Atorvastatin 
H11b: The proportion of atorvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.42 shows incident diabetes distribution for atorvastatin users and non-
statin users. An unadjusted chi-square analysis showed that the proportion of atorvastatin 
users with incident diabetes (9.1%, N=2,690) was higher compared to the proportion of 
non-statin users with incident diabetes (3.3%, N=1,915) (χ2 = 1,334.9; df=1; p<0.0001). 
Table 4.42: Frequency and Percent of Atorvastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Atorvastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
2,690 (9.1) 
26,784 (90.9) 
1,915 (3.3) 
56,197 (96.7) 
4,605 (5.3) 
82,981 (94.7) 
Total 29,474 (100.0) 58,112 (100.0) 87,586 (100.0) 
χ2=1,334.9; df=1; p<0.0001 
 
Table 4.43 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between atorvastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=2,249.7; 
df=8, p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.257) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, atorvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=2.485; 99% 
C.I.=2.246 – 2.749; p<0.0001]. In other words, the odds of incident diabetes for 
atorvastatin users were 2.485 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing atorvastatin users to non-statin users increased marginally and remained 
significant [OR=2.490; 99% C.I.=2.251 – 2.755; p<0.0001]. [Conclusion: alternative 
hypothesis H11c was supported]. 
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Table 4.43: Logistic Regression Model Comparing Incident Diabetes between Atorvastatin Users and Non-statin 
Users while Controlling for Covariates (N=87,586) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Atorvastatina 0.910 0.039 538.842 p<0.0001 2.485 2.246 2.749 
Age 0.034 0.002 406.603 p<0.0001 1.035 1.030 1.040 
Gender: Maleb -0.068 0.031 4.793 0.029 0.935 0.863 1.012 
Hyperlipidemia -0.412 0.038 115.884 p<0.0001 0.662 0.600 0.731 
Obesity 0.368 0.168 4.800 0.028 1.445 0.937 2.229 
Hypertension 0.423 0.039 116.808 p<0.0001 1.527 1.381 1.689 
Diabetogenic medications -0.044 0.003 223.539 p<0.0001 0.957 0.950 0.964 
CCI score 0.169 0.014 137.994 p<0.0001 1.184 1.141 1.229 
Constant -4.793 0.081 3,470.367 p<0.0001 0.008 - - 
Model Parameters: χ2=2,249.7; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
atorvastatin users to non-statin users increased and remained significant [OR=2.947; 99% C.I.=2.722 – 3.191; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing atorvastatin 
users to non-statin users increased marginally and remained significant [OR=2.490; 99% C.I.=2.251 – 2.755; p<0.0001]. 
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4.6.3 Fluvastatin 
H11d: The proportion of fluvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.44 shows incident diabetes distribution for fluvastatin users and non-
statin users. An unadjusted chi-square analysis showed that the proportion of fluvastatin 
users with incident diabetes (10.7%, N=192) was higher compared to the proportion of 
non-statin users with incident diabetes (3.3%, N=1,915) (χ2 = 279.9; df=1; p<0.0001). 
Table 4.44: Frequency and Percent of Fluvastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Fluvastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
192 (10.7) 
1,607 (89.3) 
1,915 (3.3) 
56,197 (96.7) 
2,107 (3.5) 
57,804 (96.5) 
Total 1,799 (100.0) 58,112 (100.0) 59,911 (100.0) 
χ2=279.9; df=1; p<0.0001 
 
Table 4.45 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between fluvastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=683.7; df=8, 
p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.068) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, fluvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=2.161; 99% 
C.I.=1.704 – 2.742; p<0.0001]. In other words, the odds of incident diabetes for 
fluvastatin users were 2.161 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing fluvastatin users to non-statin users increased marginally and remained 
significant [OR=2.164; 99% C.I.=1.706 – 2.745; p<0.0001]. [Conclusion: alternative 
hypothesis H11d was supported]. 
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Table 4.45: Logistic Regression Model Comparing Incident Diabetes between Fluvastatin Users and Non-statin 
Users while Controlling for Covariates (N=59,911) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Fluvastatina 0.771 0.092 69.572 p<0.0001 2.161 1.704 2.742 
Age 0.037 0.002 304.870 p<0.0001 1.038 1.032 1.044 
Gender: Maleb -0.050 0.045 1.238 0.266 0.951 0.847 1.068 
Hyperlipidemia -0.050 0.076 0.428 0.513 0.952 0.782 1.157 
Obesity 0.211 0.347 0.368 0.544 1.235 0.505 3.020 
Hypertension 0.670 0.075 80.523 p<0.0001 1.955 1.613 2.370 
Diabetogenic medications -0.031 0.007 21.057 p<0.0001 0.969 0.952 0.986 
CCI score 0.182 0.030 36.504 p<0.0001 1.200 1.110 1.296 
Constant -4.982 0.100 2,492.170 p<0.0001 0.007 - - 
Model Parameters: χ2=683.7; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
fluvastatin users to non-statin users increased and remained significant [OR=3.506; 99% C.I.=2.855 – 4.306; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing fluvastatin 
users to non-statin users increased marginally and remained significant [OR=2.164; 99% C.I.=1.706 – 2.745; p<0.0001]. 
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4.6.4 Lovastatin 
H11e: The proportion of lovastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.46 shows incident diabetes distribution for lovastatin users and non-statin 
users. An unadjusted chi-square analysis showed that the proportion of lovastatin users 
with incident diabetes (13.9%, N=564) was higher compared to the proportion of non-
statin users with incident diabetes (3.3%, N=1,915) (χ2 = 1,115.7; df=1; p<0.0001). 
Table 4.46: Frequency and Percent of Lovastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Lovastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
564 (13.9) 
3,490 (86.1) 
1,915 (3.3) 
56,197 (96.7) 
2,479 (4.0) 
59,687 (96.0) 
Total 4,054 (100.0) 58,112 (100.0) 62,166 (100.0) 
χ2=1,115.7; df=1; p<0.0001 
 
Table 4.47 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between lovastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=1,322.8; 
df=8, p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.327) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, lovastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=3.565; 99% 
C.I.=3.051 – 4.165; p<0.0001]. In other words, the odds of incident diabetes for 
lovastatin users were 3.565 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing lovastatin users to non-statin users increased marginally and remained 
significant [OR=3.610; 99% C.I.=3.092 – 4.215; p<0.0001]. [Conclusion: alternative 
hypothesis H11e was supported]. 
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Table 4.47: Logistic Regression Model Comparing Incident Diabetes between Lovastatin Users and Non-statin 
Users while Controlling for Covariates (N=62,166) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Lovastatina 1.271 0.060 442.002 p<0.0001 3.565 3.051 4.165 
Age 0.038 0.002 344.972 p<0.0001 1.039 1.033 1.044 
Gender: Maleb -0.063 0.042 2.296 0.130 0.939 0.843 1.045 
Hyperlipidemia -0.178 0.068 6.971 0.008 0.837 0.703 0.996 
Obesity 0.475 0.204 5.431 0.020 1.609 0.951 2.720 
Hypertension 0.631 0.066 90.109 p<0.0001 1.880 1.584 2.231 
Diabetogenic medications -0.057 0.006 96.347 p<0.0001 0.944 0.930 0.959 
CCI score 0.171 0.027 38.749 p<0.0001 1.187 1.106 1.274 
Constant -4.989 0.097 2,650.133 p<0.0001 0.007 - - 
Model Parameters: χ2=1,322.8; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
lovastatin users to non-statin users increased and remained significant [OR=4.742; 99% C.I.=4.159 – 5.408; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing lovastatin users 
to non-statin users increased marginally and remained significant [OR=3.610; 99% C.I.=3.092 – 4.215; p<0.0001]. 
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4.6.5 Pravastatin 
H11f: The proportion of pravastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.48 shows incident diabetes distribution for pravastatin users and non-
statin users. An unadjusted chi-square analysis showed that the proportion of pravastatin 
users with incident diabetes (9.2%, N=587) was higher compared to the proportion of 
non-statin users with incident diabetes (3.3%, N=1,915) (χ2 = 537.1; df=1; p<0.0001). 
Table 4.48: Frequency and Percent of Pravastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Pravastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
587 (9.2) 
5,796 (90.8) 
1,915 (3.3) 
56,197 (96.7) 
2,502 (3.9) 
61,993 (96.1) 
Total 6,383 (100.0) 58,112 (100.0) 64,495 (100.0) 
χ2=537.1; df=1; p<0.0001 
 
Table 4.49 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between pravastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=1,048.5; 
df=8, p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.247) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, pravastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=1.952; 99% 
C.I.=1.663 – 2.290; p<0.0001]. In other words, the odds of incident diabetes for 
pravastatin users were 1.952 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing pravastatin users to non-statin users increased marginally and remained 
significant [OR=1.953; 99% C.I.=1.664 – 2.292; p<0.0001]. [Conclusion: alternative 
hypothesis H11f was supported]. 
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Table 4.49: Logistic Regression Model Comparing Incident Diabetes between Pravastatin Users and Non-statin 
Users while Controlling for Covariates (N=64,495) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Pravastatina 0.669 0.062 115.773 p<0.0001 1.952 1.663 2.290 
Age 0.038 0.002 349.001 p<0.0001 1.039 1.034 1.045 
Gender: Maleb -0.069 0.041 2.743 0.098 0.934 0.839 1.039 
Hyperlipidemia -0.143 0.063 5.174 0.023 0.866 0.737 1.019 
Obesity 0.201 0.302 0.444 0.505 1.223 0.562 2.661 
Hypertension 0.652 0.062 110.212 p<0.0001 1.920 1.636 2.253 
Diabetogenic medications -0.043 0.005 67.234 p<0.0001 0.958 0.945 0.971 
CCI score 0.193 0.023 68.223 p<0.0001 1.213 1.142 1.289 
Constant -5.007 0.097 2,673.707 p<0.0001 0.007 - - 
Model Parameters: χ2=1,048.5; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
pravastatin users to non-statin users increased and remained significant [OR=2.972; 99% C.I.=2.619 – 3.373; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing pravastatin 
users to non-statin users increased marginally and remained significant [OR=1.953; 99% C.I.=1.664 – 2.292; p<0.0001]. 
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4.6.6 Rosuvastatin 
H11f: The proportion of rosuvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.50 shows incident diabetes distribution for rosuvastatin users and non-
statin users. An unadjusted chi-square analysis showed that the proportion of rosuvastatin 
users with incident diabetes (8.1%, N=242) was higher compared to the proportion of 
non-statin users with incident diabetes (3.3%, N=1,915) (χ2 = 192.7; df=1; p<0.0001). 
Table 4.50: Frequency and Percent of Rosuvastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Rosuvastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
242 (8.1) 
2,745 (91.9) 
1,915 (3.3) 
56,197 (96.7) 
2,157 (3.5) 
58,942 (96.5) 
Total 2,987 (100.0) 58,112 (100.0) 61,099 (100.0) 
χ2=192.7; df=1; p<0.0001 
 
Table 4.51 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between rosuvastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=701.3; df=8, 
p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.05) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, rosuvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=1.495; 99% 
C.I.=1.199 – 1.865; p<0.0001]. In other words, the odds of incident diabetes for 
rosuvastatin users were 1.495 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing rosuvastatin users to non-statin users increased marginally and remained 
significant [OR=1.500; 99% C.I.=1.203 – 1.871; p<0.0001]. [Conclusion: alternative 
hypothesis H11g was supported]. 
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Table 4.51: Logistic Regression Model Comparing Incident Diabetes between Rosuvastatin Users and Non-
statin Users while Controlling for Covariates (N=61,099) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Rosuvastatina 0.402 0.086 22.000 p<0.0001 1.495 1.199 1.865 
Age 0.037 0.002 303.221 p<0.0001 1.038 1.032 1.043 
Gender: Maleb -0.068 0.044 2.318 0.128 0.935 0.833 1.048 
Hyperlipidemia -0.013 0.073 0.030 0.862 0.987 0.818 1.191 
Obesity 0.583 0.292 3.984 0.046 1.791 0.844 3.801 
Hypertension 0.742 0.071 109.468 p<0.0001 2.099 1.749 2.520 
Diabetogenic medications -0.029 0.006 21.163 p<0.0001 0.971 0.956 0.987 
CCI score 0.205 0.027 56.259 p<0.0001 1.227 1.144 1.317 
Constant -4.975 0.099 2,505.964 p<0.0001 0.007 - - 
Model Parameters: χ2=701.3; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
rosuvastatin users to non-statin users increased and remained significant [OR=2.587; 99% C.I.=2.155 – 3.106; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing rosuvastatin 
users to non-statin users increased marginally and remained significant [OR=1.500; 99% C.I.=1.203 – 1.871; p<0.0001]. 
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4.6.7 Simvastatin 
H11f: The proportion of simvastatin users with incident diabetes will be 
significantly higher than that of non-statin users while controlling for age, 
gender and clinical covariates. 
Table 4.52 shows incident diabetes distribution for simvastatin users and non-
statin users. An unadjusted chi-square analysis showed that the proportion of simvastatin 
users with incident diabetes (10.5%, N=1,403) was higher compared to the proportion of 
non-statin users with incident diabetes (3.3%, N=1,915) (χ2 = 1,264.2; df=1; p<0.0001). 
Table 4.52: Frequency and Percent of Simvastatin Users and Non-statin Users 
with Incident Diabetes 
Diabetes Simvastatin Users 
N (%) 
Non-statin Users 
N (%) 
Total 
N (%) 
Yes 
No 
1,403 (10.5) 
12,012 (89.5) 
1,915 (3.3) 
56,197 (96.7) 
3,318 (4.6) 
68,209 (95.4) 
Total 13,415 (100.0) 58,112 (100.0) 71,527 (100.0) 
χ2=1,264.2; df=1; p<0.0001 
 
Table 4.53 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between simvastatin users and non-statin users while 
controlling for covariates. The overall model was statistically significant (χ2=1,814.5; 
df=8, p<0.0001). This means that at least one of the predictor variables was significantly 
associated with the dependent variable (incident diabetes). Furthermore, the p-value 
(p=0.290) associated with the Hosmer-Lemeshow goodness of fit test was greater than 
0.01. This shows that the logit model was a good fitting model.  
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Compared to no statin use, and controlling for covariates, simvastatin use was 
significantly associated with increased risk of incident diabetes mellitus [OR=2.651; 99% 
C.I.=2.347 – 2.994; p<0.0001]. In other words, the odds of incident diabetes for 
simvastatin users were 2.651 times the odds of incident diabetes for non-statin users. 
However, when obesity was not controlled for in another separate model, the odds ratio 
comparing simvastatin users to non-statin users increased marginally and remained 
significant [OR=2.658; 99% C.I.=2.354 – 3.002; p<0.0001]. [Conclusion: alternative 
hypothesis H11g was supported]. 
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Table 4.53: Logistic Regression Model Comparing Incident Diabetes between Simvastatin Users and Non-statin 
Users while Controlling for Covariates (N=71,527) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Simvastatina 0.975 0.047 426.171 p<0.0001 2.651 2.347 2.994 
Age 0.037 0.002 391.723 p<0.0001 1.038 1.033 1.043 
Gender: Maleb -0.016 0.036 0.183 0.669 0.985 0.897 1.081 
Hyperlipidemia -0.310 0.050 38.862 p<0.0001 0.733 0.645 0.834 
Obesity 0.652 0.204 10.234 0.001 1.919 1.135 3.244 
Hypertension 0.505 0.050 102.804 p<0.0001 1.657 1.457 1.884 
Diabetogenic medications -0.050 0.004 160.006 p<0.0001 0.951 0.942 0.961 
CCI score 0.149 0.018 69.685 p<0.0001 1.161 1.109 1.215 
Constant -4.968 0.090 3042.707 p<0.0001 0.007 - - 
Model Parameters: χ2=1,814.5; df=8, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
simvastatin users to non-statin users increased and remained significant [OR=3.428; 99% C.I.=3.120 – 3.766; p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing simvastatin 
users to non-statin users increased marginally and remained significant [OR=2.658; 99% C.I.=2.354 – 3.002; p<0.0001]. 
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4.6.8 Dosage Intensity 
Objective 12: To assess whether incidence of diabetes differed between intensive-dose 
statin users and moderate-dose statin users, while controlling for demographic variables 
(i.e., age and gender), and clinical covariates (i.e., hyperlipidemia, obesity, hypertension, 
diabetogenic medication use, CCI score, and medication adherence). 
H12: The proportion of intensive-dose statin users with incident diabetes will be 
significantly higher than that of moderate-dose statin users while 
controlling for age, gender and clinical covariates. 
Table 4.54 shows incident diabetes distribution for intensive-dose statin users and 
moderate-dose statin users. An unadjusted chi-square analysis showed that the proportion 
of intensive-dose statin users with incident diabetes (13.4%, N=831) was higher 
compared to the proportion of moderate-dose statin users with incident diabetes (9.3%, 
N=4,847) (χ2 = 103.4; df=1; p<0.0001). 
Table 4.54: Frequency and Percent of Intensive and Moderate-dose Statin 
Users with Incident Diabetes 
Diabetes Intensive-dose  
N (%) 
Moderate-dose  
N (%) 
Total 
N (%) 
Yes 
No 
831 (13.4) 
5,374 (86.6) 
4,847 (9.3) 
47,060 (90.7) 
5,678 (9.8) 
52,434 (90.2) 
Total 6,205 (100.0) 51,907 (100.0) 58,112 (100.0) 
χ2 = 103.4; df=1; p<0.0001 
 
 
 
322 
 
Table 4.55 shows the results of the binary logistic regression model comparing 
the odds of incident diabetes between intensive-dose statin users and moderate-dose 
statin users while controlling for covariates. The overall model was statistically 
significant (χ2=1,339.2; df=9, p<0.0001). This means that at least one of the predictor 
variables was significantly associated with the dependent variable (incident diabetes). 
Furthermore, the p-value (p=0.011) associated with the Hosmer-Lemeshow goodness of 
fit test was greater than 0.01. This shows that the logit model was a good fitting model.  
Compared to moderate-dose statin use, and controlling for covariates, intensive-
dose statin use was significantly associated with increased risk of incident diabetes 
mellitus [OR=1.578; 99% C.I.=1.414 – 1.761; p<0.0001]. In other words, the odds of 
incident diabetes for intensive-dose statin users were 1.578 times the odds of incident 
diabetes for moderate-dose statin users. However, when obesity was not controlled for in 
another separate model, the odds ratio comparing intensive-dose statin users to moderate-
dose statin users did not change and remained significant [OR=1.578; 99% C.I.=1.414 – 
1.761; p<0.0001]. [Conclusion: alternative hypothesis H12 was supported]. 
Table 4.56 is a summary that gives a visual comparison of the strength of 
association (i.e., odds ratios) between different statin use and incident diabetes. 
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Table 4.55: Logistic Regression Model Comparing Incident Diabetes between Intensive-dose Statin Users and 
Moderate-dose Statin Users while Controlling for Covariates (N=50,557)a 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
ratio 
99% Confidence Interval 
Lower Upper 
Dosage intensity: 
Intensive-doseb 
0.456 0.043 114.477 p<0.0001 1.578 1.414 1.761 
Age 0.027 0.002 160.577 p<0.0001 1.028 1.022 1.034 
Gender: Malec -0.112 0.031 13.455 p<0.0001 0.894 0.826 0.967 
Hyperlipidemia -0.533 0.031 300.554 p<0.0001 0.587 0.542 0.635 
Obesity 0.620 0.126 24.293 p<0.0001 1.858 1.344 2.569 
Hypertension 0.299 0.032 87.163 p<0.0001 1.348 1.241 1.464 
Diabetogenic medications -0.054 0.002 515.364 p<0.0001 0.947 0.942 0.953 
CCI score 0.133 0.012 116.751 p<0.0001 1.142 1.107 1.179 
Adherence (MPR)d -0.013 0.060 0.045 0.831 0.987 0.847 1.152 
Constant -3.299 0.122 729.184 p<0.0001 0.037   
Model Parameters: χ2=1,339.2; df=9, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aN is less than 58,112 because of missing values for MPR. MPR values was set to missing for cases with only one prescription of the 
statin filled (MPR numerator and denominator=0), or if two or more prescriptions filled, one or more number of days supply is 0 
or negative (MPR numerator=0). 
bReference=Moderate-dose statin users. 
cReference=Female. 
dAdherence evaluated using the medication possession ratio, MPR. 
Sensitivity Analysis I: When none of the model covariates were controlled for in a separate model, the odds ratio comparing 
intensive-dose statin users to moderate-dose statin users decreased and remained significant [OR=1.501; 99% C.I.=1.354 – 1.665; 
p<0.0001]. 
Sensitivity Analysis II: When obesity was not controlled for in another separate model, the odds ratio comparing statin users to 
non-statin users did not change and remained significant [OR=1.578; 99% C.I.=1.414 – 1.761; p<0.0001]. 
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Table 4.56: A Summary Showing the Statistical Significance of the Odds Ratios of the Association between Statin 
Use and Incident Diabetes (Logistic Regression) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.038 0.033 993.897 p<0.0001 2.824 2.594 3.074 
Atorvastatina,c 0.910 0.039 538.842 p<0.0001 2.485 2.246 2.749 
Fluvastatina,c 0.771 0.092 69.572 p<0.0001 2.161 1.704 2.742 
Lovastatina,c 1.271 0.060 442.002 p<0.0001 3.565 3.051 4.165 
Pravastatina,c 0.669 0.062 115.773 p<0.0001 1.952 1.663 2.290 
Rosuvastatina,c 0.402 0.086 22.000 p<0.0001 1.495 1.199 1.865 
Simvastatina,c 0.975 0.047 426.171 p<0.0001 2.651 2.347 2.994 
Intensive-dose statinb,d 0.456 0.043 114.477 p<0.0001 1.578 1.414 1.761 
[Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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4.4 SUMMARY OF HYPOTHESES TESTS 
 Table 4.57 presents a summary of all the hypotheses tested in the study. A total of 
35 hypotheses (24 alternative and 11 null) were tested. All alternative hypotheses were 
supported, while all null hypotheses were rejected except null hypothesis H0(5g).  
Table 4.57: Summary of Study Hypotheses 
Study 
Hypothesis 
Description Conclusion:  
Supported/Rejected 
AIM 1: TO COMPARE THE DEMOGRAPHIC (I.E., AGE AND GENDER), AND CLINICAL 
CHARACTERISTICS (I.E., HYPERLIPIDEMIA, OBESITY, HYPERTENSION, 
DIABETOGENIC MEDICATION USE, AND CCI SCORE) BETWEEN STATIN USERS AND 
NON-STATIN USERS (OBJECTIVES 1 – 6) 
Objective 1: To assess whether demographic characteristics (i.e., age and gender) 
differs between statin users and non-statin users 
H1a Statin users will have a significantly higher 
mean age compared to non-statin users 
Supported 
H1b There is a significant association between the 
exposure group (i.e., statin users and non-statin 
users) and gender 
Supported 
Objective 2:  To assess whether hyperlipidemia diagnosis differs between statin 
users and non-statin users 
H2 The proportion of statin users with a 
hyperlipidemia diagnosis will be significantly 
higher compared to that of non-statin users 
Supported 
Objective 3: To assess whether obesity diagnosis differs between statin users and 
non-statin users 
H0(3) There is no significant difference in the 
proportion of statin users and non-statin users 
who have an obesity diagnosis 
Rejected 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion:  
Supported/Rejected 
Objective 4: To assess whether hypertension diagnosis differs between statin 
users and non-statin users 
H4 The proportion of statin users with a 
hypertension diagnosis will be significantly 
higher compared to that of non-statin users 
Supported 
Objective 5: To assess whether the mean number of prescriptions for all 
diabetogenic medications differs between statin users and non-statin users 
H0(5a) There is no significant difference in the mean 
number of prescriptions for all diabetogenic 
medications between statin users and non-
statin users 
Rejected 
H0(5b-f) There is no significant difference in the mean 
number of prescriptions for each diabetogenic 
medication (i.e., thiazide diuretics [H0(5b)], β-
blockers [H0(5c)], antipsychotics [H0(5d)], 
antidepressants[H0(5e)], and 
immunosuppressants [H0(5f)] between statin 
users and non-statin users 
Rejected 
H0(5g) There is no significant difference in the mean 
number of glucocorticoids prescriptions for 
statin users and non-statin users 
Supported 
Objective 6: To compare the mean CCI score between statin users and non-statin 
users 
H0(6) There is no significant difference in the mean 
CCI score between statin users and non-statin 
users 
Rejected 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion: 
Supported/Rejected 
AIM 2: TO COMPARE MEDICATION ADHERENCE AMONG USERS OF EACH STATIN 
TYPE, AND BETWEEN INTENSIVE-DOSE STATIN USERS AND MODERATE-DOSE 
STATIN USERS (OBJECTIVE 7) 
Objective 7: To assess whether medication adherence (using MPR) differs among 
users of each statin type, and between intensive-dose statin users and moderate-
dose statin users 
H0(7a) There is no significant difference in mean MPR 
among users of each statin type 
Rejected 
H7b Mean MPR will be significantly lower among 
intensive-dose statin users compared to 
moderate-dose statin users 
Supported 
AIM 3: USING SURVIVAL ANALYSIS, TO COMPARE TIME TO DIABETES (OR 
SURVIVAL TIME) BETWEEN STATIN USERS AND NON-STATIN USERS, BETWEEN 
USERS OF EACH STATIN TYPE AND NON-STATIN  USERS, AND BETWEEN 
INTENSIVE-DOSE STATIN USERS AND MODERATE-DOSE STATIN USERS 
(OBJECTIVES 8 – 10). 
Objective 8 (Survival Analysis – Log-rank test and Kaplan-Meier Curves): To 
assess whether survival time (i.e., time to occurrence of diabetes) differs between 
statin users and non-statin users, among users of each statin type, and between 
intensive-dose statin users and moderate-dose statin users 
H8a 
 
Statin users will have a shorter survival time 
compared to non-statin users 
Supported 
H0(8b) 
 
There is no significant difference in mean 
survival time among users of each statin type 
Rejected 
H8c Intensive-dose statin users will have a shorter 
survival time compared to moderate-dose 
statin users 
Supported 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion: 
Supported/Rejected 
Objective 9 (Survival Analysis – Cox Regression): To assess whether survival 
times differ between statin users and non-statin users, and between users of each 
statin type and non-statin users, while controlling for demographic variables (i.e., 
age and gender), and clinical covariates (i.e., hyperlipidemia, obesity, hypertension, 
diabetogenic medication use, and CCI score) 
H9a Statin users will have a significantly shorter 
survival time compared to non-statin users 
while controlling for age, gender, and clinical 
covariates 
Supported 
H9b Atorvastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
H9c Fluvastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
H9d Lovastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
H9e Pravastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion: 
Supported/Rejected 
H9f Rosuvastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
H9g Simvastatin users will have a significantly 
shorter survival time compared to non-statin 
users while controlling for age, gender, and 
clinical covariates 
Supported 
Objective 10 (Survival Analysis – Cox Regression):   To assess whether survival 
times differ between intensive-dose statin users and moderate-dose statin users, 
while controlling for demographic variables (i.e., age and gender), and clinical 
covariates (i.e., hyperlipidemia, obesity, hypertension, diabetogenic medication use, 
CCI score, and medication adherence) 
H10 Intensive-dose statin users will have a 
significantly shorter survival time compared to 
moderate-dose statin users while controlling 
for age, gender, and clinical covariates 
Supported 
AIM 4: USING BINARY LOGISTIC REGRESSION ANALYSIS, TO COMPARE INCIDENCE 
OF DIABETES BETWEEN STATIN USERS AND NON-STATIN USERS, BETWEEN 
USERS OF EACH STATIN TYPE AND NON-STATIN USERS, AND BETWEEN 
INTENSIVE-DOSE STATIN USERS AND MODERATE-DOSE STATIN USERS 
(OBJECTIVES 11 & 12) 
Objective 11 (Binary Logistic Regression):   To assess whether incidence of 
diabetes differs between statin users and non-statin users, and between users of 
each statin type and non-statin users, while controlling for demographic variables 
(i.e., age and gender), and clinical covariates (i.e., hyperlipidemia, obesity, 
hypertension, diabetogenic medication use, and CCI score) 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion: 
Supported/Rejected 
H11a The proportion of statin users with incident 
diabetes will be significantly higher compared 
to that of non-statin users 
Supported 
H11b The proportion of statin users with incident 
diabetes will be significantly higher than that of 
non-statin users while controlling for age, 
gender and clinical covariates 
Supported 
H11c The proportion of atorvastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
H11d The proportion of fluvastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
H11e The proportion of lovastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
H11f The proportion of pravastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
H11g The proportion of rosuvastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
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Table 4.57: Summary of Study Hypotheses (cont’d) 
Study 
Hypothesis 
Description Conclusion: 
Supported/Rejected 
H11h The proportion of simvastatin users with 
incident diabetes will be significantly higher 
than that of non-statin users while controlling 
for age, gender and clinical covariates 
Supported 
Objective 12 (Binary Logistic Regression):   To assess whether incidence of 
diabetes differs between intensive-dose statin users and moderate-dose statin 
users, while controlling for demographic variables (i.e., age and gender), and clinical 
covariates (i.e., hyperlipidemia, obesity, hypertension, diabetogenic medication use, 
CCI score, and medication adherence) 
H12 The proportion of intensive-dose statin users 
with incident diabetes will be significantly 
higher than that of moderate-dose statin users 
while controlling for age, gender and clinical 
covariates 
Supported 
Number of alternative hypotheses not supported=0. 
Number of null hypotheses not rejected=1 [H0(5g)]. 
  
332 
 
CHAPTER 5: DISCUSSION AND CONCLUSIONS 
This chapter presents an in-depth discussion of the study results. First, the result 
of the differences in demographic and clinical characteristics between statin users and 
non-statin users is discussed. This is followed by a discussion of the rates of incident 
diabetes among the study population compared to rates found in the US population and 
similar studies of statin use and incidence of diabetes. The hazards and odds of diabetes 
that were associated with statin use as a class, with each statin type, and with different 
statin dosage intensities are discussed and compared with risk ratios obtained in similar 
observational studies of statin use and incidence of diabetes. Lastly, the study strengths, 
study limitations, suggestions for future research, and study implications are discussed. 
5.1 REVIEW OF BACKGROUD AND STUDY PURPOSE 
The FDA approved labeling changes to statins in February 2012 to include an 
increased risk of incident diabetes mellitus due to increases in glycosylated hemoglobin 
(A1C) and fasting plasma glucose (FPG) that were found to be associated with statin 
therapy.
422
 The decision to approve these labeling changes was based on results from 
RCTs,
423
 meta-analyses of RCTs,
424
 systematic review,
425
 and a few observational 
                                                 
422 Food and Drug Administration, "FDA Drug Safety Communication: Important safety label changes to 
cholesterol-lowering statin drugs". 
423 Thongtang N et al., "Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose 
homeostasis and inflammation."; Koh KK et al., "Atorvastatin causes insulin resistance and increases 
ambient glycemia in hypercholesterolemic patients."; Sabatine MS et al., "High-dose atorvastatin 
associated with worse glycemic control: a PROVE-IT TIMI 22 substudy."; Ridker PM et al., "Rosuvastatin 
to prevent vascular events in men and women with elevated C-reactive protein." 
424 Mills EJ et al., "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-
analysis of 170,255 patients from 76 randomized trials."; Sattar N et al., "Statins and risk of incident 
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studies
426
 which suggest an increased risk of incident diabetes due to statin therapy. 
Several studies have also discussed whether the cardiovascular gain by using high dose 
statins may be offset by an increased risk in diabetes.
427
 
The majority of previously published observational studies that had evaluated the 
association of statin therapy and development of new-onset diabetes used non-US 
population data. Because the US population may be different than other populations in 
terms of the prevalence of risk factors such as overweight, obesity, and cardiovascular 
diseases that may put people at an increased risk of diabetes that is independent of the 
effects of statins,
428
 there is a need to further investigate this phenomenon among the US 
population. Thus, this need informed the two study purposes.  
                                                                                                                                                 
diabetes: a collaborative meta-analysis of randomised statin trials."; Rajpathak SN et al., "Statin therapy 
and risk of developing type 2 diabetes: a meta-analysis." 
425 Kostapanos MS et al., "Do statins beneficially or adversely affect glucose homeostasis?." 
426 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative."; Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic 
patients." 
427 Cannon CP et al., "Intensive versus moderate lipid lowering with statins after acute coronary 
syndromes."; LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in 
patients with stable coronary disease. Ibid.2005;352(14):1425-35; Armitage J et al., "Intensive lowering of 
LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a 
double-blind randomised trial."; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more 
intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised 
trials. Ibid.:1670-81; de Lemos JA et al., "Early intensive vs a delayed conservative simvastatin strategy in 
patients with acute coronary syndromes: phase Z of the A to Z trial."; ibid.; Pedersen TR, Faergeman O, 
Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after 
myocardial infarction: the IDEAL study: a randomized controlled trial. Ibid.2005;294(19):2437-45; ibid.; 
Ko DT et al., "Diabetes mellitus and cardiovascular events in older patients with myocardial infarction 
prescribed intensive-dose and moderate-dose statins."; Preiss D et al., "Risk of incident diabetes with 
intensive-dose compared with moderate-dose statin therapy: a meta-analysis." 
428 Graham I et al., "Dyslipidemias in the prevention of cardiovascular disease: risks and causality."; 
Kirkman MS et al., "Diabetes in older adults."; Lawrence JM et al., "Trends in the prevalence of 
preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of 
pregnant women, 1999-2005." 
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The first purpose of this study was to examine whether the development of 
incident diabetes differed between statin users (the exposed group) and non-statin users 
(the unexposed group), and between users of each statin type and non-statin users.  
The second purpose of this study was to examine whether the development of 
incident diabetes differed by the intensity of the statin dosages (i.e., intensive-dose statin 
vs. moderate-dose statin) to which subjects were exposed. In addition to these two main 
study purposes, two types of statistical analyses (Cox regression and logistic regression) 
were conducted to examine the risk of diabetes associated with statin use. The magnitude 
of the risk ratios (i.e., hazard ratio and odds ratio, respectively) obtained from these two 
analyses were then compared for consistency. 
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5.2 REVIEW OF STUDY OBJECTIVES 
Twelve study objectives (and 35 hypotheses) were examined in the overall aim of 
assessing the association between statin use and incidence of diabetes. However, these 12 
objectives were reduced to four interrelated themes that focused on achieving the overall 
study aim. 
I. Demographic and Clinical Characteristics 
Objectives 1 – 6 compared the demographic (i.e., age and gender), and clinical 
characteristics (i.e., hyperlipidemia, obesity, hypertension, diabetogenic medication use, 
and CCI score) between statin users and non-statin users. This comparison was necessary 
to be sure the two groups being compared are similar on these diabetes risk factors. A 
statistically significant difference (or association) between the two groups on any 
demographic or clinical characteristic should warrant controlling for such variable(s) in 
all regression analyses comparing the risk of diabetes between statin users and non-statin 
users. Furthermore, medication adherence was compared among users of each statin type 
and between intensive-dose statin users and moderate-dose statin users (objective 7). 
II. Statins Users vs. Non-statin Users and Incidence of Diabetes  
Objective 8 (hypothesis 8a: KM curves and log-rank test) compared the survival 
time and the probability of survival over time for statin users and non-statin users without 
controlling for any confounding variable. However, objective 9 (hypothesis 9a: Cox 
regression) compared survival time (i.e., time from receipt of the index medication to 
development of incident diabetes) between statin users and non-statin users while 
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controlling for demographic and clinical variables. Similarly, objective 11 (hypothesis 
11b: logistic regression) compared incidence of diabetes between statin users and non-
statin users while controlling for demographic and clinical variables. 
III. Users of Each Statin Type vs. Non-statin Users and Incidence of Diabetes 
Objective 8 (hypothesis 8b: KM curves and log-rank test) compared the survival 
time and the probability of survival over time for users of each statin type without 
controlling for any confounding variable. However, objective 9 (hypotheses 9b-g: six 
different Cox regression models) compared survival time between users of each statin 
type (i.e., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin) 
and non-statin users while controlling for demographic and clinical variables. Similarly, 
objective 11 (hypotheses 11c-h: six different logistic regression models) compared 
incidence of diabetes between users of each statin type and non-statin users while 
controlling for demographic and clinical variables. 
IV. Intensive-dose Statin Users vs. Moderate-dose Statin Users and Incidence of 
Diabetes 
Objective 8 (hypothesis 8c: KM curves and log-rank test) compared the survival 
time and the probability of survival over time for intensive-dose and moderate-dose statin 
users without controlling for any confounding variable. However, objective 10 
(hypothesis 10: Cox regression) compared survival time between intensive-dose statin 
users and moderate-dose statin users while controlling for medication adherence, and 
demographic and clinical variables. Similarly, objective 12 (hypothesis 12: logistic 
337 
 
regression) compared incidence of diabetes between intensive-dose statin users and 
moderate-dose statin users while controlling for medication adherence, and demographic 
and clinical variables. 
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5.3 DEMOGRAPHIC CHARACTERISTICS AND CLINICAL 
COVARIATES 
A total of 13 hypotheses (4 alternative and 9 null) were tested by univariate 
analyses (i.e., t-tests and chi-square tests) to assess if statin users differed significantly 
from  non-statin users on important demographic characteristics such as age and gender, 
and on clinical characteristics such as hyperlipidemia, obesity, hypertension, diabetogenic 
medication use, and CCI score. If the two groups differed significantly on any of these 
variables (and because these variables are important risk factors for diabetes), then it is 
important that such variable(s) be controlled for in all regression models that examined 
the association between statin use and incident diabetes.  
A discussion of the differences in demographic and clinical variables between 
statin users and non-statin users that were examined by univariate analyses is presented 
below. 
5.3.1 Age  
Age is an independent risk factor for diabetes mellitus because diabetes risk 
increases as age increases.
429
 Results of the univariate t-test indicated that mean age (in 
years) was significantly higher (p<0.0001) among statin users (52.2) compared to non-
statin users (40.6). This result is in line with what was hypothesized and was expected 
because the prevalence of high LDL-C (defined as level that is at or above LDL-C goal 
for a patient’s cardiovascular risk group, or current use of cholesterol medication) among 
                                                 
429 American Diabetes Association. Standards of medical care in diabetes--2014. Ibid.2014;37 Suppl 
1:S14-80. 
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Americans increases with age.
430
 This means that statin users are older than the average 
American population.  
This result is consistent with results of similar observational studies of statin use 
and incidence of diabetes. The mean age of statin users or statin initiators (64.1) was 
higher than that of non-statin users or non-initiators (61.3) in the Danaei et al. study.
431
 
This UK-based study examined the risk of diabetes among 285,864 men and women who 
were aged 50 – 84 years. Similarly, the mean age of statin users was higher than those of 
non-statin users, respectively, in the Sukhija et al. (69 vs. 63; p<0.0001),
432
 Culver et al. 
(65.7 vs. 62.9; p<0.001),
433
 and Izzo et al. (62.5 vs. 57.9; p<0.0001)
434
 observational 
studies of statin use and incidence of diabetes.  
In addition, when age was categorized into four age groups (i.e., 20 – 34, 35 – 44, 
45 – 54, and 55 – 63 years), there was a significant association (p<0.0001) between 
whether a subject took statin medication or not and the different age categories. 
Specifically, the majority of statin users (83.6%) were aged 45 years or older whereas the 
majority of non-statin users (59.6%) were below 45 years of age. This finding is 
reasonable because, in addition to LDL-C values, age ≥45 years in men or ≥55 years in 
women is a major risk factor for dyslipidemia and atherosclerotic cardiovascular disease 
                                                 
430 Centers for Disease Control and Prevention, "Vital signs: prevalence, treatment, and control of high 
levels of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008." 
431 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival." 
432 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients." 
433 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
Health Initiative." 
434 Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive patients at high 
cardiovascular risk." 
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(ASCVD) – the two main indications for statin use.435 Furthermore, prevalence of high 
LDL-C (thus, statin use) was correlated with age. Among Americans aged 20 years or 
older, the prevalence of high LDL-C was highest among those  65 years or older (58.2%) 
compared to those aged 40 – 64 years (41.2%) and 20 – 39 years (11.7%).436 
  
                                                 
435 "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III)." 
436 Centers for Disease Control and Prevention, "Vital signs: prevalence, treatment, and control of high 
levels of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008." 
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5.3.2 Gender 
Among US adult population aged 20 years or older, the prevalence of diabetes 
differs by gender. Diabetes prevalence is higher among males (13.6%) compared to 
females (11.2%).
437
 This study’s results showed there was a gender difference between 
statin users and non-statin users. Because the need for cardiovascular protection and use 
of statins are associated more with males,
438
 we expected the majority of statin users to be 
males. The study results barely supported this hypothesis as the proportion of statin users 
that were males (50.2%) was almost equal to the proportion of statin users that were 
females (49.8%). The association of the male gender with statin use is consistent with 
previous research. A study that examined the prevalence of high LDL-C among 
American adults who were aged 20 years and older found that the proportion of males 
with high LDL-C (36.2%) was higher compared to the proportion of females with high 
LDL-C (31%).
439
  
This observation is also consistent with previous research of statin use and 
incidence of diabetes. Izzo et al. reported a higher proportion of males among statin users 
(51%) compared to the proportion of females among statin users (49%).
440
 Similarly, the 
proportion of males among statin users was higher than the proportion of females among 
                                                 
437 Centers for Disease Control and Prevention, "National Diabetes Statistics Report: Estimates of diabetes 
and its burden in the United States, 2014." 
438 Cho L, Hoogwerf B, Huang J, Brennan DM, and Hazen SL. Gender differences in utilization of 
effective cardiovascular secondary prevention: A cleveland clinic prevention database study. J Womens 
Health. 2008;17(4):515-21. 
439 Centers for Disease Control and Prevention, "Vital signs: prevalence, treatment, and control of high 
levels of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008." 
440 Izzo R et al., "Primary prevention with statins and incident diabetes in hypertensive patients at high 
cardiovascular risk." 
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statin users, respectively, in the Danaei et al. (50.2% vs. 49.8%),
441
 Ko et al. (53.7% vs. 
46.3%),
442
 and Sukhija et al. (98% vs. 2%)
443
studies. The Sukhija et al. study was a 
retrospective cohort study which examined the effects of statin therapy on fasting plasma 
glucose among 345,417 United States military veterans.
444
 However, the gender direction 
for non-statin users was unclear because there is more theoretical interest in statin use 
than non-use. 
  
                                                 
441 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival." 
442 Ko DT et al., "Diabetes mellitus and cardiovascular events in older patients with myocardial infarction 
prescribed intensive-dose and moderate-dose statins." 
443 Sukhija R et al., "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients." 
444 Ibid. 
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5.3.3 Hyperlipidemia 
Hyperlipidemia is a risk factor for metabolic syndrome and cardiovascular 
diseases,
445
 which are in turn risk factors for diabetes mellitus.
446
 Among the study 
population, 28% had a diagnosis of hyperlipidemia. This hyperlipidemia prevalence 
among the study population was consistent but lower compared to the proportion of 
American adults aged 20 years and older with high LDL-C (34%).
447
 Because the 
prevalence of hyperlipidemia has been shown to increase with age, the lower prevalence 
of hyperlipidemia as found in this study might be due to the lower age range (20 – 63 
years) of the study population. One study showed that the prevalence of high LDL-C 
among Americans is highest among those aged 65 years or older (58.2%) compared to 
those aged 40 – 64 years (41.2%) or 20 – 39 years (11.7%).448 
Furthermore, the result of a chi-square analysis showed that the proportion of 
statin users with a diagnosis of hyperlipidemia (49.8%) was higher compared to the 
proportion of non-statin users with a diagnosis of hyperlipidemia (6.1%). This result is in 
line with what was hypothesized and was expected because statins are indicated for the 
management of hyperlipidemia and cardiovascular disease. Statins are used for most 
forms of dyslipidemias, including hypercholesterolemia (high TC) and 
                                                 
445 Wilson PW et al., "Prediction of coronary heart disease using risk factor categories."; "The Lipid 
Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart 
disease."; "Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial 
results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering." 
446 Carr MC and Brunzell JD, "Abdominal obesity and dyslipidemia in the metabolic syndrome: 
Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk." 
447 Centers for Disease Control and Prevention, "Vital signs: prevalence, treatment, and control of high 
levels of low-density lipoprotein cholesterol. United States, 1999–2002 and 2005–2008." 
448 Ibid. 
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hypertriglyceridemia (high TG). In addition, statin therapies are also used to either 
prevent the incidence of CHD through reduction of the risk factors associated with CHD 
(i.e., primary prevention), or they are used in secondary prevention to reduce the 
incidence and prevalence of recurrent CHD in people with established CHD.
449
  
The result of this study is consistent with those of previous observational studies 
of statin use and incidence of diabetes that compared mean cholesterol (i.e., TC and 
LDL-C) levels among statin users and non-statin users.
450
 Mean LDL cholesterol (in 
mg/dL) was higher among statin users compared to non-statin users, respectively, in the 
Danaei et al. (161.6 vs. 134.6)
451
 and Sukhija et al. (116 vs. 111; p<0.0001)
452
 studies. In 
addition, Izzo et al. reported that mean total cholesterol and non-HDL cholesterol levels 
(in mg/dL), respectively, were significantly higher (p<0.0001) among statin users (217.9 
and 167.2) compared to non-statin users (205.3 and 155.2).
453
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5.3.4 Obesity 
The epidemic of gestational and type 2 diabetes in the US has been attributed to 
increasing rates of overweight and obesity.
454
 Because obesity increases insulin 
resistance, overweight and obese individuals have a greater risk for diabetes.
455
  
Among the study population, 0.6% had a diagnosis of obesity. This low 
prevalence of obesity among the study population is not consistent with the proportion of 
American adults aged 20 years and older who are obese (34.9%).
456
 This discrepancy 
may be due to underreporting (or under-coding) of obesity diagnosis in administrative 
databases (via ICD-9-CM diagnosis codes) compared to obesity rates captured in 
registries (via recorded height and weight, and calculated BMIs).
457
 One study reported 
that obesity prevalence (2.4%) was lower in an administrative database that utilized ICD-
9-CM obesity codes compared to when the obesity prevalence (20.3%) for the same set 
of patients was estimated using a linkable registry that utilizes BMI values.
458
  The 
disproportionate low number of patients with an obesity diagnosis code in the study 
sample is a limitation of this study. 
                                                 
454 Kirkman MS et al., "Diabetes in older adults."; Lawrence JM et al., "Trends in the prevalence of 
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However, even though the prevalence of obesity was lower among the study 
population compared to the US adult population, it should be noted that the current study 
population is unique by itself and the result of a chi-square analysis showed that the 
proportion of statin users with an obesity diagnosis (1.0%) was significantly higher 
(p<0.0001) compared to the proportion of non-statin users with an obesity diagnosis 
(0.3%). For this reason, the obesity variable was retained as a covariate that was 
controlled for in all regression analyses. However, sensitivity analyses of all study results 
were carried out without controlling for the obesity variable. Results of the sensitivity 
analyses indicate that the risk ratios associating statin use with incident diabetes only 
increased marginally when the obesity variable was not accounted for in all regression 
analyses. 
Moreover, the result of this study is consistent with the results of previous 
research that compared the extent of overweight among study populations that used or 
did not use statins. Danaei et al. found that mean BMI (in kg/m
2
) among statin users 
(28.1) was higher compared to that among non-statin users (27.7).
459
 Similarly, mean 
BMI was significantly higher (p<0.001) among statin users (28.56) compared to non-
statin users (27.70) in the Culver et al. study of statin use and incident diabetes among 
postmenopausal women participating in the longitudinal Women’s Health Initiative 
study.
460
 These higher rates of overweight (defined as BMI ≥25, and by inference, 
                                                 
459 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival." 
460 Culver AL et al., "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's 
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obesity) that were observed among statin users compared to non-statin users are 
consistent with literature findings. This is because there is a direct relationship between 
hyperlipidemia, overweight/obesity, and cardiovascular diseases,
461
 with 
overweight/obesity being a risk factor for hyperlipidemia and coronary heart disease, and 
hyperlipidemia and coronary heart disease being indications for statin use. 
  
                                                 
461 "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
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5.3.5 Hypertension 
Hypertension (high blood pressure) is an independent risk factor for diabetes 
mellitus.
462
 Among the study population, 17.5% had a hypertension diagnosis. This 
prevalence of hypertension recorded for the study population is comparable but lower 
than the 2011 – 2012 overall prevalence of hypertension (29.1%) among US adults aged 
18 years and older.
463
  It unknown as to why this discrepancy was found, except to say 
that the study population were actively employed and composed of a lower age range (20 
– 63 years), whereas the US population may include non-employed and older people. 
In addition, the result of a chi-square analysis showed that the proportion of statin 
users with a hypertension diagnosis (30.8%) was higher compared to the proportion of 
non-statin users with a hypertension diagnosis (4.2%). This result is in line with what was 
hypothesized and was expected because hypertension is a risk factor for CHD,
464
 and 
high risk of CHD or established CHD are indications for statin use. 
The study result is consistent with previous observational studies of statin use and 
incidence of diabetes where prevalence of hypertension among statin users and non-statin 
users was reported. The proportion of statin users with hypertension was higher 
compared to the proportion of non-statin users with hypertension, respectively, in the 
                                                 
462 American Diabetes Association, "Standards of medical care in diabetes--2014." 
463 Nwankwo T, Yoon SS, Burt V, and Q G. Hypertension among adults in the United States: National 
Health and Nutrition Examination Survey, 2011–2012. Hyattsville, MD: National Center for Health 
Statistics; 2013. 
464 Centers for Disease Control and Prevention, "Million Hearts: strategies to reduce the prevalence of 
leading cardiovascular disease risk factors in United States." 
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Danaei et al. (62.1% vs. 50.7%)
465
 and Sukhija et al. (88% vs. 66%; p<0.0001)
466
 studies. 
In addition, Izzo et al. reported that the mean duration of hypertension (in years) was 
significantly higher among statin users (7.20) compared to non-statin users (5.44).
467
 
Even though the results of this study was similar to other studies in terms of the 
proportion of statin users with hypertension being higher than that of non-statin users 
with hypertension; overall, the percentages were lower in this study. This might be 
attributed to the fact that study participants were older in these previous studies. Among 
Americans aged 18 years and older, the prevalence of hypertension has been shown to be 
higher among those aged 60 years and above (65%) compared to those aged 40 – 59 
(32.4%) and 18 – 39 (7.3%).468 Compared to the mean age for our study population (46.4 
years), the study population mean age was higher in the Sukhija et al. (61 years) and Izzo 
et al. (59 years) studies. The study population in the Danaei et al. study was also older, 
with age ranging from 50 – 84 years.   
                                                 
465 Danaei G et al., "Statins and risk of diabetes: an analysis of electronic medical records to evaluate 
possible bias due to differential survival." 
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5.3.6 Diabetogenic Medication Use 
Certain drugs and agents have the ability to increase the risk of diabetes 
independent of the use of statins. These agents include thiazide diuretics,
469
 β-blockers,470 
antipsychotic agents,
471
 antidepressants,
472
 glucocorticoids (especially prednisolone and 
dexamethasone),
473
 and immunosuppressive agents (especially tacrolimus and 
cyclosporine).
474
 
Study results showed that the mean number of prescriptions for all diabetogenic 
medications was significantly higher (p<0.0001) among statin users (5.7) compared to 
non-statin users (0.8). In addition, the proportion of statin users with at least one 
diabetogenic medication prescription (44.7%) was higher compared to the proportion of 
non-statin users with at least one diabetogenic medication prescription (12.3%). This 
means that statin users were at a higher risk of having diabetes, independent of their use 
of statins, compared to non-statin users.  
When the analysis was broken down by the type of diabetogenic medications 
involved, the study results indicated that the proportion of statin users that received at 
                                                 
469 Zillich AJ et al., "Thiazide diuretics, potassium, and the development of diabetes: A quantitative 
review."; Elliott WJ and Meyer PM, "Incident diabetes in clinical trials of antihypertensive drugs: a 
network meta-analysis." 
470 Kuti EL et al., "The development of new-onset type 2 diabetes associated with choosing a calcium 
channel blocker compared to a diuretic or beta-blocker."; Bangalore S et al., "A meta-analysis of 94,492 
patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus." 
471 Holt RI and Peveler RC, "Association between antipsychotic drugs and diabetes." 
472 Khoza S et al., "Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case-control 
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473 Kwon S and Hermayer KL, "Glucocorticoid-induced hyperglycemia." 
474 Penfornis A and Kury-Paulin S, "Immunosuppressive drug-induced diabetes."; Vincenti F et al., 
"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with 
cyclosporine versus tacrolimus." 
351 
 
least one diabetogenic medication prescription was higher compared to the proportion of 
non-statin users that received at least one diabetogenic medication prescription, 
respectively, for thiazide diuretics (8.7% vs. 1.9%), beta-blockers (21.8% vs. 3.1%), 
antipsychotics (1.4% vs. 0.4%), antidepressants (24.6% vs. 8.3%), and 
immunosuppressants (0.40% vs. 0.06%). However, the proportion of statin users (0.10%) 
and non-statin users (0.06%) that received at least one glucocorticoid prescription was 
similar.  
Even though there is limited information regarding the use of diabetogenic drugs 
among statin users; the results were consistent with the results of previous observational 
studies.
475
 For example, the proportion of statin users who used β-blockers was higher 
than the proportion of non-statin users who used β-blockers, respectively, in the Danaei et 
al. (22.8% vs. 14.8%)
476
 and Sukhija et al. (58% vs. 25%; p<0.0001)
477
 studies. In the 
current study, a higher proportion of statin users used both thiazide diuretics and β-
blockers compared to non-statin users. This is not unexpected because both drugs are 
used in the management of hypertension; and as mentioned earlier, hypertension is a risk 
factor for CHD,
478
 and statins are indicated for prevention or management of CHD. In 
concordance with this observation, this study’s results mentioned that the proportion of 
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statin users with a hypertension diagnosis (30.8%) was higher compared to the proportion 
of non-statin users with a hypertension diagnosis (4.2%). Even though the results were 
similar to the results obtained in the Sukhija et al. study with regards to the proportion of 
statin users that received at least one beta-blocker being higher compared to that of non-
statin users, it is worth noting that the magnitudes of the proportions were lower in this 
study. This might be due to demographic differences between this study and the Sukhija 
et al. study. Participants in the Sukhija et al. study were predominantly males and older. 
Beta-blockers are used in the management of hypertension, and the prevalence of 
hypertension is higher among males and older people.
479
 
Apart from these aforementioned antihypertensive diabetogenic medications, 
other diabetogenic medications mentioned in the literature included use of oral steroids 
and antidepressants. Our result is consistent with results of similar studies that compared 
the proportion of statin users and non-statin users that used antidepressants, but the result 
was inconsistent with previous research regarding the proportion of statin users and non-
statin users who used steroids. The Danaei et al. study showed that the proportions of 
subjects who used oral steroids and antidepressants, respectively, were higher among 
statin users (2% and 9.6%) compared to non-statin users (1.8% and 8.4%).
480
 Compared 
to our study, there is a more noticeable difference in the proportion of statin users and 
non-statin users that used antidepressants (24.6% vs. 8.3%). However, our study did not 
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find a significant difference in the proportion of statin users and non-statin users that used 
glucocorticoids (0.10% vs. 0.06%). 
 The reasons why statin users may be more inclined to use antidepressants than 
the general population is unknown. However, previous research has associated increasing 
age and the female gender with antidepressants use among Americans aged 12 years and 
older.
481
 In this study conducted by the CDC’s National Center for Health Statistics, and 
using data from the 2005 – 2008 National Health and Nutrition Examination Surveys, the 
proportions of Americans that used antidepressants were higher among those aged 40 – 
59 (15.9%) and 60+ (14.5%) compared to those aged 12 – 17 (3.7%) and 18 – 39 (6.1%). 
In addition, females were 2.5 times more likely to take antidepressants compared to 
males. The age argument is consistent with the demographics of our study population 
where the majority of statin users (83.6%) was aged 45 years and above, whereas the 
majority of non-statin users (59.6%) was aged below 45 years. Unlike the CDC study 
above, the gender distribution in our study cannot explain the strong association of the 
female gender and use of antidepressants as noted in the CDC study since statin users 
were composed of an almost equal proportion of females (49.8%) and males (50.2%). 
  
                                                 
481 Pratt L, Brody D, and Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–
2008. Hyattsville, MD: National Center for Health Statistics; 2011. NCHS data brief, no 76. 
354 
 
5.3.7 Charlson Comorbidity Index Score 
Comorbidity is the co-occurrence of two or more disease conditions in a patient. 
The higher the CCI score for a patient, the higher the risk of mortality associated with 
such two or more comorbid conditions in the patient.
482
 Higher CCI scores are also 
predictive of complications resulting from chronic diseases such as diabetes.
483
 
The study results found that the mean CCI score was significantly higher 
(p<0.0001) among statin users (0.25) compared to non-statin users (0.04). In addition, the 
proportion of statin users with CCI score of one or more (12.9%) was higher compared to 
the proportion of non-statin users with CCI score of one or more (2.3%). This finding is 
not surprising because it was mentioned earlier that the proportions of statin users with 
chronic diseases such as hyperlipidemia, obesity, and hypertension were significantly 
higher compared to the proportions of non-statin users with such chronic diseases. Higher 
CCI scores, and thus, higher likelihood of diabetes may be present among statin users 
compared to non-statin users because hyperlipidemia, obesity, and hypertension are 
common comorbid conditions in people with diabetes.
484
 
Not many studies that evaluated the association between statin use and incidence 
of diabetes controlled for differences in CCI score between statin users and non-statin 
users. Nevertheless, the result of this study is consistent with the results of Danaei et al. 
study which compared the prevalence of certain disease conditions (used in estimating 
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the CCI score) among statin users and non-statin users. The Danaei et al. study found that 
the proportions of statin users who were diagnosed with chronic pulmonary disease 
(4.7% vs. 3.4%), atrial fibrillation (2.2% vs. 1.6%), and rheumatoid arthritis (2.2% vs. 
2%) were higher compared to the proportions of non-statin users who were diagnosed 
with such diseases, respectively.
485
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5.3.8 Statin Use and Medication Adherence 
A secondary study objective was to compare medication adherence among users 
of each statin type and between intensive-dose statin users and moderate-dose statin 
users. The medication possession ratio (MPR) was used as a proxy to measure adherence 
to statin medications. Subjects with MPRs ≥ 80% were considered ‘adherent’ while those 
with MPRs <80% were classified as ‘non-adherent.’  
There is a direct correlation between statin adherence and statin efficacy. One 
study found that each 25% increase in adherence was associated with a ~3.8mg/dL 
decrease in LDL cholesterol.
486
 Statin non-adherence has also been found to be 
associated with increased risk of mortality. One study found that the risk of mortality 
increased by 12 – 25% among patients with acute myocardial infarction who were non-
adherent with their statin medications.
487
 
In this study, the results indicated that statin users had a mean MPR of 75%, and 
the majority (54.2%) were adherent (i.e., had MPRs of 80 percent or higher). The rate of 
statin adherence in this study is comparable to that of a study similar to ours with respect 
to the demographics of the study population and follow-up time. In this study conducted 
by Pittman et al., statin users aged 18 – 61 years had a mean MPR of 82.7%, and the 
majority (67.6%) were adherent (i.e., MPR≥80%) after 18 months of follow-up.488  
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However, studies have shown that statin adherence decreases with time. The rates 
of statin adherence might have been high in this study because of the shorter follow-up 
period (18 months). Subjects that are followed for a shorter period of time have fewer 
opportunities to discontinue their medications compared to subjects that are followed for 
a much longer period of time.
489
 For example, several studies have reported a decreasing 
trend in adherence rates as the time of follow-up increases. Caspard et al. reported that 
80% of statin users were adherent when followed for six months.
490
 However, the 
proportion of statin users who were adherent with their statin medication decreases as  
follow-up time increases to one year (74%), two years (65%), and three years (61%). 
Similarly, Benner et al. reported that 79% of statin users were adherent after just three 
months of follow-up. However, this proportion decreased to 42% after the cohort was 
followed for 10 years.
491
 
Predictors of Statin Non-Adherence 
The results of this study indicate that medication adherence was highest among 
lovastatin users whereas it was lowest among fluvastatin users. Similarly, adherence was 
higher among moderate-dose statin users compared to intensive-dose statin users. Several 
factors could be responsible for differences in statin adherence from one patient to the 
other, or from the use of one statin type or dose to another. Since this was not the main 
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focus of this study, such factors were not explored. However, the literature provides 
guidance on numerous interrelated factors that could influence adherence among statin 
users. These factors include patient factors such as demographics, socioeconomic status, 
comorbidities, and level of sensitivity of the patient to the drug’s adverse effect; 
physician factors such as physician’s demographic characteristics and interaction with 
patients; and health system factors such as patient cost and access to care.
492
  
Patient and Physician Factors 
Similar to adherence with medications in general, adherence to statins is strongly 
predicted by patients’ demographic characteristics. A meta-analysis of 22 cohort studies 
in which each of the component studies evaluated adherence among statin users indicated 
that age, gender, and race/ethnicity were strong predictors of adherence. The meta-
analysis by Mann et al. found that the association between age and adherence is not linear 
but is presented as an inverted ‘U-shaped’ relationship.493 Younger (age <50 years) and 
older (age ≥70 years) adults are more likely to have lower adherence and higher 
discontinuation rates compared to ‘middle aged’ (ages 50 – 65 years) adults. The reason 
for this may be that younger individuals may be less likely to perceive themselves as 
being particularly at risk for heart diseases, whereas older individuals may have more 
comorbidities, more poly-pharmacy, or are more susceptible to statin adverse effects due 
to leaner muscle mass.  
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In addition, the meta-analysis showed that women are generally more likely than 
men to have lower medication adherence.
494
 One study showed that females were 11% 
less likely than men to be adherent with their medication.
495
 Furthermore, the literature 
reported that minority populations may be less adherent with their medications. In one 
study involving a large cohort of diabetic patients, African Americans, Hispanics, and 
Asians were significantly less likely to be adherent with their medications compared to 
non-Hispanic whites.
496
 However, race concordance was seen to modify the relationship 
between race and adherence rates, especially among African Americans. It was observed 
that adherence subsequently increased if both patient and physician were of the same 
African American race. On the other hand, medication adherence improved among 
Hispanic patients if there was Spanish language concordance between patients and their 
physicians.
497
 
Apart from demographic factors, patient’s socioeconomic status is also a 
significant determinant of medication adherence. The meta-analysis by Mann et al. 
showed that patients with higher income were more likely to be adherent than those with 
poorer income.
498
 One study also showed that statin adherence was higher among patients 
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living in higher income neighborhoods.
499
 People with higher income may be more likely 
to be able to afford the cost of their medications or have better access to their physicians 
or may have higher education levels. 
In addition to socio-economic factors and demographics characteristics, a 
patient’s comorbidity may also be influential in long-term adherence. Research suggests 
that adherence is better in patients with more cardiovascular risk factors. The meta-
analysis by Mann et al. showed that people with a history of myocardial infarction or 
stroke were 32% more likely to be adherent than those without such history.
500
 Thus, 
statin adherence might be better among those taking statins for secondary prevention (i.e., 
those with established CVD) than among those using statins as primary prevention. 
Perhaps, the former are more motivated to take their medications due to the gravity of 
their condition, while the latter are not currently experiencing any adverse cardiovascular 
events and may sometimes question the wisdom of refilling or taking their medications. 
Lastly, statin adherence may be influenced by a patients’ intolerance to side 
effects. Even though statins are generally well tolerated and are believed to have minimal 
adverse effects,
501
 statin therapies may be associated with bothersome side effects that are 
mostly related to muscle toxicity. These muscle-related problems range from muscle 
aches and weaknesses found in myopathies, myalgia, and myositis, to the more life-
threatening condition of rhabdomyolysis (the basis on which cerivastatin was withdrawn 
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from the US market in 2001). One study that evaluated statin-related side effects found 
that 19.8% of patients with muscle-related discomfort discontinued their medications and 
16.7% required a reduction in the statin dose after 3 months of initiation of statin therapy. 
Furthermore, most of the side effects were thought to be related to the more potent statins 
such as atorvastatin.
502
 
The argument for a linear relationship between higher statin potency and higher 
discontinuation rates or low statin adherence due to adverse effects does not seem to be 
supported among individual statins in this study. This is because adherence was higher 
among users of more potent statins such as rosuvastatin (MPR=76.5) and atorvastatin 
(MPR=74.8) compared to users of less potent statins such as fluvastatin (MPR=72.8) and 
pravastatin (MPR=74.5). However, it is doubtful if the statistical significance of these 
marginal differences in adherence translates into practical clinical significance.  
As mentioned earlier, one study indicated that there is a correlation between statin 
efficacy and statin adherence.
503
 Thus, higher efficacy (in terms of the percent of LDL-C 
reductions achieved), rather than more side effect, might be the better explanation of why 
there was higher adherence among rosuvastatin and atorvastatin users compared to users 
of less efficacious statins such as fluvastatin and pravastatin. Patients may be more 
inclined to use their medication if they found them effective. However, the relationship 
between potency and adverse effect was stronger when statin dosages were accounted 
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for. As a result, intensive-dose (high potency + high dose, MPR=70.7) statin use was 
associated with lower adherence than moderate-dose (mainly low potency + low dose, 
MPR=75.6) statin use. Thus, adherence may have been lower among intensive-dose statin 
users compared to moderate-dose statin users due to more incidences of adverse effects. 
Health Care System Factors 
In addition to patient and physician factors, health care factors such as medication 
cost and access to care has influenced medication adherence.
504
 Research has shown that 
medication adherence is inversely related to patient costs across many different types of 
drug products. The use of statin drug products follows similar patterns. For example, 
several studies have shown that lower copayments are associated with higher levels of 
statin adherence. A study by Gibson et al. shows that when copayment for a statin drug 
increase by $10, the likelihood of adherence was reduced by 1.8% for new statin users 
and by 3% for continuing statin users.
505
 Another study showed that patients were 58% 
less likely to be adherent with their statin medications when copayment was greater than 
$20 compared to when copayment was $10.
506
 Furthermore, a study which examined the 
association between out-of-pocket cost and statin utilization among Medicare Part D 
patients noted that the proportion of the patients who were adherent with their 
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medications reduced from 67% to 56%, respectively, when annual out-of-pocket costs 
increased from $200 to $240.
507
 
In regard to access to health care, a meta-analysis by Mann et al. showed that 
there was no clear relationship between access to healthcare (e.g., number of healthcare 
provider visits) and medication adherence.
508
 An increased number of physician visits 
was associated with better adherence in some studies,
509
 while a higher number of 
physician visits was not associated with better adherence in other studies.
510
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5.4 INCIDENCE OF DIABETES  
The unadjusted cumulative incidence of diabetes (over 2003 – 2004) among this 
study population aged 20 – 63 years was 65.3 per 1,000 population (or 6.53%). This 
means that if 1,000 study subjects were followed from 2003 – 2004, 65.3 new cases of 
diabetes will be recorded. This rate is higher compared to the unadjusted incidence of 
diabetes of 7.8 per 1,000 population of US adults aged 20 years and over (diabetes 
incidence was estimated using the 2010 – 2012 National Health Interview Survey 
data).
511
 In addition, the unadjusted cumulative incidence of diabetes among statin users 
and non-statin users were 98 per 1,000 population (9.8%) and 33 per 1,000 population 
(3.3%), respectively.  
The higher rates of incident diabetes found among the study population may be 
attributed to the way ‘new’ cases of diabetes was defined in the current study. Due to the 
fact that study data were limited to two years in length, six months of pre-index period 
was used in identifying and excluding prevalent cases of diabetes. This means that only 
six months was used to establish a history of diabetes. The length of this pre-index period 
may not be sufficient. A longer data period could have allowed the flexibility to assign a 
longer pre-index period to identify and exclude more prevalent diabetes cases. Thus, it is 
possible that diabetes cases that were identified as incident cases in the current study 
might have been correctly classified as prevalent cases and thus excluded from the 
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numerator that was used in estimating the cumulative incidence, therefore yielding a 
lower value. 
In addition, because statin users constituted half the study population at risk (and 
statin users may be more likely than the average population to have several risk factors 
for diabetes), it might be reasonable that the rate of incident diabetes for the current study 
population would be higher than that of the US population that does not have half its 
population at risk composed essentially of statin users. 
Primarily for the first reason given above (i.e., insufficiently long observation 
period), the unadjusted incident density rate of diabetes obtained among this study 
population (4.45 per 1,000 person-months) might have been higher compared to rates 
obtained in similar population-based observational studies of statin use and incidence of 
diabetes. The unadjusted study population incident density rates of diabetes were lower in 
the Culver et al. (0.85 per 1,000 person-months),
512
 Danaei et al. (0.96 per 1,000 person-
months),
513
 and Wang et al. (1.75 per 1,000 person-months)
514
 studies. The observation 
period in this study (2003 – 2004) was shorter compared to the observation periods in the 
Culver et al. (1993 – 2005),515 Danaei et al. (2000 – 2010),516 and Wang et al. (2000 – 
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2003)
517
 studies. Due to the luxury of having longer observational data periods, these 
studies were able to assign longer pre-index periods to identify and exclude more 
prevalent diabetes cases. 
Furthermore, only one observational study has compared diabetes incident density 
rates between statin users and non-statin users. The unadjusted incident density rate of 
diabetes reported among statin users in this study (6.82 per 1,000 person-months) was 
higher compared to that reported in the Danaei et al. study (1.30 per 1,000 person-
months). Similarly, a higher incident density rate of diabetes was reported among non-
statin users in this study (2.20 per 1,000 person-months) compared to that reported in the 
Danaei et al. study (0.94 per 1,000 person-months). For the same reasons given above, 
higher diabetes incidence density rates were reported among statin users and non-statin 
users in this study compared to reported rates in the literature. 
Sensitivity Analysis 
 A sensitivity analysis was conducted to examine how varying lengths of the pre-
index period affected the reclassification of incident diabetes cases as prevalent ones. 
Study results found in Appendix G shows that 1,777 incident diabetes cases were 
reclassified as prevalent diabetes cases and removed from the study cohort when the pre-
index period for identifying prevalent diabetes cases was increased from six months to 
one year. In contrast, 5,017 incident diabetes cases were reclassified as prevalent diabetes 
cases and removed from the study cohort when the pre-index period for identifying 
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prevalent diabetes cases was increased from six months to 1.5 years. In addition, the 
unadjusted diabetes cumulative incidence and incidence density rates decreased 
‘substantially’ when the pre-index period was increased from six months to one year and 
then to 1.5 years. 
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5.5 STATIN USE AND INCIDENCE OF DIABETES 
The main objective of this study was to investigate if statin users were at an 
increased risk of new-onset diabetes compared to non-statin users. Results from both the 
Cox regression and the logistic regression analyses indicate that statin therapy was 
significantly associated with increased risk of incident diabetes. The Cox regression 
analysis showed that the hazard of incident diabetes among statin users was 2.752 times 
the hazard of incident diabetes among non-statin users (HR=2.752, 99% C.I.=2.535 – 
2.987). The logistic regression analysis also showed that the odds of incident diabetes 
among statin users was 2.824 times the odds of incident diabetes among non-statin users 
(OR=2.824, 99% C.I.=2.594 – 3.074).  
Even though the strength of association (or magnitude of the risk ratios) of statin 
use and incidence of diabetes was higher in this study (HR=2.75 and OR=2.82), the 
increase in the risk of diabetes that was associated with statin therapy, compared to no 
statin therapy, is consistent with those of several observational studies. Statin therapy was 
significantly associated with a 14 percent, 15 percent, 20 percent, and 48 percent increase 
in risk of incident diabetes in the Danaei et al. (HR=1.14, 95% C.I.=1.10 – 1.19),518 
Wang et al. (HR=1.15, 95% C.I.=1.08 – 1.22),519 Zaharan et al. (HR=1.20, 95% C.I.=1.17 
– 1.23),520 and Culver et al. (HR=1.48, 95% C.I..=1.38 – 1.59)521 studies, respectively. 
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As mentioned earlier, the higher risk ratios observed in this present study 
compared to those of previous studies may be due to the fact that the pre-index period 
used in identifying occurrence of incident diabetes was limited to a period of six months 
(there was only two years of data available to work with in the database). Had a longer 
time frame of data been available, a longer pre-index period may have classified some 
incident diabetes cases as prevalent diabetes cases, and those cases would have been 
excluded from the study cohort. The current study had only six months of pre-index 
period (for identifying new users of statin and previous cases of diabetes) and a 
maximum 18 months of observation period. These periods were shorter compared to the 
11 years of observation period and 2 years of pre-index period in the Danaei et al. 
study,
522
 the 6 years of observation period in the Zaharan et al. study,
523
 and the 4 years 
of observation period in the Wang et al. study.
524
  
For similar reason, the magnitude of the risk ratios obtained for the association of 
each statin type and incidence of diabetes (discussed in the next section) might have been 
higher in this study compared to those obtained in previous studies.  
Sensitivity Analysis 
A sensitivity analysis was conducted to examine how varying lengths of the pre-
index period affected the magnitudes of the risk ratios. Study results found in Appendix 
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G shows that the magnitudes of the hazard and odds ratios decreased ‘slightly’ when the 
pre-index period for identifying prevalent diabetes cases was increased from six months 
to one year. In contrast, the magnitudes of the hazard and odds ratios decreased 
‘substantially’ when the pre-index period for identifying prevalent diabetes cases was 
increased from six months to 1.5 years.  
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5.6 STATIN TYPES AND INCIDENCE OF DIABETES 
Apart from examining the association of incident diabetes with statins as a class, 
the associations of each statin type (i.e., atorvastatin, fluvastatin, lovastatin, pravastatin, 
rosuvastatin, and simvastatin) with incident diabetes were also examined. The 
magnitudes of the risk ratios (hazard ratio and odds ratio) obtained in this study were 
compared to values obtained for similar studies of statin use and incidence of diabetes. It 
was hypothesized that the use of each statin type will be associated with an increase in 
diabetes risk and all the hypotheses were supported; however, the magnitude of the risk 
ratios obtained in this study for each statin type was higher compared to those found in 
the literature.  
As mentioned earlier, one reason the risk ratios might have been higher in this 
study may be due to misclassification of prevalent cases of diabetes as incident diabetes 
cases because of the limited pre-index data period used in identifying prevalent diabetes 
cases. However, since both the statin user group and the non-statin user group were both 
subjected to the same inclusion and exclusion criteria (for example, same six months of 
pre-index period for identifying and excluding prevalent cases of diabetes in both 
groups), it is possible that the risk ratios might still have been on the high side even if 
longer data periods were available. 
The demographics of the study population and the kinds of variables controlled 
for in the regression analyses could also explain the discrepancies of the risk ratios 
obtained in this study compared to those of previous studies. Important diabetes risk 
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factors that would have been ideal to control for but were not available in the MarketScan 
data used for this study include race/ethnicity information, family history of diabetes, 
physical activity level, cholesterol level (HDL-C, LDL-C, TG), height and weight data 
(thus, BMI), and presence or absence of prediabetes. Some of these variables were 
controlled for in previous research. 
With regards to one of the demographic characteristics that was controlled for in 
this study (i.e., age), it appears that the argument of differences in study population age 
do not support why the risk ratios were higher in this study. Since the risk of diabetes has 
been found to increase with age,
525
 it will be expected that the risk of diabetes that was 
associated with statin use should be lower in this study compared to previous studies. The 
2014 National Diabetes Statistics Report showed that diabetes prevalence is higher 
among people aged 65 years and older (25.9%) compared to those aged 45 – 64 years 
(16.2%) and 20 – 44 years (4.1%).526 However, this hypothesis was not supported as the 
risk of diabetes was higher in our study even though the mean age of our study 
population was lower compared to the study population mean age of previous studies.  
In addition, prevalence of diabetes has been shown to differ by race/ethnicity. The 
2014 National Diabetes Statistics Report cited above also showed that the prevalence of 
diagnosed diabetes is higher among American Indians/Alaska Natives (15.9%) compared 
to among Hispanic blacks (13.2%), Hispanics (12.8%), Asian-Americans (9.0%) and 
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non-Hispanic whites (7.6%).
527
 However, we were not able to control for this important 
demographic factor. Only one study (Culver et al.) controlled for race/ethnicity among its 
study population.
528
 Thus, the race/ethnicity argument may or may not explain why 
diabetes rates were higher in this study. 
Perhaps the age and race/ethnicity arguments presented above lends more 
credence to the argument that the higher rates of diabetes as observed in this study may 
be due to the first reason proposed above (i.e., possibility of a misclassification error due 
to short data range). This might be compounded by the inability to account for some 
important diabetes risk factors (such as family history of diabetes, BMI and cholesterol 
levels) that were accounted for in some studies. Moreover, a handful of previous 
studies
529
 accounted for about the same types of diabetes risk factors that were accounted 
for in our study but obtained risk ratios that were less than those obtained in this study.  
Nevertheless, the following section discusses the association of each statin type 
and incidence of diabetes and how the risk ratios compares to those obtained in previous 
studies. 
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5.6.1 Atorvastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that atorvastatin therapy was significantly associated with increase an in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among atorvastatin users was 2.425 times the hazard 
of incident diabetes among non-statin users (HR=2.425, 99% C.I.=2.200 – 2.673). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
atorvastatin users was 2.485 times the odds of incident diabetes among non-statin users 
(OR=2.485, 99% C.I.=2.246 – 2.749).  
The increase in risk of diabetes associated with atorvastatin therapy in this study 
is consistent (but with a higher risk ratio magnitude) compared to results of previous 
observational studies that found a statistically significant association between atorvastatin 
use and increase in risk of incident diabetes. The hazard ratios of these previous 
significant associations ranged from 1.22 – 1.61, as found in the Danaei et al. (HR=1.22, 
95% C.I.=1.12 – 1.32),530 Zaharan et al. (HR=1.25, 95% C.I.=1.21 – 1.28),531 and Culver 
et al. (HR=1.61, 95% C.I.=1.26 – 2.06)532 studies.  
Differences in the magnitudes of the risk ratios obtained in this study compared to 
those of previous studies might be due to differences in study design. For example, 
Danaei et al. used primary markers such as LDL-C and HDL-C, and BMI to account for 
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differences in subjects’ cholesterol levels and obesity, respectively. This study used 
diagnoses of hyperlipidemia and obesity (which was underreported) as proxies for 
cholesterol levels and BMI, respectively. In addition, the Culver et al. study was a 
prospective cohort study of statin use in postmenopausal women and the study controlled 
for race/ethnicity, family history of diabetes, and physical activity. Our study was 
retrospective in nature, and controlled for some important diabetes risk factors that 
included gender and CCI score but not the other variables used in Culver’s study. 
However, the study result is consistent (with respect to the magnitude of the risk 
ratio) as those obtained in the Chen et al. case-control study.
533
 That study reported that 
the odds of incident diabetes among atorvastatin users was 2.80 times the odds of 
incident diabetes among non-statin users (OR=2.80, 95% C.I.=1.74 – 4.49). The odds 
ratio for atorvastatin in this study was 2.485. The Chen et al. study was a population-
based case-control study of the differential impact of statins on new-onset diabetes in 
1,065 Taiwanese women with mean age of 61 years and their 10,650 matched-controls.
534
 
However, it is unclear why the odds ratio and the upper range of the 95% confidence 
interval of the odds ratio were high in the Chen et al. study compared to what was 
generally reported in the literature. Matching on important study variables as done in the 
Chen et al. study should have minimized differences between the groups. In addition, 
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rates of obesity (a very important diabetes risk factor) are also lower among Asian 
population compared to other populations.
535
  
Nevertheless, rather than a statistically significant increase in the risk of diabetes 
with atorvastatin therapy as found in the majority of previous studies, one study reported 
a protective effect of atorvastatin use against diabetes,
536
 while other studies reported a 
non-statistically significant increase in risk of diabetes with atorvastatin use.
537
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5.6.2 Fluvastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that fluvastatin therapy was significantly associated with an increase in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among fluvastatin users was 2.064 times the hazard of 
incident diabetes among non-statin users (HR=2.064, 99% C.I.=1.647 – 2.586). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
fluvastatin users was 2.161 times the odds of incident diabetes among non-statin users 
(OR=2.161, 99% C.I.=1.704 – 2.742).  
The increase in the risk of diabetes associated with fluvastatin therapy in this 
study is consistent (but with a higher risk ratio magnitude) when compared to results of 
previous observational studies. Danaei et al. found a 2% increase in risk of diabetes 
associated with fluvastatin use (HR=1.02, 95% C.I.=0.69 – 1.50),538 while Culver et al. 
found a 61% increase in risk of diabetes associated with fluvastatin use (HR=1.61, 95% 
C.I.=1.35 – 1.92).539 As mentioned earlier (under atorvastatin), differences in the 
magnitudes of the risk ratios obtained in our study compared to these studies might be 
due to differences in study design and whether certain independent risk factors for 
diabetes were accounted for in the regression analyses. Moreover, rather than a 
statistically significant increase in diabetes risk with fluvastatin therapy that was 
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observed in many studies, some studies reported a protective effect of fluvastatin use 
against diabetes,
540
 while the increase in risk of diabetes with fluvastatin use was not  
statistically significant in another study.
541
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5.6.3 Lovastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that lovastatin therapy was significantly associated with an increase in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among lovastatin users was 3.413 times the hazard of 
incident diabetes among non-statin users (HR=3.413, 99% C.I.=2.949 – 3.951). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
lovastatin users was 3.565 times the odds of incident diabetes among non-statin users 
(OR=3.565, 99% C.I.=3.051 – 4.165).  
The increase in risk of diabetes associated with lovastatin therapy in this study is 
consistent (but with a higher risk ratio magnitude) when compared to previous research. 
Ma et al. found a 36% increase in risk of diabetes associated with lovastatin use 
(HR=1.36, 95% C.I.=1.24 – 1.48),542 while Culver et al. found a 35% increase in risk of 
diabetes associated with lovastatin use (HR=1.35, 95% C.I.=1.19 – 1.55).543  
While similar kinds of variables were controlled for in our study and the Ma et al. 
study, the magnitude of the risk ratio was higher in our study even though differences 
were minimized between the groups by controlling for CCI score, obesity (though, 
underreported), and hyperlipidemia – variables that were not controlled for in the Ma et 
al. study. One explanation could be that our study used data from the United States while 
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the Ma et al. study comprised of subjects from an Asian country (Taiwan). The US 
population may be different than the Asian population in terms of the prevalence of 
diabetes risk factors such as overweight and obesity. Studies indicate that the US has the 
highest rate of obesity among all high income population of North America and 
Europe.
544
 This is in contrast to people from East Asian countries who have mean BMIs 
that are among the lowest in the world.
545
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5.6.4 Pravastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that pravastatin therapy was significantly associated with an increase in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among pravastatin users was 1.889 times the hazard 
of incident diabetes among non-statin users (HR=1.889, 99% C.I.=1.620 – 2.202). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
pravastatin users was 1.952 times the odds of incident diabetes among non-statin users 
(OR=1.952, 99% C.I.=1.663 – 2.290).  
The increase in risk of diabetes associated with lovastatin therapy in this study is 
consistent (and within the same magnitude) with results of two observational studies. Ma 
et al. found a 30% increase in risk of diabetes associated with pravastatin use (HR=1.30, 
95% C.I.=1.13 – 1.56),546 while Culver et al. found a 63% increase in risk of diabetes 
associated with pravastatin use (HR=1.63, 95% C.I.=1.43 – 1.87).547  
However, the study result was inconsistent with respect to the magnitude of the 
risk ratio found in the Chen et al. case-control study. The Chen et al. study reported that 
the odds of incident diabetes among pravastatin users was 3.41 times the odds of incident 
diabetes among non-statin users (OR=3.41, 95% C.I.=1.66 – 7.04).548 The odds ratio in 
this study was 1.95. The fact that the Chen et al. study was conducted only among 
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women from an Asian country (Taiwan) couldn’t possibly explain why the magnitude of 
the odds ratio in the Chen et al. study was high compared to results of every study on this 
topic. Perhaps, there was statistical inefficiency as a result of the 1:10 case to control 
matching.  
Furthermore, rather than a statistically significant increase in risk, one study 
reported a protective effect of pravastatin use against diabetes,
549
 while the increases in 
risk of diabetes that were associated with pravastatin use were not statistically significant 
in some studies.
550
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5.6.5 Rosuvastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that rosuvastatin therapy was significantly associated with an increase in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among rosuvastatin users was 1.615 times the hazard 
of incident diabetes among non-statin users (HR=1.615, 99% C.I.=1.307 – 1.996). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
rosuvastatin users was 1.495 times the odds of incident diabetes among non-statin users 
(OR=1.495, 99% C.I.=1.199 – 1.865).  
The increase in risk of diabetes associated with rosuvastatin therapy in this study 
is consistent (and within the same magnitude) with the results of an observational study 
that found a statistically significant association between rosuvastatin use and increase in 
risk of incident diabetes. Zaharan et al. found a 42% increase in risk of diabetes 
associated with rosuvastatin use (HR=1.42, 95% C.I.=1.33 – 1.52).551 The hazard ratio 
obtained in this study was 1.62 (a 62% increase in risk). 
However, just like the risk ratios obtained for atorvastatin and pravastatin, the 
magnitude of the risk ratio obtained for rosuvastatin in the Chen et al. study was 
inconsistent with those obtained in this and other studies. The Chen et al. study reported 
that the odds of incident diabetes among rosuvastatin users was 4.69 times the odds of 
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incident diabetes among non-statin users (OR=4.69, 95% C.I.=2.78 – 7.92).552 The odds 
ratio for rosuvastatin was 1.49 in this study. Even though the Chen et al. study used a 
case-control design to examine statin use and the risk of diabetes among Asian women 
while our study used a retrospective cohort design to examine the use of statins and 
incidence of diabetes among American men and women, it is difficult to speculate what 
could be responsible for the stark differences in risk ratio magnitudes between the Chen 
et al. study, our study, and similar studies on the topic. 
 Nevertheless, rather than reporting a statistically significant increase in risk of 
diabetes with rosuvastatin therapy, some studies have reported a protective effect of 
rosuvastatin use against diabetes,
553
 while one study reported a non-statistically 
significant increase in diabetes risk with rosuvastatin use.
554
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5.6.6 Simvastatin Use and Incidence of Diabetes 
Results from both the Cox regression and the logistic regression analyses 
indicated that simvastatin therapy was significantly associated with an increase in risk of 
incident diabetes compared to non-statin therapy. The Cox regression analysis indicated 
that the hazard of incident diabetes among simvastatin users was 2.567 times the hazard 
of incident diabetes among non-statin users (HR=2.567, 99% C.I.=2.284 – 2.884). The 
logistic regression analysis also indicated that the odds of incident diabetes among 
simvastatin users was 2.651 times the odds of incident diabetes among non-statin users 
(OR=2.651, 99% C.I.=2.347 – 2.994).  
The increase in risk of diabetes associated with simvastatin therapy in this study is 
consistent (but with a higher risk ratio magnitude) compared to results of previous 
observational studies. The risk ratios of these previous significant associations ranged 
from 1.10 – 1.41, as found in the Danaei et al. (HR=1.14, 95% C.I.=1.09 – 1.20),555 
Zaharan et al. (HR=1.14, 95% C.I.=1.06 – 1.23),556 Ma et al. (HR=1.30, 95% C.I.=1.14 – 
1.47),
557
 and Culver et al. (HR=1.10, 95% C.I.=1.04 – 1.17)558 studies. As mentioned 
earlier, differences in the magnitudes of the risk ratios obtained in our study compared to 
these previous studies could be due to differences in the demographics of the study 
population and differences in study design. 
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Similar to atorvastatin, pravastatin, and rosuvastatin therapies, the magnitude of 
the risk ratio obtained for simvastatin was higher in the Chen et al. study compared to 
what was obtained in this study. The Chen et al. study reported that the odds of incident 
diabetes among simvastatin users was 4.09 times the odds of incident diabetes among 
non-statin users (OR=4.09, 95% C.I.=2.92 – 6.64).559 The odds ratio for simvastatin was 
2.65 in this study. However, the increase in diabetes risk that was associated with 
simvastatin use was not statistically significant in some studies.
560
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5.7 INTENSIVE-DOSE STATIN USE AND INCIDENCE OF 
DIABETES 
In addition to examining the risk of diabetes associated with use of statins as a 
class and with each statin type, it was imperative to examine how statin dosage intensities 
influenced the risk of diabetes among statin users. Some studies have suggested that the 
risk of diabetes is higher with high potency, high dose (i.e., intensive-dose) statin 
therapies such as atorvastatin 40 and 80mg, rosuvastatin 20 and 40mg, and simvastatin 
80mg compared to moderate/high potency and low/moderate dose (i.e., moderate-dose) 
statin therapies such as atorvastatin 10 and 20mg, rosuvastatin 5 and 10mg, simvastatin 5, 
10, 20, and 40mg, and all doses of fluvastatin, pravastatin, and lovastatin.
561
 
Results from both the Cox regression and the logistic regression analyses 
indicated that intensive-dose statin therapy was significantly associated with an increase 
in risk of incident diabetes compared to moderate-dose statin therapy. The Cox regression 
analysis indicated that the hazard of incident diabetes among intensive-dose statin users 
was 1.525 times the hazard of incident diabetes among moderate-dose statin users 
(HR=1.525, 99% C.I.=1.378 – 1.686). The logistic regression analysis also indicated that 
the odds of incident diabetes among intensive-dose statin users was 1.578 times the odds 
of incident diabetes among moderate-dose statin users (OR=1.578, 99% C.I.=1.414 – 
1.761).  
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Only one observational study had examined the association between statin dosage 
intensity and incidence of diabetes.
562
 The increase in risk of diabetes associated with 
intensive-dose statin therapy in our study is not consistent compared to what was found in 
this previous observational study. The Ko et al. study examined the occurrence of 
diabetes mellitus in 8,540 hospitalized patients (mean age=78 years) with myocardial 
infarction and their 8,540 matched-pair controls who were prescribed intensive-dose and 
moderate-dose statins. Study results suggests that at 5 years, there was no statistically 
significant difference (p=0.19) in the proportion of intensive-dose statin patients (13.6%) 
and moderate-dose statin patients (13.0%) that had new onset diabetes.
563
 In comparison, 
the results of our univariate analysis showed that the proportion of intensive-dose statin 
users that had incident diabetes (13.4%) was significantly higher than the proportion of 
moderate-dose statin users (9.3%) that had incident diabetes (χ2=103.4; df=1, p<0.0001). 
However, the results of this study is consistent with results from a randomized 
control trial (RCT)
564
 and a study involving meta-analysis of five RCTs.
565
 These studies 
suggests that there is an increased risk of diabetes among intensive-dose statin user 
compared to moderate-dose statin users. Meanwhile, many researchers have argued that 
the lipid-lowering effects and the larger cardiovascular benefit gained from using high 
potency, high dose statins far outweigh the potential increase in risk of new onset 
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diabetes associated with such intensive-dose statins.
566
 Moreover, increases in diabetes 
risk that was associated with intensive-dose statin use were not statistically significant in 
many RCTs.
567
 It is worth noting that the primary interest of these RCTs was not to 
measure the risk of diabetes. These RCTs were designed essentially to examine the 
superiority of the lipid-lowering effect of higher statin dosages over moderate or usual 
statin dosages. 
Even though it is unclear how intensive-dose statin use may increase the risk of 
new onset diabetes compared to moderate-dose statin use, several plausible hypotheses 
has been advanced. These hypotheses include the potency hypothesis,
568
 and effects 
related to the hydrophilic/lipophilic nature of each statin.
569
 The potency hypothesis 
suggests that more side effects (including diabetes occurrence) might be associated with 
higher potency statins compared to lower potency statins. Furthermore, due to the 
utilization of different transport systems that may lead to varying degrees of intercellular 
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concentrations of the statin,
570
 the hydrophilic/lipophilic hypothesis posits that more 
adverse effects may be associated with lipophilic statins compared to hydrophilic statins. 
Interestingly, the results of this study does not seem to support the potency hypothesis 
because the risks of diabetes (as evidenced by the magnitudes of the hazard ratios) were 
not consistently higher among high potency statins such as atorvastatin (HR=2.42), 
rosuvastatin (HR=1.62), and simvastatin (HR=2.57) compared to low/moderate potency 
statins such as fluvastatin (HR=2.06), lovastatin (HR=3.41), and pravastatin (HR=1.88). 
However, the hydrophilic/lipophilic hypothesis appears to be supported by our 
results because the magnitudes of the hazard ratios for hydrophilic statins such as 
pravastatin (HR=1.88) and rosuvastatin (HR=1.61) were consistently lower compared to 
the magnitudes of the hazard ratios associated with lipophilic statins such as atorvastatin 
(HR=2.43), fluvastatin (HR=2.06), lovastatin (HR=3.41), and simvastatin (HR=2.57). 
The higher risks of diabetes associated with lipophilic statins might be explained by their 
higher potential to reduce adiponectin hormone and increase insulin resistance compared 
to hydrophilic statins.
571
 
  
                                                 
570 Bitzur R, Cohen H, Kamari Y, and Harats D. Intolerance to statins: mechanisms and management. 
Diabetes Care. 2013;36 Suppl 2:S325-30. 
571 Dormuth CR et al., Higher potency statins and the risk of new diabetes: multicentre, observational 
study of administrative databases, 348. 
391 
 
5.8 COMPARISON OF THE RISK OF DIABETES AMONG 
USERS OF DIFFERENT STATIN TYPES 
One of the main study objectives was to estimate the risk of diabetes for users of 
each statin type (i.e., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and 
simvastatin). In order to be consistent, a common group was chosen as the comparison 
group. Thus, users of each statin type were compared to non-statin users and the risk ratio 
(i.e., hazard ratio or odds ratio) associating the use of each statin with new onset diabetes 
was estimated. From the results, lovastatin users (HR=3.41, OR=3.57) had the highest 
risk of new onset diabetes and were followed, consecutively, by users of simvastatin 
(HR=2.57, OR=2.65), atorvastatin (HR=2.43, OR=2.49), fluvastatin (HR=2.06, 
OR=2.16), and pravastatin (HR=1.89, OR=1.95). Rosuvastatin users (HR=1.62, 
OR=1.50) had the least risk of new onset diabetes among all statin users. 
As mentioned earlier, the potency hypothesis (which correlates higher potencies 
with higher side effects) does not seem to explain why the risks of diabetes was highest 
among lovastatin, simvastatin, atorvastatin, and fluvastatin users since it will be expected 
that higher potency statins such as atorvastatin, rosuvastatin, and simvastatin should 
consistently have higher risk ratios compared to lower potency statins such as lovastatin 
and fluvastatin. However, the lipophilic/hydrophilic hypothesis may explain why users of 
lipophilic statins such as atorvastatin, fluvastatin, lovastatin, rosuvastatin, and simvastatin 
all had higher risks of diabetes compared to users of hydrophilic statins such as 
pravastatin and rosuvastatin.  
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It has been hypothesized that lipophilic and hydrophilic statins have differential 
effects on adiponectin and insulin resistance.
572
 Adiponectin is a hormone that decreases 
gluconeogenesis (i.e., endogenous production of glucose from non-carbohydrate 
substrates and the target of antidiabetic drug such as metformin) and increases glucose 
uptake. One study showed a correlation between high blood levels of adiponectin and 
reduction in the risk of type 2 diabetes.
573
 Simvastatin – a lipophilic statin – has been 
shown to significantly reduce both insulin sensitivity and adiponectin levels in patients 
with hypercholesterolemia.
574
 In contrast, one study showed that pravastatin, a 
hydrophilic statin, had less deleterious effects on levels of adiponectin and insulin 
sensitivity.
575
 
Other postulated mechanisms by which statins may induce new onset diabetes 
include down-regulation of the pancreatic beta-cell function,
576
 suppression of 
ubiquinone (CoQ10) biosynthesis,
577
 promotion of beta-cell apoptosis (cell death),
578
 and 
                                                 
572 Ibid. 
573 Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. 
Lancet. 2003;361(9353):226-8. 
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576 Ibid. 
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hypercholesterolemic patients." 
578 Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, and Yada T. Effects of statins on the 
adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. 
Diabetologia. 2006;49(8):1881-92. 
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impairment of glucose transport.
579
 Atorvastatin and lovastatin, both lipophilic statins, 
have been shown to impair glucose transportation by suppression of isoprenoid synthesis, 
which in turn decreases the expression of insulin-responsive glucose transporter type 
(GLUT)-4.
580
 
Evaluation of current observational studies of statin use and incidence of diabetes 
appear to suggest that simvastatin and atorvastatin had the greatest potential to be 
significantly associated with increased risk of incident diabetes, while fluvastatin and 
lovastatin had the least potential to be significantly associated with an increase in risk. 
Pravastatin and rosuvastatin appear to have moderate potential to be significantly 
associated with increased risk of diabetes. This observation is partly consistent with our 
results which showed that lovastatin, simvastatin, atorvastatin, and fluvastatin (all statins 
with HR or OR >2) had the strongest association with incident diabetes while fluvastatin, 
pravastatin, and rosuvastatin had moderate associations with incident diabetes. 
   
                                                 
579 Ibid.; Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 
adipocytes. FEBS Lett. 2001;507(3):357-61. 
580 Chamberlain LH, "Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 
adipocytes."; Nakata M et al., "Effects of statins on the adipocyte maturation and expression of glucose 
transporter 4 (SLC2A4): implications in glycaemic control." 
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5.9 COMPARISON OF THE RESULTS OF THE COX AND 
LOGISTIC REGRESSION ANALYSES 
This study utilized a retrospective cohort design to investigate the association of 
statin therapy and increased risk of new onset diabetes. To achieve this purpose, two 
kinds of dependent variables were defined as measures for diabetes. The first measure 
was survival time, and it was defined as the time between receipt of the index medication 
and manifestation of diabetes. A group with the shorter survival time may be more likely 
to be at an increased risk of the disease. Because survival time is continuous in nature and 
there were censored data, the Cox proportional hazard regression analysis was 
appropriate to estimate the hazard ratio of diabetes between the active group (i.e., users of 
statins as a class and users of each statin type) and the reference group (i.e., non-statin 
users). Hazard ratios above 1.0 means that the active group has a higher hazard for 
diabetes compared to the reference group. 
Furthermore, incidence of diabetes was used as the second measure for diabetes. 
It is a dichotomous variable (yes/no) that either indicates the presence or absence of new 
onset diabetes among the two groups that are being compared. Because of the 
dichotomous nature of this variable and because other covariates will be controlled for, a 
binary logistic regression analysis was appropriate. Similar to the hazard ratio in Cox 
regression, an odds ratio was calculated to measure the odds of diabetes among the active 
group compared to the odds of diabetes among the reference group. Odds ratios above 1.0 
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also means that the active group has a higher odds of diabetes compared to the reference 
group.  
The premise for conducting two different statistical analyses was for the results of 
one analysis to validate the results of the other (given two different forms of dependent 
variables in each analysis). The results of the two statistical analyses were expected to be 
consistent and comparable in terms of the magnitude and direction of the hazard and odds 
ratios.  
Study results from both the Cox and logistic regression analyses indicated that 
there was consistency in the magnitude and direction of the estimated hazard and odds 
ratios. For example, the hazard and odds ratios (i.e., HR=2.75, OR=2.82) associating 
statin use with incident diabetes were consistent and approximately equal. Similarly, 
compared to no statin use, the hazard and odds ratios for the use of atorvastatin 
(HR=2.43, OR=2.49), fluvastatin (HR=2.06, OR=2.16), lovastatin (HR=3.41, OR=3.57), 
pravastatin (HR=1.89, OR=1.95), rosuvastatin (HR=1.62, OR=1.50), and simvastatin 
(HR=2.57, OR=2.65) were consistent and approximate values of each other. There was 
also consistency of the risk ratios comparing intensive-dose statin users to moderate-dose 
statin users (HR=1.53, OR=1.58).  
The magnitudes of the hazard and odds ratios obtained in this study might have 
been consistent, approximate values of each other because the study design (retrospective 
cohort) was the same even though two different statistical analyses were employed. 
Similar to the results of this study, there was consistency in the magnitudes of the hazard 
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and odds ratio obtained in one study that employed a retrospective cohort design but used 
two different statistical analyses (i.e., Cox and logistic regression) to evaluate the hazard 
and odds of incidence of type 2 diabetes that was associated with the use of 
antidepressants.
581
 The value of the hazard and odds ratios in that study was 1.56 and 
1.49, respectively. In concordance, hazard and odds ratios of 2.75 and 2.82, respectively, 
were associated with statin use and incidence of diabetes in this study.  
Perhaps, differences and/or concordance in the magnitude and direction of the 
hazard and odds ratios are more dictated by the type of study design implemented rather 
than the statistical analysis employed (though the latter is often dictated by the former). 
For example, results of previous observational studies suggest that the magnitudes of the 
risk ratios appear to be higher for case-control studies (mostly analyzed using logistic 
regression) than for prospective or retrospective cohort studies (mostly analyzed using 
Cox regression). The magnitudes of the hazard ratios in cohort studies of statin use and 
incidence of diabetes ranged from 0.77 – 1.61 (atorvastatin), 0.46 – 1.61 (fluvastatin), 
0.70 – 1.36 (lovastatin), 1.01 – 1.63 (pravastatin), 0.54 – 1.42 (rosuvastatin), and 1.10 – 
1.41 (simvastatin). The lower magnitude of these hazard ratios are in contrast to the high 
magnitude of the odds ratios associated with the use of atorvastatin (OR=2.80), 
pravastatin (OR=3.41), rosuvastatin (OR=4.69), and simvastatin (OR=4.09) in the Chen 
et al. case-control study.
582
 Nevertheless, the lower risk ratios obtained in cohort studies 
                                                 
581 Khoza S, "Use of antidepressant agents and the incidence of type 2 diabetes mellitus: A methodological 
comparison."; Khoza S et al., "Use of antidepressant agents and the risk of type 2 diabetes." 
582 Chen CW et al., "Differential impact of statin on new-onset diabetes in different age groups: a 
population-based case-control study in women from an Asian country." 
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were not consistently supported as low odds ratios were also associated with the use of 
pravastatin (OR=0.70) and simvastatin (OR=1.00) in the Jick et al. case-control study.
583
 
It should be noted, however, that odds ratios are more appropriate for estimating 
risk ratios in case-control studies but are considered less appropriate for cohort studies 
where the relative risk may be overestimated especially when the event is frequent.
584
 
This observation was supported in the results of this retrospective cohort study where the 
values of the odds ratios were consistently higher (but of comparable magnitude) than the 
values of the hazard ratios.  
  
 
  
                                                 
583 Jick SS and Bradbury BD, "Statins and newly diagnosed diabetes." 
584 Deeks J. When can odds ratios mislead? : Odds ratios should be used only in case-control studies and 
logistic regression analyses. BMJ : British Medical Journal. 1998;317(7166):1155-55. 
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5.10 STUDY STRENGTHS AND LIMITATIONS 
Before discussing the limitations of the current study, it is worthwhile to 
acknowledge some of its merits. First, the large MarketScan database used for this study 
ensured that the study was adequately powered to detect significant associations between 
statin use and incident diabetes if they truly existed. Second, the study used two different 
statistical approaches to estimate the risks of diabetes associated with statin use. This is 
the first observational study of statin use and incidence of diabetes that utilized this 
approach. Third, accuracy of disease ascertainment was increased by the use of ICD-9-
CM codes instead of proxies such as medication use. Fourth, this study is among the few 
observational studies that used real-world data to evaluate the influence of high statin 
dosage intensity on the risk of new-onset diabetes. The current ATP IV cholesterol 
guidelines advocates for more aggressive management of LDL-C and ASCVD by using 
high dose statins. This new guideline has implications for those using statins for primary 
prevention who may be at higher risk of diabetes than the cardiovascular gains of statin 
therapy. Lastly, the validity of the study results was increased by the ability to control for 
some important risk factors that would have increased the risk of diabetes for one group 
compared to the other, independent of the use of statin. Of note was the possibility to 
control for confounding by indication (i.e., the premise that hyperlipidemia – the 
indication for which statins are used – was responsible for the increase in diabetes risk 
rather than the statin itself).  
399 
 
Despite these study strengths, it is important that the study results be interpreted 
bearing in mind the study limitations. One of the main study limitations was the 
possibility of disease misclassification. Because the data were limited to two years in 
length, only a six-month pre-index period was used to identify and exclude prevalent 
diabetes cases. This has the potential to increase diabetes incidence among the study 
population (this hypothesis was confirmed by a sensitivity analysis found in Appendix G 
where longer pre-index periods resulted in lower diabetes incidence and risk ratios). 
However, this limitation might be attenuated by the fact that both statin users and non-
statin users were equally exposed to the same sets of study inclusion and exclusion 
criteria. In addition, only one diabetes diagnosis served as the proxy for classifying 
subjects as having diabetes mellitus. Using two or more diabetes diagnosis could 
decrease disease misclassification. Future studies should evaluate the association between 
statin therapy and incidence of diabetes using longer data periods and more robust 
definitions of the disease. 
Second, some critical variables were not available in the dataset. These include 
variables such as race/ethnicity, family history of diabetes, physical activity level, 
cholesterol level, body mass index, smoking status, diet, and presence or absence of 
prediabetes. All of these factors could be associated with an increased risk of diabetes 
that is independent of the use of statins. It is possible that higher risk of diabetes 
(compared to what is reported in the literature) that was associated with statin use as 
found in this study might be due to not accounting for these variables. In addition, the 
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prevalence of obesity diagnosis recorded among the study population was low compared 
to the prevalence of obesity among adult US population. Even though this variable was 
accounted for in the analyses, it is possible that the variable may not have been 
adequately accounted for as obesity might be more prevalent among statin users 
compared to non-statin users. Future observational studies should control for these 
important variables that could be responsible for the increased risk of diabetes, 
irrespective of statin therapy.  
Third, even though the data integrity of the MarketScan data is very high, it is 
nevertheless not immune from limitations surrounding claims databases. There is the 
possibility of missing data, errors in data coding (i.e., over/under-coding of ICD-9-CM 
codes), and exclusion of subjects due to eligibility changes for insurance programs. For 
example, the data used for this study did not include people who were 65 years and older. 
Bias could be introduced because older people may have more comorbidities and risk 
factors for diabetes. 
Finally, the MarketScan Database that was used for this study used data collected 
in 2003 – 2004. Due to changes in statin prescribing and utilization pattern, there is a 
possibility that study results might be different if current data were applied. In addition, 
the MarketScan Commercial Claims and Encounters Database used for this study is a 
convenience sample that may not generalized well to other US populations. This is 
because the data were sourced mainly from large employers which have private 
insurance. Small and medium-sized firms were underrepresented in the dataset. Thus, this 
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study’s population may be different from other groups such as the Medicaid 
(predominantly females and low socio-economic status), Medicare (predominantly older 
with more disease comorbidities) and uninsured populations.  
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5.11 STUDY IMPLICATIONS 
The main objective of this study was to assess whether statin therapy was 
associated with an increase in risk of new onset diabetes. This study confirmed the 
hypothesis that statin therapy is associated with an increase in risk of incident diabetes 
and helped fill some gaps in the literature because there are few observational studies 
examining this phenomenon using US-based data. The results of the study revealed the 
following about statin use: 
1)  The hazard and odds of incident diabetes increased significantly by almost three-
fold in patients receiving statins compared to patients not receiving statin therapy. 
2) Compared to patients receiving no statin therapies, the hazard and odds of 
incident diabetes increased significantly by about two-fold in patients receiving all types 
of statins, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and 
simvastatin. The risk of diabetes was highest among lovastatin users and lowest among 
rosuvastatin users. 
3)  The hazard and odds of incident diabetes increased significantly by about one and 
one-half-fold in patients receiving intensive-dose statins compared to those receiving 
moderate-dose statins. 
Although statins are generally safe and well tolerated, this study and several other 
studies have suggested that statins are associated with a moderate increase in risk of new-
onset diabetes. These previous observations prompted the FDA to revise statin labels to 
now include a warning of an increased risk of incident diabetes mellitus as a result of 
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increases in glycosylated hemoglobin (A1C) and fasting plasma glucose (FPG).
585
 Even 
though the precise pathway by which statins induce incident diabetes is still unclear, 
statins are thought to worsen glycemic control and increase fasting plasma glucose and 
insulin resistance, thereby possibly leading to diabetes mellitus.
586
  
Because cardiovascular disease is a major cause of mortality and morbidity in 
America and around the world, several researchers have debated whether the larger 
cardiovascular benefits gained from using statins (including the use of intensive doses) 
far outweigh the potential increase in risk of new onset diabetes that is associated with 
statin therapy. Several landmark statin trials and meta-analyses of statin RCTs have 
demonstrated the beneficial effects of statins in primary and secondary prevention of 
cardiovascular disease. The meta-analysis study by Sattar et al. indicated that statin 
therapy was associated with 5.4 fewer deaths from CHD and non-fatal MI per 255 
patients treated over 4 years. This is in contrast to only one additional case of new onset 
diabetes recorded per 255 patients treated with statins.
587
 Preiss et al. conducted a meta-
analysis of five statin RCTs comprising 32,752 patients who were prescribed intensive-
dose and moderate-dose statins.
588
 The study found that while only two additional cases 
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404 
 
of incident diabetes were recorded, intensive-dose statin therapy was associated with 6.5 
fewer cardiovascular events. This translates into a lesser number needed to treat of 155 
for cardiovascular events compared to a larger number needed to harm of 498 for new-
onset diabetes. Thus, these studies argue that there is little controversy regarding the 
beneficial effects of statins in secondary prevention of cardiovascular diseases. 
However, there has been controversy as to whether the absolute benefits of statins 
in primary prevention far outweigh the risk of development of diabetes, especially among 
low-risk patients without a history of cardiovascular disease.
589
 This controversy was 
heightened by the December 2013 release of the American College of 
Cardiology/American Heart Association Guideline on the Treatment of Blood 
Cholesterol (colloquially, ATP IV guidelines).
590
 Among others, this new guideline 
recommends statin therapy (including the use of intensive doses) for individuals without 
clinical ASCVD or diabetes who are 40 to 75 years of age with LDL-C of 70 – 189 
mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher.  
Compared to the ATP III guidelines, some physicians believe that the new ATP 
IV guidelines will expand statin use to millions of patients. This is because the LDL-C 
(for example, LDL-C of 70 – 100mg/dL were often considered ‘normal levels’) and the 
ASCVD risk thresholds were considered too low and several millions of people (who 
may be truly at low risk of cardiovascular diseases and might not need statins) were 
                                                 
589 Navarese E et al., "Statins and risk of new-onset diabetes mellitus: Is there a rationale for individualized 
statin therapy?." 
590 Stone NJ et al., "2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce 
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Heart Association Task Force on Practice Guidelines." 
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easily categorized as high risk on the basis of their age, race, and smoking status – 
demographic and clinical factors that disproportionately increase the estimated 10-year 
ASCVD risk even in people with the so-called ‘normal’ LDL-C levels. 
Thus, if there is a possibility that several million people are needlessly being 
treated with statins for primary prevention; then, there is an equal chance that several 
million people may also be potentially at risk for new-onset diabetes by the reason of 
their statin therapy. A Cochrane review of the benefit and risk associated with statin use 
in primary prevention noted that even though statin therapy significantly reduced all-
cause cardiovascular mortality, the absolute benefits were very small – 1,000 people will 
have to be treated for one year to prevent one cardiovascular death.
591
 Thus, the merits of 
statin therapy may be minimal among people with low cardiovascular risk as a higher 
‘number needed to treat’ may be needed to gain marginal benefits. Furthermore, one 
author believed that the exact point at which cardiovascular benefits begins to outweigh 
the risk of diabetes among primary prevention patients may still be unclear.
592
 
Therefore, in conjunction with the new ATP IV guidelines, it might be important 
for physicians to individualize statin therapy, especially among people with low 
cardiovascular risk. This tailored therapy should be based on sound clinical judgment, the 
patient’s overall cardiovascular risk and metabolic profile, and the type and dose of statin 
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used.
593
 Within the tailored therapy framework, the specific type and dose of statin used 
may be crucial. This is because different types and doses of statin vary in their ability to 
reduce LDL-C as well as in their diabetogenic potentials. Identifying patients who would 
benefit more from less diabetogenic statin types could help optimize the treatment by 
providing the highest benefit achievable while reducing the number of patients 
developing diabetes under statin therapy. 
Despite its lower cost and potential to reduce LDL-C, and its being marginalized 
by newer, higher potency, and more advertised statins, one author suggests that 
pravastatin seems to be the least diabetogenic statin currently available on the market and 
it could be the ideal statin for patients with hyperlipidemia who have a low risk of 
cardiovascular disease but who have a high predisposition for diabetes.
594
 The results of 
this study also support this argument as the risk of diabetes was lowest among pravastatin 
and rosuvastatin users.  
Despite the association of statin use with incident diabetes, it is important to 
remember that statin therapy alone cannot possibly account for all the new cases of 
diabetes diagnosed during anti-hyperlipidemic therapy. The hazard and odds of 
development of new-onset diabetes may also be significantly accounted for by baseline 
diabetes risk factors that include increasing age, and clinical comorbidities such as 
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obesity, hyperlipidemia, and hypertension.
595
 More long-term prospective RCTs and cost-
effectiveness research may be needed to examine the benefit/risk ratios of statins, 
especially in the area of primary prevention. 
  
                                                 
595 Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes 
during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61(2):148-
52. 
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5.12 CONCLUSION  
In conclusion, the results of the study lend support to the hypothesis that statin 
therapy is significantly associated with increase in the risk of new-onset diabetes. This 
increased risk was found not only in the use of statins as a class, but each statin type was 
also significantly associated with an increase in risk of incident diabetes mellitus. 
Furthermore, risk of diabetes was significantly increased in those that used intensive 
statin doses. 
The recently released ATP IV cholesterol guideline advocates for the aggressive 
control of LDL-C in people with clinical evidence of ASCVD as well as in individuals 
without clinical evidence of ASCVD or diabetes who may be at increased risk of 
coronary heart disease by virtue of their age, cholesterol levels and estimated 10-year 
ASCVD risk. Even though a preponderance of the literature argues that the benefits of 
using statins in secondary prevention outweighs the potential for increase in risk of 
diabetes, there may be less confidence about the benefits of using statins among those 
with ‘normal’ LDL-C levels who do not have evidence of clinical ASCVD or diabetes 
and who may thus be more exposed to diabetes risks than the cardiovascular benefits 
gained. 
Nevertheless, health care professionals can use targeted approach to optimize the 
management of their patient’s hyperlipidemia. They can do this by using better clinical 
judgments to identify patients who would benefit more from less diabetogenic statin 
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types, thus providing the highest benefit achievable while reducing the number of 
patients developing diabetes under statin therapy. 
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APPENDIX A 
Results of Normality Testing 
Tables A.1 and A.2 shows the summary statistics for the continuous dependent 
variables age, CCI score, MPR, diabetogenic medications (i.e., number of prescriptions 
for all diabetogenic medications and number of prescriptions for each diabetogenic 
medication), while Figures A.1 – A.10 shows the corresponding histograms (with 
normality curves) for these variables, respectively. 
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Table A.1: Summary Statistics for Age, Comorbidity Index Score, MPR, and Diabetogenic Medications 
 Age  CCI score  MPR   Diabetogenic 
Medicationsa 
N   Valid 
      Missing 
Mean (SD) 
Median 
Skewness (SE) 
Kurtosis (SE) 
Minimum 
Maximum 
116,224 
0 
46.42 (11.61) 
49 
-0.64 (0.007) 
-0.49 (0.014) 
20 
63 
116,224 
0 
0.15 (0.73) 
0 
8.15 (0.007) 
80.35 (0.014) 
0 
15 
50,557 
7,555 
75.0 (25.3) 
83.3 
-0.89 (0.011) 
-0.29 (0.022) 
0.2 
100 
116,224 
0 
3.24 (7.12) 
0 
3.16 (0.007) 
14.07 (0.014) 
0 
107 
Abbreviation: MPR, medication possession ratio; SD, standard deviation; SE, standard error. 
aNumber of prescriptions for all diabetogenic medications. 
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Table A.2: Summary Statistics of Number of Prescriptions for Each Diabetogenic Medication 
 Thiazides Beta- 
blockers 
Anti- 
psychotics 
Anti-
depressants 
Immuno-
suppressants 
Gluco- 
corticoids  
N   Valid 
      Missing 
Mean (SD) 
Median 
Skewness (SE) 
Kurtosis (SE) 
Minimum 
Maximum 
116,224 
0 
0.42 (2.15) 
0 
6.17 (0.007) 
41.99 (0.014) 
0 
37 
116,224 
0 
1.23 (3.78) 
0 
3.38 (0.007) 
11.48 (0.014) 
0 
38 
116,224 
0 
0.07 (0.99) 
0 
19.73 (0.007) 
510.25 (0.014) 
0 
50 
116,224 
0 
1.49 (4.50) 
0 
4.13 (0.007) 
22.74 (0.014) 
0 
94 
116,224 
0 
0.03 (0.80) 
0 
38.22 (0.007) 
1,796.15 (0.014) 
0 
64 
116,224 
0 
0.003 (0.09) 
0 
64.76 (0.007) 
5,429.19 (0.014) 
0 
9.93 
414 
 
Figure A.1: Histogram (with normality plot) for age 
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Figure A.2: Histogram (with normality plot) for Charlson comorbidity index 
score 
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Figure A.3: Histogram (with normality plot) for medication possession ratio 
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Figure A.4: Histogram (with normality plot) for ‘number of prescriptions for 
all diabetogenic medications’ 
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Figure A.5: Histogram (with normality plot) for number of prescriptions for 
thiazide diuretics 
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Figure A.6: Histogram (with normality plot) for number of prescriptions for 
beta-blockers 
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Figure A.7: Histogram (with normality plot) for number of prescriptions for 
antipsychotics 
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Figure A.8: Histogram (with normality plot) for number of prescriptions for 
antidepressants 
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Figure A.9: Histogram (with normality plot) for number of prescriptions for 
immunosuppressants 
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Figure A.10: Histogram (with normality plot) for number of prescriptions  for 
glucocorticoids 
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APPENDIX B 
SPSS Syntax for Cox Regression Model with Multiple Time-dependent Covariates 
The following SPSS syntax shows how a Cox regression model with multiple 
time-dependent covariates can be run in SPSS. For the syntax below, gender, 
hyperlipidemia, hypertension, and diabetogenic variables were retained as significant 
time-dependent covariates (T_COV) that were controlled for in the model. Time-
dependent covariates were formed by the product of the variable and the natural log (LN) 
of survival time (T_). 
TIME PROGRAM. 
COMPUTE T_COV_GENDER = LN(T_) * GENDER. 
COMPUTE T_COV_HYPERLIPIDEMIA = LN(T_) * HYPERLIPIDEMIA. 
COMPUTE T_COV_HYPERTENSION = LN(T_) * HYPERTENSION. 
COMPUTE T_COV_DIABETOGENIC = LN(T_) * DIABETOGENIC. 
COXREG   SURVIVAL_MONTHS 
  /STATUS=DIABETES(1) 
/METHOD=ENTER EXPOSURE AGE GENDER HYPERLIPIDEMIA OBESITY 
HYPERTENSION DIABETOGENIC CCI T_COV_GENDER 
T_COV_HYPERLIPIDEMIA T_COV_HYPERTENSION 
T_COV_DIABETOGENIC 
  /PRINT=CI(99) 
  /CRITERIA=PIN(.05) POUT(.10) ITERATE(20). 
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APPENDIX C 
Cox Regression Models while Controlling for Time-dependent Covariates 
Tables C.1 – C.7 shows a summary of the sensitivity analyses of the hazard ratios 
(Cox regression) of the association between statin use and incidence of diabetes when 
time-dependent covariates were controlled for in the models. The magnitudes of the 
hazard ratios for the predictor variables of interest (i.e., statin users and each statin type) 
increased by an average of 0.04 points from the hazard ratios in models that did not 
control for time-dependent covariates.
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Table C.1: Cox Regression Model Comparing Incident Diabetes between Statin Users and Non-statin Users while 
Controlling for Covariates, including Time-dependent Covariates (N=116,224) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Statina 1.034 0.032 1053.572 p<0.0001 2.812 2.590 3.052 
Age 0.032 0.001 530.516 p<0.0001 1.033 1.029 1.036 
Gender: Maleb -0.014 0.038 0.130 0.719 0.986 0.894 1.088 
Hyperlipidemia -0.631 0.045 197.181 p<0.0001 0.532 0.474 0.597 
Obesity 0.587 0.101 33.492 p<0.0001 1.798 1.385 2.334 
Hypertension 0.436 0.043 101.132 p<0.0001 1.546 1.383 1.729 
Diabetogenic medications -0.221 0.008 679.054 p<0.0001 0.802 0.785 0.820 
CCI score 0.134 0.009 213.121 p<0.0001 1.144 1.117 1.171 
T_COV_Gender -0.036 0.020 3.374 0.066 0.964 0.917 1.015 
T_COV_Hyperlipidemia 0.127 0.023 31.733 p<0.0001 1.135 1.071 1.203 
T_COV_Hypertension -0.051 0.022 5.420 0.020 0.950 0.898 1.005 
T_COV_Diabetogenic medications 0.085 0.004 555.755 p<0.0001 1.089 1.079 1.099 
Model Parameters: χ2=4,400.8; df=12, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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Table C.2: Cox Regression Model Comparing Incident Diabetes between Atorvastatin Users and Non-statin 
Users while Controlling for Covariates, including Time-dependent Covariates (N=87,586) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Atorvastatina 0.906 0.038 574.037 p<0.0001 2.474 2.244 2.727 
Age 0.033 0.002 407.219 p<0.0001 1.034 1.030 1.038 
Gender: Maleb 0.053 0.049 1.147 0.284 1.054 0.929 1.196 
Hyperlipidemia -0.550 0.061 80.820 p<0.0001 0.577 0.493 0.676 
Obesity 0.382 0.157 5.901 0.015 1.465 0.977 2.196 
Hypertension 0.423 0.037 130.978 p<0.0001 1.526 1.388 1.679 
Diabetogenic medications -0.200 0.011 310.358 p<0.0001 0.819 0.795 0.843 
CCI score 0.156 0.012 164.067 p<0.0001 1.168 1.132 1.205 
T_COV_Gender -0.077 0.025 9.288 0.002 0.926 0.868 0.988 
T_COV_Hyperlipidemia 0.098 0.030 10.726 0.001 1.103 1.021 1.191 
T_COV_Diabetogenic medications 0.076 0.005 253.610 p<0.0001 1.079 1.066 1.092 
Model Parameters: χ2=2,848.3; df=11, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]..
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Table C.3: Cox Regression Model Comparing Incident Diabetes between Fluvastatin Users and Non-statin Users 
while Controlling for Covariates, including Time-dependent Covariates (N=59,911) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Fluvastatina 0.729 0.088 68.786 p<0.0001 2.072 1.653 2.599 
Age 0.048 0.004 181.267 p<0.0001 1.049 1.040 1.059 
Gender: Maleb -0.049 0.044 1.228 0.268 0.953 0.851 1.066 
Hyperlipidemia -0.040 0.073 0.306 0.580 0.960 0.796 1.159 
Obesity 0.204 0.334 0.372 0.542 1.226 0.518 2.901 
Hypertension 0.674 0.072 88.675 p<0.0001 1.961 1.631 2.358 
Diabetogenic medications -0.276 0.032 73.634 p<0.0001 0.759 0.698 0.824 
CCI score 0.174 0.027 41.524 p<0.0001 1.190 1.110 1.275 
T_COV_Age -0.007 0.002 16.703 p<0.0001 0.993 0.988 0.997 
T_COV_Diabetogenic medications 0.115 0.013 75.964 p<0.0001 1.122 1.085 1.161 
Model Parameters: χ2=935.3; df=10, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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Table C.4: Cox Regression Model Comparing Incident Diabetes between Lovastatin Users and Non-statin Users 
while Controlling for Covariates, including Time-dependent Covariates (N=62,166) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Lovastatina 1.253 0.057 488.482 p<0.0001 3.501 3.025 4.051 
Age 0.037 0.002 347.728 p<0.0001 1.038 1.033 1.043 
Gender: Maleb 0.072 0.068 1.141 0.285 1.075 0.903 1.280 
Hyperlipidemia -0.183 0.064 8.161 0.004 0.832 0.706 0.982 
Obesity 0.484 0.185 6.810 0.009 1.622 1.006 2.614 
Hypertension 0.624 0.062 100.579 p<0.0001 1.866 1.590 2.191 
Diabetogenic medications -0.356 0.029 146.911 p<0.0001 0.700 0.649 0.755 
CCI score 0.159 0.024 44.075 p<0.0001 1.172 1.102 1.247 
T_COV_Gender -0.084 0.035 5.802 0.016 0.920 0.841 1.006 
T_COV_Diabetogenic medications 0.138 0.012 134.904 p<0.0001 1.148 1.113 1.184 
Model Parameters: χ2=2,025.0; df=10, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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Table C.5: Cox Regression Model Comparing Incident Diabetes between Pravastatin Users and Non-statin Users 
while Controlling for Covariates, including Time-dependent Covariates (N=64,495) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Pravastatina 0.644 0.060 116.424 p<0.0001 1.905 1.633 2.222 
Age 0.038 0.002 352.448 p<0.0001 1.038 1.033 1.044 
Gender: Maleb 0.063 0.068 0.863 0.353 1.065 0.894 1.268 
Hyperlipidemia -0.291 0.104 7.871 0.005 0.748 0.573 0.976 
Obesity 0.187 0.290 0.416 0.519 1.205 0.572 2.541 
Hypertension 0.641 0.059 116.940 p<0.0001 1.898 1.629 2.211 
Diabetogenic medications -0.187 0.020 89.068 p<0.0001 0.829 0.788 0.873 
CCI score 0.173 0.020 76.227 p<0.0001 1.188 1.129 1.250 
T_COV_Gender -0.081 0.035 5.487 0.019 0.922 0.844 1.008 
T_COV_Hyperlipidemia 0.091 0.050 3.359 0.067 1.096 0.964 1.246 
T_COV_Diabetogenic medications 0.071 0.008 69.818 p<0.0001 1.074 1.050 1.097 
Model Parameters: χ2=1,414.8; df=11, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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Table C.6: Cox Regression Model Comparing Incident Diabetes between Rosuvastatin Users and Non-statin 
Users while Controlling for Covariates, including Time-dependent Covariates (N=61,099) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Rosuvastatina 0.510 0.082 38.601 p<0.0001 1.665 1.348 2.057 
Age 0.036 0.002 303.968 p<0.0001 1.037 1.031 1.042 
Gender: Maleb 0.065 0.072 0.802 0.371 1.067 0.886 1.285 
Hyperlipidemia -0.007 0.070 0.009 0.923 0.993 0.829 1.190 
Obesity 0.574 0.278 4.246 0.039 1.775 0.866 3.637 
Hypertension 0.742 0.068 119.768 p<0.0001 2.100 1.764 2.501 
Diabetogenic medications -0.270 0.030 80.947 p<0.0001 0.763 0.706 0.824 
CCI score 0.194 0.024 66.619 p<0.0001 1.214 1.142 1.291 
T_COV_Gender -0.084 0.037 5.221 0.022 0.919 0.836 1.011 
T_COV_Diabetogenic medications 0.115 0.013 84.371 p<0.0001 1.122 1.086 1.159 
Model Parameters: χ2=1,014.4; df=10, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
432 
 
Table C.7: Cox Regression Model Comparing Incident Diabetes between Simvastatin Users and Non-statin Users 
while Controlling for Covariates, including Time-dependent Covariates (N=71,527) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Simvastatina 0.964 0.045 453.534 p<0.0001 2.622 2.334 2.946 
Age 0.037 0.002 396.265 p<0.0001 1.037 1.032 1.042 
Gender: Maleb -0.014 0.035 0.159 0.690 0.986 0.901 1.079 
Hyperlipidemia -0.394 0.077 25.919 p<0.0001 0.675 0.553 0.823 
Obesity 0.659 0.187 12.442 p<0.0001 1.933 1.195 3.128 
Hypertension 0.490 0.047 109.166 p<0.0001 1.632 1.446 1.841 
Diabetogenic medications -0.218 0.015 200.538 p<0.0001 0.804 0.773 0.836 
CCI score 0.130 0.015 73.001 p<0.0001 1.139 1.095 1.184 
T_COV_Hyperlipidemia 0.058 0.038 2.364 0.124 1.060 0.962 1.168 
T_COV_Diabetogenic medications 0.083 0.007 161.663 p<0.0001 1.086 1.068 1.105 
Model Parameters: χ2=2,419.9; df=10, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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Table C.8: Cox Regression Model Comparing Incident Diabetes between Intensive-dose Statin Users and 
Moderate-dose Statin Users while Controlling for Covariates, including Time-dependent Covariates (N=71,527) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence 
Interval 
Lower Upper 
Dosage intensity: Intensive-
dosea 
0.432 0.039 121.963 p<0.0001 1.540 1.393 1.704 
Age 0.020 0.003 41.800 p<0.0001 1.021 1.012 1.029 
Gender: Maleb -0.088 0.046 3.593 0.058 0.916 0.812 1.032 
Hyperlipidemia -0.825 0.051 264.720 p<0.0001 0.438 0.385 0.499 
Obesity 0.603 0.113 28.557 p<0.0001 1.828 1.367 2.445 
Hypertension 0.271 0.049 30.084 p<0.0001 1.311 1.154 1.489 
Diabetogenic medications -0.233 0.009 630.494 p<0.0001 0.792 0.773 0.811 
CCI score 0.122 0.010 137.855 p<0.0001 1.130 1.100 1.161 
Adherence (MPR)c 0.020 0.056 0.126 0.723 1.020 0.883 1.178 
T_COV_Age 0.004 0.002 4.910 0.027 1.004 0.999 1.008 
T_COV_Gender -0.014 0.024 0.350 0.554 0.986 0.926 1.049 
T_COV_Hyperlipidemia 0.206 0.026 61.225 p<0.0001 1.228 1.148 1.315 
T_COV_Hypertension 0.017 0.026 0.465 0.495 1.018 0.953 1.087 
T_COV_Diabetogenic medications 0.090 0.004 509.669 p<0.0001 1.094 1.083 1.105 
Model Parameters: χ2=1,564.6; df=14, p<0.0001 [Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Female. 
cAdherence evaluated using the medication possession ratio, MPR. 
T_COV_: Time-dependent covariate [obtained by multiplying the natural log of survival time and the corresponding variable]. 
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APPENDIX D 
Diabetes Incidence Density Rate and Cumulative Incidence 
Table D.1 shows the weighted and unweighted incidence density rates and 
cumulative incidence of diabetes by statin use. From Table D.1, the unweighted 
incidence density rate for statin users (6.82 per 1,000 person-months) was higher 
compared to that for non-statin users (2.2 per 1,000 person-months). This means that if 
1,000 statin users were followed for one month, 6.82 new cases of diabetes will be 
recorded compared to 2.2 new cases of diabetes that will be recorded if 1,000 non-statin 
users were followed for one month. 
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Table D.1: Weighteda and Unweighted Incidence Density Rate and Cumulative Incidence of Diabetes by Statin 
Use (pre-index period for excluding prevalent diabetes=6 months) 
 Number of subjects 
[𝒂] 
Sum of follow-up 
months 
(person-months) 
[𝒃] 
Number of new 
cases of diabetes 
[𝒄] 
Incidence density 
rates per 1,000 
person-months 
[𝒄 𝒃⁄ × 𝟏𝟎𝟎𝟎] 
Cumulative 
incidence (in 
percent) 
[𝒄 𝒂⁄ × 𝟏𝟎𝟎%] 
Statin users 58,112 832,018.86 5,678 6.82 9.8 
2,682,918 38,396,263.29 268,287 6.99 10.0 
Non-statin users 58,112 870,604.42 1,915 2.20 3.3 
2,296,349 34,429,716.96 80,006 2.32 3.5 
Study population 116,224 1,702,623.28 7,593 4.45 6.5 
4,979,267 72,825,980.25 348,293 4.78 6.9 
Atorvastatin users 29,474 424,669.37 2,690 6.33 9.1 
1,352,831 19,485,749.98 126,544 6.49 9.4 
Fluvastatin users 1,799 25,991.59 192 7.39 10.7 
84,328 1,217,091.22 9,205 7.56 10.9 
Lovastatin users 4,054 56,420.67 564 9.99 13.9 
203,368 2,826,918.77 29,049 10.28 14.3 
aWeighted values are in shaded rows. 
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Table D.1: Weighteda and Unweighted Incidence Density Rate and Cumulative Incidence of Diabetes by Statin 
Use (cont’d) 
 Number of subjects 
[𝒂] 
Sum of follow-up 
months 
(person-months) 
[𝒃] 
Number of new 
cases of diabetes 
[𝒄] 
Incidence density 
rates per 1,000 
person-months 
[𝒄 𝒃⁄ × 𝟏𝟎𝟎𝟎] 
Cumulative 
incidence (in 
percent) 
[𝒄 𝒂⁄ × 𝟏𝟎𝟎%] 
Pravastatin users 6,383 93,339.04 587 6.29 9.2 
300,164 4,384,533.75 28,361 6.47 9.5 
Rosuvastatin users 2,987 38,808.51 242 6.24 8.1 
134,386 1,744,581.78 11,266 6.46 8.4 
Simvastatin users 13,415 192,789.68 1,403 7.42 10.5 
607,841 8,737,387.80 63,862 7.31 10.5 
Intensive-dose  
statin users 
6,205 87,639.06 831 9.48 13.4 
267,855 3,777,161.36 36,962 9.79 13.8 
Moderate-dose  
statin users 
51,907 744,379.79 4847 6.51 9.3 
2,415,063 34,619,101.93 231,325 6.68 9.6 
aWeighted values are in shaded rows. MarketScan person-level national weights were constructed utilizing weight estimates from 
the Household Component of the Medical Expenditure Panel Survey (MEPS). MEPS’s weights accounts for demographic variables 
that includes region (Northest, North Central, South, West); age (0 – 17, 18 – 44, 45 – 64); and sex (male, female). The MarketScan 
weight is the ratio of MEPS-based estimates in the different age/sex/region categories and the MarketScan number in the same 
category. 
437 
 
APPENDIX E 
Unadjusted Cox Regression and Logistic Regression Models 
Tables E.1 and E.2 shows a summary of the sensitivity analyses of the hazard 
ratios (Cox regression) and odds ratios (logistic regression) of the association between 
statin use and incident diabetes without controlling for any covariate. The covariates not 
controlled for include age, gender, hyperlipidemia, hypertension, diabetogenic 
medications, CCI score, and medication possession ratio (MPR). In general, the values of 
the hazard and odds ratios associated with statin use increased significantly when none of 
the covariate was controlled for in the model. Risk ratios comparing intensive-dose users 
to moderate-dose users decreased. 
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Table E.1: A Summary Showing the Statistical Significance of the Unadjusted Hazard Ratios of the Association 
between Statin Use and Incident Diabetes (Cox Regression) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina 1.128 0.026 1821.244 p<0.0001 3.089 2.886 3.307 
Atorvastatina 1.055 0.030 1244.233 p<0.0001 2.871 2.658 3.101 
Fluvastatina 1.210 0.076 255.585 p<0.0001 3.354 2.760 4.076 
Lovastatina 1.509 0.048 991.338 p<0.0001 4.521 3.996 5.115 
Pravastatina 1.050 0.047 495.666 p<0.0001 2.859 2.532 3.228 
Rosuvastatina 1.021 0.068 222.425 p<0.0001 2.777 2.328 3.313 
Simvastatina 1.194 0.035 1153.586 p<0.0001 3.299 3.014 3.612 
Intensive-dose statinb 0.376 0.038 100.201 p<0.0001 1.456 1.322 1.604 
Significance of each parameter estimate was evaluated at p<0.01. No covariate was controlled for in any of the model. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
 
  
439 
 
Table E.2: A Summary Showing the Statistical Significance of the Unadjusted Odds Ratios of the Association 
between Statin Use and Incident Diabetes (Logistic Regression) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina 1.156 0.027 1818.301 p<0.0001 3.178 2.963 3.408 
Atorvastatina 1.081 0.031 1231 p<0.0001 2.947 2.722 3.191 
Fluvastatina 1.255 0.080 247.043 p<0.0001 3.506 2.855 4.306 
Lovastatina 1.557 0.051 932.010 p<0.0001 4.742 4.159 5.408 
Pravastatina 1.089 0.049 491.064 p<0.0001 2.972 2.619 3.373 
Rosuvastatina 0.951 0.071 179.398 p<0.0001 2.587 2.155 3.106 
Simvastatina 1.232 0.037 1135.827 p<0.0001 3.428 3.120 3.766 
Intensive-dose statinb 0.406 0.040 102.122 p<0.0001 1.501 1.354 1.665 
Significance of each parameter estimate was evaluated at p<0.01. No covariate was controlled for in any of the model. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
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APPENDIX F 
Cox Regression and Logistic Regression Models without Controlling for Obesity 
Tables F.1 and F.2 shows a summary of the sensitivity analysis of the hazard and 
the odds ratios when the obesity variable was not controlled for in the Cox regression and 
logistic regression models of the association between statin use and incidence of diabetes. 
The obesity variable was left out because of the underreporting of obesity diagnosis 
(0.6%) among the study population. Removing the obesity variable from the model did 
not change the significance of the p-values. However, the magnitudes of the risk ratios 
increased only marginally.
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Table F.1: A Summary Showing the Statistical Significance of the Hazard Ratios of the Association between 
Statin Use and Incident Diabetes (Cox regression without controlling for obesity) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.017 0.032 1020.014 p<0.0001 2.765 2.548 3.002 
Atorvastatina,c 0.888 0.038 551.155 p<0.0001 2.430 2.204 2.678 
Fluvastatina,c 0.726 0.088 68.723 p<0.0001 2.067 1.649 2.589 
Lovastatina,c 1.240 0.056 481.736 p<0.0001 3.455 2.988 3.997 
Pravastatina,c 0.637 0.060 114.121 p<0.0001 1.890 1.621 2.203 
Rosuvastatina,c 0.483 0.082 34.509 p<0.0001 1.621 1.311 2.003 
Simvastatina,c 0.945 0.045 436.293 p<0.0001 2.574 2.291 2.892 
Intensive-dose statinb,d 0.423 0.039 116.595 p<0.0001 1.526 1.379 1.688 
[Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin users. 
cCovariates controlled for include age, gender, hyperlipidemia, hypertension, diabetogenic medications, and CCI score . 
dCovariates controlled for include age, gender, hyperlipidemia, hypertension, diabetogenic medications, CCI score, and medication 
possession ratio (MPR). 
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Table F.2: A Summary Showing the Statistical Significance of the Odds Ratios of the Association between Statin 
Use and Incident Diabetes (Logistic regression without controlling for obesity) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.043 0.033 1004.646 p<0.0001 2.838 2.607 3.089 
Atorvastatina,c 0.912 0.039 542.014 p<0.0001 2.490 2.251 2.755 
Fluvastatina,c 0.772 0.092 69.818 p<0.0001 2.164 1.706 2.745 
Lovastatina,c 1.284 0.060 455.711 p<0.0001 3.610 3.092 4.215 
Pravastatina,c 0.669 0.062 116.047 p<0.0001 1.953 1.664 2.292 
Rosuvastatina,c 0.406 0.086 22.401 p<0.0001 1.500 1.203 1.871 
Simvastatina,c 0.978 0.047 428.901 p<0.0001 2.658 2.354 3.002 
Intensive-dose statinb,d 0.456 0.043 114.588 p<0.0001 1.578 1.414 1.761 
[Significance of each parameter estimate was evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin users. 
cCovariates controlled for include age, gender, hyperlipidemia, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, hypertension, diabetogenic medications, CCI score, and medication 
possession ratio (MPR). 
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APPENDIX G 
Pre-index Period Sensitivity Analysis 
The purpose of this analysis was to investigate how changes to the length of the 
pre-index period affected the risk ratios associating statin use with incidence of diabetes. 
The length of the pre-index period that was used to identify and exclude prevalent 
diabetes cases in the original study design was 6 months. Sensitivity analyses were 
conducted by increasing the lengths of the pre-index period from 6 months to 1 year and 
then to 1.5 years. Diabetes incidence rates and risk ratios (i.e., hazard ratios and odds 
ratios) associating statin use with incidence of diabetes were then recalculated. The 
following results in Tables G.1 – G.12 were obtained.  
Results and Discussion 
1. Incidence of Diabetes  
 1,777 incident diabetes cases were reclassified as prevalent diabetes cases and 
removed from the study cohort when the pre-index period for identifying 
prevalent diabetes cases was increased from 6 months (Table G.1) to one year 
(Table G.2). 
 5,017 incident diabetes cases were reclassified as prevalent diabetes cases and 
removed from the study cohort when the pre-index period for identifying 
prevalent diabetes cases was increased from 6 months (Table G.1) to 1.5 years 
(Table G.3). 
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 The unadjusted cumulative incidence of diabetes and the unadjusted diabetes 
incidence density rates for the study population as well as for statin users and non-
statin users decreased ‘significantly’ when the pre-index period was increased 
from 6 months (Table G.4) to 1 year (Table G.5) and then to 1.5 years (Table 
G.6). 
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Table G.1: Frequency and Percent of Statin Users and Non-statin Users by 
Incidence of Diabetes (6 months of pre-index period =Jan 1, 2003 – Jun 30, 
2003) 
Diabetes Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
5,678 (9.8) 
52,434 (90.2) 
1,915 (3.3) 
56,197 (96.7) 
7,593 (6.5) 
108,631 (93.5) 
Total 58,112 (100.0) 58,112 (100.0) 116,224 (100.0) 
χ2 = 1,995.2; df=1; p<0.0001 
 
Table G.2: Frequency and Percent of Statin Users and Non-statin Users by 
Incident Diabetes (1 year of pre-index period =Jan 1, 2003 – Dec 31, 2003) 
Diabetes Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
4,315 (7.6) 
52,434 (92.4) 
1,501 (2.6) 
56,197 (97.4) 
5,816 (5.1) 
108,631 (94.9) 
Total 56,749 (100.0) 57,698 (100.0) 114,447 (100.0) 
χ2 = 1,484.1; df=1; p<0.0001 
 
Table G.3: Frequency and Percent of Statin Users and Non-statin Users by 
Incident Diabetes (1.5 years of pre-index period =Jan 1, 2003 – Jun 30, 2004) 
Diabetes Statin Users 
N (%) 
Non-statin Users 
N (%) 
Study Population 
N (%) 
Yes 
No 
1,878 (3.5) 
52,434 (96.5) 
698 (1.2) 
56,197 (98.8) 
2,576 (2.3) 
108,631 (97.7) 
Total 54,312 (100.0) 56,895 (100.0) 111,207 (100.0) 
χ2 = 611.2; df=1; p<0.0001 
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Table G.4: Weighteda and Unweighted Incidence Density Rate and Cumulative Incidence of Diabetes by Statin 
Use (pre-index period for excluding prevalent diabetes=6 months) 
 Number of subjects 
[𝒂] 
Sum of follow-up 
months 
(person-months) 
[𝒃] 
Number of new 
cases of diabetes 
[𝒄] 
Incidence density 
rates per 1,000 
person-months 
[𝒄 𝒃⁄ × 𝟏𝟎𝟎𝟎] 
Cumulative 
incidence (in 
percent) 
[𝒄 𝒂⁄ × 𝟏𝟎𝟎%] 
Statin users 58,112 832,018.86 5,678 6.82 9.8 
2,682,918 38,396,263.29 268,287 6.99 10.0 
Non-statin users 58,112 870,604.42 1,915 2.20 3.3 
2,296,349 34,429,716.96 80,006 2.32 3.5 
Study population 116,224 1,702,623.28 7,593 4.45 6.5 
4,979,267 72,825,980.25 348,293 4.78 6.9 
aWeighted values are in shaded rows. MarketScan person-level national weights were constructed utilizing weight estimates from 
the Household Component of the Medical Expenditure Panel Survey (MEPS). MEPS’s weights accounts for demographic variables 
that includes region (Northest, North Central, South, West); age (0 – 17, 18 – 44, 45 – 64); and sex (male, female). The MarketScan 
weight is the ratio of MEPS-based estimates in the different age/sex/region categories and the MarketScan number in the same 
category. 
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Table G.5: Weighteda and Unweighted Incidence Density Rate and Cumulative Incidence of Diabetes by Statin 
Use (pre-index period for excluding prevalent diabetes=1 year) 
 Number of subjects 
[𝒂] 
Sum of follow-up 
months 
(person-months) 
[𝒃] 
Number of new 
cases of diabetes 
[𝒄] 
Incidence density 
rates per 1,000 
person-months 
[𝒄 𝒃⁄ × 𝟏𝟎𝟎𝟎] 
Cumulative 
incidence (in 
percent) 
[𝒄 𝒂⁄ × 𝟏𝟎𝟎%] 
Statin users 56,749 829,714.83 4,315 5.20 7.6 
2,619,961 38,289,211.37 205,330 5.36 7.8 
Non-statin users 57,698 869,975.34 1,501 1.73 2.6 
2,279,498 34,403,944.31 63,155 1.84 2.8 
Study population 114,447 1,699,690.17 5,816 3.42 5.1 
4,899,459 72,693,155.68 268,485 3.69 5.5 
Table G.6: Weighteda and Unweighted Incidence Density Rate and Cumulative Incidence of Diabetes by Statin 
Use (pre-index period for excluding prevalent diabetes=1.5 years) 
Statin users 54,312 815,384.15 1,878 2.30 3.5 
2,504,997 37,609,199.80 90,366 2.40 3.6 
Non-statin users 56,895 865,118.46 698 0.81 1.2 
2,246,090 34,201,951.93 29,747 0.87 1.3 
Study population 111,207 1,680,502.60 2,576 1.53 2.3 
4,751,087 71,811,151.74 120,113 1.67 2.5 
aWeighted values are in shaded rows. 
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2. Cox regression 
 The hazard ratios for statin users and for users of each statin type reduced 
‘slightly’ and remained statistically significant when the pre-index period for 
identifying prevalent diabetes cases was increased from 6 months (Table G.7) to 1 
year (Table G.8). 
 In contrast, the hazard ratios for statin users and for users of each statin type 
reduced ‘substantially’ when the pre-index period for identifying prevalent 
diabetes cases was increased from 6 months (Table G.7) to 1.5 years (Table G.9).  
 In fact, the hazard ratio for pravastatin was no longer significant (p=0.048) when 
the pre-index period was 1.5 years (Table G.9). 
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Table G.7: Cox Regression (6 months of pre-index period for excluding prevalent diabetes cases, N=116,224) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.012 0.032 1009.438 p<0.0001 2.752 2.535 2.987 
Atorvastatina,c 0.886 0.038 548.135 p<0.0001 2.425 2.200 2.673 
Fluvastatina,c 0.725 0.088 68.452 p<0.0001 2.064 1.647 2.586 
Lovastatina,c 1.228 0.057 466.996 p<0.0001 3.413 2.949 3.951 
Pravastatina,c 0.636 0.060 113.865 p<0.0001 1.889 1.620 2.202 
Rosuvastatina,c 0.480 0.082 34.043 p<0.0001 1.615 1.307 1.996 
Simvastatina,c 0.943 0.045 433.518 p<0.0001 2.567 2.284 2.884 
Intensive-dose statinb,d 0.422 0.039 116.165 p<0.0001 1.525 1.378 1.686 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
 dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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Table G.8: Cox Regression (1 year of pre-index period for excluding prevalent diabetes cases, N=114,447) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 0.913 0.037 625.225 p<0.0001 2.491 2.267 2.737 
Atorvastatina,c 0.797 0.044 334.815 p<0.0001 2.218 1.983 2.481 
Fluvastatina,c 0.719 0.099 52.261 p<0.0001 2.053 1.589 2.652 
Lovastatina,c 1.059 0.068 244.622 p<0.0001 2.883 2.422 3.433 
Pravastatina,c 0.563 0.069 66.859 p<0.0001 1.756 1.471 2.097 
Rosuvastatina,c 0.616 0.090 46.532 p<0.0001 1.851 1.467 2.336 
Simvastatina,c 0.858 0.052 270.338 p<0.0001 2.358 2.062 2.697 
Intensive-dose statinb,d 0.399 0.045 77.624 p<0.0001 1.490 1.326 1.674 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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Table G.9: Cox Regression (1.5 years of pre-index period for excluding prevalent diabetes cases, N=111,207) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Hazard 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 0.688 0.055 157.815 p<0.0001 1.989 1.727 2.290 
Atorvastatina,c 0.624 0.065 93.344 p<0.0001 1.866 1.580 2.203 
Fluvastatina,c 0.420 0.152 7.677 0.006 1.523 1.030 2.251 
Lovastatina,c 0.685 0.107 41.308 p<0.0001 1.984 1.507 2.610 
Pravastatina,c 0.210 0.106 3.910 0.048 1.234 0.938 1.623 
Rosuvastatina,c 0.414 0.139 8.914 0.003 1.513 1.058 2.161 
Simvastatina,c 0.533 0.081 43.616 p<0.0001 1.705 1.385 2.099 
Intensive-dose statinb,d 0.295 0.070 17.596 p<0.0001 1.343 1.121 1.611 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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3. Logistic regression 
 Similar to the Cox regression analysis results, the odds ratios for statin users and 
for users of each statin type reduced ‘slightly’ and remained statistically 
significant when the pre-index period for identifying prevalent diabetes cases was 
increased from 6 months (Table G.10) to 1 year (Table G.11). 
 In contrast, the odds ratios for statin users and for users of each statin type 
reduced ‘substantially’ when the pre-index period for identifying prevalent 
diabetes cases was increased from 6 months (Table G.10) to 1.5 years (Table 
G.12).  
 In fact, the hazard ratios for pravastatin (p=0.026) and rosuvastatin (p=0.325) 
were no longer significant when the pre-index period was 1.5 years (Table G.12).
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Table G.10: Logistic Regression (6 months of pre-index period for excluding prevalent diabetes cases, 
N=116,224) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds 
Ratio 
99% Confidence Interval 
Lower Upper 
Statina,c 1.038 0.033 993.897 p<0.0001 2.824 2.594 3.074 
Atorvastatina,c 0.910 0.039 538.842 p<0.0001 2.485 2.246 2.749 
Fluvastatina,c 0.771 0.092 69.572 p<0.0001 2.161 1.704 2.742 
Lovastatina,c 1.271 0.060 442.002 p<0.0001 3.565 3.051 4.165 
Pravastatina,c 0.669 0.062 115.773 p<0.0001 1.952 1.663 2.290 
Rosuvastatina,c 0.402 0.086 22.000 p<0.0001 1.495 1.199 1.865 
Simvastatina,c 0.975 0.047 426.171 p<0.0001 2.651 2.347 2.994 
Intensive-dose statinb,d 0.456 0.043 114.477 p<0.0001 1.578 1.414 1.761 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR).
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Table G.11: Logistic Regression (1 year of pre-index period for excluding prevalent diabetes cases, N=114,447) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Statina,c 0.929 0.037 615.966 p<0.0001 2.533 2.300 2.789 
Atorvastatina,c 0.813 0.045 330.226 p<0.0001 2.255 2.009 2.530 
Fluvastatina,c 0.754 0.104 52.813 p<0.0001 2.125 1.627 2.775 
Lovastatina,c 1.080 0.071 233.524 p<0.0001 2.946 2.456 3.535 
Pravastatina,c 0.589 0.071 68.745 p<0.0001 1.803 1.501 2.165 
Rosuvastatina,c 0.505 0.093 29.280 p<0.0001 1.657 1.303 2.107 
Simvastatina,c 0.882 0.054 268.002 p<0.0001 2.416 2.103 2.776 
Intensive-dose statinb,d 0.426 0.048 78.384 p<0.0001 1.532 1.353 1.734 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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Table G.12: Logistic Regression (1.5 years of pre-index period for excluding prevalent diabetes cases, 
N=111,207) 
 Parameter 
Estimate 
Standard 
Error 
Wald Chi-
Square 
p-value Odds Ratio 99% Confidence Interval 
Lower Upper 
Statina,c 0.686 0.055 153.580 p<0.0001 1.987 1.722 2.291 
Atorvastatina,c 0.626 0.065 91.656 p<0.0001 1.871 1.581 2.214 
Fluvastatina,c 0.446 0.155 8.328 0.004 1.563 1.049 2.328 
Lovastatina,c 0.673 0.108 38.581 p<0.0001 1.960 1.483 2.591 
Pravastatina,c 0.241 0.108 4.984 0.026 1.272 .964 1.680 
Rosuvastatina,c 0.138 0.140 0.969 0.325 1.148 .800 1.647 
Simvastatina,c 0.547 0.082 44.567 p<0.0001 1.728 1.399 2.133 
Intensive-dose statinb,d 0.320 0.072 19.631 p<0.0001 1.377 1.143 1.658 
[Significance of each parameter estimate is evaluated at p<0.01]. 
aReference=Non-statin users. 
bReference=Moderate-dose statin. 
cCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, and CCI score. 
dCovariates controlled for include age, gender, hyperlipidemia, obesity, hypertension, diabetogenic medications, CCI score, and 
medication possession ratio (MPR). 
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Conclusion 
The length of the pre-index period used to identify and exclude prevalent diabetes 
cases matters (as hypothesized in the dissertation discussion section) when estimating the 
association between statin use and incidence of diabetes. A pre-index period of at least 
1.5 – 2 years is more robust for establishing a history of diabetes. 
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